U.S. patent application number 12/657731 was filed with the patent office on 2010-11-04 for stem cell factor-like proteins and uses thereof.
Invention is credited to Bryan J. Boyle, Peter C.R. Emtage, Walter Funk, Y. Tom Tang, Jingsong Zhao.
Application Number | 20100278800 12/657731 |
Document ID | / |
Family ID | 36684722 |
Filed Date | 2010-11-04 |
United States Patent
Application |
20100278800 |
Kind Code |
A1 |
Boyle; Bryan J. ; et
al. |
November 4, 2010 |
Stem cell factor-like proteins and uses thereof
Abstract
The invention relates to pharmaceutical compositions comprising
gastrointestinal proliferative factor SCFA2, SCFA4 or SCFA4v
polynucleotides and polypeptides. The invention further relates to
the therapeutic use of SCFA2, SCFA4 or SCFA4v to prevent or treat
conditions or disorders associated with the degeneration of the
epithelial mucosa.
Inventors: |
Boyle; Bryan J.; (Santa
Clara, CA) ; Emtage; Peter C.R.; (Edmonton, CA)
; Funk; Walter; (Hayward, CA) ; Tang; Y. Tom;
(Beverly, MA) ; Zhao; Jingsong; (Fremont,
CA) |
Correspondence
Address: |
FULBRIGHT & JAWORSKI L.L.P.
600 CONGRESS AVE., SUITE 2400
AUSTIN
TX
78701
US
|
Family ID: |
36684722 |
Appl. No.: |
12/657731 |
Filed: |
January 25, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12080212 |
Apr 1, 2008 |
7674890 |
|
|
12657731 |
|
|
|
|
11334081 |
Jan 17, 2006 |
7439327 |
|
|
12080212 |
|
|
|
|
60645354 |
Jan 18, 2005 |
|
|
|
Current U.S.
Class: |
424/94.5 ;
435/194; 435/320.1; 435/6.16; 536/23.2 |
Current CPC
Class: |
A61P 1/14 20180101; A61P
43/00 20180101; C07K 14/47 20130101; A61P 1/04 20180101; A61P 29/00
20180101; A61P 1/00 20180101; A61K 38/00 20130101 |
Class at
Publication: |
424/94.5 ;
536/23.2; 435/320.1; 435/194; 435/6 |
International
Class: |
A61K 38/45 20060101
A61K038/45; C07H 21/00 20060101 C07H021/00; A61P 29/00 20060101
A61P029/00; A61P 43/00 20060101 A61P043/00; A61P 1/00 20060101
A61P001/00; C12N 15/63 20060101 C12N015/63; C12N 9/12 20060101
C12N009/12; C12Q 1/68 20060101 C12Q001/68 |
Claims
1. An adenoviral vector comprising a gene encoding SEQ ID NO: 3, 6,
8, 10, 12, 14, 17, 19, 21, 23, 26, 36, 40, 44, 51, or 55 operably
associated with an expression control sequence.
2. A transgene construct comprising a nucleic acid encoding the
polypeptide of SEQ ID NO: 23, 26, 44, fragment or analog
thereof.
3. An isolated polypeptide comprising an amino acid sequence which
is at least 95% identical to the amino acid sequence of SEQ ID NOS.
26 or 44, or fragment or analog thereof.
4. The polypeptide of claim 3, wherein the polypeptide comprises
the amino acid sequence of SEQ ID NOS: 26 or 44, or a fragment or
analog thereof.
5. A method for detecting a polynucleotide comprising the
nucleotide sequence of SEQ ID NO:22 in a sample, comprising: (a)
contacting the sample with a compound that binds to and forms a
complex with said polynucleotide for a period sufficient to form
the complex; and (b) detecting the complex, so that if a complex is
detected, said polynucleotide is detected.
6. A method for detecting a polynucleotide comprising the
nucleotide sequence of SEQ ID NO:22 in a sample, comprising: (a)
contacting the same under stringent hybridization conditions with
nucleic acid primers that anneal to said polynucleotide under such
conditions; (b) amplifying a product comprising at least a portion
of said polynucleotide; and (c) detecting said product and thereby
said polynucleotide in the sample.
7. The method of claim 6, wherein the polynucleotide is an RNA
molecule and the method further comprises reverse transcribing an
annealed RNA molecule into a cDNA polynucleotide.
8. A method for detecting the polypeptide of claim 3 in a sample,
comprising: (a) contacting the sample with a compound that binds to
and forms a complex with a polypeptide under conditions and for a
period sufficient to form the complex; and (b) detecting formation
of the complex, so that if a complex formation is detected, the
polypeptide of claim 3 is detected.
9. A method for identifying a compound that binds to the
polypeptide of claim 3, comprising: (a) contacting the compound
with the polypeptide of claim 3 under conditions sufficient to form
a polypeptide/compound complex; and (b) detecting the complex, so
that if the polypeptide/compound complex is detected, a compound
that binds to the polypeptide of claim 3 is identified.
10. A method for identifying a compound that binds to the
polypeptide of claim 3, comprising: (a) contacting the compound
with the polypeptide claim 3, in a cell, under conditions
sufficient to form a polypeptide/compound complex, wherein the
complex drives expression of a reporter gene sequence in the cell;
and (b) detecting the complex by detecting reporter gene sequence
expression, so that if the polypeptide/compound complex is
detected, a compound that binds to the polypeptide of claim 3 is
identified.
11. A composition comprising a therapeutically effective amount of
a polypeptide of SEQ ID NO: 3, 6, 8, 10, 12, 14, 17, 19, 21, 23,
26, 36, 40, 44, 51, or 55, fragment, or analog thereof, and a
pharmaceutically acceptable carrier.
12. A method of stimulating epithelial cell proliferation in a
subject comprising administering to a mammalian subject in need
thereof a therapeutically effective amount of the composition of
claim 11.
13. The method of claim 12, wherein the subject has mucositis,
inflammatory bowel disease, or short bowel syndrome.
14. The method of claim 12, wherein the mammalian subject is a
human.
Description
[0001] This application is a continuation of U.S. application Ser.
No. 12/080,212, filed Apr. 1, 2008, now U.S. Pat. No. 7,674,890,
which is a continuation application of U.S. patent application Ser.
No. 11/334,081, filed Jan. 17, 2006, now U.S. Pat. No. 7,439,327,
from which applications priority is claimed pursuant to 35 U.S.C.
.sctn.120, which in turn claims benefit under 35 U.S.C.
.sctn.119(e) of provisional application 60/645,354, filed Jan. 18,
2005, which applications are hereby incorporated by reference in
their entireties.
1. BACKGROUND
[0002] 1.1 Field of the Invention
[0003] The present invention provides a method for augmenting
proliferation of gastrointestinal epithelial cells. The invention
further provides a method for treating or preventing mucositis in
patients undergoing cancer treatment, to treat patients with
inflammatory bowel disease, and to ameliorate digestion and
nutritional absorption of patients with short bowel syndrome.
[0004] 1.2 Sequence Listing
[0005] The sequences of the polynucleotides and polypeptides of the
invention are listed in the Sequence Listing and are submitted on a
compact disc containing the file labeled "NUVO-21A.ST25.txt"--94.0
KB (96,256 bytes) which was created on an IBM PC, Windows 2000
operating system on Jan. 17, 2006 at 2:00:52 PM. The Sequence
Listing entitled "NUVO-21A.ST25.txt" is herein incorporated by
reference in its entirety. A computer readable format ("CRF") and
three duplicate copies ("Copy 1/2" and "Copy 2/2") of the Sequence
Listing "NUVO-21A.ST25.txt" are submitted herein. Applicants hereby
state that the content of the CRF and Copies 1/1 and 2/2 of the
Sequence Listing, submitted in accordance with 37 CFR
.sctn.1.821(c) and (e), respectively, are the same.
[0006] 1.3 Background
[0007] Ionizing radiation therapy and cytotoxic chemotherapy
produce injuries to the oral and gastrointestinal mucosa, which
remain significant problems for patients undergoing antineoplastic
treatments. Mucositis is the inflammation of the mucous membranes
and is a particularly common problem in this patient population due
to the use of chemotherapy and radiation therapy used with curative
or palliative intent. The mucosal injuries to the gastrointestinal
tract seen with radiation and chemotherapy (to these areas) include
the destruction of crypt cells, a decrease in villous height and
ulceration and necrosis of the gastrointestinal epithelium
(Berthrong M, World J Surg 10:155-170 (1986)), which underlie
disorders including gastrointestinal mucositis and enterocolitis.
To the patients this can mean abdominal pain, bloody diarrhea,
malabsorption and in some cases bacterial translocation (Guzman et
al., J Surg Res 46:104-107 (1989)). In addition, chemotherapy and
ionizing radiation can affect other mucous membranes including
those of the oropharynx and lips, and those of the esophagus. It is
well known that combined modality therapy of concurrent radiation
and chemotherapy can produce highly symptomatic stomatitis in
patients with head and neck cancer, and esophagitis in patients
with small cell lung cancer.
[0008] Chemotherapy and radiation therapy cause injury to the oral
and gastrointestinal mucosa through direct and indirect toxicity.
The mechanism for direct mucositis is nonspecific cell killing of
rapidly dividing basal epithelial cells that results in epithelial
thinning, inflammation, decreased cell renewal, and ultimately
ulceration. These painful lesions also produce an increased risk
for local and systemic infection. Indirect mucotoxicity is a
byproduct of chemotherapy-induced myelosuppression, which permits
bacterial and viral infections at the site of direct mucosal
injury. The severity of these effects may preclude dose escalation,
delay treatment, and warrant dose reductions, thus limiting the
effectiveness of cancer therapy.
[0009] A well-established prophylaxis or therapy for chemotherapy
and radiation therapy-induced (mucosal) gastrointestinal injuries
(mucositis) is unavailable, other than a prescription of suboptimal
doses of chemotherapy or radiotherapy, a downward dose modification
in subsequent treatment courses following toxicity, or the use of
specific antidotes such as leucovorin after moderate-dose or
high-dose methotrexate (Allegra C J. Antifolates. In: Chabner and
Collins, eds. Cancer Chemotherapy: Principles and Practice.
Philadelphia, Pa. JP Lippincott Co; 1990:110-153.)
[0010] Injury to the gastrointestinal mucosa is also associated
with chronic inflammatory disorders of the gastrointestinal tract,
which are collectively referred to as inflammatory bowel disease.
While cytokine-based therapies are available for the treatment of
inflammatory bowel disease, none can be considered as a permanent
cure (Bouma and Strober Nature Rev 3:521-533 (2003)). Often
resection of the small intestine is indicated in patients with
inflammatory bowel disease such as Crohn's disease. Surgical
resection of the small intestine may also be necessary following
traumatic injury, vascular accidents, and cancer. Surgical
resection that leaves less than 200 cm of viable small bowel places
a patient at risk for developing short-bowel syndrome (SBS). SBS is
a disorder that is clinically defined by malabsorption, diarrhea,
fluid and electrolyte disturbances, and malnutrition. The
management of patients with SBS frequently requires long-term, if
not life long use of parenteral nutrition DiBaise et al., Am J
Gastroenterol 99:1823-1832 (2004)).
[0011] Thus, there is a need to find agents that may be used
prophylactically or therapeutically to increase the tolerance to
anteneoplastic treatments, to advance current therapies for
treating inflammatory bowel disease, and to restore the digestive
and absorptive processes that are compromised following surgical
resection of the intestine.
[0012] To this end Applicants have discovered an agent that induces
the proliferation of gastrointestinal epithelial cells, and which
may be useful for treating conditions in which proliferation of
epithelial cells may be desired.
2. SUMMARY OF THE INVENTION
[0013] The present invention is based on the discovery that stem
cell factor-like proteins SCFA2, SCFA4 and SCFA4v induce the
proliferation of epithelial cells of the gastrointestinal tract.
Thus, compositions comprising SCFA2, SCFA4 or SCFA4v, fragments or
analogs thereof, may be used for the treatment of conditions where
epithelialization is required, such as for the treatment of
gastrointestinal disorders including chemotherapy and radiation
therapy-induced mucositis, mucositis of the oropharynx, lips and
esophagus, inflammatory bowel disease, and other conditions
including wounds, burns, ophthalmic disorders, and any disorder
where stimulation of epithelial cell proliferation or regeneration
is desired.
[0014] The polynucleotide (SEQ ID NO: 22) which encodes the
polypeptide of SEQ ID NO: 23, is novel. Therefore, one embodiment
of the invention is directed to the polynucleotide of SEQ ID NO:
22. The invention also comprises vectors that comprise the
polynucleotide sequence of SEQ ID NO: 22, a host cell that
comprises the polynucleotide of SEQ ID NO: 22, a transgene
construct that comprise the polynucleotide sequence of SEQ ID NO:
22; and a method for detecting the polynucleotide of SEQ ID NO: 22
in a sample.
[0015] Another embodiment is directed to the polypeptide of SEQ ID
NO: 23, a fragment or analog thereof. The invention also comprises
a method for producing the polypeptide of SEQ ID NO: 23, fragment
or analog thereof; a method for detecting the polypeptide of SEQ ID
NO: 23 in a sample, a method for identifying a compound that binds
the polypeptide of SEQ ID NO: 23, fragment or analog thereof.
[0016] In another embodiment, the invention is directed to a
composition comprising a therapeutically effective amount of a
SCFA2 (SEQ ID NO: 3, 6, 8, 10, 12, 36, 51 or 55), SCFA4 (SEQ ID NO:
14, 17, 19, 21, or 40) or SCFA4v (SEQ ID NO: polypeptide (SEQ ID
NO: 23, 26, or 44) and a pharmaceutically acceptable carrier.
[0017] The compositions of the present invention include isolated
polynucleotides (SEQ ID NO: 1, 2, 4, 5, 7, 9, 11, 13, 15, 16, 18,
20, 22, 24, 25, 35, 39, 43, 50, 52, 53, or 54) encoding SCFA2,
SCFA4 or SCFA4v polypeptides, including recombinant DNA molecules,
and cloned genes or degenerate variants thereof, especially
naturally occurring variants such as allelic variants. The
compositions of the present invention also include vectors such as
expression vectors containing the polynucleotides of the invention,
cells genetically engineered to contain such polynucleotides and
cells genetically engineered to express such polynucleotides.
[0018] The compositions of the invention comprise isolated
polynucleotides that include, but are not limited to, a SCFA2,
SCFA4 or SCFA4v polynucleotide, a fragment, or variant thereof; a
polynucleotide comprising the full length protein coding sequence
of the SEQ ID NO: 2, 13, or 22 (for example, SEQ ID NO: 4, 14, or
23); a polynucleotide comprising the nucleotide sequence of the
dominant mature protein coding sequence of SEQ ID NO: 5, 16, or 25
(for example SEQ ID NO: 6, 17, or 26); a polynucleotide comprising
the nucleotide sequence of the mature protein coding sequence of
SEQ ID NO: 7 (for example SEQ ID NO: 8); a polynucleotide
comprising the nucleotide sequence of the C-terminal deletion
protein of SCFA2 coding sequence of SEQ ID NO: 50 (for example SEQ
ID NO: 51); a polynucleotide comprising the nucleotide sequence of
the thrombospondin domain of SEQ ID NO: 11 or 20 (for example SEQ
ID NO: 12 or 21); a polynucleotide of SEQ ID NO: 9 or 18 comprising
the nucleotide sequence that encodes furin-like cysteine-rich
domains (for example SEQ ID NO: 10 or 19). The polynucleotide
compositions of the present invention also include, but are not
limited to, a polynucleotide that hybridizes under stringent
hybridization conditions to (a) the complement of any of the
nucleotide sequences set forth in SEQ ID NO: 1, 2, 4, 5, 7, 9, 11,
13, 15, 16, 18, 20, 22, 24, 25, 35, 39, 43, 50, 52, 53, or 54 (b) a
nucleotide sequence encoding any of SEQ ID NO: 3, 6, 8, 10, 12, 14,
17, 19, 21, 23, 26, 36, 40, 44, 51, or 55; a polynucleotide which
is an allelic variant of any polynucleotides recited above having
at least 70% polynucleotide sequence identity to the
polynucleotides; a polynucleotide which encodes a species homolog
(e.g. ortholog) of any of the peptides recited above; or a
polynucleotide that encodes a polypeptide comprising a specific
domain or truncation of the polypeptide of SEQ ID NO: 3, 14, or
23.
[0019] This invention further provides cloning or expression
vectors comprising at least a fragment of the polynucleotides set
forth above and host cells or organisms transformed with these
expression vectors. Useful vectors include plasmids, cosmids,
lambda phage derivatives, phagemids, and the like, that are well
known in the art. Accordingly, the invention also provides a vector
including a polynucleotide of the invention and a host cell
containing the polynucleotide. In general, the vector contains an
origin of replication functional in at least one organism,
convenient restriction endonuclease sites, and a selectable marker
for the host cell. Vectors according to the invention include
expression vectors, replication vectors, probe generation vectors,
and sequencing vectors. A host cell according to the invention can
be a prokaryotic or eukaryotic cell and can be a unicellular
organism or part of a multicellular organism.
[0020] The pharmaceutical compositions of the present invention
include polypeptides comprising, but not limited to, an isolated
polypeptide selected from the group comprising the amino acid
sequence of SEQ ID NO: 3, 6, 8, 10, 12, 14, 17, 19, 21, 23, 26, 36,
40, 44, 51 or 55. Polypeptides of the invention also include
polypeptides with biological activity that are encoded by (a) any
of the polynucleotides having a nucleotide sequence set forth in
the SEQ ID NO: 1, 2, 4, 5, 7, 9, 11, 13, 15, 16, 18, 20, 22, 24,
25, 35, 39, 43, 50, 52, 53, or 54 above; or (b) polynucleotides
that hybridize to the complement of the polynucleotides of (a)
under stringent hybridization conditions. Biologically or
immunologically active analogs of any of the protein sequences
listed as SEQ ID NO: 3, 6, 8, 10, 12, 14, 17, 19, 21, 23, 26, 36,
40, 44, 51, or 55, and substantial equivalents thereof that retain
biological are also contemplated. The polypeptides of the invention
may be wholly or partially chemically synthesized but are
preferably produced by recombinant means using the genetically
engineered cells (e.g. host cells) of the invention.
[0021] The invention also relates to methods for producing a SCFA2,
SCFA4 or SCFA4v polypeptide comprising culturing host cells
comprising an expression vector containing at least a fragment of a
SCFA2, SCFA4 or SCFA4v polynucleotide encoding the SCFA2, SCFA4 or
SCFA4v polypeptide of the invention in a suitable culture medium
under conditions permitting expression of the desired polypeptide,
and purifying the protein or peptide from the culture or from the
host cells. Preferred embodiments include those in which the
protein produced by such a process is a mature or dominant mature
form of the protein.
[0022] The polypeptides according to the invention can be used in a
variety of conventional procedures and methods that are currently
applied to other proteins. For example, a polypeptide of the
invention can be used to generate an antibody that specifically
binds the polypeptide. Such antibodies, particularly monoclonal
antibodies, are useful for detecting or quantifying the polypeptide
in tissue.
[0023] In further embodiments, the subject invention is directed to
a method of stimulating epithelial cell proliferation. The method
comprises contacting epithelial cells with a composition that
includes a therapeutically effective amount of a SCFA2, SCFA4 or
SCFA4v polypeptide, fragment or analog thereof, and a
pharmaceutically acceptable carrier. Specifically, a subject in
need of stimulation (including cytoprotection, proliferation and/or
differentiation) of epithelial cells will be administered
therapeutically-effective or prophylactically-effective amounts of
SCFA2, SCFA4 or SCFA4v protein, fragments or analogs thereof.
[0024] In all the methods described, epithelial cells may be
contacted with the SCFA2, SCFA4 or SCFA4v polypeptides in vitro or
in vivo.
[0025] Methods are also provided for preventing, treating, or
ameliorating a medical condition which comprises the step of
administering to a mammalian subject a therapeutically effective
amount of a composition comprising a peptide of the present
invention and a pharmaceutically acceptable carrier.
[0026] In particular, the SCFA2, SCFA4 or SCFA4v polypeptides of
the invention may be used to induce the proliferation and/or
differentiation of gastrointestinal crypt cells to regenerate the
epithelial layer of the alimentary tract. Thus, the SCFA2, SCFA4 or
SCFA4v polypeptides and polynucleotides of the invention may be
used in the treatment of chemotherapy or radiation therapy-induced
mucositis and enterocolitis, and inflammatory bowel disease. They
may also be used in the treatment of diseases, and other conditions
including wounds, burns, ophthalmic disorders, and any disorder
where stimulation of epithelial cell proliferation or regeneration
is desired.
[0027] Polynucleotides and polypeptides of the invention may also
be used as markers of differentiation and development of
gastrointestinal epithelium.
[0028] The methods of the invention also provide methods for the
treatment of disorders as recited herein which comprise the
administration of a therapeutically effective amount of a
composition comprising a polynucleotide or polypeptide of the
invention and a pharmaceutically acceptable carrier to a mammalian
subject exhibiting symptoms or tendencies related to disorders as
recited herein. In addition, the invention encompasses methods for
treating diseases or disorders as recited herein comprising the
step of administering a composition comprising compounds and other
substances that modulate the overall activity of the target gene
products and a pharmaceutically acceptable carrier. Compounds and
other substances can effect such modulation either on the level of
target gene/protein expression or target protein activity.
Specifically, methods are provided for preventing, treating or
ameliorating a medical condition, including mucositis and
inflammatory bowel disease, wounds, which comprises administering
to a mammalian subject, including but not limited to humans, a
therapeutically effective amount of a composition comprising a
polypeptide of the invention or a therapeutically effective amount
of a composition comprising a binding partner of SCFA2, SCFA4 or
SCFA4v polypeptides of the invention. The mechanics of the
particular condition or pathology will dictate whether the
polypeptides of the invention or binding partners of these would be
beneficial to the individual in need of treatment.
[0029] The invention further provides methods for manufacturing
medicaments useful in the above-described methods.
[0030] The present invention further relates to methods for
detecting the presence of the polynucleotides or polypeptides of
the invention in a sample (e.g., tissue or sample). Such methods
can, for example, be utilized as part of prognostic and diagnostic
evaluation of disorders as recited herein and for the
identification of subjects exhibiting a predisposition to such
conditions.
[0031] The invention provides a method for detecting a polypeptide
of the invention in a sample comprising contacting the sample with
a compound that binds to and forms a complex with the polypeptide
under conditions and for a period sufficient to form the complex
and detecting formation of the complex, so that if a complex is
formed, the polypeptide is detected.
[0032] The invention also provides kits comprising polynucleotide
probes and/or monoclonal antibodies, and optionally quantitative
standards, for carrying out methods of the invention. Furthermore,
the invention provides methods for evaluating the efficacy of
drugs, and monitoring the progress of patients, involved in
clinical trials for the treatment of disorders as recited
above.
[0033] The invention also provides methods for the identification
of compounds that modulate (i.e., increase or decrease) the
expression or activity of the polynucleotides and/or polypeptides
of the invention. Such methods can be utilized, for example, for
the identification of compounds that can enhance the therapeutic
activity of the SCFA2, SCFA4 or SCFA4v polypeptides, and ameliorate
symptoms of disorders as recited herein. Such methods can include,
but are not limited to, assays for identifying compounds and other
substances that interact with (e.g., bind to) the polypeptides of
the invention.
[0034] The invention provides a method for identifying a compound
that binds to the polypeptide of the present invention comprising
contacting the compound with the polypeptide under conditions and
for a time sufficient to form a polypeptide/compound complex and
detecting the complex, so that if the polypeptide/compound complex
is detected, a compound that binds to the polypeptide is
identified.
[0035] Also provided is a method for identifying a compound that
binds to the polypeptide comprising contacting the compound with
the polypeptide in a cell for a time sufficient to form a
polypeptide/compound complex wherein the complex drives expression
of a reporter gene sequence in the cell and detecting the complex
by detecting reporter gene sequence expression so that if the
polypeptide/compound complex is detected a compound that binds to
the polypeptide is identified.
[0036] Another embodiment of the invention provides gene therapy by
delivery of SCFA2, SCFA4 or SCFA4v polypeptides for the treatment
of conditions or disorders recited herein.
[0037] In a related embodiment, the invention is directed to use of
a vector comprising a gene encoding a SCFA2, SCFA4 or SCFA4v
polypeptide operably associated with an expression control sequence
that provides for expression of the SCFA2, SCFA4 or SCFA4v
polypeptide in the manufacture of a medicament for treating
disorders as recited herein. More particularly, the invention
provides for use of an adenoviral vector of the invention, e.g., as
set out below, in the manufacture of a medicament for treating
mucositis, inflammatory bowel disease or short bowel syndrome.
[0038] In addition to the foregoing methods and uses, the invention
provides a virus vector comprising a gene encoding a SCFA2, SCFA4
or SCFA4v polypeptide operably associated with an expression
control sequence. In a preferred embodiment, the virus vector is an
adenovirus vector. The virus vectors of the invention can provide a
gene encoding any of the SCFA2, SCFA4 or SCFA4v polypeptides, as
set forth above.
[0039] The invention further provides a pharmaceutical composition
comprising a virus vector of the invention and a pharmaceutically
acceptable carrier.
[0040] Additional aspects and advantages of the invention will be
apparent to those skilled in the art upon consideration of the
following description, which details the practice of the
invention.
3. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] FIG. 1: Schematic representation of the SCFA2 (SEQ ID NO:
3), SCFA4 (SEQ ID NO: 14) and SCFA4v (SEQ ID NO: 23) polypeptides
of the compositions of the invention. The length of the amino acid
sequences includes the stop codon.
[0042] FIG. 2: ALIGN0 amino acid sequence alignment between SCFA4v
(SEQ ID NO: 23) and a human protein similar to mouse thrombospondin
type 1 domain protein R-spondin (SEQ ID NO: 48). The figure
indicates that the two sequences share 69.2% identity over the
entire length of the proteins. The letters represent amino acids as
follows: A=Alanine, C=Cysteine, D=Aspartic Acid, E=Glutamic Acid,
F=Phenylalanine, G=Glycine, H=Histidine, I=Isoleucine, K=Lysine,
L=Leucine, M=Methionine, N=Asparagine, P=Proline, Q=Glutamine,
R=Arginine, S=Serine, T=Threonine, V=Valine, W=Tryptophan,
Y=Tyrosine. Gaps are presented as dashes.
[0043] FIG. 3: CLUSTALW alignment of SCFA2 (SEQ ID NO: 3), SCFA4
(SEQ ID NO: 14) and SCFA4v (SEQ ID NO: 23). The positions of the
signal peptide, furin cleavage site, furin-like cysteine-rich
domains, thrombospondin type 1 domain and nuclear localization
signal are shown.
[0044] FIG. 4: H&E staining of cross-sections derived from the
small intestine (SI) and colon (Co) derived from a control mouse
(PBS), from a mouse treated with 1.times.10.sup.10 viral particles
of empty adenovirus (AdCV), from a mouse treated with adenovirus
expressing SCFA2-V5H is6 (AdhSCFA2; 1.times.10.sup.10 viral
particles), from a mouse treated with adenovirus expressing
SCFA4-V5H is6 (AdhSCFA4; 1.times.10.sup.10 viral particles, and
from a mouse treated with adenovirus expressing SCFA4v-V5H is6
(AdhSCFA4v; 1.times.10.sup.10 viral particles), as described in
Example 5. The sections were obtained three days following
injection of the empty or SCFA2, SCFA4 or SCFA4v adenovirus,
respectively.
[0045] FIG. 5: Incorporation of BrdU into proliferating crypt cells
of the small intestine (SI) and colon (Co) of mice that had
received SCFA2, SCFA4 or SCFA4v adenovirus. The sections shown were
obtained from the same mice for which the H&E staining is
described in FIG. 4.
[0046] FIG. 6: Efficacy of SCFA2 (A) and SCFA2.DELTA.C (B) on
animal survival in 5-FU-induced mucositis in normal BDF-1 mice.
[0047] FIG. 7: Gross pathology of the intestinal tract of BDF-1
mice with 5-FU-induced mucositis treated with SCFA2 (A) and
SCFA2.DELTA.C (B).
[0048] FIG. 8: H&E staining of cross sections derived from the
small intestine (SI) and colon (Co) of normal BDF-1 mice with
5-FU-induced mucositis treated with SCFA2 (A) or SCFA2.DELTA.C
(B).
[0049] FIG. 9: Efficacy of SCFA2 (A) and SCFA2.DELTA.C (B) on
villus height or crypt depth in 5-FU-induced mucositis in normal
BDF-1 mice.
[0050] FIG. 10: Effect of SCFA2 (A) and SCFA2.DELTA.C (B) on the
crypt proliferative index in 5-FU-induced mucositis in normal BDF-1
mice.
[0051] FIG. 11: Incorporation of BrdU into the small intestine of
normal BDF-1 mice with 5-FU-induced mucositis and treated with
either SCFA2 (A) or SCFA2.DELTA.C (B).
[0052] FIG. 12: Incorporation of BrdU into the colon of normal
BDF-1 mice with 5-FU-induced mucositis and treated with SCFA2 (A)
or SCFA2.DELTA.C (B).
[0053] FIG. 13: H&E staining of and incorporation of BrdU into
cross-sections derived from the tongue of normal BDF-1 mice with
5-FU-induced mucositis and treated with SCFA2 (A) or SCFA2.DELTA.C
(B).
[0054] FIG. 14: Effect of SCFA2 (A) or SCFA2.DELTA.C (B) on the
number of basal layer epithelial cells per mm of the ventral tongue
of normal BDF-1 mice with 5-FU-induced mucositis.
[0055] FIG. 15: Effect of SCFA2 (A) or SCFA2.DELTA.C (B) on mucosal
thickness of the ventral tongue of normal BDF-1 mice with
5-FU-induced mucositis.
[0056] FIG. 16: Effect of SCFA2 (A) or SCFA2.DELTA.C (B) on the
basal layer BrdU proliferative index of ventral tongue of normal
BDF-1 mice with 5-FU-induced mucositis.
4. DETAILED DESCRIPTION OF THE INVENTION
[0057] The polypeptides of the invention are depicted in FIG. 1,
and are described in detail below.
[0058] The SCFA2 polypeptide of SEQ ID NO: 3 is an approximately
243-amino acid protein with a predicted molecular mass of
approximately 27 kDa unglycosylated. The initial methionine starts
at position 262 of SEQ ID NO: 2 and the putative stop codon begins
at position 991 of SEQ ID NO: 2. Protein database searches with the
BLAST algorithm (Altschul S. F. et al., J. Mol. Evol. 36:290-300
(1993) and Altschul S. F. et al., J. Mol. Biol. 21:403-10 (1990),
herein incorporated by reference) indicate that SEQ ID NO: 3 is
homologous to Xenopus laevis R-spondin2 (SEQ ID NO: 49) (accession
numbers AAV31037.1; gi54145368)
[0059] A predicted approximately twenty-two amino acid residue
signal peptide is encoded from approximately residue 1 to residue
22 of SEQ ID NO: 3. The extracellular portion is useful on its own.
The signal peptide region was predicted using the Neural Network
Signal P VI.I program (Nielsen et al., Int. J. Neural Syst.
8:581-599 (1997)), incorporated herein by reference) and/or using
Neural Network SignalP V1.1 program (Nielsen et al, (1997) Int. J.
Neural Syst. 8, 581-599). One of skill in the art will recognize
that the actual cleavage site may be different than that predicted
by the computer program. SEQ ID NO: 6 is the SCFA2 polypeptide of
SEQ ID NO: 3 that lacks the signal peptide i.e SED ID NO: 6 is the
dominant mature form of SCFA2 (SEQ ID NO: 3). SCFA2 contains a
predicted furin protease cleavage site between amino acids 32 and
33 of SEQ ID NO: 3. Therefore, it is possible that two forms of
SCFA2 exist: the dominant mature form (SEQ ID NO: 6), which lacks
the signal peptide, and the mature form (SEQ ID NO: 8), which lacks
the signal peptide and the amino acids residues between amino acid
33 and amino acid 38 of SEQ ID NO: 3. Deletion of the C-terminal 37
amino acids (residues 207 through 243 of SEQ ID NO: 3) yields
increased secretion of SCFA2, herein denoted as SCFA2.DELTA.C (SEQ
ID NO: 51), without any change in biological activity (Kazanskaya
et al. Dev. Cell 7:525-534 (2004)).
[0060] The SCFA4 polypeptide of SEQ ID NO: 14 is an approximately
234-amino acid protein with a predicted molecular mass of
approximately 26 kDa unglycosylated. The initial methionine starts
at position 101 of SEQ ID NO: 13 and the putative stop codon begins
at position 803 of SEQ ID NO: 13. The variant of SCFA4, SCFA4v (SEQ
ID NO: 23), is identical to SCFA4 but for the fact that SCFA4v
lacks the TSP1 domain. SCFA4v is a protein of approximately 172
amino acid residues with a predicted molecular weight of
approximately 19 kDa unglycosylated. The initial methionine starts
at position 101 of SEQ ID NO: 23 and the putative stop codon begins
at position 667 of SEQ ID NO: 23. Protein database searches with
the BLAST algorithm (Altschul S. F. et al., J. Mol. Evol.
36:290-300 (1993) and Altschul S. F. et al., J. Mol. Biol.
21:403-10 (1990), herein incorporated by reference) indicate that
SEQ ID NO: 14 is identical to dJ824F16.3, which is a novel human
protein that is similar to mouse thrombospondin type 1 domain
protein R-spondin (SEQ ID NO: 48) (accession numbers CAB65783.3;
gi14627121). SCFA4v is also homologous to the human R-spondin
protein of SEQ ID NO: 48, and it shares 69% identity with it (FIG.
2).
[0061] A predicted approximately twenty amino acid residue signal
peptide is encoded from approximately residue 1 to residue 20 of
SEQ ID NO: 14 and SEQ ID NO: 23. The signal peptide region was
predicted using the Neural Network SignalP V1.1 program (Nielsen et
al., Int. J. Neural Syst. 8:581-599 (1997)), incorporated herein by
reference). One of skill in the art will recognize that the actual
cleavage site may be different than that predicted by the computer
program. SEQ ID NO: 17 is the SCFA4 polypeptide of SEQ ID NO: 14
that lacks the signal peptide, and SEQ ID NO: 26 is the SCFA4v
polypeptide of SEQ ID NO: 23 that lacks the signal peptide. Unlike
SCFA2, SCFA4 and SCFA4v do not contain a predicted furin protease
cleavage (Zhou et al. J Biol Chem 274:20745-20748 (1999).
Therefore, it is possible that one form of SCFA4 and SCFA4v exist:
the dominant mature form of SEQ ID NO: 17 and SEQ ID NO: 26,
respectively.
[0062] Using the Pfam software program (Sonnhammer et al., Nucleic
Acids Res., Vol. 26(1) pp. 320-322 (1998) herein incorporated by
reference) the SCFA2, SCFA4 and SCFA4v polypeptides (SEQ ID NO: 3,
14 and 23, respectively) were examined for domains with homology to
known peptide domains. SCFA2, SCFA4 and SCFA4v each contain 2 (two)
furin-like domains. The furin-like domains of SCFA2 (SEQ ID NO: 10)
are encoded by the polynucleotide of SEQ ID NO: 9, and the
polypeptide domains span from amino acid 39 to 85, and from amino
acid 91-132 of SEQ ID NO: 3. The two furin-like domains of SCFA4
and SCFA4v are identical. The domains, which are encompassed in SEQ
ID NO: 19, are encoded by the polynucleotide of SEQ ID NO: 18. The
first furin domain of SCFA4 and SCFA4v spans amino acids 34 to 79,
and the second spans amino acids 85-126 of the respective
full-length sequences. These furin-like domains have been found in
a variety of eukaryotic proteins involved in signal transduction
via receptor tyrosine kinases (Raz et al. Genetics 129:191-201
(1991)). Thus, the furin-like cysteine-rich domains of SCFA2,
SCFA4, and SCFA4v may effect the proliferation of the intestinal
epithelium.
[0063] SCFA2 and SCFA4 polypeptides of SEQ ID NO: 3 and 14,
respectively, are expected to have a thrombospondin type 1 domain
(TSP1) (SEQ ID NO: 12 and 21, respectively) encoded by the
nucleotide sequence of SEQ ID NO: 11 and 20, respectively). The
thrombospondin type 1 domain contained within SEQ ID NO: 3 is
predicted to be from amino acid residue 147 to 203, and the TSP1
domain of SEQ ID NO: 14 is predicted to be from amino acid residue
141 to 195. SCFA4v lacks the TSP1 domain.
[0064] Thrombospondins are a family of extracellular matrix
proteins that are involved in cell-cell and cell-matrix
communication (Lawler et al., Curr. Opin. Cell Bio. 12:634-640
(2000)). More than five different thrombospondins are known with
distinct patterns of tissue distribution. Some tissues like heart,
cartilage, and brain express most of the thrombospondin gene
products. Thrombospondin-1 is a major constituent of blood
platelets. Thrombospondin-1 appears to function at the cell surface
to bring together membrane proteins and cytokines and other soluble
factors. Membrane proteins that bind thrombospondin-1 include
integrins, integrin-associated protein (CD47), CD36, and
proteoglycans. Transforming growth factor .beta. (TGF.beta.) and
platelet-derived growth factor also bind thrombospondin-1.
[0065] Thrombospondin-1 is a large protein with many distinct
domains. It contains a globular domain at both amino and carboxy
termini, a region of homology with procollagen, and three types of
repeated sequence motifs termed thrombospondin (TSP) type 1, type
2, and type 3 repeats. The TSP1 repeat has been found in various
different proteins including, complement components (C6, C7, C8A
etc.) extracellular matrix proteins like ADAMTS, mindin, axonal
guidance molecule like F-spondin semaphorins, and also SCO-spondin,
and TRAP proteins of Plasmodium.
[0066] Thrombospondin type 1 repeats can activate TGF.beta.
epithelial tissues which are involved in regulation of cell growth,
differentiation, adhesion, migration, and death. TSP1 is further
involved in protein binding, heparin binding, cell attachment,
neurite outgrowth, inhibition of proliferation, inhibition of
angiogenesis, and activation of apoptosis. TSP1 domains of
Plasmodium circumsporozoite (CS) protein and TRAP proteins are
implicated in salivary gland invasion by the sporozoite.
[0067] TSP1 sequences are characterized by conserved cysteines,
closely spaced tryptophans, and a cluster of basic residues.
Spatial configuration of TSP1 sequences shows two .beta.-sheet
domains which are shown to bind heparin (Kilpelainen et al (2000)
J. Biol. Chem. 275, 13564-13570, incorporated herein by reference).
A similar spatial fold has been described for heparin-binding
growth associated molecule (HB-GAM). HB-GAM is identical to
mitogenic and neurite outgrowth-promoting protein pleitrophin;
osteoblast specific factor-1; heparin-binding neurotrophic factor;
and heparin affin regulatory peptide. Expression of HB-GAM was
shown to be associated with extracellular matrix of axonal tracts
and synapses, and also with basement membranes outside of brain and
in the cartilage matrix. Recently, N-syndecan has been shown to be
the receptor for HB-GAM in brain and has been suggested to play a
role in regulation of hippocampal long-term potentiation, a form of
brain plasticity implicated in memory and learning. Therefore,
TSP1-containing proteins may act as growth promoters and may
exhibit SCFA2, SCFA4 or SCFA4v activities.
[0068] In addition, thrombospondin, synthesized in bone marrow and
deposited within the extracellular matrix, functions as a
cytoadhesion molecule for primary pluripotent progenitor cells, as
well as for hematopoietic progenitor cells committed to erythroid,
granulocytic, and megakaryocytic lineages. Thus thrombospondins may
be important in blood cell development (Long and Dixit (1990) Blood
75, 2311-2318, incorporated herein by reference).
[0069] SCFA2, SCFA4 or SCFA4v polypeptides and polynucleotides of
the invention can be used to induce proliferation or
differentiation of gastrointestinal crypt cells. They can also be
used in the treatment of conditions where epithelialization is
required, such as for the treatment of gastrointestinal disorders
including chemotherapy and radiation therapy-induced mucositis,
mucositis of the oropharynx, lips and esophagus, inflammatory bowel
disease, and other conditions including wounds, burns, ophthalmic
disorders, and any disorder where stimulation of epithelial cell
proliferation or regeneration is desired. The polynucleotides and
polypeptides of the invention can further be utilized to generate
new tissues and organs that may aid patients in need of
transplanted tissues.
4.1 DEFINITIONS
[0070] In describing the present invention the following terms will
be employed and are intended to be defined as indicated below.
[0071] It must be noted that as used herein and in the appended
claims, the singular forms "a", "an" and "the" include plural
references unless the context clearly dictates otherwise.
[0072] In accordance with the present invention, the term "SCFA2,
SCFA4 or SCFA4v protein(s)" or "SCFA2, SCFA4 or SCFA4v
polypeptide(s) refers to the full-length protein defined by amino
acids Met.sup.1 to Ala.sup.243 (SEQ ID NO: 3), Met.sup.1 to
Ala.sup.234 (SEQ ID NO: 14), and Met.sup.1 to Ala.sup.172 fragments
and analogs thereof.
[0073] The term "full-length SCFA2, SCFA4 or SCFA4v," wild type
SCFA2, SCFA4 or SCFA4v'', or "native SCFA2, SCFA4 or SCFA4v" as
used herein all refer to the polypeptide that contains 243, 234,
and 172 amino acid residues (SEQ ID NO: 3, 14, and 23,
respectively).
[0074] The term "fragment" refers to a polypeptide derived from the
native SCFA2, SCFA4 or SCFA4v that does not include the entire
sequence of SCFA2, SCFA4 or SCFA4v. Such a fragment may be a
truncated version of the full-length molecule, for example SEQ ID
NO: 8 as well as an internally deleted polypeptide. A SCFA2, SCFA4
or SCFA4v fragment may have SCFA2, SCFA4 or SCFA4v bioactivity as
determined by the effect SCFA2, SCFA4 or SCFA4v on the
proliferation of epithelial cells in vitro and/or in vivo, as
described herein.
[0075] The term "analog" refers to derivatives of the reference
molecule. The analog may retain biological activity, as described
above. In general, the term "analog" refers to compounds having a
native polypeptide sequence and structure with one or more amino
acid additions, substitutions (generally conservative in nature)
and/or deletions, relative to the native molecule, so long as the
modifications do not destroy activity. Preferably, the analog has
at least the same biological activity as the parent molecule, and
may even display enhanced activity over the parent molecule.
Methods for making polypeptide analogs are known in the art.
Particularly preferred analogs include substitutions that are
conservative in nature, i.e., those substitutions that take place
within a family of amino acids that are related in their side
chains. Specifically, amino acids are generally divided into four
families: (1) acidic: aspartate, glutamate; (2) basic: lysine,
arginine, histidine; (3) non-polar: alanine, valine, leucine,
isoleucine, proline, phenylalanine, methionine, tryptophan; and (4)
uncharged polar: glycine, asparagine, glutamine, cysteine, serine,
threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are
sometimes classified as aromatic amino acids. For example, it is
reasonably predictable that an isolated replacement of leucine with
isoleucine or valine, an aspartate with a glutamate, a threonine
with a serine, or a similar conservative replacement of an amino
acid with a structurally related amino acid will preserve the
biological activity of SCFA2, SCFA4 or SCFA4v.
[0076] Guidance in determining which amino acid residues may be
replaced, added or deleted without abolishing activities of
interest, may be found by comparing the sequence of the particular
polypeptide with that of homologous peptides and minimizing the
number of amino acid sequence changes made in regions of high
homology (conserved regions) or by replacing amino acids with
consensus sequence.
[0077] Alternatively, recombinant analogs encoding these same or
similar polypeptides may be synthesized or selected by making use
of the "redundancy" in the genetic code. Various codon
substitutions, such as the silent changes which produce various
restriction sites, may be introduced to optimize cloning into a
plasmid or viral vector or expression in a particular prokaryotic
or eukaryotic system. Mutations in the polynucleotide sequence may
be reflected in the polypeptide or domains of other peptides added
to the polypeptide to modify the properties of any part of the
polypeptide, to change characteristics such as ligand-binding
affinities, interchain affinities, or degradation/turnover
rate.
[0078] Preferably, amino acid "substitutions" are the result of
replacing one amino acid with another amino acid having similar
structural and/or chemical properties, i.e., conservative amino
acid replacements. "Conservative" amino acid substitutions may be
made on the basis of similarity in polarity, charge, solubility,
hydrophobicity, hydrophilicity, and/or the amphipathic nature of
the residues involved. For example, nonpolar (hydrophobic) amino
acids include alanine, leucine, isoleucine, valine, proline,
phenylalanine, tryptophan, and methionine; polar neutral amino
acids include glycine, serine, threonine, cysteine, tyrosine,
asparagine, and glutamine; positively charged (basic) amino acids
include arginine, lysine, and histidine; and negatively charged
(acidic) amino acids include aspartic acid and glutamic acid.
"Insertions" or "deletions" are preferably in the range of about 1
to 20 amino acids, more preferably 1 to 10 amino acids. The
variation allowed may be experimentally determined by
systematically making insertions, deletions, or substitutions of
amino acids in a polypeptide molecule using recombinant DNA
techniques and assaying the resulting recombinant variants for
activity.
[0079] Alternatively, where alteration of function is desired,
insertions, deletions or non-conservative alterations can be
engineered to produce altered polypeptides. Such alterations can,
for example, alter one or more of the biological functions or
biochemical characteristics of the polypeptides of the invention.
For example, such alterations may change polypeptide
characteristics such as ligand-binding affinities, interchain
affinities, or degradation/turnover rate. Further, such alterations
can be selected so as to generate polypeptides that are better
suited for expression, scale up and the like in the host cells
chosen for expression. For example, cysteine residues can be
deleted or substituted with another amino acid residue in order to
eliminate disulfide bridges.
[0080] The term "derivative" refers to polypeptides chemically
modified by such techniques as ubiquitination, labeling (e.g., with
radionuclides or various enzymes), covalent polymer attachment such
as pegylation (derivatization with polyethylene glycol) and
insertion or substitution by chemical synthesis of amino acids such
as ornithine, which do not normally occur in human proteins.
[0081] The terms "polypeptide" and "protein" refer to a polymer of
amino acid residues and are not limited to a minimum length of the
product. The terms also include, unless otherwise indicated,
modifications of the polypeptide that do not change the sequence of
amino acids, for example, glycosylated, acetylated and
phosphorylated forms. A polypeptide or protein, for purposes of the
present invention, may be synthetically or recombinantly produced,
as well as isolated from natural sources.
[0082] By "purified" and "isolated" is meant, when referring to a
polypeptide or polynucleotide, that the indicated molecule is
present in the substantial absence of other biological
macromolecules of the same type. The term "purified" as used herein
preferably means at least 75% by weight, more preferably at least
85% by weight, more preferably still at least 95% by weight, and
most preferably at least 98% by weight, of biological
macromolecules of the same type are present in the sample. In one
embodiment, the polynucleotide or polypeptide is purified such that
it constitutes at least 95% by weight of the indicated biological
macromolecules present but water, buffers, and other small
molecules, especially molecules having a molecular weight of less
than 1000 daltons, can be present.
[0083] An "isolated polynucleotide which encodes a particular
polypeptide" refers to a nucleic acid molecule which is
substantially free of other nucleic acid molecules that do not
encode the subject polypeptide; however, the molecule may include
some additional bases or moieties which do not deleteriously affect
the basic characteristics of the composition.
[0084] The term "naturally occurring polypeptide" refers to
polypeptides produced by cells that have not been genetically
engineered and specifically contemplates various polypeptides
arising from post-translational modifications of the polypeptide
including, but not limited to, acetylation, carboxylation,
glycosylation, phosphorylation, lipidation and acylation.
[0085] The term "translated protein coding portion" means a
sequence which encodes for the full length protein which may
include any leader sequence or a processing sequence.
[0086] The term "dominant mature protein coding sequence" refers to
a sequence which encodes a peptide or protein without any
leader/signal sequence. The "dominant mature protein portion"
refers to that portion of the protein without the leader/signal
sequence. The "mature" form refers to a SCFA2 polypeptide that
lacks the leader/signal sequence and the sequence to the furin
cleavage site. The peptide may have the leader sequence and/or the
furin cleavage site removed during processing in the cell or the
protein may have been produced synthetically or using a
polynucleotide only encoding for the mature protein coding
sequence. It is contemplated that the mature or dominant mature
protein portion may or may not include an initial methionine
residue. The initial methionine is often removed during processing
of the peptide.
[0087] The term "isolated" as used herein refers to a nucleic acid
or polypeptide separated from at least one other component (e.g.,
nucleic acid or polypeptide) present with the nucleic acid or
polypeptide in its natural source. In one embodiment, the nucleic
acid or polypeptide is found in the presence of (if anything) only
a solvent, buffer, ion, or other components normally present in a
solution of the same. The terms "isolated" and "purified" do not
encompass nucleic acids or polypeptides present in their natural
source.
[0088] The term "recombinant," when used herein to refer to a
polypeptide or protein, means that a polypeptide or protein is
derived from recombinant (e.g., microbial, insect, or mammalian)
expression systems. "Microbial" refers to recombinant polypeptides
or proteins made in bacterial or fungal (e.g., yeast) expression
systems. As a product, "recombinant microbial" defines a
polypeptide or protein essentially free of native endogenous
substances and unaccompanied by associated native glycosylation.
Polypeptides or proteins expressed in most bacterial cultures,
e.g., E. coli, will be free of glycosylation modifications;
polypeptides or proteins expressed in yeast will have a
glycosylation pattern in general different from those expressed in
mammalian cells.
[0089] By a "recombinant polypeptide" is intended a polypeptide
which has been prepared by recombinant DNA techniques as described
herein. In general, the gene coding for the desired polypeptide is
cloned and then expressed in transformed organisms, as described
farther below. The host organism expresses the foreign gene to
produce the polypeptide under expression conditions. Alternatively,
the promoter controlling expression of an endogenous polypeptide
can be altered to render a recombinant polypeptide.
[0090] The term "active" refers to those forms of the polypeptide
that retain the biologic and/or immunologic activities of any
naturally occurring polypeptide. According to the invention, the
terms "biologically active" or "biological activity" refer to a
protein or peptide having structural, regulatory or biochemical
functions of a naturally occurring molecule. Likewise "biologically
active" or "biological activity" refers to the capability of the
natural, recombinant or synthetic SCFA2, SCFA4 or SCFA4v peptide,
or any peptide thereof, to induce a specific biological response in
appropriate animals or cells and to bind with specific
antibodies.
[0091] The term "secreted" includes a protein that is transported
across or through a membrane, including transport as a result of
signal sequences in its amino acid sequence when it is expressed in
a suitable host cell. "Secreted" proteins include without
limitation proteins secreted wholly (e.g., soluble proteins) or
partially (e.g., receptors) from the cell in which they are
expressed. "Secreted" proteins also include without limitation
proteins that are transported across the membrane of the
endoplasmic reticulum. "Secreted" proteins are also intended to
include proteins containing non-typical signal sequences (e.g.
Interleukin-1 Beta, see Krasney, P. A. and Young, P. R. (1992)
Cytokine 4(2):134-143) and factors released from damaged cells
(e.g. Interleukin-1 Receptor Antagonist, see Arend, W. P. et. al.
(1998) Annu. Rev. Immunol. 16:27-55)
[0092] The term "polynucleotide" or "nucleic acid molecule" as used
herein refers to a polymeric form of nucleotides of any length,
either ribonucleotides or deoxyribonucleotides. This term refers
only to the primary structure of the molecule and thus includes
double- and single-stranded DNA and RNA. It also includes known
types of modifications, for example, labels which are known in the
art, methylation, "caps", substitution of one or more of the
naturally occurring nucleotides with an analog, internucleotide
modifications such as, for example, those with uncharged linkages
(e.g., methyl phosphonates, phosphotriesters, phosphoamidates,
carbamates, etc.) and with charged linkages (e.g.,
phosphorothioates, phosphorodithioates, etc.), those containing
pendant moieties, such as, for example proteins (including for
e.g., nucleases, toxins, antibodies, signal peptides,
poly-L-lysine, etc.), those with intercalators (e.g., acridine,
psoralen, etc.), those containing chelates (e.g., metals,
radioactive metals, boron, oxidative metals, etc.), those
containing alkylators, those with modified linkages (e.g., alpha
anomeric nucleic acids, etc.), as well as unmodified forms of the
polynucleotide. Generally, nucleic acid segments provided by this
invention may be assembled from fragments of the genome and short
oligonucleotide linkers, or from a series of oligonucleotides, or
from individual nucleotides, to provide a synthetic nucleic acid
which is capable of being expressed in a recombinant
transcriptional unit comprising regulatory elements derived from a
microbial or viral operon, or a eukaryotic gene.
[0093] The terms "oligonucleotide fragment" or a "polynucleotide
fragment", "portion," or "segment" or "probe" or "primer" are used
interchangeably and refer to a sequence of nucleotide residues
which are at least about 5 nucleotides, more preferably at least
about 7 nucleotides, more preferably at least about 9 nucleotides,
more preferably at least about 11 nucleotides and most preferably
at least about 17 nucleotides. The fragment is preferably less than
about 500 nucleotides, preferably less than about 200 nucleotides,
more preferably less than about 100 nucleotides, more preferably
less than about 50 nucleotides and most preferably less than 30
nucleotides. Preferably the probe is from about 6 nucleotides to
about 200 nucleotides, preferably from about 15 to about 50
nucleotides, more preferably from about 17 to 30 nucleotides and
most preferably from about 20 to 25 nucleotides. Preferably the
fragments can be used in polymerase chain reaction (PCR), various
hybridization procedures or microarray procedures to identify or
amplify identical or related parts of mRNA or DNA molecules. A
fragment or segment may uniquely identify each polynucleotide
sequence of the present invention. Preferably the fragment
comprises a sequence substantially similar to a portion of SEQ ID
NO: 1, 2, 4, 5, 7, 9, 11, 13, 15, 16, 18, 20, 22, 24, 25, 35, 39,
43, 50, 52, 53, or 54.
[0094] Probes may, for example, be used to determine whether
specific mRNA molecules are present in a cell or tissue or to
isolate similar nucleic acid sequences from chromosomal DNA as
described by Walsh et al. (Walsh, P. S. et al., 1992, PCR Methods
Appl 1:241-250). They may be labeled by nick translation, Klenow
fill-in reaction, PCR, or other methods well known in the art.
Probes of the present invention, their preparation and/or labeling
are elaborated in Sambrook, J. et al., 1989, Molecular Cloning: A
Laboratory Manual, Cold Spring Harbor Laboratory, NY; or Ausubel,
F. M. et al., 1989, Current Protocols in Molecular Biology, John
Wiley & Sons, New York N.Y., both of which are incorporated
herein by reference in their entirety.
[0095] The nucleic acid sequences of the present invention also
include the sequence information from any of the nucleic acid
sequences of SEQ ID NO: 1, 2, 4, 5, 7, 9, 11, 13, 15, 16, 18, 20,
22, 24, 25, 35, 39, 43, 50, 52, 53, or 54. The sequence information
can be a segment of SEQ ID NO: 1, 2, 4, 5, 7, 9, 11, 13, 15, 16,
18, 20, 22, 24, 25, 35, 39, 43, 50, 52, 53, or 54 that uniquely
identifies or represents the sequence information of SEQ ID NO: 1,
2, 4, 5, 7, 9, 11, 13, 15, 16, 18, 20, 22, 24, 25, 35, 39, 43, 50,
52, 53, or 54. One such segment can be a twenty-mer nucleic acid
sequence because the probability that a twenty-mer is fully matched
in the human genome is 1 in 300. In the human genome, there are
three billion base pairs in one set of chromosomes. Because
4.sup.20 possible twenty-mers exist, there are 300 times more
twenty-mers than there are base pairs in a set of human
chromosomes. Using the same analysis, the probability for a
seventeen-mer to be fully matched in the human genome is
approximately 1 in 5. When these segments are used in arrays for
expression studies, fifteen-mer segments can be used. The
probability that the fifteen-mer is fully matched in the expressed
sequences is also approximately one in five because expressed
sequences comprise less than approximately 5% of the entire genome
sequence.
[0096] Similarly, when using sequence information for detecting a
single mismatch, a segment can be a twenty-five mer. The
probability that the twenty-five mer would appear in a human genome
with a single mismatch is calculated by multiplying the probability
for a full match (1/4.sup.25) times the increased probability for
mismatch at each nucleotide position (3.times.25). The probability
that an eighteen mer with a single mismatch can be detected in an
array for expression studies is approximately one in five. The
probability that a twenty-mer with a single mismatch can be
detected in a human genome is approximately one in five.
[0097] The term "open reading frame (ORF)" means a series of
nucleotide triplets coding for amino acids without any termination
codons and is a sequence translatable into protein.
[0098] The terms "operably linked" or "operably associated" refer
to functionally related nucleic acid sequences. For example, a
promoter is operably associated or operably linked with a coding
sequence if the promoter controls the transcription of the coding
sequence. While operably linked nucleic acid sequences can be
contiguous and in the same reading frame, certain genetic elements
e.g. repressor genes are not contiguously linked to the coding
sequence but still control transcription/translation of the coding
sequence.
[0099] The terms "recombinant DNA molecule," or "recombinant
polynucleotide" are used herein to refer to a polynucleotide of
genomic, cDNA, semisynthetic, or synthetic origin which, by virtue
of its origin or manipulation: (1) is not associated with all or a
portion of a polynucleotide with which it is associated in nature,
(2) is linked to a polynucleotide other than that to which it is
linked in nature, or (3) does not occur in nature. Thus, the term
encompasses "synthetically derived" nucleic acid molecules.
[0100] The terms "complementary" or "complementarity" refer to the
natural binding of polynucleotides by base pairing. For example,
the sequence 5'-AGT-3' binds to the complementary sequence
3'-TCA-5'. Complementarity between two single-stranded molecules
may be "partial" such that only some of the nucleic acids bind or
it may be "complete" such that total complementarity exists between
the single stranded molecules. The degree of complementarity
between the nucleic acid strands has significant effects on the
efficiency and strength of the hybridization between the nucleic
acid strands.
[0101] The term "stringent" is used to refer to conditions that are
commonly understood in the art as stringent. Stringent conditions
can include highly stringent conditions (i.e., hybridization to
filter-bound DNA in 0.5 M NaHPO.sub.4, 7% sodium dodecyl sulfate
(SDS), 1 mM EDTA at 65.degree. C., and washing in
0.1.times.SSC/0.1% SDS at 68.degree. C.), and moderately stringent
conditions (i.e., washing in 0.2.times.SSC/0.1'')/0.1% SDS at
42.degree. C.). Other exemplary hybridization conditions are
described herein in the examples.
[0102] In instances of hybridization of deoxyoligonucleotides,
additional exemplary stringent hybridization conditions include
washing in 6.times.SSC/0.05% sodium pyrophosphate at 37.degree. C.
(for 14-base oligonucleotides), 48.degree. C. (for 17-base
oligonucleotides), 55.degree. C. (for 20-base oligonucleotides),
and 60.degree. C. (for 23-base oligonucleotides).
[0103] As used herein, "substantially equivalent" can refer both to
nucleotide and amino acid sequences, for example a mutant sequence,
that varies from a reference sequence by one or more substitutions,
deletions, or additions, the net effect of which does not result in
an adverse functional dissimilarity between the reference and
subject sequences. Typically, such a substantially equivalent
sequence varies from one of those listed herein by no more than
about 35% (i.e., the number of individual residue substitutions,
additions, and/or deletions in a substantially equivalent sequence,
as compared to the corresponding reference sequence, divided by the
total number of residues in the substantially equivalent sequence
is about 0.35 or less). Such a sequence is said to have 65%
sequence identity to the listed sequence. In one embodiment, a
substantially equivalent, e.g., mutant, sequence of the invention
varies from a listed sequence by no more than 30% (70% sequence
identity); in a variation of this embodiment, by no more than 25%
(75% sequence identity); and in a further variation of this
embodiment, by no more than 20% (80% sequence identity) and in a
further variation of this embodiment, by no more than 10% (90%
sequence identity) and in a further variation of this embodiment,
by no more that 5% (95% sequence identity). Substantially
equivalent, e.g., mutant, amino acid sequences according to the
invention preferably have at least 80% sequence identity with a
listed amino acid sequence, more preferably at least 90% sequence
identity. Substantially equivalent nucleotide sequence of the
invention can have lower percent sequence identities, taking into
account, for example, the redundancy or degeneracy of the genetic
code. Preferably, nucleotide sequence has at least about 65%
identity, more preferably at least about 75% identity, and most
preferably at least about 95% identity. For the purposes of the
present invention, sequences having substantially equivalent
biological activity and substantially equivalent expression
characteristics are considered substantially equivalent. For the
purposes of determining equivalence, truncation of the mature
sequence (e.g., via a mutation which creates a spurious stop codon)
should be disregarded. Sequence identity may be determined, e.g.,
using the Jotun Hein method (Hein, J. (1990) Methods Enzymol.
183:626-645). Identity between sequences can also be determined by
other methods known in the art, e.g. by varying hybridization
conditions.
[0104] The term "vector" refers to a nucleic acid molecule capable
of transporting another nucleic acid to which it has been linked.
The term "expression vector" includes plasmids, cosmids or phages
capable of synthesizing the SCFA2, SCFA4 or SCFA4v protein encoded
by the respective recombinant gene carried by the vector. Preferred
vectors are those capable of autonomous replication and expression
of nucleic acids to which they are linked.
[0105] The term "transformation" means introducing DNA into a
suitable host cell so that the DNA is replicable, either as an
extrachromosomal element, or by chromosomal integration.
[0106] The term "transfection" refers to the taking up of an
expression vector by a suitable host cell, whether or not any
coding sequences are in fact expressed. The term "infection" refers
to the introduction of nucleic acids into a suitable host cell by
use of a virus or viral vector.
[0107] The term "transcriptional regulatory elements" and
transcriptional regulatory sequences" are used interchangeably to
refer to DNA sequences necessary for the expression of an operably
linked coding sequence in a particular organism. The control
sequences that are suitable for prokaryotes, for example, include a
promoter, optionally an operator sequence, and a ribosome binding
site. Eukaryotic cells are known to utilize promoters, enhancers,
splicing signals and polyadenylation signals. These terms are
intended to encompass all elements that promote or regulate
transcription, including promoters, core elements required for
basic interaction of RNA polymerase and transcription factors,
upstream elements, enhancers, and response elements (Lewin, "Genes
V" (Oxford University Press, Oxford) pages 847-873).
[0108] A coding sequence is "under the control" of transcriptional
and translational control sequences in a cell when RNA polymerase
transcribes the coding sequence into mRNA, which is then optionally
trans-RNA spliced and translated into the protein encoded by the
coding sequence.
[0109] The term "expression modulating fragment (EMF)" means a
series of nucleotides that modulates the expression of an operably
linked ORF or another EMF.
[0110] As used herein, a sequence is said to "modulate the
expression of an operably linked sequence" when the expression of
the sequence is altered by the presence of the EMF. EMFs include,
but are not limited to, promoters, and promoter modulating
sequences (inducible elements). One class of EMFs is nucleic acid
fragments which induce the expression of an operably linked ORF in
response to a specific regulatory factor or physiological
event.
[0111] The term "recombinant expression vehicle or vector" refers
to a plasmid or phage or virus or vector, for expressing a
polypeptide from a DNA (RNA) sequence. An expression vehicle can
comprise a transcriptional unit comprising an assembly of (1) a
genetic element or elements having a regulatory role in gene
expression, for example, promoters or enhancers, (2) a structural
or coding sequence which is transcribed into mRNA and translated
into protein, and (3) appropriate transcription initiation and
termination sequences. Structural units intended for use in yeast
or eukaryotic expression systems preferably include a leader
sequence enabling extracellular secretion of translated protein by
a host cell. Alternatively, where recombinant protein is expressed
without a leader or transport sequence, it may include an amino
terminal methionine residue. This residue may or may not be
subsequently cleaved from the expressed recombinant protein to
provide a final product.
[0112] The term "recombinant expression system" means host cells
which have stably integrated a recombinant transcriptional unit
into chromosomal DNA or carry the recombinant transcriptional unit
extrachromosomally. Recombinant expression systems as defined
herein will express heterologous polypeptides or proteins upon
induction of the regulatory elements linked to the DNA segment or
synthetic gene to be expressed. This term also means host cells
which have stably integrated a recombinant genetic element or
elements having a regulatory role in gene expression, for example,
promoters or enhancers. Recombinant expression systems as defined
herein will express polypeptides or proteins endogenous to the cell
upon induction of the regulatory elements linked to the endogenous
DNA segment or gene to be expressed. The cells can be prokaryotic
or eukaryotic.
[0113] The term "pluripotent" refers to the capability of a cell to
differentiate into a number of differentiated cell types that are
present in an adult organism. A pluripotent cell is restricted in
its differentiation capability in comparison to a totipotent
cell.
[0114] The term "non-human mammal" refers to all members of the
class Mammalia except humans. "Mammal" refers to any animal
classified as a mammal, including humans, domestic and farm
animals, and zoo, sports, or pet animals, such as a mouse, rat,
rabbit, pig, sheep, goat, cattle and higher primates.
[0115] The terms "treat" or "treatment" refer to both therapeutic
and prophylactic or preventative measures, wherein the object is to
prevent or lessen an undesired physiological change or condition,
such as chemotherapy or radiation therapy-induced mucositis. For
the purposes of this invention, beneficial or desired clinical
results include, but are not limited to alleviation of symptoms,
diminishment of extent of the disease, stabilized state of the
disease, whether detectable or undetectable.
[0116] A "disorder" is any condition that would benefit from
treatment with a molecule identified using the transgenic animal
model of the invention. This includes chronic and acute disorders
or diseases including those pathological conditions which
predispose the mammal to the disorder in question. Non-limiting
examples of disorders to be treated herein include mucositis,
inflammatory bowel disease and skin lesions. A preferred disorder
to be treated in accordance with the present invention is
mucositis.
[0117] "Inflammatory bowel disease (IBD)" herein refers to
idiopathic or chronic inflammatory disease of either or both the
small intestine and large bowel, and includes Crohn's disease,
ulcerative colitis, IBD caused by infectious agents, and antibiotic
associated IBD.
[0118] "Mucositis" herein refers to inflammation of the mucous
membranes of the alimentary tract including the oropharynx and
lips, esophagus, and large and small intestine.
[0119] "Short Bowel Syndrome" or "SBS" herein refers to a condition
of nutritional malabsorption resulting from anatomical or
functional loss of a significant length of the small intestine.
[0120] The terms "effective amount" or "pharmaceutically effective
amount" refer to a nontoxic but sufficient amount of the agent to
provide the desired biological result. That result can be reduction
and/or alleviation of the signs, symptoms, or causes of a disease,
or any other desired alteration of a biological system. For
example, an effective amount of a SCFA2, SCFA4 or SCFA4v fragment
for use with the present methods is an amount sufficient to
stimulate epithelial cell stimulation or proliferation, and
preferably an amount sufficient to cause increased regeneration of
the gastrointestinal epithelium in a subject suffering from
chemotherapy or radiation therapy-induced mucositis, inflammatory
bowel disease, or other disorders where epithelial cell
proliferation is desired. Such amounts are described below. An
appropriate "effective" amount in any individual case may be
determined by one of ordinary skill in the art using routine
experimentation.
[0121] By "pharmaceutically acceptable" or "pharmacologically
acceptable" is meant a material which is not biologically or
otherwise undesirable, i.e., the material may be administered to an
individual without causing any undesirable biological effects or
interacting in a deleterious manner with any of the components of
the composition in which it is contained.
[0122] By "physiological pH" or a "pH in the physiological range"
is meant a pH in the range of approximately 7.0 to 8.0 inclusive.
Preferred physiological pH is in the range of approximately 7.2 to
7.6 inclusive.
[0123] As used herein, the term "subject" encompasses mammals and
non-mammals. Examples of mammals include, but are not limited to,
any member of the Mammalia class: humans, non-human primates such
as chimpanzees, and other apes and monkey species; farm animals
such as cattle, horses, sheep, goats, swine; domestic animals such
as rabbits, dogs, and cats; laboratory animals including rodents,
such as rats, mice and guinea pigs, and the like. Examples of
non-mammals include, but are not limited to, birds, fish and the
like. The term does not denote a particular age or gender.
4.2 COMPOSITIONS OF THE INVENTION
[0124] 4.2.1 Nucleic Acid Compositions
[0125] The invention is based on the discovery that compositions
comprising the epithelial cell growth factor polypeptide, SCFA2,
SCFA4 or SCFA4v, and the polynucleotides encoding the SCFA2, SCFA4
or SCFA4v polypeptide stimulate the growth and proliferation of
intestinal epithelial cells including crypt cells. Therefore, the
use of these compositions for the diagnosis and treatment of
conditions wherein stimulation of epithelial cell proliferation or
regeneration is desired is contemplated. The isolated
polynucleotides of the invention include, but are not limited to a
polynucleotide comprising any of the nucleotide sequences of SEQ ID
NO: 1, 2, 4, 5, 7, 9, 11, 13, 15, 16, 18, 20, 22, 24, 25, 35, 39,
43, 50, 52, 53, or 54; a polynucleotide comprising the full length
protein coding sequence of SEQ ID NO: 2, 4, 13, 15, 22 or 24; (for
example coding for SEQ ID NO: 3, 14, or 23); and a polynucleotide
comprising the nucleotide sequence encoding the mature and dominant
mature protein coding sequence of the polypeptide of SEQ ID NO: 5.
The polynucleotides of the present invention also include, but are
not limited to, a polynucleotide that hybridizes under stringent
conditions to (a) the complement of any of the nucleotides
sequences of SEQ ID NO: 1, 2, 4, 5, 7, 9, 11, 13, 15, 16, 18, 20,
22, 24, 25, 35, 39, 43, 50, 52, 53, or 54; (b) a polynucleotide
encoding any one of the polypeptides of SEQ ID NO: 3, 6, 8, 10, 12,
14, 17, 19, 21, 23, 26, 36, 40, 44, 51, or 55; (c) a polynucleotide
which is an allelic variant of any polynucleotides recited above;
(d) a polynucleotide which encodes a species homolog of any of the
proteins recited above; or (e) a polynucleotide that encodes a
polypeptide comprising a specific domain or truncation of the
polypeptides of SEQ ID NO3, 6, 8, 10, 12, 14, 17, 19, 21, 23, 26,
36, 40, or 44. Domains of interest include extracellular,
transmembrane, or cytoplasmic domains, or combinations thereof; and
catalytic and substrate binding domains.
[0126] The polynucleotides of the invention include naturally
occurring or wholly or partially synthetic DNA, e.g., cDNA and
genomic DNA, and RNA, e.g., mRNA. The polynucleotides may include
all of the coding region of the cDNA or may represent a portion of
the coding region of the cDNA.
[0127] The present invention also provides compositions comprising
genes corresponding to the cDNA sequences disclosed herein. The
corresponding genes can be isolated in accordance with known
methods using the sequence information disclosed herein. Such
methods include the preparation of probes or primers from the
disclosed sequence information for identification and/or
amplification of genes in appropriate genomic libraries or other
sources of genomic materials. Further 5' and 3' sequence can be
obtained using methods known in the art. For example, full length
cDNA or genomic DNA that corresponds to any of the polynucleotide
of SEQ ID NO: 2, 13 or 22 can be obtained by screening appropriate
cDNA or genomic DNA libraries under suitable hybridization
conditions using any of the polynucleotides of SEQ ID NO: 1, 2, 4,
5, 7, 9, 11, 13, 15, 16, 18, 20, 22, 24, 25, 35, 39, 43, 50, 52,
53, or 54 or a portion thereof as a probe. Alternatively, the
polynucleotides of SEQ ID NO: 1, 2, 4, 5, 7, 9, 11, 13, 15, 16, 18,
20, 22, 24, 25, 35, 39, 43, 50, 52, 53, or 54 may be used as the
basis for suitable primer(s) that allow identification and/or
amplification of genes in appropriate genomic DNA or cDNA
libraries.
[0128] The nucleic acid sequences of the invention can be assembled
from ESTs and sequences (including cDNA and genomic sequences)
obtained from one or more public databases, such as dbEST, gbpri,
and UniGene. The EST sequences can provide identifying sequence
information, representative fragment or segment information, or
novel segment information for the full-length gene.
[0129] The polynucleotides of the invention also provide
polynucleotides including nucleotide sequences that are
substantially equivalent to the polynucleotides recited above.
Polynucleotides according to the invention can have, e.g., at least
about 65%, at least about 70%, at least about 75%, at least about
80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more typically
at least about 90%, 91%, 92%, 93%, or 94% and even more typically
at least about 95%, 96%, 97%, 98% or 99% sequence identity to a
polynucleotide recited above.
[0130] Included within the scope of the nucleic acid sequences of
the invention are nucleic acid sequence fragments that hybridize
under stringent conditions to any of the nucleotide sequences of
SEQ ID NO: 1, 2, 4, 5, 7, 9, 11, 13, 15, 16, 18, 20, 22, 24, 25,
35, 39, 43, 50, 52, 53, or 54, or complements thereof, which
fragment is greater than about 5 nucleotides, preferably 7
nucleotides, more preferably greater than 9 nucleotides and most
preferably greater than 17 nucleotides. Fragments of, e.g. 15, 17,
or 20 nucleotides or more that are selective for (i.e. specifically
hybridize to any one of the polynucleotides of the invention) are
contemplated. Probes capable of specifically hybridizing to a
polynucleotide can differentiate polynucleotide sequences of the
invention from other polynucleotide sequences in the same family of
genes or can differentiate human genes from genes of other species,
and are preferably based on unique nucleotide sequences.
[0131] The sequences falling within the scope of the present
invention are not limited to these specific sequences, but also
include allelic and species variations thereof. Allelic and species
variations can be routinely determined by comparing the sequence
provided in SEQ ID NO: 1, 2, 4, 5, 7, 9, 11, 13, 15, 16, 18, 20,
22, 24, 25, 35, 39, 43, 50, 52, 53, or 54, a representative
fragment thereof, or a nucleotide sequence at least 90% identical,
preferably 95% identical, to SEQ ID NO: 1, 2, 4, 5, 7, 9, 11, 13,
15, 16, 18, 20, 22, 24, 25, 35, 39, 43, 50, 52, 53, or 54 with a
sequence from another isolate of the same species. Furthermore, to
accommodate codon variability, the invention includes nucleic acid
molecules coding for the same amino acid sequences as do the
specific ORFs disclosed herein. In other words, in the coding
region of an ORF, substitution of one codon for another codon that
encodes the same amino acid is expressly contemplated.
[0132] The nearest neighbor result for the nucleic acids of the
present invention can be obtained by searching a database using an
algorithm or a program. Preferably, a BLAST which stands for Basic
Local Alignment Search Tool is used to search for local sequence
alignments (Altshul, S. F. J. Mol. Evol. 36 290-300 (1993) and
Altschul S. F. et al. J. Mol. Biol. 21:403-410 (1990)).
[0133] Species homologs (or orthologs) of the disclosed
polynucleotides and proteins are also provided by the present
invention. Species homologs may be isolated and identified by
making suitable probes or primers from the sequences provided
herein and screening a suitable nucleic acid source from the
desired species.
[0134] The invention also encompasses allelic variants of the
disclosed polynucleotides or proteins; that is, naturally-occurring
alternative forms of the isolated polynucleotide which also encodes
proteins which are identical, homologous or related to that encoded
by the polynucleotides.
[0135] The nucleic acid sequences of the invention are further
directed to sequences which encode analogs of the described nucleic
acids. These amino acid sequence analogs may be prepared by methods
known in the art by introducing appropriate nucleotide changes into
a native or variant polynucleotide. There are two variables in the
construction of amino acid sequence variants: the location of the
mutation and the nature of the mutation. Nucleic acids encoding the
amino acid sequence analogs are preferably constructed by mutating
the polynucleotide to encode an amino acid sequence that does not
occur in nature. These nucleic acid alterations can be made at
sites that differ in the nucleic acids from different species
(variable positions) or in highly conserved regions (constant
regions). Sites at such locations will typically be modified in
series, e.g., by substituting first with conservative choices
(e.g., hydrophobic amino acid to a different hydrophobic amino
acid) and then with more distant choices (e.g., hydrophobic amino
acid to a charged amino acid), and then deletions or insertions may
be made at the target site. Amino acid sequence deletions generally
range from about 1 to 30 residues, preferably about 1 to 10
residues, and are typically contiguous. Amino acid insertions
include amino- and/or carboxyl-terminal fusions ranging in length
from one to one hundred or more residues, as well as intrasequence
insertions of single or multiple amino acid residues. Intrasequence
insertions may range generally from about 1 to 10 amino residues,
preferably from 1 to 5 residues. Examples of terminal insertions
include the heterologous signal sequences necessary for secretion
or for intracellular targeting in different host cells and
sequences such as poly-histidine sequences useful for purifying the
expressed protein.
[0136] In a preferred method, polynucleotides encoding the novel
amino acid sequences are changed via site-directed mutagenesis.
This method uses oligonucleotide sequences to alter a
polynucleotide to encode the desired amino acid variant, as well as
sufficient adjacent nucleotides on both sides of the changed amino
acid to form a stable duplex on either side of the site being
changed. In general, the techniques of site-directed mutagenesis
are well known to those of skill in the art and this technique is
exemplified by publications such as, Edelman et al., DNA 2:183
(1983). A versatile and efficient method for producing
site-specific changes in a polynucleotide sequence was published by
Zoller and Smith, Nucleic Acids Res. 10:6487-6500 (1982). PCR may
also be used to create amino acid sequence variants of the novel
nucleic acids. When small amounts of template DNA are used as
starting material, primer(s) that differs slightly in sequence from
the corresponding region in the template DNA can generate the
desired amino acid variant. PCR amplification results in a
population of product DNA fragments that differ from the
polynucleotide template encoding the polypeptide at the position
specified by the primer. The product DNA fragments replace the
corresponding region in the plasmid and this gives a polynucleotide
encoding the desired amino acid variant.
[0137] A further technique for generating amino acid variants is
the cassette mutagenesis technique described in Wells et al., Gene
34:315 (1985); and other mutagenesis techniques well known in the
art, such as, for example, the techniques in Sambrook et al.,
supra, and Current Protocols in Molecular Biology, Ausubel et al.
Due to the inherent degeneracy of the genetic code, other DNA
sequences which encode substantially the same or a functionally
equivalent amino acid sequence may be used in the practice of the
invention for the cloning and expression of these novel nucleic
acids. Such DNA sequences include those which are capable of
hybridizing to the appropriate novel nucleic acid sequence under
stringent conditions.
[0138] Polynucleotides encoding preferred polypeptide truncations
of the invention can be used to generate polynucleotides encoding
chimeric or fusion proteins comprising one or more domains of the
invention and heterologous protein sequences.
[0139] The polynucleotides of the invention additionally include
the complement of any of the polynucleotides recited above. The
polynucleotide can be DNA (genomic, cDNA, amplified, or synthetic)
or RNA. Methods and algorithms for obtaining such polynucleotides
are well known to those of skill in the art and can include, for
example, methods for determining hybridization conditions that can
routinely isolate polynucleotides of the desired sequence
identities.
[0140] In accordance with the invention, polynucleotide sequences
comprising the dominant mature or mature protein coding sequences,
coding for any one of SEQ ID NO: 6, 8, 17 or 26, or functional
equivalents thereof, may be used to generate recombinant DNA
molecules that direct the expression of that nucleic acid, or a
functional equivalent thereof, in appropriate host cells. Also
included are the cDNA inserts of any of the clones identified
herein.
[0141] A polynucleotide according to the invention can be joined to
any of a variety of other nucleotide sequences by well-established
recombinant DNA techniques (see Sambrook J et al. (1989) Molecular
Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, NY).
Useful nucleotide sequences for joining to polynucleotides include
an assortment of vectors, e.g., plasmids, cosmids, lambda phage
derivatives, phagemids, and the like, that are well known in the
art. Accordingly, the invention also provides a vector including a
polynucleotide of the invention and a host cell containing the
polynucleotide. In general, the vector contains an origin of
replication functional in at least one organism, convenient
restriction endonuclease sites, and a selectable marker for the
host cell. Vectors according to the invention include expression
vectors, replication vectors, probe generation vectors, and
sequencing vectors. A host cell according to the invention can be a
prokaryotic or eukaryotic cell and can be a unicellular organism or
part of a multicellular organism.
[0142] The present invention further provides recombinant
constructs comprising a nucleic acid having any of the nucleotide
sequences of SEQ ID NO: 1, 2, 4, 5, 7, 9, 11, 13, 15, 16, 18, 20,
22, 24, 25, 35, 39, 43, 50, 52, 53, or 54 or a fragment thereof or
any other SCFA2, SCFA4 or SCFA4v polynucleotides. In one
embodiment, the recombinant constructs of the present invention
comprise a vector, such as a plasmid or viral vector, into which a
nucleic acid having any of the nucleotide sequences of SEQ ID NO:
1, 2, 4, 5, 7, 9, 11, 13, 15, 16, 18, 20, 22, 24, 25, 35, 39, 43,
50, 52, 53, or 54 or a fragment thereof is inserted. In the case of
a vector comprising one of the ORFs of the present invention, the
vector may further comprise regulatory sequences, including for
example, a promoter, operably linked to the ORF. Large numbers of
suitable vectors and promoters are known to those of skill in the
art and are commercially available for generating the recombinant
constructs of the present invention. The following vectors are
provided by way of example. Bacterial: pBs, phagescript, PsiX174,
pBluescript SK, pBs KS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene);
pTrc99A, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia). Eukaryotic:
pWLneo, pSV2cat, pOG44, PXTI, pSG (Stratagene) pSVK3, pBPV, pMSG,
and pSVL (Pharmacia).
[0143] The isolated polynucleotide of the invention may be operably
linked to an expression control sequence such as the pMT2 or pED
expression vectors disclosed in Kaufman et al., Nucleic Acids Res.
19, 4485-4490 (1991), in order to produce the protein
recombinantly. Many suitable expression control sequences are known
in the art. General methods of expressing recombinant proteins are
also known and are exemplified in R. Kaufman, Methods in Enzymology
185, 537-566 (1990). As defined herein "operably linked" means that
the isolated polynucleotide of the invention and an expression
control sequence are situated within a vector or cell in such a way
that the protein is expressed by a host cell which has been
transformed (transfected) with the ligated
polynucleotide/expression control sequence.
[0144] Promoter regions can be selected from any desired gene using
CAT (chloramphenicol transferase) vectors or other vectors with
selectable markers. Two appropriate vectors are pKK232-8 and pCM7.
Particular named bacterial promoters include lacI, lacZ, T3, T7,
gpt, lambda PR, and trc. Eukaryotic promoters include CMV immediate
early, HSV thymidine kinase, early and late SV40, LTRs from
retrovirus, and mouse metallothionein-I. Selection of the
appropriate vector and promoter is well within the level of
ordinary skill in the art. Generally, recombinant expression
vectors will include origins of replication and selectable markers
permitting transformation of the host cell, e.g., the ampicillin
resistance gene of E. coli and S. cerevisiae TRP1 gene, and a
promoter derived from a highly expressed gene to direct
transcription of a downstream structural sequence. Such promoters
can be derived from operons encoding glycolytic enzymes such as
3-phosphoglycerate kinase (PGK), a-factor, acid phosphatase, or
heat shock proteins, among others. The heterologous structural
sequence is assembled in appropriate phase with translation
initiation and termination sequences, and preferably, a leader
sequence capable of directing secretion of translated protein into
the periplasmic space or extracellular medium. Optionally, the
heterologous sequence can encode a fusion protein including an
amino terminal identification peptide imparting desired
characteristics, e.g., stabilization or simplified purification of
expressed recombinant product. Useful expression vectors for
bacterial use are constructed by inserting a structural DNA
sequence encoding a desired protein together with suitable
translation initiation and termination signals in operable reading
phase with a functional promoter. The vector will comprise one or
more phenotypic selectable markers and an origin of replication to
ensure maintenance of the vector and to, if desirable, provide
amplification within the host. Suitable prokaryotic hosts for
transformation include E. coli, Bacillus subtilis, Salmonella
typhimurium and various species within the genera Pseudomonas,
Streptomyces, and Staphylococcus, although others may also be
employed as a matter of choice.
[0145] As a representative but non-limiting example, useful
expression vectors for bacterial use can comprise a selectable
marker and bacterial origin of replication derived from
commercially available plasmids comprising genetic elements of the
well known cloning vector pBR322 (ATCC 37017). Such commercial
vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals,
Uppsala, Sweden) and GEM 1 (Promega Biotech, Madison, Wis., USA).
These pBR322 "backbone" sections are combined with an appropriate
promoter and the structural sequence to be expressed. Following
transformation of a suitable host strain and growth of the host
strain to an appropriate cell density, the selected promoter is
induced or derepressed by appropriate means (e.g., temperature
shift or chemical induction) and cells are cultured for an
additional period. Cells are typically harvested by centrifugation,
disrupted by physical or chemical means, and the resulting crude
extract retained for further purification.
[0146] In addition to the use of expression vectors in the practice
of the present invention, the present invention further includes
novel expression vectors comprising promoter elements operatively
linked to polynucleotide sequences encoding a protein of
interest.
[0147] 4.2.2 Hosts
[0148] The present invention further provides host cells
genetically engineered with the vectors of this invention, which
may be, for example, a cloning vector or an expression vector that
contain the polynucleotides of the invention. For example, such
host cells may contain nucleic acids of the invention introduced
into the host cell using known transformation, transfection or
infection methods. The vector may be, for example, in the form of a
plasmid, a viral particle, a phage etc. The engineered host cells
can be cultured in conventional nutrient media modified as
appropriate for activating promoters, selecting transformants or
amplifying SCFA2, SCFA4 or SCFA4v genes. The culture conditions,
such as temperature, pH, and the like, are those previously used
with the host cell selected for expression, and will be apparent to
the ordinarily skilled artisan. The present invention still further
provides host cells genetically engineered to express the
polynucleotides of the invention, wherein such polynucleotides are
in operative association with a regulatory sequence heterologous to
the host cell which drives expression of the polynucleotides in the
cell.
[0149] The host cell can be a higher eukaryotic host cell, such as
a mammalian cell, a lower eukaryotic host cell, such as a yeast
cell, or the host cell can be a prokaryotic cell, such as a
bacterial cell. Introduction of the recombinant construct into the
host cell can be effected by calcium phosphate transfection, DEAE,
dextran mediated transfection, or electroporation (Davis, L. et
al., Basic Methods in Molecular Biology (1986)). The host cells
containing one of polynucleotides of the invention, can be used in
conventional manners to produce the gene product encoded by the
isolated fragment (in the case of an ORF) or can be used to produce
a heterologous protein under the control of the EMF.
[0150] Any host/vector system can be used to express one or more of
the SCFA2, SCFA4 or SCFA4v polypeptides. These include, but are not
limited to, eukaryotic hosts such as HeLa cells, Cv-1 cell, COS
cells, and Sf9 cells, as well as prokaryotic host such as E. coli
and B. subtilis. The most preferred cells are those which do not
normally express the particular polypeptide or protein or which
expresses the polypeptide or protein at low natural level. Mature
proteins can be expressed in mammalian cells, yeast, bacteria, or
other cells under the control of appropriate promoters. Cell-free
translation systems can also be employed to produce such proteins
using RNAs derived from the DNA constructs of the present
invention. Appropriate cloning and expression vectors for use with
prokaryotic and eukaryotic hosts are described by Sambrook, et al.,
in Molecular Cloning: A Laboratory Manual, Second Edition, Cold
Spring Harbor, N.Y. (1989), the disclosure of which is hereby
incorporated by reference.
[0151] Various mammalian cell culture systems can be employed to
express recombinant protein. Examples of mammalian expression
systems include the COS-7 lines of monkey kidney fibroblasts,
described by Gluzman, Cell 23:175 (1981), and other cell lines
capable of expressing a compatible vector, for example, the C127,
3T3, CHO, HeLa and BHK cell tines. Mammalian expression vectors
will comprise an origin of replication, a suitable promoter, and
also any necessary ribosome binding sites, polyadenylation site,
splice donor and acceptor sites, transcriptional termination
sequences, and 5' flanking nontranscribed sequences. DNA sequences
derived from the SV40 viral genome, for example, SV40 origin, early
promoter, enhancer, splice, and polyadenylation sites may be used
to provide the required nontranscribed genetic elements.
Recombinant polypeptides and proteins produced in bacterial culture
are usually isolated by initial extraction from cell pellets,
followed by one or more salting-out, aqueous ion exchange or size
exclusion chromatography steps. Protein refolding steps can be
used, as necessary, in completing configuration of the mature
protein. Finally, high performance liquid chromatography (HPLC) can
be employed for final purification steps. Microbial cells employed
in expression of proteins can be disrupted by any convenient
method, including freeze-thaw cycling, sonication, mechanical
disruption, or use of cell lysing agents.
[0152] A number of types of cells may act as suitable host cells
for expression of the protein. Mammalian host cells include, for
example, monkey COS cells, human epidermal A431 cells, human
Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate
cell lines, normal diploid cells, cell strains derived from in
vitro culture of primary tissue, primary explants, HeLa cells,
mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells. Preferably,
SCFA2, SCFA4 or SCFA4v proteins are expressed in Chinese Hamster
Ovary (CHO) cells, and human embryonic kidney 293 (HEK293)
cells.
[0153] Alternatively, it may be possible to produce the protein in
lower eukaryotes such as yeast or in prokaryotes such as bacteria.
Potentially suitable yeast strains include Saccharomyces
cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains,
Candida, Pichia pastoris or any yeast strain capable of expressing
heterologous proteins. Potentially suitable bacterial strains
include Escherichia coli, Bacillus subtilis, Salmonella
typhimurium, or any bacterial strain capable of expressing
heterologous proteins. If the protein is made in yeast or bacteria,
it may be necessary to modify the protein produced therein, for
example by phosphorylation or glycosylation of the appropriate
sites, in order to obtain the functional protein. Such covalent
attachments may be accomplished using known chemical or enzymatic
methods.
[0154] 4.2.3 Chimeric and Fusion Proteins
[0155] The invention also provides SCFA2, SCFA4 or SCFA4v chimeric
or fusion proteins. As used herein, a SCFA2, SCFA4 or SCFA4v
"chimeric protein" or "fusion protein" comprises a SCFA2, SCFA4 or
SCFA4v polypeptide operatively-linked to a non-SCFA2, SCFA4 or
SCFA4v polypeptide. A "SCFA2, SCFA4 or SCFA4v polypeptide" refers
to a polypeptide having an amino acid sequence corresponding to a
SCFA2, SCFA4 or SCFA4v protein, whereas a "non-SCFA2, SCFA4 or
SCFA4v polypeptide" refers to a polypeptide having an amino acid
sequence corresponding to a protein that is not substantially
homologous to the SCFA2, SCFA4 or SCFA4v protein, e.g., a protein
that is different from the SCFA2, SCFA4 or SCFA4v protein and that
is derived from the same or a different organism. Within a SCFA2,
SCFA4 or SCFA4v fusion protein the SCFA2, SCFA4 or SCFA4v
polypeptide can correspond to all or a portion of a SCFA2, SCFA4 or
SCFA4v protein. In one embodiment, a SCFA2, SCFA4 or SCFA4v fusion
protein comprises at least one biologically active portion of a
SCFA2, SCFA4 or SCFA4v protein. In another embodiment, a SCFA2,
SCFA4 or SCFA4v fusion protein comprises at least two biologically
active portions of a SCFA2, SCFA4 or SCFA4v protein. In yet another
embodiment, a SCFA2, SCFA4 or SCFA4v fusion protein comprises at
least three biologically active portions of a SCFA2, SCFA4 or
SCFA4v protein. Within the fusion protein, the term
"operatively-linked" is intended to indicate that the SCFA2, SCFA4
or SCFA4v polypeptide and the non-SCFA2, SCFA4 or SCFA4v
polypeptide are fused in-frame with one another. The non-SCFA2,
SCFA4 or SCFA4v polypeptide can be fused to the N-terminus or
C-terminus of the SCFA2, SCFA4 or SCFA4v polypeptide.
[0156] In one embodiment, the fusion protein is a GST SCFA2, SCFA4
or SCFA4v fusion protein in which the SCFA2, SCFA4 or SCFA4v
sequences are fused to the C-terminus of the GST (glutathione
S-transferase) sequences. Such fusion proteins can facilitate the
purification of recombinant SCFA2, SCFA4 or SCFA4v polypeptides.
Preferably, the SCFA2, SCFA4 or SCFA4v polypeptide is fused with a
V5-His tag for easy detection with an anti-V5 antibody and for
rapid purification as described in the examples. SEQ ID NO: 36, 40,
44, and 55 which are encoded by the polynucleotides of SEQ ID NO:
35, 39, 43, and 54, respectively, represent SCFA2, SCFA2.DELTA.C,
SCFA4 and SCFA4v fusion proteins that have a V5-His6 tag.
[0157] In another embodiment, the fusion protein is a SCFA2, SCFA4
or SCFA4v protein containing a heterologous signal sequence at its
N-terminus. In certain host cells (e.g., mammalian host cells),
expression and/or secretion of SCFA2, SCFA4 or SCFA4v can be
increased through use of a heterologous signal sequence. For
example the signal sequence of SCFA2, SCFA4 or SCFA4v can be
replaced with the signal sequence from the VJ2-C region of the
mouse IgKappa (Ig.kappa.) chain. For example SEQ ID NO: 36, 40, 44,
and 55 which are encoded by the polynucleotides of SEQ ID NO: 35,
39, 43, and 54, respectively, contain an Ig.kappa. signal sequence.
The polynucleotides of SEQ ID NO: 35, 39, 43, and 54, which encode
the fusion proteins of SEQ ID NO: 36, 40, 44, and 55 were used as
described in the examples to express SCFA2, SCFA2.DELTA.C, SCFA4
and SCFA4v in vivo and determine the biological activity of the
polypeptides. A SCFA2, SCFA2.DELTA.C, SCFA4 or SCFA4v chimeric or
fusion protein of the invention can be produced by standard
recombinant DNA techniques. For example, DNA fragments coding for
the different polypeptide sequences are ligated together in-frame
in accordance with conventional techniques, e.g., by employing
blunt-ended or stagger-ended termini for ligation, restriction
enzyme digestion to provide for appropriate termini, filling-in of
cohesive ends as appropriate, alkaline phosphatase treatment to
avoid undesirable joining, and enzymatic ligation. In another
embodiment, the fusion gene can be synthesized by conventional
techniques including automated DNA synthesizers. Alternatively, PCR
amplification of gene fragments can be carried out using anchor
primers that give rise to complementary overhangs between two
consecutive gene fragments that can subsequently be annealed and
reamplified to generate a chimeric gene sequence (see, e.g.,
Ausubel, et al. (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John
Wiley & Sons, 1992). Moreover, many expression vectors are
commercially available that already encode a fusion moiety (e.g., a
GST polypeptide). A SCFA2, SCFA4 or SCFA4v-encoding nucleic acid
can be cloned into such an expression vector such that the fusion
moiety is linked in-frame to SCFA2, SCFA4 or SCFA4v protein.
[0158] 4.2.4 Polypeptide Compositions
[0159] The pharmaceutical compositions of the invention comprise
isolated SCFA2, SCFA4 or SCFA4v polypeptides that include, but are
not limited to, a polypeptide comprising: the amino acid sequence
set forth as any one of SEQ ID NO: 3, 6, 8, 10, 12, 14, 17, 19, 21,
23, 26, 36, 40, 44, 51, or 55, or an amino acid sequence encoded by
any one of the nucleotide sequences SEQ ID NO: 1, 2, 4, 5, 7, 9,
11, 13, 15, 16, 18, 20, 22, 24, 25, 35, 39, 43, 50, 52, 53, or 54.
Polypeptides of the invention also include polypeptides preferably
with biological or immunological activity that are encoded by: (a)
a polynucleotide having any one of the nucleotide sequences set
forth in SEQ ID NO: 1, 2, 4, 5, 7, 9, 11, 13, 15, 16, 18, 20, 22,
24, 25, 35, 39, 43, 50, 52, 53, or 54; or (b) polynucleotides
encoding any one of the amino acid sequences set forth as SEQ ID
NO: 3, 6, 8, 10, 12, 14, 17, 19, 21, 23, 26, 36, 40, 44, 51, or 55
or (c) polynucleotides that hybridize to the complement of the
polynucleotides of either (a) or (b) under stringent hybridization
conditions. The invention also provides biologically active or
immunologically active variants of any of the amino acid sequences
set forth as SEQ ID NO: 3, 6, 8, 10, 12, 14, 17, 19, 21, 23, 26,
36, 40, 44, 51, or 55; and "substantial equivalents" thereof (e.g.,
with at least about 65%, at least about 70%, at least about 75%, at
least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%,
more typically at least about 90%, 91%, 92%, 93%, or 94% and even
more typically at least about 95%, 96%, 97%, 98% or 99%, most
typically at least about 99% amino acid identity) that retain
biological activity. Polypeptides encoded by allelic variants may
have a similar, increased, or decreased activity compared to
polypeptides comprising SEQ ID NO: 3, 6, 8, 10, 12, 14, 17, 19, 21,
23, 26, 36, 40, 44, 51, or 55.
[0160] Fragments of the proteins of the present invention which are
capable of exhibiting biological activity are also encompassed by
the present invention. Fragments of the protein may be in linear
form or they may be cyclized using known methods, for example, as
described in H. U. Saragovi, et al., Bio/Technology 10, 773-778
(1992) and in R. S. McDowell, et al., J. Amer. Chem. Soc. 114,
9245-9253 (1992), both of which are incorporated herein by
reference. Such fragments may be fused to carrier molecules such as
immunoglobulins for many purposes, including increasing the valency
of protein binding sites.
[0161] The present invention also provides both full-length and
dominant mature forms (for example, without a signal sequence or
precursor sequence) or mature forms (for example, lacking the
signal sequence and the furin cleavage site) of the disclosed
proteins. The protein coding sequence is identified in the sequence
listing by translation of the disclosed nucleotide sequences. The
mature form of such protein may be obtained by expression of a
full-length polynucleotide in a suitable mammalian cell or other
host cell. The sequence of the mature form of the protein is also
determinable from the amino acid sequence of the full-length
form.
[0162] Protein compositions of the present invention may further
comprise an acceptable carrier, such as a hydrophilic, e.g.,
pharmaceutically acceptable, carrier.
[0163] The present invention further provides isolated polypeptides
encoded by the nucleic acid fragments of the present invention or
by degenerate variants of the nucleic acid fragments of the present
invention. By "degenerate variant" is intended nucleotide fragments
which differ from a nucleic acid fragment of the present invention
(e.g., an ORF) by nucleotide sequence but, due to the degeneracy of
the genetic code, encode an identical polypeptide sequence.
Preferred nucleic acid fragments of the present invention are the
ORFs that encode proteins.
[0164] A variety of methodologies known in the art can be utilized
to obtain any one of the isolated polypeptides or proteins of the
present invention. At the simplest level, the amino acid sequence
can be synthesized using commercially available peptide
synthesizers. The synthetically-constructed protein sequences, by
virtue of sharing primary, secondary or tertiary structural and/or
conformational characteristics with proteins may possess biological
properties in common therewith, including protein activity. This
technique is particularly useful in producing small peptides and
fragments of larger polypeptides. Fragments are useful, for
example, in generating antibodies against the native polypeptide.
Thus, they may be employed as biologically active or immunological
substitutes for natural, purified proteins in screening of
therapeutic compounds and in immunological processes for the
development of antibodies.
[0165] The polypeptides and proteins of the present invention can
alternatively be purified from cells which have been altered to
express the desired polypeptide or protein. As used herein, a cell
is said to be altered to express a desired polypeptide or protein
when the cell, through genetic manipulation, is made to produce a
polypeptide or protein which it normally does not produce or which
the cell normally produces at a lower level. One skilled in the art
can readily adapt procedures for introducing and expressing either
recombinant or synthetic sequences into eukaryotic or prokaryotic
cells in order to generate a cell which produces one of the
polypeptides or proteins of the present invention.
[0166] The invention also relates to methods for producing a
polypeptide comprising growing a culture of host cells of the
invention in a suitable culture medium, and purifying the protein
from the cells or the culture in which the cells are grown. For
example, the methods of the invention include a process for
producing a polypeptide in which a host cell containing a suitable
expression vector that includes a polynucleotide of the invention
is cultured under conditions that allow expression of the encoded
polypeptide. The polypeptide can be recovered from the culture,
conveniently from the culture medium, or from a lysate prepared
from the host cells and further purified. Preferred embodiments
include those in which the protein produced by such process is a
full length or mature form of the protein.
[0167] In an alternative method, the polypeptide or protein is
purified from bacterial cells which are transformed with SCFA2,
SCFA4 or SCFA4v-encoding DNA to produce the polypeptide or protein.
One skilled in the art can readily follow known methods for
isolating polypeptides and proteins in order to obtain one of the
isolated polypeptides or proteins of the present invention. These
include, but are not limited to, immunochromatography, HPLC,
size-exclusion chromatography, ion-exchange chromatography, and
immuno-affinity chromatography. See, e.g., Scopes, Protein
Purification: Principles and Practice, Springer-Verlag (1994);
Sambrook, et al., in Molecular Cloning: A Laboratory Manual;
Ausubel et al., Current Protocols in Molecular Biology. Polypeptide
fragments that retain biological/immunological activity include
fragments comprising greater than about 100 amino acids, or greater
than about 200 amino acids, and fragments that encode specific
protein domains.
[0168] The purified polypeptides can be used in in vitro binding
assays which are well known in the art to identify molecules which
bind to the polypeptides. These molecules include but are not
limited to, for e.g., small molecules, molecules from combinatorial
libraries, antibodies or other proteins. The molecules identified
in the binding assay are then tested for antagonist or agonist
activity in in vivo tissue culture or animal models that are well
known in the art. In brief, the molecules are titrated into a
plurality of cell cultures or animals and then tested for either
cell/animal death or prolonged survival of the animal/cells.
[0169] The protein of the invention may also be expressed as a
product of transgenic animals, e.g., as a component of the milk of
transgenic cows, goats, pigs, or sheep which are characterized by
somatic or germ cells containing a nucleotide sequence encoding the
protein.
[0170] The proteins provided herein also include proteins
characterized by amino acid sequences similar to those of purified
proteins but into which modification are naturally provided or
deliberately engineered. For example, modifications, in the peptide
or DNA sequence, can be made by those skilled in the art using
known techniques. Modifications of interest in the protein
sequences may include the alteration, substitution, replacement,
insertion or deletion of a selected amino acid residue in the
coding sequence. For example, one or more of the cysteine residues
may be deleted or replaced with another amino acid to alter the
conformation of the molecule. Techniques for such alteration,
substitution, replacement, insertion or deletion are well known to
those skilled in the art (see, e.g., U.S. Pat. No. 4,518,584).
Preferably, such alteration, substitution, replacement, insertion
or deletion retains the desired activity of the protein. Regions of
the protein that are important for the protein function can be
determined by various methods known in the art including the
alanine-scanning method which involved systematic substitution of
single or strings of amino acids with alanine, followed by testing
the resulting alanine-containing variant for biological activity.
This type of analysis determines the importance of the substituted
amino acid(s) in biological activity. Regions of the protein that
are important for protein function may be determined by the eMATRIX
program.
[0171] Other fragments and derivatives of the sequences of proteins
which would be expected to retain protein activity in whole or in
part and are useful for screening or other immunological
methodologies may also be easily made by those skilled in the art
given the disclosures herein. Such modifications are encompassed by
the present invention.
[0172] The protein may also be produced by operably linking the
isolated polynucleotide of the invention to suitable control
sequences in one or more insect expression vectors, and employing
an insect expression system. Materials and methods for
baculovirus/insect cell expression systems are commercially
available in kit form from, e.g., Invitrogen, San Diego, Calif.,
U.S.A. (the MaxBat.TM. kit), and such methods are well known in the
art, as described in Summers and Smith, Texas Agricultural
Experiment Station Bulletin No. 1555 (1987), incorporated herein by
reference. As used herein, an insect cell capable of expressing a
polynucleotide of the present invention is "transformed."
[0173] The protein of the invention may be prepared by culturing
transformed host cells under culture conditions suitable to express
the recombinant protein. The resulting expressed protein may then
be purified from such culture (i.e., from culture medium or cell
extracts) using known purification processes, such as gel
filtration and ion exchange chromatography. The purification of the
protein may also include an affinity column containing agents which
will bind to the protein; one or more column steps over such
affinity resins as concanavalin A-agarose, Heparin-Toyopearl.TM. or
Cibacrom blue 3GA Sepharose.TM.; one or more steps involving
hydrophobic interaction chromatography using such resins as phenyl
ether, butyl ether, or propyl ether; or immunoaffinity
chromatography.
[0174] Alternatively, the protein of the invention may also be
expressed in a form which will facilitate purification. For
example, it may be expressed as a fusion protein, such as those of
maltose binding protein (MBP), glutathione-S-transferase (GST) or
thioredoxin (TRX), or as a His tag. Kits for expression and
purification of such fusion proteins are commercially available
from New England BioLab (Beverly, Mass.), Pharmacia (Piscataway,
N.J.) and Invitrogen, respectively. The protein can also be tagged
with an epitope and subsequently purified by using a specific
antibody directed to such epitope. One such epitope ("FLAG.RTM.")
is commercially available from Kodak (New Haven, Conn.).
[0175] Finally, one or more reverse-phase high performance liquid
chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media,
e.g., silica gel having pendant methyl or other aliphatic groups,
can be employed to further purify the protein. Some or all of the
foregoing purification steps, in various combinations, can also be
employed to provide a substantially homogeneous isolated
recombinant protein. The protein thus purified is substantially
free of other mammalian proteins and is defined in accordance with
the present invention as an "isolated protein."
[0176] The polypeptides of the invention include SCFA2, SCFA4 or
SCFA4v analogs. This embraces fragments of SCFA2, SCFA4 or SCFA4v
polypeptide, as well as SCFA2, SCFA4 or SCFA4v polypeptides which
comprise one or more amino acids deleted, inserted, or substituted.
Also, analogs of the SCFA2, SCFA4 or SCFA4v polypeptide of the
invention embrace fusions of the SCFA2, SCFA4 or SCFA4v
polypeptides or modifications of the SCFA2, SCFA4 or SCFA4v
polypeptides, wherein the SCFA2, SCFA4 or SCFA4v polypeptide or
analog is fused to another moiety or moieties, e.g., targeting
moiety or another therapeutic agent. Such analogs may exhibit
improved properties such as activity and/or stability. Examples of
moieties which may be fused to the SCFA2, SCFA4 or SCFA4v
polypeptide or an analog include, for example, targeting moieties
which provide for the delivery of polypeptide to the small
intestine, e.g., antibodies to the small intestine, or antibodies
to receptor and ligands expressed on gastroinetestinal cells. Other
moieties which may be fused to SCFA2, SCFA4 or SCFA4v polypeptide
include therapeutic agents which are used for treatment, for
example cytokines or other medications, of gastrointestinal
disorders, and other conditions as recited herein.
[0177] 4.2.5 Gene Therapy
[0178] The invention provides gene therapy to treat the diseases
cited herein. Delivery of a functional gene encoding polypeptides
of the invention to appropriate cells is effected ex vivo, in situ,
or in vivo by use of vectors, and more particularly viral vectors
(e.g., adenovirus, adeno-associated virus, or a retrovirus), or ex
vivo by use of physical DNA transfer methods (e.g., liposomes or
chemical treatments). See, for example, Anderson, Nature,
supplement to vol. 392, no. 6679, pp. 25-20 (1998). For additional
reviews of gene therapy technology see Friedmann, Science, 244:
1275-1281 (1989); Verma, Scientific American: 68-84 (1990); and
Miller, Nature, 357: 455-460 (1992).
[0179] As discussed above, a "vector" is any means for the transfer
of a nucleic acid according to the invention into a host cell.
Preferred vectors are viral vectors, such as retroviruses, herpes
viruses, adenoviruses and adeno-associated viruses. Thus, a gene or
nucleic acid sequence encoding a SCFA2, SCFA4 or SCFA4v protein or
polypeptide domain fragment thereof is introduced in vivo, ex vivo,
or in vitro using a viral vector or through direct introduction of
DNA. Expression in targeted tissues can be effected by targeting
the transgenic vector to specific cells, such as with a viral
vector or a receptor ligand, or by using a tissue-specific
promoter, or both.
[0180] Viral vectors commonly used for in vivo or ex vivo targeting
and therapy procedures are DNA-based vectors and retroviral
vectors. Methods for constructing and using viral vectors are known
in the art [see, e.g., Miller and Rosman, BioTechniques 7:980-990
(1992)]. Preferably, the viral vectors are replication defective,
that is, they are unable to replicate autonomously in the target
cell. In general, the genome of the replication defective viral
vectors which are used within the scope of the present invention
lack at least one region which is necessary for the replication of
the virus in the infected cell. These regions can either be
eliminated (in whole or in part), be rendered non-functional by any
technique known to a person skilled in the art. These techniques
include the total removal, substitution (by other sequences, in
particular by the inserted nucleic acid), partial deletion or
addition of one or more bases to an essential (for replication)
region. Such techniques may be performed in vitro (on the isolated
DNA) or in situ, using the techniques of genetic manipulation or by
treatment with mutagenic agents. Preferably, the replication
defective virus retains the sequences of its genome which are
necessary for encapsulating the viral particles.
[0181] DNA viral vectors include an attenuated or defective DNA
virus, such as but not limited to herpes simplex virus (HSV),
papillomavirus, Epstein-Barr virus (EBV), adenovirus,
adeno-associated virus (AAV), and the like. Defective viruses,
which entirely or almost entirely lack viral genes, are preferred.
Defective virus is not infective after introduction into a cell.
Use of defective viral vectors allows for administration to cells
in a specific, localized area, without concern that the vector can
infect other cells. Thus, a specific tissue can be specifically
targeted. Examples of particular vectors include, but are not
limited to, a defective herpes virus 1 (HSV1) vector [Kaplitt et
al., Molec. Cell. Neurosci. 2:320-330 (1991)], defective herpes
virus vector lacking a glycoprotein L gene [Patent Publication RD
371005 A], or other defective herpes virus vectors [International
Patent Publication No. WO 94/21807, published Sep. 29, 1994;
International Patent Publication No. WO 92/05263, published Apr. 2,
1994]; an attenuated adenovirus vector, such as the vector
described by Stratford-Perricaudet et al. [J. Clin. Invest.
90:626-630 (1992); see also La Salle et al., Science 259:988-990
(1993)]; and a defective adeno-associated virus vector [Samulski et
al., J. Virol. 61:3096-3101 (1987); Samulski et al., J. Virol.
63:3822-3828 (1989); Lebkowski et al., Mol. Cell. Biol. 8:3988-3996
(1988)].
[0182] Preferably, for in vivo administration, an appropriate
immunosuppressive treatment is employed in conjunction with the
viral vector, e.g., adenovirus vector, to avoid immuno-deactivation
of the viral vector and transfected cells. For example,
immunosuppressive cytokines, such as interleukin-12 (IL-12),
interferon-.gamma. (IFN-.gamma.), or anti-CD4 antibody, can be
administered to block humoral or cellular immune responses to the
viral vectors [see, e.g., Wilson, Nature Medicine (1995)]. In
addition, it is advantageous to employ a viral vector that is
engineered to express a minimal number of antigens.
[0183] In a preferred embodiment, the vector is an adenovirus
vector. As shown in the Examples, the adenovirus vector has shown
itself to be particularly effective for delivery of the SCFA2,
SCFA4 or SCFA4v polypeptide, as shown by the unexpectedly efficient
effects of stimulating intestinal epithelial cell proliferation
resulting in marked, diffuse thickening of the mucosa by crypt
epithelial hyperplasia and a marked increase in crypt length and
complex branching. Adenoviruses are eukaryotic DNA viruses that can
be modified to efficiently deliver a nucleic acid of the invention
to a variety of cell types. Various serotypes of adenovirus exist.
Of these serotypes, preference is given, within the scope of the
present invention, to using type 2 or type 5 human adenoviruses (Ad
2 or Ad 5) or adenoviruses of animal origin (see WO94/26914). Those
adenoviruses of animal origin which can be used within the scope of
the present invention include adenoviruses of canine, bovine,
murine (example: Mav1, Beard et al., Virology 75 (1990) 81), ovine,
porcine, avian, and simian (example: SAV) origin.
[0184] Preferably, the replication defective adenoviral vectors of
the invention comprise the inverted terminal repeats (ITRs), an
encapsidation sequence and the nucleic acid of interest. Still more
preferably, at least the E1 region of the adenoviral vector is
non-functional. Other regions may also be modified, in particular
the E3 region (WO95/02697), the E2 region (WO94/28938), the E4
region (WO94/28152, WO94/12649 and WO95/02697), or in any of the
late genes L1-L5.
[0185] In a preferred embodiment, the adenoviral vector has a
deletion in the E1 and E3 region. Examples of E1-deleted
adenoviruses are disclosed in EP 185,573, the contents of which are
incorporated herein by reference.
[0186] The replication defective recombinant adenoviruses according
to the invention can be prepared by any technique known to the
person skilled in the art (Levrero et al., Gene 101 (1991) 195, EP
185 573; Graham, EMBO J. 3 (1984) 2917). In particular, they can be
prepared by homologous recombination between an adenovirus and a
plasmid which carries, inter alia, the DNA sequence of interest.
The homologous recombination is effected following cotransfection
of the said adenovirus and plasmid into an appropriate cell line.
The cell line which is employed should preferably (i) be
transformable by the said elements, and (ii) contain the sequences
which are able to complement the part of the genome of the
replication defective adenovirus, preferably in integrated form in
order to avoid the risks of recombination. Examples of cell lines
which may be used are the human embryonic kidney cell line 293
(Graham et al., J. Gen. Virol. 36 (1977) 59) which contains the
left-hand portion of the genome of an Ad5 adenovirus (12%)
integrated into its genome, and cell lines which are able to
complement the E1 and E4 functions, as described in applications
WO94/26914 and WO95/02697. Recombinant adenoviruses are recovered
and purified using standard molecular biological techniques, which
are well known to one of ordinary skill in the art.
[0187] Promoters that may be used in the present invention include
both constitutive promoters and regulated (inducible) promoters.
The promoter may be naturally responsible for the expression of the
nucleic acid. It may also be from a heterologous source. In
particular, it may be promoter sequences of eukaryotic or viral
genes. For example, it may be promoter sequences derived from the
genome of the cell which it is desired to infect. Likewise, it may
be promoter sequences derived from the genome of a virus, including
the adenovirus used. In this regard, there may be mentioned, for
example, the promoters of the E1A, MLP, CMV and RSV genes and the
like.
[0188] In addition, the promoter may be modified by addition of
activating or regulatory sequences or sequences allowing a
tissue-specific or predominant expression (enolase and GFAP
promoters and the like). Moreover, when the nucleic acid does not
contain promoter sequences, it may be inserted, such as into the
virus genome downstream of such a sequence.
[0189] Some promoters useful for practice of this invention are
ubiquitous promoters (e.g., HPRT, vimentin, actin, tubulin),
intermediate filament promoters (e.g., desmin, neurofilaments,
keratin, GFAP), therapeutic gene promoters (e.g., MDR type, CFTR,
factor VIII), tissue-specific promoters (e.g., actin promoter in
smooth muscle cells), promoters which are preferentially activated
in dividing cells, promoters which respond to a stimulus (e.g.,
steroid hormone receptor, retinoic acid receptor),
tetracycline-regulated transcriptional modulators, cytomegalovirus
immediate-early, retroviral LTR, metallothionein, SV-40, E1a, and
MLP promoters. Tetracycline-regulated transcriptional modulators
and CMV promoters are described in WO 96/01313, U.S. Pat. Nos.
5,168,062 and 5,385,839, the contents of which are incorporated
herein by reference.
[0190] Thus, the promoters which may be used to control gene
expression include, but are not limited to, the cytomegalovirus
(CMV) promoter, the SV40 early promoter region (Benoist and
Chambon, 1981, Nature 290:304-310), the promoter contained in the
3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al.,
1980, Cell 22:787-797), the herpes thymidine kinase promoter
(Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445),
the regulatory sequences of the metallothionein gene (Brinster et
al., 1982, Nature 296:39-42); prokaryotic expression vectors such
as the b-lactamase promoter (Villa-Kamaroff, et al., 1978, Proc.
Natl. Acad. Sci. U.S.A. 75:3727-3731), or the tac promoter (DeBoer,
et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25); see also
"Useful proteins from recombinant bacteria" in Scientific American,
1980, 242:74-94; promoter elements from yeast or other fungi such
as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter,
PGK (phosphoglycerol kinase) promoter, alkaline phosphatase
promoter; and the animal transcriptional control regions, which
exhibit tissue specificity and have been utilized in transgenic
animals: elastase I gene control region which is active in
pancreatic acinar cells (Swift et al., 1984, Cell 38:639-646;
Ornitz et al., 1986, Cold Spring Harbor Symp. Quant. Biol.
50:399-409; MacDonald, 1987, Hepatology 7:425-515); insulin gene
control region which is active in pancreatic beta cells (Hanahan,
1985, Nature 315:115-122), immunoglobulin gene control region which
is active in lymphoid cells (Grosschedl et al., 1984, Cell
38:647-658; Adames et al., 1985, Nature 318:533-538; Alexander et
al., 1987, Mol. Cell. Biol. 7:1436-1444), mouse mammary tumor virus
control region which is active in testicular, breast, lymphoid and
mast cells (Leder et al., 1986, Cell 45:485-495), albumin gene
control region which is active in liver (Pinkert et al., 1987,
Genes and Devel. 1:268-276), alpha-fetoprotein gene control region
which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol.
5:1639-1648; Hammer et al., 1987, Science 235:53-58), alpha
1-antitrypsin gene control region which is active in the liver
(Kelsey et al., 1987, Genes and Devel. 1:161-171), beta-globin gene
control region which is active in myeloid cells (Mogram et al.,
1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94),
myelin basic protein gene control region which is active in
oligodendrocyte cells in the brain (Readhead et al., 1987, Cell
48:703-712), myosin light chain-2 gene control region which is
active in skeletal muscle (Sani, 1985, Nature 314:283-286), and
gonadotropic releasing hormone gene control region which is active
in the hypothalamus (Mason et al., 1986, Science
234:1372-1378).
[0191] Introduction of any one of the nucleotides of the present
invention or a gene encoding the polypeptides of the present
invention can also be accomplished with extrachromosomal substrates
(transient expression) or artificial chromosomes (stable
expression). Cells may also be cultured ex vivo in the presence of
proteins of the present invention in order to proliferate or to
produce a desired effect on or activity in such cells. Treated
cells can then be introduced in vivo for therapeutic purposes. In
addition to the use of viral vectors in the practice of the present
invention, the present invention further includes a novel vector
comprising operator and promoter elements operatively linked to
polynucleotide sequences encoding a protein of interest. The
adenoviral vector of the invention is the pAdenoVator-CMV5-Intron
vector, which is described in detail in Examples.
[0192] 4.2.6 Crypt Cell and Tissue Growth Activity
[0193] The SCFA2, SCFA4 or SCFA4v polypeptide of the invention
exhibits growth factor activity and is involved in the
proliferation and differentiation of intestinal crypt cells. SCFA2,
SCFA4 or SCFA4v may also exhibit growth factor activity on other
epithelial cells of the gastrointestinal tract. Administration of
the polypeptide of the invention to crypt cells in vivo or ex vivo
may maintain and expand cell populations in a totipotential state
which would be useful for re-engineering damaged or diseased
tissues, transplantation, manufacture of bio-pharmaceuticals and
the development of bio-sensors. The ability to produce large
quantities of human cells has important working applications for
the production of human proteins which currently must be obtained
from non-human sources or donors, implantation of cells to treat
tissues for grafting such gastrointestinal cells.
[0194] It is contemplated that multiple different exogenous growth
factors and/or cytokines may be administered in combination with
the polypeptide of the invention to achieve the desired effect,
including any of the growth factors listed herein, other stem cell
maintenance factors, and specifically including stem cell factor
(SCF), leukemia inhibitory factor (LIF), Flt-3 ligand (Flt-3L), any
of the interleukins, recombinant soluble IL-6 receptor fused to
IL-6, macrophage inflammatory protein 1-alpha (MIP-1-alpha), G-CSF,
GM-CSF, thrombopoietin (TPO), platelet factor 4 (PF-4),
platelet-derived growth factor (PDGF), neural growth factors, basic
fibroblast growth factor (bFGF), keratinocyte growth factor-2
(KGF2), and glucagons-like peptide 2 (GLP-2).
[0195] Intestinal epithelial cells including crypt cells can be
transfected with a polynucleotide of the invention to induce
autocrine expression of the polypeptide of the invention. This will
allow for generation of undifferentiated cell lines that are useful
as is or that can then be differentiated into the desired mature
cell types. These stable cell lines can also serve as a source of
undifferentiated mRNA to create cDNA libraries and templates for
polymerase chain reaction experiments. These studies would allow
for the isolation and identification of differentially expressed
genes in crypt cell populations that regulate crypt proliferation
and/or maintenance.
[0196] Expansion and maintenance of epithelial stem cell
populations will be useful in the treatment of many pathological
conditions. For example, polypeptides of the present invention may
be used to manipulate crypt cells in culture to give rise to
gastrointestinal epithelial cells that can be used to augment or
replace cells damaged by illness, autoimmune disease, accidental
damage or genetic disorders inflammation caused by ionizing
radiation, chemotherapy, infection and inflammation.
[0197] Expression of the polypeptide of the invention and its
effect on crypt cells can also be manipulated to achieve controlled
differentiation of the crypt cells into more differentiated cell
types. A broadly applicable method of obtaining pure populations of
a specific differentiated cell type from undifferentiated stem cell
populations involves the use of a cell-type specific promoter
driving a selectable marker In vitro cultures of intestinal
epithelial cells including crypt cells can be used to determine if
the polypeptide of the invention exhibits growth factor activity.
Crypt cells are isolated from disaggregated colonic crypts from
human and murine colonic mucosa, and the clonogenic activity of
SCFA2, SCFA4 or SCFA4v can be assessed using the method described
by Whitehead et al., Gastroenterology 117:858-865 (1999), which is
herein incorporated by reference in its entirety. Growth factor
activity can be assessed in the presence of the polypeptide of the
invention alone or in combination with other growth factors or
cytokines.
[0198] The compositions of the present invention can also be useful
for proliferation of intestinal epithelial cells including crypt
cells and for regeneration of oral and gastrointestinal tissue,
i.e. for the treatment of injuries sustained by the epithelial
layer which involve degeneration, death or trauma to epithelial
crypt cells. More specifically, a composition can be used in the
treatment of diseases of the gastrointestinal tract as recited
herein.
[0199] Compositions of the invention can also be useful to promote
better or faster closure of non-healing wounds, including without
limitation pressure ulcers, ulcers associated with vascular
insufficiency, surgical and traumatic wounds, and the like. Assays
for wound healing activity include, without limitation, those
described in: Winter, Epidermal Wound Healing, pp. 71-112 (Maibach,
H. I. and Rovee, D. T., eds.), Year Book Medical Publishers, Inc.,
Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol.
71:382-84 (1978).
[0200] 4.2.7 Immunomodulatory Activity
[0201] A polypeptide of the present invention may exhibit activity
relating to regulation of immune system components including, but
not limited to cytokine production and/or activity, and/or cells of
the immune system. A polynucleotide of the invention can encode a
polypeptide exhibiting such attributes. Regulation of cytokines
and/or cells of the immune system may include increasing and/or
decreasing levels of cytokines or numbers of particular cells of
the immune system.
[0202] With such immunomodulatory activity, polypeptides of the
invention can be used to treat various immune disorders. These
disorders include, but are not limited to inflammatory bowel
disease (IBD), which includes ulcerative colitis and/or Crohn's
disease, and mucositis as a consequence of anti-cancer therapies
including radiation treatment and/or chemotherapy. The cause of
these immune disorders can be, for example, idiopathic (i.e. of
unknown cause), genetic, by infectious agents (eg. viruses,
bacteria, fungi), and/or by damage induced by anti-cancer therapies
(eg. radiation therapy and/or chemotherapy).
[0203] Modulation of immune responses and/or components of the
immune system can be accomplished in a number of ways.
Down-regulation may be in the form of inhibiting or blocking an
immune response already in progress or may involve preventing the
induction of an immune response. The functions of activated T cells
may be inhibited by suppressing T cell responses or by inducing
specific tolerance in T cells, or both. Immunosuppression of T cell
responses is generally an active, non-antigen-specific, process
that requires continuous exposure of the T cells to the suppressive
agent. Tolerance, which involves inducing non-responsiveness or
anergy in T cells, is distinguishable from immunosuppression in
that it is generally antigen-specific and persists after exposure
to the tolerizing agent has ceased. Operationally, tolerance can be
demonstrated by the lack of a T cell response upon reexposure to
specific antigen in the absence of tolerizing agent.
[0204] Inflammatory bowel disease is almost always mediated by one
of two pathways: excessive T helper 1 (Th1)-cell response
associated with high levels of IL-12, IFN-gamma, and/or TNF or
excessive T helper 2 (Th2)-cell response associated with high
levels of IL-4, IL-5, and/or IL-13 (Bouma et al., herein
incorporated by reference in its entirety). Therefore a mechanism
through which polypeptides of the invention could mediate
immunomodulatory activity in disease treatment would be to
down-regulate the numbers of Th1 and/or Th2 cell populations.
Alternatively, another activity could be to decrease the levels of
cytokines (eg. IL-12, IFN-gamma, TNF, IL-4, IL-5, and/or IL-13)
that are associated with and/or mediate the inflammatory
response.
[0205] The activity of the polypeptide of the present invention
can, among other means, be measured by the following methods:
[0206] Assays for T-cell or thymocyte proliferation include without
limitation those described in: Current Protocols in Immunology, Ed
by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach,
W. Strober, Pub. Greene Publishing Associates and
Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte
Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai
et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J.
Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular
Immunology 133:327-341, 1991; Bertagnolli, et al., I. Immunol.
149:3778-3783, 1992; Bowman et al., I. Immunol. 152:1756-1761,
1994.
[0207] Assays for cytokine production and/or proliferation of
spleen cells, lymph node cells or thymocytes include, without
limitation, those described in: Polyclonal T cell stimulation,
Kruisbeek, A. M. and Shevach, E. M. In Current Protocols in
Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John
Wiley and Sons, Toronto. 1994; and Measurement of mouse and human
interferon-.gamma., Schreiber, R. D. In Current Protocols in
Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John
Wiley and Sons, Toronto. 1994.
[0208] Assays for T-cell clone responses to antigens (which will
identify, among others, proteins that affect APC-T cell
interactions as well as direct T-cell effects by measuring
proliferation and cytokine production) include, without limitation,
those described in: Current Protocols in Immunology, Ed by J. E.
Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W
Strober, Pub. Greene Publishing Associates and Wiley-Interscience
(Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter
6, Cytokines and their cellular receptors; Chapter 7, Immunologic
studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA
77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411,
1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al.,
J. Immunol. 140:508-512, 1988.)
[0209] 4.2.8 Chemotactic/Chemokinetic Activity
[0210] A polypeptide of the present invention may be involved in
chemotactic or chemokinetic activity for mammalian cells,
including, for example, monocytes, fibroblasts, neutrophils,
T-cells, mast cells, eosinophils, epithelial and/or endothelial
cells. A polynucleotide of the invention can encode a polypeptide
exhibiting such attributes. Chemotactic and chemokinetic receptor
activation can be used to mobilize or attract a desired cell
population to a desired site of action. Chemotactic or chemokinetic
compositions (e.g. proteins, antibodies, binding partners, or
modulators of the invention) provide particular advantages in
treatment of wounds and other trauma to tissues, as well as in
treatment of localized infections. For example, attraction of
lymphocytes, monocytes or neutrophils to tumors or sites of
infection may result in improved immune responses against a tumor
or an infecting agent.
[0211] A protein or peptide has chemotactic activity for a
particular cell population if it can stimulate, directly or
indirectly, the directed orientation or movement of such cell
population. Preferably, the protein or peptide has the ability to
directly stimulate directed movement of cells. Whether a particular
protein has chemotactic activity for a population of cells can be
readily determined by employing such protein or peptide in any
known assay for cell chemotaxis.
[0212] Assays for chemotactic activity (which will identify
proteins that induce or prevent chemotaxis) consist of assays that
measure the ability of a protein to induce the migration of cells
across a membrane as well as the ability of a protein to induce the
adhesion of one cell population to another cell population.
Suitable assays for movement and adhesion include, without
limitation, those described in: Current Protocols in Immunology, Ed
by J. E. Coligan, A. M. Kruisbeek, D. H. Marguiles, E. M. Shevach,
W. Strober, Pub. Greene Publishing Associates and
Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta
Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest.
95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et
al Eur. J. Immunol. 25:1744-1748; Gruber et al. J. of Immunol.
152:5860-5867, 1994; Johnston et al. J. of Immunol. 153:1762-1768,
1994.
[0213] 4.2.9 Drug Screening
[0214] Screening for a useful compound involves administering the
candidate compound over a range of doses to a non-human animal, and
assaying at various time points for the effect(s) of the compound
on the activity of the SCFA2, SCFA4 or SCFA4v protein. The compound
may be administered prior to or at the onset of abdominal
distension. Administration may be oral, or by suitable injection,
depending on the chemical nature of the compound being evaluated.
The cellular response to the compound is evaluated over time using
appropriate biochemical and/or histological assays.
[0215] Sources for test compounds that may be screened for ability
to bind to or modulate (i.e., increase or decrease) the activity of
polypeptides of the invention include (1) inorganic and organic
chemical libraries, (2) natural product libraries, and (3)
combinatorial libraries comprised of either random or mimetic
peptides, oligonucleotides or organic molecules.
[0216] Chemical libraries may be readily synthesized or purchased
from a number of commercial sources, and may include structural
analogs of known compounds or compounds that are identified as
"hits" or "leads" via natural product screening.
[0217] The sources of natural product libraries are microorganisms
(including bacteria and fungi), animals, plants or other
vegetation, or marine organisms, and libraries of mixtures for
screening may be created by: (1) fermentation and extraction of
broths from soil, plant or marine microorganisms or (2) extraction
of the organisms themselves. Natural product libraries include
polyketides, non-ribosomal peptides, and (non-naturally occurring)
variants thereof. For a review, see Science 282:63-68 (1998).
[0218] Combinatorial libraries are composed of large numbers of
peptides, oligonucleotides or organic compounds and can be readily
prepared by traditional automated synthesis methods, PCR, cloning
or proprietary synthetic methods. Of particular interest are
peptide and oligonucleotide combinatorial libraries. Still other
libraries of interest include peptide, protein, peptidomimetic,
multiparallel synthetic collection, recombinatorial, and
polypeptide libraries. For a review of combinatorial chemistry and
libraries created therefrom, see Myers, Curr. Opin. Biotechnol.
8:701-707 (1997). For reviews and examples of peptidomimetic
libraries, see Al-Obeidi et al., Mol. Biotechnol, 9(3):205-23
(1998); Hruby et al., Curr Opin Chem Biol, 1(1):114-19 (1997);
Dorner et al., Bioorg Med Chem, 4(5):709-15 (1996) (alkylated
dipeptides).
4.3 DISEASES AMENABLE TO SCFA2, SCFA4 OR SCFA4v THERAPY
[0219] In one aspect, the present invention provides pharmaceutical
reagents and methods useful for treating diseases and conditions
wherein epithelialization is desired. SCFA2, SCFA4 and SCFA4v
polypeptides are useful to increase cytoprotection, proliferation
and/or differentiation of epithelial cells of the oral and
gastrointestinal tract. Specifically, SCFA2, SCFA4 and SCFA4v
polypeptides are useful to treat or prevent diseases or conditions
that include without limitation gastrointestinal diseases,
mucositis of the gastrointestinal tract, mucositis of the
oropharynx, lips and esophagus (oral mucositis), inflammatory bowel
disease, short bowel syndrome, gastric and duodenal ulcers,
erosions of the gastrointestinal tract including erosive gastritis,
esophagitis, esophageal reflux and other conditions including
wounds, burns, ophthalmic disorders, and any disorder where
stimulation of epithelial cell proliferation or regeneration is
desired. Treatment of diseases that result in insufficient
production of mucus throughout the oral and gastrointestinal tract
is also contemplated.
[0220] Mucositis, which includes oral and gastrointestinal
mucositis, is a complication of some cancer therapies in which the
lining of the digestive system becomes inflamed. SCFA2, SCFA4 and
SCFA4v is useful for preventing and/or ameliorating the
degeneration of the mucosa of the alimentary tract that is caused
by chemotherapy and/or radiation therapy given to a patient for the
treatment of cancer, or is given as an adjuvant therapy following
the removal of a tumor. Exemplary chemotherapeutic agents include,
without limitation, BCNU, busulfan, carboplatin, cyclophosphamide,
tannorubicin, doxorubicin, etoposide, 5-fluorouracil (5-FU),
gemcytabine, ifophamide, irinotecan, melphalan, methotrexate,
navelbine, totpotecan, and taxol, and exemplary treatment regimens
include without limitation, BEAM (busulfan, etoposide, cytosine,
arabinoside, methotrexate); cyclophosphamide and total body
irradiation; cyclophosphamine, total body irradiation and
etoposide; cyclophosphamide and busulfan; and 5-fluorouracil with
leucovorin or levamisole. Treatment, pretreatment or post-treatment
with SCFA2, SCFA4 and SCFA4v is useful to generate a cytoprotective
effect or regeneration or both, for example, of the mucosa of the
small intestine and colon, allowing increased dosages of therapies
while reducing their potential side effects.
[0221] Inflammatory bowel disease that can be treated with SCFA2,
SCFA4 and SCFA4v includes general inflammatory bowel disease that
is characterized by chronic, relapsing, inflammatory disorders of
unknown origin, Crohn's disease, dysplasia associated with
inflammatory bowel disease, intermediate colitis, ulcerative
colitis; non-infectious colitis including active colitis,
antibiotic-associated colitis, collagenous colitis, diversion
colitis, eosinophilic colitis, graft versus host disease,
granulomatous colitis, ischaemic colitis, hemorrhagic colitis,
malakoplakia, necrotizing enterocolitis, radiation enterocolitis,
typhlitis; infectious colitis including adenovirus and amebic
colitis, balantidiasis, HSV/AIDS associated colitis, and colitis
caused by trypanosomes, E. coli, Mycobacterium avium
intracellulare, Sotavirus, Salmonella, Shigella, Campylobacter
jejuni, Clostridium, Botulinum, and colitis associated with
schistosomiasis, spirochetosis, syphilis, trichuriasis,
tuberculosis typhoid fever, Vibrio cholera, and Yersinia.
[0222] Short bowel syndrome is a group of problems affecting people
who have had half or more of their small intestine removed. The
most common reason for removing part of the small intestine is to
treat Crohn's disease. In addition, surgical resection of part of
the intestine may be required to remove cancerous growths. Diarrhea
is the main symptom of short bowel syndrome. Other symptoms include
cramping, bloating, and heartburn. Many people with short bowel
syndrome are malnourished because their remaining small intestine
is unable to absorb enough water, vitamins, and other nutrients
from food. They may also become dehydrated, which can be life
threatening. Problems associated with dehydration and malnutrition
include weakness, fatigue, depression, weight loss, bacterial
infections, and food sensitivities. Short bowel syndrome is treated
through changes in diet, intravenous feeding, vitamin and mineral
supplements, and medicine to relieve symptoms. SCFA2, SCFA4 and
SCFA4v polypeptides can be useful to increase the proliferation of
the unresected intestinal tissue, thereby increasing the absorptive
surface area of the intestine, and ameliorate the symptoms
associated with short bowel syndrome.
[0223] The cytoprotective and/or regenerative activity of SCFA2,
SCFA4 and SCFA4v polypeptides can be tested in in vivo models of
radiation induced mucositis (Withers and Elkind, Int J Radiat
17:261-267 (1970), herein incorporated by reference; in in vivo
chemotherapy-induced mucositis (Soris et al., Oral Surg Oral Med
Oral Pathol 69:437-443 (1990); Moore, Cancer Chemother Pharmacol
15:11-15 (1985); Fareell et al., Cell Prolif 35:78-85 (2002), all
of which are incorporated by reference in their entirety); in a
dextran sulfate sodium (DSS) model of colitis and small intestinal
ulceration or inflammation (Jeffers et al., Gastroenterology
123:1151-1162 (2002), Han et al., Am J Physiol Gastrointest Liver
Physiol 279:G1011-G1022 (2000); and in a surgical model of short
bowel syndrome (SBS) (Scott et al. Am J Physiol G911-G921 (1998);
Helmrath et al., J Am Coll Surg 183:441-449 (1996)), herein
incorporated by reference in their entirety).
[0224] Comparisons of SCFA2, SCFA4 and SCFA4v mRNA and protein
expression levels between diseased cells, tissue and corresponding
normal samples are made to determine if the subject is responsive
to SCFA2, SCFA4 and SCFA4v therapy. Methods for detecting and
quantifying the expression of SCFA2, SCFA4 and SCFA4v polypeptide
mRNA or protein use standard nucleic acid and protein detection and
quantitation techniques that are well known in the art and are
described in Sambrook, et al., Molecular Cloning: A Laboratory
Manual, Cold Spring Harbor Laboratory, NY (1989) or Ausubel, et
al., Current Protocols in Molecular Biology, John Wiley & Sons,
New York, N.Y. (1989), both of which are incorporated herein by
reference in their entirety. Standard methods for the detection and
quantification of SCFA2, SCFA4 and SCFA4v mRNA include in situ
hybridization using labeled SCFA2, SCFA4 and SCFA4v riboprobes
(Gemou-Engesaeth, et al., Pediatrics 109: E24-E32 (2002), herein
incorporated by reference in its entirety), northern blot and
related techniques using SCFA2, SCFA4 and SCFA4v polynucleotide
probes (Kunzli, et al., Cancer 94: 228 (2002), herein incorporated
by reference in its entirety, herein incorporated by reference in
its entirety), RT-PCR analysis using SCFA2, SCFA4 and
SCFA4v-specific primers (Angchaiskisiri, et al., Blood 99:130
(2002)), and other amplification detection methods, such as
branched chain DNA solution hybridization assay (Jardi, et al., J.
Viral Hepat. 8:465-471 (2001), herein incorporated by reference in
its entirety), transcription-mediated amplification (Kimura, et
al., J. Clin. Microbiol. 40:439-445 (2002)), microarray products,
such as oligos, cDNAs, and monoclonal antibodies, and real-time PCR
(Simpson, et al., Molec. Vision, 6:178-183 (2000), herein
incorporated by reference in its entirety). Standard methods for
the detection and quantification of SCFA2, SCFA4 and SCFA4v protein
include western blot analysis (Sambrook, et al., Molecular Cloning:
A Laboratory Manual, Cold Spring Harbor Laboratory, NY (1989),
Ausubel, et al., Current Protocols in Molecular Biology, John Wiley
& Sons, New York, N.Y. (1989)), immunocytochemistry (Racila, et
al., Proc. Natl. Acad. Sci. USA 95:4589-4594 (1998) supra), and a
variety of immunoassays, including enzyme-linked immunosorbant
assay (ELISA), radioimmuno assay (RIA), and specific enzyme
immunoassay (EIA) (Sambrook, et al., Molecular Cloning: A
Laboratory Manual, Cold Spring Harbor Laboratory, NY (1989),
Ausubel, et al., Current Protocols in Molecular Biology, John Wiley
& Sons, New York, N.Y. (1989)).
[0225] The diseases and conditions treatable by methods of the
present invention preferably occur in mammals. Mammals include, for
example, humans and other primates, as well as pet or companion
animals such as dogs and cats, laboratory animals such as rats,
mice and rabbits, and farm animals such as horses, pigs, sheep, and
cattle.
[0226] 4.3.1 Therapeutic Methods
[0227] The compositions (including polypeptide fragments, analogs,
variants and antibodies or other binding partners or modulators
including antisense polynucleotides) of the invention have numerous
applications in a variety of therapeutic methods. Examples of
therapeutic applications include, but are not limited to, those
exemplified herein.
[0228] One embodiment of the invention is the administration of an
effective amount of SCFA2, SCFA4 and SCFA4v polypeptides or other
composition of the invention to individuals affected by a disease
or disorder that can be treated the peptides of the invention.
While the mode of administration is not particularly important,
parenteral administration is preferred. Exemplary modes of
administration are to deliver asubcutaneous or intravenous bolus.
The dosage of SCFA2, SCFA4 and SCFA4v polypeptides or other
composition of the invention will normally be determined by the
prescribing physician. It is to be expected that the dosage will
vary according to the age, weight, condition and response of the
individual patient. Typically, the amount of polypeptide
administered per dose will be in the range of about 0.01 .mu.g/kg
to 100 mg/kg of body weight, with the preferred dose being about
0.1 .mu.g/kg to 10 mg/kg of patient body weight. For parenteral
administration, SCFA2, SCFA4 and SCFA4v polypeptides of the
invention will be formulated in an injectable form combined with a
pharmaceutically acceptable parenteral vehicle. Such vehicles are
well known in the art and examples include water, saline, Ringer's
solution, dextrose solution, and solutions consisting of small
amounts of the human serum albumin. The vehicle may contain minor
amounts of additives that maintain the isotonicity and stability of
the polypeptide or other active ingredient. The preparation of such
solutions is within the skill of the art.
[0229] 4.3.2 Pharmaceutical Formulations
[0230] A protein or other composition of the present invention
(from whatever source derived, including without limitation from
recombinant and non-recombinant sources and including antibodies
and other binding partners of the polypeptides of the invention)
may be administered to a patient in need, by itself, or in
pharmaceutical compositions where it is mixed with suitable
carriers or excipient(s) at doses to treat or ameliorate a variety
of disorders. Such a composition may optionally contain (in
addition to protein or other active ingredient and a carrier)
diluents, fillers, salts, buffers, stabilizers, solubilizers, and
other materials well known in the art. The term "pharmaceutically
acceptable" means a non-toxic material that does not interfere with
the effectiveness of the biological activity of the active
ingredient(s). The characteristics of the carrier will depend on
the route of administration. The pharmaceutical composition of the
invention may also contain cytokines, lymphokines, or other
hematopoietic factors and various growth factors such as any of the
FGFs, epidermal growth factor (EGF), platelet-derived growth factor
(PDGF), transforming growth factors (TGF-.alpha. and TGF-.beta.),
insulin-like growth factor (IGF), keratinocyte growth factor (KGF),
and the like, as well as cytokines described herein.
[0231] The pharmaceutical composition may further contain other
agents which either enhance the activity of the protein or other
active ingredient or complement its activity or use in treatment.
Such additional factors and/or agents may be included in the
pharmaceutical composition to produce a synergistic effect with
protein or other active ingredient of the invention, or to minimize
side effects. Conversely, protein or other active ingredients of
the present invention may be included in formulations of the
particular cytokine, lymphokine, other hematopoietic factor,
thrombolytic or anti-thrombotic factor, or anti-inflammatory agent
to minimize side effects of the clotting factor, cytokine,
lymphokine, other hematopoietic factor, thrombolytic or
anti-thrombotic factor, or anti-inflammatory agent (such as IL-1
Ra, IL-1 Hy1, IL-1 Hy2, anti-TNF, corticosteroids,
immunosuppressive agents). A protein of the present invention may
be active in multimers (e.g., heterodimers or homodimers) or
complexes with itself or other proteins. As a result,
pharmaceutical compositions of the invention may comprise a protein
of the invention in such multimeric or complexed form.
[0232] As an alternative to being included in a pharmaceutical
composition of the invention including a first protein, a second
protein or a therapeutic agent may be concurrently administered
with the first protein (e.g., at the same time, or at differing
times provided that therapeutic concentrations of the combination
of agents is achieved at the treatment site). Techniques for
formulation and administration of the compounds of the instant
application may be found in "Remington's Pharmaceutical Sciences,"
Mack Publishing Co., Easton, Pa., latest edition. A therapeutically
effective dose further refers to that amount of the compound
sufficient to result in amelioration of symptoms, e.g., treatment,
healing, prevention or amelioration of the relevant medical
condition, or an increase in rate of treatment, healing, prevention
or amelioration of such conditions. When applied to an individual
active ingredient, administered alone, a therapeutically effective
dose refers to that ingredient alone. When applied to a
combination, a therapeutically effective dose refers to combined
amounts of the active ingredients that result in the therapeutic
effect, whether administered in combination, serially or
simultaneously.
[0233] In practicing the method of treatment or use of the present
invention, a therapeutically effective amount of protein or other
active ingredient of the present invention is administered to a
mammal having a condition to be treated. Protein or other active
ingredient of the present invention may be administered in
accordance with the method of the invention either alone or in
combination with other therapies such as treatments employing
cytokines, lymphokines or other hematopoietic factors. When
co-administered with one or more cytokines, lymphokines or other
hematopoietic factors, protein or other active ingredient of the
present invention may be administered either simultaneously with
the cytokine(s), lymphokine(s), other hematopoietic factor(s),
thrombolytic or anti-thrombotic factors, or sequentially. If
administered sequentially, the attending physician will decide on
the appropriate sequence of administering protein or other active
ingredient of the present invention in combination with
cytokine(s), lymphokine(s), other hematopoietic factor(s),
thrombolytic or anti-thrombotic factors.
[0234] 4.3.3 Routes of Administration
[0235] Suitable routes of administration may, for example, include
oral, rectal, transmucosal, or intestinal administration;
parenteral delivery, including intramuscular, subcutaneous,
intramedullary injections, as well as intrathecal, direct
intraventricular, intravenous, intraperitoneal, intranasal, or
intraocular injections. Administration of protein or other active
ingredient of the present invention used in the pharmaceutical
composition or to practice the method of the present invention can
be carried out in a variety of conventional ways, such as oral
ingestion, inhalation, topical application or cutaneous,
subcutaneous, intraperitoneal (IP), parenteral or intravenous
injection. Subcutaneous or intravenous administration to the
patient is preferred.
[0236] Alternatively, one may administer the compound in a local
rather than systemic manner, for example, via injection of the
compound directly into the tissue, often in a depot or sustained
release formulation.
[0237] In another embodiment, the implantation of cells producing
SCFA2, SCFA4 and SCFA4v (cell therapy) into a subject in need of
proliferation and/or stimulation of epithelial cells is
contemplated. Cells that do not normally express SCFA2, SCFA4 and
SCFA4v or that express low levels of SCFA2, SCFA4 and SCFA4v may be
modified to produce therapeutic levels of SCFA2, SCFA4 and SCFA4v
by transformation with a polynucleotide that encodes SCFA2, SCFA4
and SCFA4v. The cells may be of the same species as the subject, or
may be derived from a different species. Preferably, the cells are
derived from the subject in need of SCFA2, SCFA4 and SCFA4v
therapy. Human or nonhuman cells may be implanted in a subject
using a biocompatible, semi-permeable polymeric enclosure to allow
release of SCFA2, SCFA4 and SCFA4v protein, or may be implanted
directly without encapsulation.
[0238] In another embodiment, in vivo gene therapy is contemplated.
A nucleotide sequence encoding SCFA2, SCFA4 and SCFA4v is
introduced directly into a subject for secretion of the protein to
prevent or treat the diseases as recited herein. The nucleotide
encoding SCFA2, SCFA4 and SCFA4v may be injected directly into the
tissue to be treated, or it may be delivered into the cells of the
affected tissue by a viral vector e.g. adenovirus vector or
retrovirus vector. Physical transfer of appropriate vectors
containing a SCFA2, SCFA4 and SCFA4v-encoding nucleic acid may also
be achieved by methods including liposome-mediated transfer, direct
injection of naked DNA, receptor-mediated transfer, or
microparticle bombardment.
[0239] The polypeptides of the invention are administered by any
route that delivers an effective dosage to the desired site of
action. The determination of a suitable route of administration and
an effective dosage for a particular indication is within the level
of skill in the art. Preferably for wound treatment, one
administers the therapeutic compound directly to the site. Suitable
dosage ranges for the polypeptides of the invention can be
extrapolated from these dosages or from similar studies in
appropriate animal models. Dosages can then be adjusted as
necessary by the clinician to provide maximal therapeutic
benefit.
[0240] 4.3.4 Compositions/Formulations
[0241] Pharmaceutical compositions for use in accordance with the
present invention thus may be formulated in a conventional manner
using one or more physiologically acceptable carriers comprising
excipients and auxiliaries which facilitate processing of the
active compounds into preparations which can be used
pharmaceutically. These pharmaceutical compositions may be
manufactured in a manner that is itself known, e.g., by means of
conventional mixing, dissolving, granulating, dragee-making,
levigating, emulsifying, encapsulating, entrapping or lyophilizing
processes. Proper formulation is dependent upon the route of
administration chosen. When a therapeutically effective amount of
protein or other active ingredient of the present invention is
administered orally, protein or other active ingredient of the
present invention will be in the form of a tablet, capsule, powder,
solution or elixir. When administered in tablet form, the
pharmaceutical composition of the invention may additionally
contain a solid carrier such as a gelatin or an adjuvant. The
tablet, capsule, and powder contain from about 5 to 95% protein or
other active ingredient of the present invention, and preferably
from about 25 to 90% protein or other active ingredient of the
present invention. When administered in liquid form, a liquid
carrier such as water, petroleum, oils of animal or plant origin
such as peanut oil, mineral oil, soybean oil, or sesame oil, or
synthetic oils may be added. The liquid form of the pharmaceutical
composition may further contain physiological saline solution,
dextrose or other saccharide solution, or glycols such as ethylene
glycol, propylene glycol or polyethylene glycol. When administered
in liquid form, the pharmaceutical composition contains from about
0.5 to 90% by weight of protein or other active ingredient of the
present invention, and preferably from about 1 to 50% protein or
other active ingredient of the present invention.
[0242] When a therapeutically effective amount of protein or other
active ingredient of the present invention is administered by
intravenous, cutaneous or subcutaneous injection, protein or other
active ingredient of the present invention will be in the form of a
pyrogen-free, parenterally acceptable aqueous solution. The
preparation of such parenterally acceptable protein or other active
ingredient solutions, having due regard to pH, isotonicity,
stability, and the like, is within the skill in the art. A
preferred pharmaceutical composition for intravenous, cutaneous, or
subcutaneous injection should contain, in addition to protein or
other active ingredient of the present invention, an isotonic
vehicle such as Sodium Chloride Injection, Ringer's Injection,
Dextrose Injection, Dextrose and Sodium Chloride Injection,
Lactated Ringer's Injection, or other vehicle as known in the art.
The pharmaceutical composition of the present invention may also
contain stabilizers, preservatives, buffers, antioxidants, or other
additives known to those of skill in the art. For injection, the
agents of the invention may be formulated in aqueous solutions,
preferably in physiologically compatible buffers such as Hanks's
solution, Ringer's solution, or physiological saline buffer. For
transmucosal administration, penetrants appropriate to the barrier
to be permeated are used in the formulation. Such penetrants are
generally known in the art.
[0243] For oral administration, the compounds can be formulated
readily by combining the active compounds with pharmaceutically
acceptable carriers well known in the art. Such carriers enable the
compounds of the invention to be formulated as tablets, pills,
dragees, capsules, liquids, gels, syrups, slurries, suspensions and
the like, for oral ingestion by a patient to be treated.
Pharmaceutical preparations for oral use can be obtained solid
excipient, optionally grinding a resulting mixture, and processing
the mixture of granules, after adding suitable auxiliaries, if
desired, to obtain tablets or dragee cores. Suitable excipients
are, in particular, fillers such as sugars, including lactose,
sucrose, mannitol, or sorbitol; cellulose preparations such as, for
example, maize starch, wheat starch, rice starch, potato starch,
gelatin, gum tragacanth, methyl cellulose,
hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose,
and/or polyvinylpyrrolidone (PVP). If desired, disintegrating
agents may be added, such as the cross-linked polyvinyl
pyrrolidone, agar, or alginic acid or a salt thereof such as sodium
alginate. Dragee cores are provided with suitable coatings. For
this purpose, concentrated sugar solutions may be used, which may
optionally contain gum arabic, talc, polyvinyl pyrrolidone,
carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer
solutions, and suitable organic solvents or solvent mixtures.
Dyestuffs or pigments may be added to the tablets or dragee
coatings for identification or to characterize different
combinations of active compound doses.
[0244] Pharmaceutical preparations which can be used orally include
push-fit capsules made of gelatin, as well as soft, sealed capsules
made of gelatin and a plasticizer, such as glycerol or sorbitol.
The push-fit capsules can contain the active ingredients in
admixture with filler such as lactose, binders such as starches,
and/or lubricants such as talc or magnesium stearate and,
optionally, stabilizers. In soft capsules, the active compounds may
be dissolved or suspended in suitable liquids, such as fatty oils,
liquid paraffin, or liquid polyethylene glycols. In addition,
stabilizers may be added. All formulations for oral administration
should be in dosages suitable for such administration. For buccal
administration, the compositions may take the form of tablets or
lozenges formulated in conventional manner.
[0245] For administration by inhalation, the compounds for use
according to the present invention are conveniently delivered in
the form of an aerosol spray presentation from pressurized packs or
a nebuliser, with the use of a suitable propellant, e.g.,
dichlorodifluoromethane, trichlorofluoromethane,
dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In
the case of a pressurized aerosol the dosage unit may be determined
by providing a valve to deliver a metered amount. Capsules and
cartridges of, e.g., gelatin for use in an inhaler or insufflator
may be formulated containing a powder mix of the compound and a
suitable powder base such as lactose or starch. The compounds may
be formulated for parenteral administration by injection, e.g., by
bolus injection or continuous infusion. Formulations for injection
may be presented in unit dosage form, e.g., in ampules or in
multi-dose containers, with an added preservative. The compositions
may take such forms as suspensions, solutions or emulsions in oily
or aqueous vehicles, and may contain formulatory agents such as
suspending, stabilizing and/or dispersing agents.
[0246] Pharmaceutical formulations for parenteral administration
include aqueous solutions of the active compounds in water-soluble
form. Additionally, suspensions of the active compounds may be
prepared as appropriate oily injection suspensions. Suitable
lipophilic solvents or vehicles include fatty oils such as sesame
oil, or synthetic fatty acid esters, such as ethyl oleate or
triglycerides, or liposomes. Aqueous injection suspensions may
contain substances which increase the viscosity of the suspension,
such as sodium carboxymethyl cellulose, sorbitol, or dextran.
Optionally, the suspension may also contain suitable stabilizers or
agents which increase the solubility of the compounds to allow for
the preparation of highly concentrated solutions. Alternatively,
the active ingredient may be in powder form for constitution with a
suitable vehicle, e.g., sterile pyrogen-free water, before use.
[0247] The compounds may also be formulated in rectal compositions
such as suppositories or retention enemas, e.g., containing
conventional suppository bases such as cocoa butter or other
glycerides. In addition to the formulations described previously,
the compounds may also be formulated as a depot preparation. Such
long acting formulations may be administered by implantation (for
example subcutaneously or intramuscularly) or by intramuscular
injection. Thus, for example, the compounds may be formulated with
suitable polymeric or hydrophobic materials (for example as an
emulsion in an acceptable oil) or ion exchange resins, or as
sparingly soluble derivatives, for example, as a sparingly soluble
salt.
[0248] A pharmaceutical carrier for the hydrophobic compounds of
the invention is a co-solvent system comprising benzyl alcohol, a
nonpolar surfactant, a water-miscible organic polymer, and an
aqueous phase. The co-solvent system may be the VPD co-solvent
system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the
nonpolar surfactant polysorbate 80, and 65% w/v polyethylene glycol
300, made up to volume in absolute ethanol. The VPD co-solvent
system (VPD:5W) consists of VPD diluted 1:1 with a 5% dextrose in
water solution. This co-solvent system dissolves hydrophobic
compounds well, and itself produces low toxicity upon systemic
administration. Naturally, the proportions of a co-solvent system
may be varied considerably without destroying its solubility and
toxicity characteristics. Furthermore, the identity of the
co-solvent components may be varied: for example, other
low-toxicity nonpolar surfactants may be used instead of
polysorbate 80; the fraction size of polyethylene glycol may be
varied; other biocompatible polymers may replace polyethylene
glycol, e.g. polyvinyl pyrrolidone; and other sugars or
polysaccharides may substitute for dextrose. Alternatively, other
delivery systems for hydrophobic pharmaceutical compounds may be
employed. Liposomes and emulsions are well known examples of
delivery vehicles or carriers for hydrophobic drugs. Certain
organic solvents such as dimethylsulfoxide also may be employed,
although usually at the cost of greater toxicity. Additionally, the
compounds may be delivered using a sustained-release system, such
as semipermeable matrices of solid hydrophobic polymers containing
the therapeutic agent. Various types of sustained-release materials
have been established and are well known by those skilled in the
art. Sustained-release capsules may, depending on their chemical
nature, release the compounds for a few weeks up to over 100 days.
Depending on the chemical nature and the biological stability of
the therapeutic reagent, additional strategies for protein or other
active ingredient stabilization may be employed.
[0249] The pharmaceutical compositions also may comprise suitable
solid or gel phase carriers or excipients. Examples of such
carriers or excipients include but are not limited to calcium
carbonate, calcium phosphate, various sugars, starches, cellulose
derivatives, gelatin, and polymers such as polyethylene glycols.
Many of the active ingredients of the invention may be provided as
salts with pharmaceutically compatible counter ions. Such
pharmaceutically acceptable base addition salts are those salts
which retain the biological effectiveness and properties of the
free acids and which are obtained by reaction with inorganic or
organic bases such as sodium hydroxide, magnesium hydroxide,
ammonia, trialkylamine, dialkylamine, monoalkylamine, dibasic amino
acids, sodium acetate, potassium benzoate, triethanol amine and the
like.
[0250] The pharmaceutical composition of the invention may be in
the form of a complex of the protein(s) or other active ingredient
of present invention along with protein or peptide antigens. The
protein and/or peptide antigen will deliver a stimulatory signal to
both B and T lymphocytes. B lymphocytes will respond to antigen
through their surface immunoglobulin receptor. T lymphocytes will
respond to antigen through the T cell receptor (TCR) following
presentation of the antigen by MHC proteins. MHC and structurally
related proteins including those encoded by class I and class II
MHC genes on host cells will serve to present the peptide
antigen(s) to T lymphocytes. The antigen components could also be
supplied as purified MHC-peptide complexes alone or with
co-stimulatory molecules that can directly signal T cells.
Alternatively antibodies able to bind surface immunoglobulin and
other molecules on B cells as well as antibodies able to bind the
TCR and other molecules on T cells can be combined with the
pharmaceutical composition of the invention.
[0251] The pharmaceutical composition of the invention may be in
the form of a liposome in which protein of the present invention is
combined, in addition to other pharmaceutically acceptable
carriers, with amphipathic agents such as lipids which exist in
aggregated form as micelles, insoluble monolayers, liquid crystals,
or lamellar layers in aqueous solution. Suitable lipids for
liposomal formulation include, without limitation, monoglycerides,
diglycerides, sulfatides, lysolecithins, phospholipids, saponin,
bile acids, and the like. Preparation of such liposomal
formulations is within the level of skill in the art, as disclosed,
for example, in U.S. Pat. Nos. 4,235,871; 4,501,728; 4,837,028; and
4,737,323, all of which are incorporated herein by reference.
[0252] The amount of protein or other active ingredient of the
present invention in the pharmaceutical composition of the present
invention will depend upon the nature and severity of the condition
being treated, and on the nature of prior treatments which the
patient has undergone. Ultimately, the attending physician will
decide the amount of protein or other active ingredient of the
present invention with which to treat each individual patient.
Initially, the attending physician will administer low doses of
protein or other active ingredient of the present invention and
observe the patient's response. Larger doses of protein or other
active ingredient of the present invention may be administered
until the optimal therapeutic effect is obtained for the patient,
and at that point the dosage is not increased further. It is
contemplated that the various pharmaceutical compositions used to
practice the method of the present invention should contain about
0.01 .mu.g to about 100 mg (preferably about 0.1 .mu.g to about 10
mg, more preferably about 0.1 .mu.g to about 1 mg) of protein or
other active ingredient of the present invention per kg body
weight. For compositions of the present invention which are useful
for bone, cartilage, tendon or ligament regeneration, the
therapeutic method includes administering the composition
topically, systematically, or locally as an implant or device. When
administered, the therapeutic composition for use in this invention
is, of course, in a pyrogen-free, physiologically acceptable form.
Further, the composition may desirably be encapsulated or injected
in a viscous form for delivery to the site of bone, cartilage or
tissue damage. Topical administration may be suitable for wound
healing and tissue repair. Therapeutically useful agents other than
a protein or other active ingredient of the invention which may
also optionally be included in the composition as described above,
may alternatively or additionally, be administered simultaneously
or sequentially with the composition in the methods of the
invention. Preferably for bone and/or cartilage formation, the
composition would include a matrix capable of delivering the
protein-containing or other active ingredient-containing
composition to the site of bone and/or cartilage damage, providing
a structure for the developing bone and cartilage and optimally
capable of being resorbed into the body. Such matrices may be
formed of materials presently in use for other implanted medical
applications.
[0253] The choice of matrix material is based on biocompatibility,
biodegradability, mechanical properties, cosmetic appearance and
interface properties. The particular application of the
compositions will define the appropriate formulation. Potential
matrices for the compositions may be biodegradable and chemically
defined calcium sulfate, tricalcium phosphate, hydroxyapatite,
polylactic acid, polyglycolic acid and polyanhydrides. Other
potential materials are biodegradable and biologically
well-defined, such as bone or dermal collagen. Further matrices are
comprised of pure proteins or extracellular matrix components.
Other potential matrices are nonbiodegradable and chemically
defined, such as sintered hydroxyapatite, bioglass, aluminates, or
other ceramics. Matrices may be comprised of combinations of any of
the above mentioned types of material, such as polylactic acid and
hydroxyapatite or collagen and tricalcium phosphate. The
bioceramics may be altered in composition, such as in
calcium-aluminate-phosphate and processing to alter pore size,
particle size, particle shape, and biodegradability. Presently
preferred is a 50:50 (mole weight) copolymer of lactic acid and
glycolic acid in the form of porous particles having diameters
ranging from 150 to 800 microns. In some applications, it will be
useful to utilize a sequestering agent, such as carboxymethyl
cellulose or autologous blood clot, to prevent the protein
compositions from disassociating from the matrix.
[0254] A preferred family of sequestering agents is cellulosic
materials such as alkylcelluloses (including
hydroxyalkylcelluloses), including methylcellulose, ethylcellulose,
hydroxyethylcellulose, hydroxypropylcellulose,
hydroxypropyl-methylcellulose, and carboxymethylcellulose, the most
preferred being cationic salts of carboxymethylcellulose (CMC).
Other preferred sequestering agents include hyaluronic acid, sodium
alginate, poly(ethylene glycol), polyoxyethylene oxide,
carboxyvinyl polymer and poly(vinyl alcohol). The amount of
sequestering agent useful herein is 0.5-20 wt %, preferably 1-10 wt
% based on total formulation weight, which represents the amount
necessary to prevent desorption of the protein from the polymer
matrix and to provide appropriate handling of the composition, yet
not so much that the progenitor cells are prevented from
infiltrating the matrix, thereby providing the protein the
opportunity to assist the osteogenic activity of the progenitor
cells. In further compositions, proteins or other active ingredient
of the invention may be combined with other agents beneficial to
the treatment of the bone and/or cartilage defect, wound, or tissue
in question. These agents include various growth factors such as
epidermal growth factor (EGF), platelet derived growth factor
(PDGF), transforming growth factors (TGF-.alpha. and TGF-.beta.),
and insulin-like growth factor (IGF).
[0255] The therapeutic compositions are also presently valuable for
veterinary applications. Particularly domestic animals and
thoroughbred horses, in addition to humans, are desired patients
for such treatment with proteins or other active ingredient of the
present invention. The dosage regimen of a protein-containing
pharmaceutical composition to be used in tissue regeneration will
be determined by the attending physician considering various
factors which modify the action of the proteins, e.g., amount of
tissue weight desired to be formed, the site of damage, the
condition of the damaged tissue, the size of a wound, type of
damaged tissue (e.g., bone), the patient's age, sex, and diet, the
severity of any infection, time of administration and other
clinical factors. The dosage may vary with the type of matrix used
in the reconstitution and with inclusion of other proteins in the
pharmaceutical composition. For example, the addition of other
known growth factors, such as IGF I (insulin like growth factor I),
to the final composition, may also effect the dosage. Progress can
be monitored by periodic assessment of tissue/bone growth and/or
repair, for example, X-rays, histomorphometric determinations and
tetracycline labeling.
[0256] Polynucleotides of the present invention can also be used
for gene therapy. Such polynucleotides can be introduced either in
vivo or ex vivo into cells for expression in a mammalian subject.
Polynucleotides of the invention may also be administered by other
known methods for introduction of nucleic acid into a cell or
organism (including, without limitation, in the form of viral
vectors or naked DNA). Cells may also be cultured ex vivo in the
presence of proteins of the present invention in order to
proliferate or to produce a desired effect on or activity in such
cells. Treated cells can then be introduced in vivo for therapeutic
purposes.
[0257] 4.3.5 Effective Dosage
[0258] Pharmaceutical compositions suitable for use in the present
invention include compositions wherein the active ingredients are
contained in an effective amount to achieve its intended purpose.
More specifically, a therapeutically effective amount means an
amount effective to prevent development of or to alleviate the
existing symptoms of the subject being treated. Determination of
the effective amount is well within the capability of those skilled
in the art, especially in light of the detailed disclosure provided
herein. For any compound used in the method of the invention, the
therapeutically effective dose can be estimated initially from
appropriate in vitro assays. For example, a dose can be formulated
in animal models to achieve a circulating concentration range that
can be used to more accurately determine useful doses in humans.
For example, a dose can be formulated in animal models to achieve a
circulating concentration range that includes the IC.sub.50 as
determined in cell culture (La, the concentration of the test
compound which achieves a half-maximal inhibition of the protein's
biological activity). Such information can be used to more
accurately determine useful doses in humans.
[0259] A therapeutically effective dose refers to that amount of
the compound that results in amelioration of symptoms or a
prolongation of survival in a patient. Toxicity and therapeutic
efficacy of such compounds can be determined by standard
pharmaceutical procedures in cell cultures or experimental animals,
e.g., for determining the LD.sub.50 (the dose lethal to 50% of the
population) and the ED.sub.50 (the dose therapeutically effective
in 50% of the population). The dose ratio between toxic and
therapeutic effects is the therapeutic index and it can be
expressed as the ratio between LD.sub.50 and ED.sub.50. Compounds
which exhibit high therapeutic indices are preferred. The data
obtained from these cell culture assays and animal studies can be
used in formulating a range of dosage for use in human. The dosage
of such compounds lies preferably within a range of circulating
concentrations that include the ED.sub.50 with little or no
toxicity. The dosage may vary within this range depending upon the
dosage form employed and the route of administration utilized. The
exact formulation, route of administration and dosage can be chosen
by the individual physician in view of the patient's condition.
See, e.g., Fingl et al., 1975, in "The Pharmacological Basis of
Therapeutics", Ch. 1 p. 1. Dosage amount and interval may be
adjusted individually to provide plasma levels of the active moiety
which are sufficient to maintain the desired effects, or minimal
effective concentration (MEC). The MEC will vary for each compound
but can be estimated from in vitro data. Dosages necessary to
achieve the MEC will depend on individual characteristics and route
of administration. However, HPLC assays or bioassays can be used to
determine plasma concentrations.
[0260] Dosage intervals can also be determined using MEC value.
Compounds should be administered using a regimen which maintains
plasma levels above the MEC for 10-90% of the time, preferably
between 30-90% and most preferably between 50-90%. In cases of
local administration or selective uptake, the effective local
concentration of the drug may not be related to plasma
concentration.
[0261] An exemplary dosage regimen for polypeptides or other
compositions of the invention will be in the range of about 0.01
.mu.g/kg to 100 mg/kg of body weight daily, with the preferred dose
being about 0.1 .mu.g/kg to 25 mg/kg of patient body weight daily,
varying in adults and children. Dosing may be once daily, or
equivalent doses may be delivered at longer or shorter
intervals.
[0262] The amount of composition administered will, of course, be
dependent on the subject being treated, on the subject's age and
weight, the severity of the affliction, the manner of
administration and the judgment of the prescribing physician.
[0263] 4.3.6 Diagnostic Assays and Kits
[0264] The present invention further provides methods to identify
the presence or expression of one of the ORFs of the present
invention, or homolog thereof, in a test sample, using a nucleic
acid probe or antibodies of the present invention, optionally
conjugated or otherwise associated with a suitable label.
[0265] In general, methods for detecting a polynucleotide of the
invention can comprise contacting a sample with a compound that
binds to and forms a complex with the polynucleotide for a period
sufficient to form the complex, and detecting the complex, so that
if a complex is detected, a polynucleotide of the invention is
detected in the sample. Such methods can also comprise contacting a
sample under stringent hybridization conditions with nucleic acid
primers that anneal to a polynucleotide of the invention under such
conditions, and amplifying annealed polynucleotides, so that if a
polynucleotide is amplified, a polynucleotide of the invention is
detected in the sample.
[0266] In general, methods for detecting a polypeptide of the
invention can comprise contacting a sample with a compound that
binds to and forms a complex with the polypeptide for a period
sufficient to form the complex, and detecting the complex, so that
if a complex is detected, a polypeptide of the invention is
detected in the sample.
[0267] In detail, such methods comprise incubating a test sample
with one or more of the antibodies or one or more of the nucleic
acid probes of the present invention and assaying for binding of
the nucleic acid probes or antibodies to components within the test
sample.
[0268] Conditions for incubating a nucleic acid probe or antibody
with a test sample vary. Incubation conditions depend on the format
employed in the assay, the detection methods employed, and the type
and nature of the nucleic acid probe or antibody used in the assay.
One skilled in the art will recognize that any one of the commonly
available hybridization, amplification or immunological assay
formats can readily be adapted to employ the nucleic acid probes or
antibodies of the present invention. Examples of such assays can be
found in Chard, T., An Introduction to Radioimmunoassay and Related
Techniques, Elsevier Science Publishers, Amsterdam, The Netherlands
(1986); Bullock, G. R. et al., Techniques in Immunocytochemistry,
Academic Press, Orlando, Fla. Vol. 1 (1982), Vol. 2 (1983), Vol. 3
(1985); Tijssen, P., Practice and Theory of immunoassays:
Laboratory Techniques in Biochemistry and Molecular Biology,
Elsevier Science Publishers, Amsterdam, The Netherlands (1985). The
test samples of the present invention include cells, protein or
membrane extracts of cells, or biological fluids such as sputum,
blood, serum, plasma, or urine. The test sample used in the
above-described method will vary based on the assay format, nature
of the detection method and the tissues, cells or extracts used as
the sample to be assayed. Methods for preparing protein extracts or
membrane extracts of cells are well known in the art and can be
readily be adapted in order to obtain a sample which is compatible
with the system utilized.
[0269] In another embodiment of the present invention, kits are
provided which contain the necessary reagents to carry out the
assays of the present invention. Specifically, the invention
provides a compartment kit to receive, in close confinement, one or
more containers which comprises: (a) a first container comprising
one of the probes or antibodies of the present invention; and (b)
one or more other containers comprising one or more of the
following: wash reagents, reagents capable of detecting presence of
a bound probe or antibody.
[0270] In detail, a compartment kit includes any kit in which
reagents are contained in separate containers. Such containers
include small glass containers, plastic containers or strips of
plastic or paper. Such containers allows one to efficiently
transfer reagents from one compartment to another compartment such
that the samples and reagents are not cross-contaminated, and the
agents or solutions of each container can be added in a
quantitative fashion from one compartment to another. Such
containers will include a container which will accept the test
sample, a container which contains the antibodies used in the
assay, containers which contain wash reagents (such as phosphate
buffered saline, Tris-buffers, etc.), and containers which contain
the reagents used to detect the bound antibody or probe. Types of
detection reagents include labeled nucleic acid probes, labeled
secondary antibodies, or in the alternative, if the primary
antibody is labeled, the enzymatic, or antibody binding reagents
which are capable of reacting with the labeled antibody. One
skilled in the art will readily recognize that the disclosed probes
and antibodies of the present invention can be readily incorporated
into one of the established kit formats which are well known in the
art.
[0271] 4.3.7 Screening Assays
[0272] Using the isolated proteins and polynucleotides of the
invention, the present invention further provides methods of
obtaining and identifying modulatory agents which bind to a
polypeptide encoded by an ORF corresponding to the nucleotide
sequence set forth in SEQ ID NO: 4, 15, 24, or 50, or bind to a
specific domain of the polypeptide encoded by the nucleic acid. In
detail, said method comprises the steps of:
[0273] (a) contacting an agent with an isolated protein encoded by
an ORF of the present invention, or nucleic acid of the invention;
and
[0274] (b) determining whether the agent binds to said protein or
said nucleic acid.
[0275] The modulatory agents may increase or decrease the
proliferative activity of SCFA2, SCFA4 and SCFA4v on epithelial
cells.
[0276] In general, such methods for identifying compounds that bind
to a polynucleotide of the invention can comprise contacting a
compound with a polynucleotide of the invention for a time
sufficient to form a polynucleotide/compound complex, and detecting
the complex, so that if a polynucleotide/compound complex is
detected, a compound that binds to a polynucleotide of the
invention is identified.
[0277] Likewise, in general, therefore, such methods for
identifying compounds that bind to a polypeptide of the invention
can comprise contacting a compound with a polypeptide of the
invention for a time sufficient to form a polypeptide/compound
complex, and detecting the complex, so that if a
polypeptide/compound complex is detected, a compound that binds to
a polynucleotide of the invention is identified.
[0278] Methods for identifying compounds that bind to a polypeptide
of the invention can also comprise contacting a compound with a
polypeptide of the invention in a cell for a time sufficient to
form a polypeptide/compound complex, wherein the complex drives
expression of a target gene sequence in the cell, and detecting the
complex by detecting reporter gene sequence expression, so that if
a polypeptide/compound complex is detected, a compound that binds a
polypeptide of the invention is identified.
[0279] Compounds identified via such methods can include compounds
which modulate the activity of a polypeptide of the invention (that
is, increase or decrease its activity, relative to activity
observed in the absence of the compound). Alternatively, compounds
identified via such methods can include compounds which modulate
the expression of a polynucleotide of the invention (that is,
increase or decrease expression relative to expression levels
observed in the absence of the compound). Compounds, such as
compounds identified via the methods of the invention, can be
tested using standard assays well known to those of skill in the
art for their ability to modulate activity/expression.
[0280] The agents screened in the above assay can be, but are not
limited to, peptides, carbohydrates, vitamin derivatives, or other
pharmaceutical agents. The agents can be selected and screened at
random or rationally selected or designed using protein modeling
techniques.
[0281] For random screening, agents such as peptides,
carbohydrates, pharmaceutical agents and the like are selected at
random and are assayed for their ability to bind to the protein
encoded by the ORF of the present invention. Alternatively, agents
may be rationally selected or designed. As used herein, an agent is
said to be "rationally selected or designed" when the agent is
chosen based on the configuration of the particular protein. For
example, one skilled in the art can readily adapt currently
available procedures to generate peptides, pharmaceutical agents
and the like, capable of binding to a specific peptide sequence, in
order to generate rationally designed antipeptide peptides, for
example see Hurby et al., Application of Synthetic Peptides:
Antisense Peptides," In Synthetic Peptides, A User's Guide, W.H.
Freeman, NY (1992), pp. 289-307, and Kaspczak et al., Biochemistry
28:9230-8 (1989), or pharmaceutical agents, or the like.
[0282] In addition to the foregoing, one class of agents of the
present invention, as broadly described, can be used to control
gene expression through binding to one of the ORFs or EMFs of the
present invention. As described above, such agents can be randomly
screened or rationally designed/selected. Targeting the ORF or EMF
allows a skilled artisan to design sequence specific or element
specific agents, modulating the expression of either a single ORF
or multiple ORFs which rely on the same EMF for expression control.
One class of DNA binding agents are agents which contain base
residues which hybridize or form a triple helix formation by
binding to DNA or RNA. Such agents can be based on the classic
phosphodiester, ribonucleic acid backbone, or can be a variety of
sulfhydryl or polymeric derivatives which have base attachment
capacity.
[0283] Agents suitable for use in these methods usually contain 20
to 40 bases and are designed to be complementary to a region of the
gene involved in transcription (triple helix--see Lee et al., Nucl.
Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988);
and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself
(antisense--Okano, J. Neurochem. 56:560 (1991);
Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression,
CRC Press, Boca Raton, Fla. (1988)). Triple helix-formation
optimally results in a shut-off of RNA transcription from DNA,
while antisense RNA hybridization blocks translation of an mRNA
molecule into polypeptide. Both techniques have been demonstrated
to be effective in model systems. Information contained in the
sequences of the present invention is necessary for the design of
an antisense or triple helix oligonucleotide and other DNA binding
agents.
[0284] Agents which bind to a protein encoded by one of the ORFs of
the present invention can be used as a diagnostic agent. Agents
which bind to a protein encoded by one of the ORFs of the present
invention can be formulated using known techniques to generate a
pharmaceutical composition.
5. EXAMPLES
Example 1
Isolation of SEQ ID NO: 1 from a cDNA Library of Human Cells
[0285] The novel nucleic acid of SEQ ID NO: 1 was obtained from a
human cDNA library prepared from adult brain, using standard PCR,
sequencing by hybridization sequence signature analysis, and Sanger
sequencing techniques. The insert of the library was amplified with
PCR using primers specific for vector sequences flanking the
inserts. The sample was spotted onto nylon membranes and
interrogated with oligonucleotide probes to give sequence
signatures. The clones were clustered into a group of similar or
identical sequences, and a single representative clone was selected
for gel sequencing. The 5' sequence of the amplified insert was
then deduced using the reverse M13 sequencing primer in a typical
Sanger sequencing protocol. PCR products were purified and
subjected to fluorescent dye terminator cycle sequencing.
Single-pass gel sequencing was done using a 377 Applied Biosystems
(ABI) sequencer. The insert of SEQ ID NO: 1 was described in
co-owned international publication WO 03/029405.
Example 2
Assemblage of SEQ ID NO: 2
[0286] The nucleic acid encoding SCFA2 (SEQ ID NO: 2) was assembled
from sequences that were obtained from a cDNA library by methods
described in Example 1 above, and in some cases obtained from one
or more public databases. The final sequence was assembled using
the EST sequence as seed. Then a recursive algorithm was used to
extend the seed into an extended assemblage, by pulling additional
sequences from different databases (i.e. Hyseq's database
containing EST sequences, dbEST version 124, gbpri 124, and UniGene
version 124) that belong to this assemblage. The algorithm
terminated when there were no additional sequences from the above
databases that would extend the assemblage. Inclusion of component
sequences into the assemblage was based on a BLASTN hit to the
extending assemblage with BLAST score greater than 300 and percent
identity greater than 95%.
[0287] Using PHRAP (Univ. of Washington) or CAP4 (Paracel), a
full-length gene cDNA sequence and its corresponding protein
sequence were generated from the assemblage. Any frame shifts and
incorrect stop codons were corrected by hand editing. During
editing, the sequence was checked using FASTY and BLAST against
Genbank (i.e. dbEST version 124, gbpri 124, UniGene version 124,
Genpept release 124). Other computer programs which may have been
used in the editing process were phredPhrap and Consed (University
of Washington) and ed-ready, ed-ext and cg-zip-2 (Hyseq, Inc.). The
full-length nucleotide and amino acid sequences are shown in the
Sequence Listing as SEQ ID NOS: 2 and 3, respectively. SEQ ID NO: 2
and 3 were described previously in co-owned international
publication WO 03/029405.
Example 3
Cloning and Expression of SCFA2, SCFA4 AND SCFA4v
[0288] In order to express SCFA2 polypeptide, the full-length SCFA2
DNA (SEQ ID NO: 2) was PCR amplified from a cDNA library that was
constructed using human mRNA from cerebellum (Ambion). The sequence
was also isolated from pools of cDNAs that were derived from human
mRNAs from various tissues. The first round of PCR was performed
using the forward primer (SEQ ID NO: 27) and reverse primer (SEQ ID
NO: 28) 5'-GAGCAGCACAAAGGCTGCAC-3'. A second round of PCR was then
performed using the primary PCR as template using the forward
primer SEQ ID NO: 29 and reverse primer of SEQ ID NO: 30. The
restriction sites NheI and XbaI, which are embedded in the forward
and reverse primers (SEQ ID NO: 29 and 30) were used for subcloning
of the NheI-XbaI fragment into the mammalian expression vector
pintron/Ig.kappa.. The NheI-XbaI fragment contains polynucleotide
sequence (SEQ ID NO: 5) which encodes the amino acid sequence of
SCFA2 that lacks the signal peptide (SEQ ID NO: 6) and stop codon.
The mammalian expression vector pintron/Ig.kappa. was obtained by
genetically modifying the pSectag vector (Invitrogen Inc.,
Carlsbad, Calif.) by introducing an engineered chimeric intron
derived from the pCI mammalian expression vector (Promega, Madison,
Wis.) as follows. A fragment of the pCI vector containing the pCMV
and intron sequence was excised from the pCI vector using BglII and
NheI restriction enzymes, and subcloned into the pSectag vector,
from which its sequence flanked by BglII and NheI had been
removed.
[0289] cDNA encoding SCFA2.DELTA.C was isolated from the cDNA pools
described above using PCR. PCR was performed using the forward
primer of SEQ ID NO: 52 and the reverse primer of SEQ ID NO: 53.
The NheI and XbaI sites contained in the primers were used to
subclone the NheI-XbaI fragment of SCFA2.DELTA. into the mammalian
expression vector pintron/Ig.kappa.. The NheI-XbaI fragment of
SCFA2.DELTA.C contains the polynucleotide sequence (SEQ ID NO: 50)
which encodes the amino acid sequence of SEQ ID NO: 51.
[0290] cDNAs encoding SCFA4 and SCFA4v were isolated from the cDNA
pools described above using PCR. The first round of PCR was
performed using the forward primer of SEQ ID NO: 31 and the reverse
primer of SEQ ID NO: 32. Ethidium bromide staining of the agarose
gels that were used to resolve the PCR products revealed that two
distinct inserts had been amplified from each of the cDNA
libraries. The sequence of each insert was determined. One insert
contained the sequence that encodes SCFA4 (SEQ ID NO: 13), while
the second insert contained a sequence that encodes a variant of
SCFA4 (SEQ ID NO: 22), identified herein as SCFA4v.
[0291] A second round of PCR was performed using the primary PCR as
a template and using the forward primer of SEQ ID NO: 33 and the
reverse primer of SEQ ID NO: 34. The NheI and XbaI sites contained
in the primers were used to subclone the NheI -XbaI fragment of
SCFA4 and SCFA4v into the mammalian expression vector
pintron/Ig.kappa.. The NheI-XbaI fragment of SCFA4 contains the
polynucleotide sequence (SEQ ID NO: 16), which encodes the amino
acid sequence of SCFA4 that lacks the signal peptide (SEQ ID NO:
17) and the stop codon. The NheI-XbaI fragment of SCFA4v contains
polynucleotide sequence (SEQ ID NO: 25), which encodes the amino
acid sequence of SCFA4 that lacks the signal peptide (SEQ ID NO:
26) and the stop codon.
Example 4
The Adenoviral Vector
[0292] The polynucleotides encoding the dominant mature forms of
SCFA2 (SEQ ID NO: 5), SCFA4 (SEQ ID NO: 16), and SCFA4v (SEQ ID NO:
25), as well as the C-terminal deletion of SCFA2, SCFA2.DELTA.C
(SEQ ID NO: 51) were amplified from the pIntron/Ig.kappa. vector
together with the Ig.kappa. leader sequence and the V5H is6 tag of
the pIntron/Ig.kappa. vector, and cloned into the
pAdenovator-CMVIntron adenoviral vector (SEQ ID NO: 47) as follows.
The polynucleotide sequence (SEQ ID NO: 35) that encodes
pintron-SCFA2-V5H is6 (SEQ ID NO: 36) was amplified from the
pintron/Ig.kappa. using the forward primer of SEQ ID NO: 37 and the
reverse primer of SEQ ID NO: 38. The restriction enzyme sites XbaI
and NotI that are contained in the primers were used to clone SEQ
ID NO: 35 into the NheI and NotI sites of the pAdenovator-CMVIntron
vector (SEQ ID NO: 47).
[0293] The polynucleotide sequence (SEQ ID NO: 39) that encodes
pIntron-SCFA4-V5H is6 (SEQ ID NO: 40) was amplified from the
pintron/Ig.kappa. using the forward primer of SEQ ID NO: 41 and the
reverse primer of SEQ ID NO: 42. The restriction enzyme sites XbaI
and NotI that are contained in the primers were used to clone SEQ
ID NO: 39 into the NheI and NotI sites of the pAdenovator-CMVIntron
vector (SEQ ID NO: 47).
[0294] The primers of SEQ ID NO: 40 and 41 were also used to
amplify the polynucleotide sequence (SEQ ID NO: 43) that encodes
pintron-SCFA4v-V5H is6 (SEQ ID NO: 44). SEQ ID NO: 43 was subcloned
into the pAdenovator-CMVIntron vector using the XbaI and NotI
sites, as described above.
[0295] The polynucleotide sequence (SEQ ID NO: 54) that encodes
pIntron-SCFA2.DELTA.C-V5His6 (SEQ ID NO: 55) was amplified from the
pintron/Ig.kappa. and cloned into the NheI and NotI sites of the
pAdenovator-CMVIntron vector (SEQ ID NO: 47).
[0296] The adenoviral vector pAdenovator-CMVIntron was obtained by
modifying the pAdenoVator CMV5-IRES-GFP (Qbiogene, Carlsbad,
Calif., U.S. as follows. pAdenoVator-CMV5-IRES-GFP was digested
with SpeI to remove its MCS, IRES and GFP and ligated with PCR
amplified Intron-MCS-V5His-BGH polyA from pcDNA/Intron vector using
forward primer (SEQ ID NO: 45) and reverse primer (SEQ ID
NO:46).
[0297] Transformation of linearized transfer vector into bacterial
cells, BJ5183, (Qbiogene, Carlsbad, Calif., U.S.A) which carry
AdEasy-1 plasmid that encode Adenovirus-5 genome (E1/E3 deleted)
was performed by electroporation according to the manufacturer's
instructions. Recombinant adenovirus was generated and amplified in
QBI-293A cells (Qbiogene, Carlsbad, Calif., U.S.A) and purified by
CsCl banding as previously described (Garnier, A., J. Cote et al.
1994). Recombinant protein expression by 293A cells that had been
infected with the recombinant adenovirus was measured by Western
analysis using anti-V5 antibody (Invitrogene Inc., Carlsbad,
Calif.). The titer of CsCl purified recombinant viruses was
measured using the Adeno-X rapid titer kit (BD Biosciences, Palo
Alto, U.S.A.) according to the manufacturer's protocols. Briefly, a
viral stock was tested by infecting 293A cells with serial
dilutions of the recombinant adenovirus stock followed by fixation
and staining of the transduced cells with mouse anti-hexon antibody
48 hours after infection. The signal was detected with a goat
anti-mouse antibody conjugated to horseradish peroxidase and
developed with metal-enhanced 3,3'-diaminobenzidine
tetrahydro-chloride (DAB).
Example 5
Administration of Recombinant Adenovirus as a Model to Evaluate the
Biological Activity of SCFA2, SCFA4, and SCFA4v
[0298] The SCFA2, SCFA4, and SCFA4v recombinant adenovirus was
administered to normal mice to determine the effect SCFA2, SCFA4,
and SCFA4v on the intestinal and colonic epithelium. Prior to
injection of adenovirus, BALB/c mice, 9-11 weeks of age, were
anesthetized using isoflurane. 1.times.10.sup.10 viral particles
per mouse were injected via the retro-orbital vein. The same titer
of control virus (empty virus) or PBS alone was used as controls. A
total of 46 mice were used in the study. Mice were sacrificed 3
days after receiving the virus injection. 4 hours before sacrifice,
1 mg of bromodeoxyuridine (BrdU) was injected intraperitoneally
(IP) to determine in vivo proliferation of epithelial cells.
Various tissues including small intestine, colon, spleen, liver and
bone marrow were collected and fixed in formaline. Paraffin
embedded sections were stained with hematoxyline and eosin
(H&E) for histological evaluation. Sections were also processed
for BrdU immunohistochemistry according to the manufacturer's
instruction (Oncogene Research product, Boston, U.S.A.) as
previously described (McKinley, J. N. et al. 2000).
Immunohistochemistry using monoclonal rat anti-mouse Ki67 antigen
(Dako Ltd., High Wycombe, UK) is also performed to assess the
proliferation of intestinal epithelial cells according to the
method previously described (Scholzen, T. et al. 2000).
[0299] H&E staining of sections from the small intestine that
had been sacrificed 3 days following the adenovirus injection (FIG.
4) show that the small intestine of mice that had received the
SCFA2, SCFA4, or SCFA4v adenovirus was significantly altered. The
histological changes caused by SCFA2, SCFA4, and SCFA4v included a
marked, diffuse thickening of the mucosa by crypt epithelial
hyperplasia with a marked increased in crypt length and complexity
of branching. In addition to the effect seen in the small
intestine, SCFA2, SCFA4, and SCFA4v also induced crypt epithelial
hyperplasia with a marked increased in crypt length and an
increased number and size of Goblet cells in the colon.
[0300] To evaluate the effect of SCFA2, SCFA4, and SCFA4v on the
proliferation of intestinal epithelial cells, BrdU incorporation
was performed on sections from the small intestine and the colon of
control mice and mice that had received SCFA2, SCFA4, and SCFA4v
adenovirus. As shown in FIG. 5, the mice that had received the
SCFA2, SCFA4, or SCFA4v adenovirus had small intestinal and colonic
crypts that had significantly more BrdU positive cells, when
compared to the small intestine from the control animals. Thus,
SCFA2, SCFA4, and SCFA4v stimulate the proliferation of
gastrointestinal epithelial cells.
Example 6
Prophylactic Effect of SCFA2, SCFA4 and SCFA4v On Radiation-Induced
Mucositis
[0301] The efficacy of SCFA2, SCFA4 or SCFA4v as a prophylactic and
therapeutic agent is tested in an animal model of radiation-induced
mucositis.
[0302] Forty eight adult male BDF1 mice, aged 10-12 weeks, are
used. On delivery from the supplier and prior to the experiment,
the animals are housed for two weeks in individually ventilated
cages on a 12 hour light:dark cycle to stabilize the circadian
rhythm. Animals are allowed food and water ad libitum. The animals
are divided into 8 groups of 6 animals, and treated as follows:
[0303] 1. Injected with 2 mg/kg SCFA2, SCFA4 or SCFA4v iv at 72,
48, and 24 hours prior to being exposed to 13 Gy X-ray (whole
body); [0304] 2. Injected with 5 mg/kg SCFA2, SCFA4 or SCFA4v iv at
72, 48, and 24 hours prior to being exposed to 13 Gy X-ray (whole
body); [0305] 3. Injected with 125 .mu.g KGF iv at 72, 48, and 24
hours prior to being exposed to 13 Gy X-ray (whole body); [0306] 4.
Injected with saline vehicle iv at 72, 48, and 24 hours prior to
being exposed to 13 Gy X-ray (whole body); [0307] 5. Untreated,
non-irradiated controls; [0308] 6. Injected with 2 mg/kg SCFA2,
SCFA4 or SCFA4v iv 24, 48, and 72 hours post irradiation with 13 Gy
X-rays (whole body); [0309] 7. Injected with 5 mg/kg SCFA2, SCFA4
or SCFA4v iv 24, 48, and 72 hours post irradiation with 13 Gy
X-rays (whole body); [0310] 8. Injected with saline iv at 24, 48,
and 72 hours post irradiation with 13 Gy X-rays (whole body).
[0311] All injections are given at the same time of day. Intestinal
damage is induced using a single dose of 13 Gy X-irradiation
(delivered at 0.7 Gy/min) at 15:00.
[0312] Four days after irradiation the animals are sacrificed. The
small intestine is removed and fixed in Carnoy's fixative prior to
processing for histological analysis. Transverse sections 3 .mu.m
thick are cut and stained with haematoxylin and eosin
(H&E).
[0313] Immediately after sacrifice, the duodenum, mid-colon, liver,
lung, tongue, spleen, stomach and pancreas are also removed and
fixed in formal saline overnight prior to storage in 70%
ethanol.
[0314] For each animal, ten intestinal circumferences are analyzed
(60 per group)--a circumference is equivalent to a given length of
intestine and therefore a convenient baseline unit of length. The
number of surviving crypts per circumference is scored and the
average per group determined.
[0315] The average crypt width (measured at its widest point) is
also measured in order to correct for scoring errors due to crypt
size difference. The correction is applied thus:
Corrected number of crypts / circumference = Mean crypt width in
untreated control Mean crypt width in treated animal .times. Mean
number of surviving crypts in treatment group ##EQU00001##
[0316] SCFA2, SCFA4 or SCFA4v can be administered to protect the
epithelium of the small intestine from the injurious effects of
irradiation, and can be used as potent prophylactics in patients
for whom radiation therapy has been indicated.
Example 7
Prophylactic Effect of SCFA2, SCFA4 and SCFA4v on
Chemotherapy-Induced Mucositis
A. Normal Mice
[0317] The efficacy of recombinant SCFA2 and SCFA2.DELTA.C in
treating chemotherapy-induced mucositis was evaluated in normal
mice. The experimental protocol was based on that previously
described by Boushey et al. (Cancer Res. 61:687-693 (2001)).
[0318] Female BDF-1 mice (11-13 weeks old) were used. The mice were
divided into experimental groups of 13 mice each and treated as
follows: [0319] 1. Negative control: vehicle (50% DMSO) injected ip
from day 0 to day 3, saline injected iv daily from day -3 to day 6;
[0320] 2. Mucositis control: 50 mg/kg 5-FU injected ip from day 0
to day 3, saline injected iv daily from day -3 to day 6; [0321] 3.
50 mg/kg 5-FU injected ip from day 0 to day 3, 50 .mu.g SCFA2 in
100 .mu.l saline injected daily from day -3 to day 6; [0322] 4. 50
mg/kg 5-FU injected ip from day 0 to day 3, 5 .mu.g SCFA2 in 100
.mu.l saline injected daily from day -3 to day 6; [0323] 5. 50
mg/kg 5-FU injected ip from day 0 to day 3, 50 .mu.g SCFA2.DELTA.C
in 100 .mu.g saline injected daily from day -3 to day 6; [0324] 6.
50 mg/kg 5-FU injected ip from day 0 to day 3, 5 .mu.g
SCFA2.DELTA.C in 100 .mu.g saline injected daily from day -3 to day
6.
[0325] Starting at day 0, the animals' body weight, severity of
diarrhea, and mortality were recorded daily. A diarrhea score of 0
to 3 reflected a corresponding worsening of the symptom from 0
being normal to 3 being severe. The change in body weight was
calculated as the percent body weight of that of the untreated
group.
[0326] All animals were euthanized on day 6 and injected with 4
mg/0.1 ml BrdU two hours prior to sacrifice. The large and small
intestine were removed and weighed, their length was measured, and
the diameter of the mid-jejunum was recorded. A segment (1 cm) of
the mid-jejunum was excised about 14-15 cm from the pylorus, and a
segment (1 cm) of the transverse colon was excised at about 4 cm
from the ileocaecal junction. The bowel segments were flushed and
fixed using 10% neutral buffered formalin for histological
analysis. Histological examination and morphometry of the mucosa
were performed on tissue sections using the ImagePro Software
(ImagePro, Ltd., Ashford, Middlesex, UK).
[0327] The effect of SCFA2 and SCFA2.DELTA.C on body weight is
summarized in Tables 1 and 2, respectively and FIG. 6.
TABLE-US-00001 TABLE 1 Chemotherapy toxicity Maximum weight
Mortality Survival time.sup.# 5-FU Treatment loss (%) (%) (day) Yes
Saline control 22.4 .+-. 5.3 80 11.3 .+-. 1.4 Yes SCFA2 (50 .mu.g)
5.9 .+-. 7.8* 20 10.5 .+-. 0.7 Yes SCFA2 (5 .mu.g) 18.5 .+-. 6.8 40
11.2 .+-. 1.9 *P < 0.05 (ANOVA, 5-FU/Saline vs. 5-FU/SCFA2).
.sup.#only animals found dead were calculated for survival
time.
TABLE-US-00002 TABLE 2 Chemotherapy toxicity Maximum weight
Diarrhea Mortality 5-FU Treatment loss (%) score (%) Yes Saline
control 15.4 .+-. 6.1 1.0 .+-. 0.0 60 Yes SCFA2.DELTA.C (50 .mu.g)
11.2 .+-. 3.7 0.7 .+-. 0.5 0 Yes SCFA2.DELTA.C (5 .mu.g) 15.2 .+-.
5.5 1.0 .+-. 0.5 30 *P < 0.05 (ANOVA, 5-FU/Saline vs.
5-FU/SCFA2).
[0328] SCFA2 and SCFA2.DELTA.C significantly reduced the severity
of the diarrhea and mortality caused by 5-FU-induced mucositis when
compared to mice which did not receive SCFA2 or SCFA2.DELTA.C.
Similarly, SCFA2 and SCFA2.DELTA.C reduced the loss of body weight
that the 5-FU-treated animals experienced.
[0329] The effect of SCFA2 and SCFA2.DELTA.C on the gross
appearance of the intestines is shown in FIG. 7. The intestines of
the mice treated with 5-FU were atrophied and numerous lesions
associated with bleeding were observed while the appearance of the
intestines from the mice that had received SCFA2 or SCFA2.DELTA.C
were overtly normal and accompanied by the typical distension due
to the proliferative effect of SCFA2 and SCFA2.DELTA.C on the
intestinal epithelium.
[0330] Histological analysis of intestinal sections of the small
intestine and colon of all experimental groups showed that SCFA2
and SCFA2.DELTA.C preserved the intestinal architecture of the mice
with 5-FU-induced mucositis by preventing the massive damage to the
villi and crypt compartments of the intestinal mucosa caused by
5-FU (FIG. 8). Micromorphometry measurements of villus height and
crypt depth in the mid-jejunum confirm that the effect of SCFA2 and
SCFA2.DELTA.C is significant (FIG. 9). The crypt proliferative
index, which is calculated as the percent of crypt cells that
stained positive for BrdU, was significantly greater in the
5-FU-treated mice that received SCFA2 or SCFA2.DELTA.C than in
those that received saline (P<0.05) (FIG. 10). Histological
analysis of BrdU incorporation in both small intestine and colon of
mice treated with SCFA2 and SCFA2.DELTA.C is shown in FIGS. 11 and
12, respectively.
[0331] SCFA2 and SCFA2.DELTA.C protect the small intestine and
colon from the deleterious effects of 5-FU; therefore, SCFA2 and
SCFA2.DELTA.C can be used in conjunction with chemotherapeutic
agents to reduce the deleterious side-effects of antineoplastic
therapies.
B. Tumor-Bearing Mice
[0332] The efficacy of recombinant human SCFA2, SCFA4 or SCFA4v in
treating chemotherapy-induced mucositis is evaluated in healthy and
in tumor-bearing mice. The experimental protocol is based on that
previously described by Boushey et al. (Cancer Res 61:687-693
(2001)).
[0333] One million CT26 murine colon carcinoma cells (ATCC,
Manassas, Va., USA) are injected sc into syngeneic female BALB/c
mice, and the tumors are allowed to develop for 5 days. Healthy and
tumor-bearing animals are divided into experimental groups of 6
mice each and treated as follows: [0334] 1. tumor bearing mice,
vehicle (50% DMSO) injected ip from day 1 to day 5, saline injected
iv from day 0 to day 7 (TVS) [0335] 2. tumor bearing mice, vehicle
(50% DMSO) injected ip from day 1 to day 5, 50 .mu.g SCFA2, SCFA4
or SCFA4v in 100 .mu.l saline injected iv daily from day 0 to day 7
(TVG); [0336] 3. tumor bearing mice, 50 mg/kg 5-FU injected ip from
day 1 to day 5, saline injected iv from day 0 to day 7 (TDS);
[0337] 4. tumor bearing mice, 50 mg/kg 5-FU injected ip from day 1
to day 5, 50 .mu.g SCFA2, SCFA4 or SCFA4v in 100 .mu.l saline
injected iv from day 0 to day 7 (TDG); [0338] 5. healthy mice, 50
mg/kg 5-FU injected ip from day 1 to day 5, saline injected iv from
day 0 to day 7 (NDS); [0339] 6. healthy mice, 50 mg/kg 5-FU
injected ip from day 1 to day 5, 50 .mu.g SCFA2, SCFA4 or SCFA4v in
100 .mu.l saline injected iv from day 0 to day 7 (NDG).
[0340] On days 0, 2, 4, 6, and 8 measurements of animal body
weight, severity of diarrhea, and size of the tumors are recorded.
A diarrhea score of 0-3 reflects a corresponding worsening of the
symptom from 0 being normal to 3 being severe. The change in body
weight is calculated as the percent body weight of that of the
untreated group. The length, width and height of the tumor are
measured with calipers, and the volume of the tumor is calculated
as (length.times.width.times.height)/2.
[0341] All animals are euthanized on day 8. The large and small
intestine are removed and weighed, their length is measured, and
the diameter of the mid-jejunum is recorded. A segment (1 cm) of
the mid-jejunum is excised about 14-15 cm from the pylorus, and a
segment (1 cm) of the transverse colon is excised at about 4 cm
from the ileocaecal junction. The bowel segments are flushed and
fixed using 10% neutral buffered formalin for histological
analysis. Histological examination and morphometry of the mucosa
were performed on tissue sections using the ImagePro Software
(Imagepro, Ltd., Ashford, Middlesex, UK).
[0342] SCFA2, SCFA4 or SCFA4v can be used in conjunction with
chemotherapeutic agents to reduce the deleterious side-effects of
antineoplastic therapies.
Example 8
Prophylactic Effect of SCFA2, SCFA4 and SCFA4v on Chemotherapy and
Radiation-Induced Oral Mucositis
A. Radiation-Induced Oral Mucositis
[0343] The effect of SCFA2, SCFA4 and SCFA4v on the proliferation
of the dorsal (buccal) and ventral epithelium of the tongue is
studied in mice that are subjected to X-ray irradiation.
[0344] Immunohistochemistry using monoclonal rat anti-mouse Ki67
antigen (Dako Ltd., High Wycombe, UK) is performed, according to
manufacturer's instruction and the method previously described
(Scholzen, T. et al. 2000), on paraffin embedded sections of tongue
from non-irradiated and irradiated mice (groups 1, 2, and 3 in
Example 7B).
[0345] The epithelial proliferative index, which is calculated as
the percent epithelial cells that stain positive for Ki67, is
calculated to confirm that SCFA2, SCFA4 or SCFA4v reduces the loss
of cellularity that is typically caused by radiation to the ventral
tongue epithelium.
B. Chemotherapy-Induced Oral Mucositis
[0346] Histological analysis of sections from the tongue of animals
that were treated with 5-FU (groups 3-6 in Example 7A) showed that
SCFA2 and SCFA.DELTA.C maintained the morphology of the tongue
epithelial layers in normal BDF-1 mice that were treated with 5-FU
(FIG. 13). Micromorphometry measurements of the number of basal
layer epithelial cells (FIG. 14) and mucosal thickness (FIG. 15)
confirmed that the effect of SCFA2 and SCFA2.DELTA.C is
significant. The basal layer BrdU proliferative index, which is
calculated as the percent of basal layer epithelial cells that
stained positive for BrdU, was significantly greater in the
5-FU-treated mice that received SCFA2 or SCFA2.DELTA.C than in
those that received saline (P<0.05) (FIG. 16).
[0347] Therefore, SCFA2, SCFA2.DELTA.C, SCFA4 or SCFA4v may be used
as a therapeutic agent for the treatment and/or prevention of
chemotherapy and radiation therapy-induced oral mucositis.
[0348] Quantitative animal models of oral mucositis (e.g. Wardly et
al., Arch Oral Biol 43:567-577 (1998); Potten et al., Cell Prolif
35:32-47 (2002)) can be used to study further the therapeutic
properties of SCFA2, SCFA4 or SCFA4v, when administered in
combination with other cytotoxic agent to further assess the
potential role of SCFA2, SCFA4 or SCFA4v in reducing the severity
of the cellular depletion and to increase the rate of regeneration
of the epithelial layers of the oral and intestinal epithelium.
Example 9
Therapeutic Effect of SCFA2, SCFA4 and SCFA4v on Dextran Sulfate
Sodium-Induced Colitis
[0349] The efficacy of recombinant human SCFA2, SCFA4 or SCFA4v (in
treating colitis is tested in a mouse model of dextran sulfate
sodium (DSS)-induced colitis, and compared to the efficacy of GLP-2
(L'Heureux and Brubaker J Pharmacol Exp Ther 306:347-354 (2003);
Kriegelstein et al., J Clin Invest 110:1773-1782 (2002); Siegmund
et al., J Pharmacol Exp Ther 296:99-105 (2001)).
[0350] Six to eight-week old female BALB/c mice (Charles River
Laboratories, Wilmington, Mass., USA) are housed in ventilated
cages and acclimated for one week to a 12 hour light:dark cycle.
Twenty four mice having similar body weight (approximately 20 g;
<5% variance) are housed in 4 cages and fed ad libitum a 4% DSS
(v/w) drinking solution for 7 days.
[0351] On day 7, the body weight of each animal is recorded, and
the scores for loss in body weight, the consistency of stools, and
anal bleeding are determined as shown in the Table below.
TABLE-US-00003 TABLE 3 Weight Stool Occult/Gross SCORE Loss (%)
Consistency Rectal bleeding 0 None Normal Normal 1 0-5% 2 5-10%
Loose Hemoccult 3 10-20% 4 >20% Diarrhea Gross
[0352] The scores are used to calculate the IBD activity index
(IBDAI), which is used as an indicator of the severity of the
colitis, and is calculated as the average of the scores given for
the tabulated parameters. The scores for weight loss, stool
consistency, and rectal bleeding are determined daily, and the
IBDAI is recorded daily for the duration of the experiment.
[0353] On day 7, the 4% (v/w) DSS drinking solution is substituted
with a 1% (v/w) DSS solution to maintain the disease activity
without exacerbating the effect of the DSS. Sixteen of the DSS-fed
animals are selected for consistent and comparable disease
activity, and are dived into groups of 4 animals and are treated as
follows: [0354] 1. Water, saline injected iv daily (10 am) for 7
days [0355] 2. DSS (1%) for 7 days, saline injected iv daily (10
am) for 7 days [0356] 3. DSS (1%) for 7 days, 100 .mu.g SCFA2,
SCFA4 or SCFA4v injected daily iv (10 am) for 7 days [0357] 4. DSS
(1%) for 7 days, 50 .mu.g SCFA2, SCFA4 or SCFA4v injected daily iv
(10 am) for 7 days [0358] 5. DSS (1%) for 7 days, 10 .mu.g GLP-2
injected sc twice daily (10 am and 6 pm) for 7 days.
[0359] On day 14, food is removed from the cages to allow for
purging of the intestine, and the animals are sacrifices by
cervical dislocation. All animals are injected with 4 mg/0.1 ml
BrdU two hours prior to sacrifice. The large and small intestine
are removed and weighed, their lengths are measured, and the
diameter of the mid-jejunum is recorded. A segment (1 cm) of the
mid-jejunum is excised about 14-15 cm from the pylorus, and a
segment (1 cm) of the transverse colon is excised at about 4 cm
from the ileocaecal junction. The bowel segments are flushed and
fixed using 10% neutral buffered formalin for histological
analysis. Histological examination and morphometry of the mucosa is
performed on tissue sections using the ImagePro Software (Imagepro,
Ltd., Ashford, Middlesex, UK). The IBDIAs for the mice of
experimental groups 2-5, and the corresponding scores for weight
loss, stool consistency and rectal bleeding are determined. Animals
receiving DSS with saline develop severe colitis that is typically
associated with atrophy, hyperemia, and diarrhea when compared to
the control group. While DSS causes disintegration of the villus
and crypt compartments of the mucosa of the small intestine and
colon, SCFA2, SCFA4 or SCFA4v can be used to reverse the effects
caused by DSS, and restore the intestinal architecture of the
crypts and villi.
Example 10
Therapeutic Effect of SCFA2, SCFA4 or SCFA4v Following Massive
Intestinal Resection
[0360] The effect of SCFA2, SCFA4 and SCFA4v in augmenting the
adaptive response to massive intestinal resection is tested in a
rat animal model of short bowel syndrome. The animal model used in
the study of the effects of enterorophic agents has been described
(Scott et al. Am J Physiol G911-G921 (1998); Helmrath et al., J Am
Coll Surg 183:441-449 (1996)), and the experimental protocol is
herein incorporated by reference).
[0361] The animals are divided into a resected group that will have
a 75% surgical resection of the midjejenunoileum, a sham-resected
operated control group in which the intestine is sectioned and
reanastomosed, and an unoperated control group. The animals are
administered saline or SCFA2, SCFA4 and SCFA4v at a dose of 2
mg/Kg. The 75% intestinal resection is chosen to maximize any
adaptive response and retention of equal portions of the proximal
jejunum and distal ileum is based on the nutritional implications
of removing the specialized absorptive capacity of the terminal
ileum for vitamin B12 and bile acids and the ileal brake. In the
rat, the retention of 25% of the small intestine inclusive of a
portion of distal ileum, is sufficient to allow resected animals to
achieve the same growth rate as control animals.
[0362] The morphological and functional response of the gut to
resection and treatment with SCFA2, SCFA4 and SCFA4v is assessed at
6, 14, and 21 days. Food intake and growth, gross and microscopic
small intestinal morphology and functional evaluation of mucosal
absorptive characteristics are evaluated as described (Scott et
al., supra).
Example 11
Effect of SCFA2, SCFA4 and SCFA4v on TNBS-Induced Colitis
[0363] The hapten agent 2,4,6-trinitrobenzenesulfonic acid (TNBS)
induces a chronic colitis that is characterized by severe,
transmural inflammation associated with diarrhea, rectal prolapse,
and weight loss. These clinical and histopathological features
indicate that TNBS-induced colitis mimics important characteristics
of human Crohn's disease (Neurath et al., J Exp Med 182:1281-1290
(1995)).
[0364] The therapeutic effect of SCFA2, SCFA4 and SCFA4v is tested
in mice with TNBS-induced colitis. Intestinal inflammation is
induced in 6-8 week-old female BALBc mice (group I) by a single
rectal administration of 1 mg TNBS, as described by Neurath et al,
supra). The control animal group (Group II) receive rectal
administration of vehicle alone (45% ethanol). The mice are
sacrificed after 7 days, and the induction of colitis by TNBS is
assessed. The TNBS-treated mice suffer from severe diarrhea, and
ulceration and bleeding accompanies the atrophy of the colon of the
TNBS animals. No deleterious effects are noted.
[0365] Histologic changes are evaluated in H&E stained
paraffin-embedded sections of the colon from the control and TNBS
groups. TNBS induces thickening of the colon wall and substantial
transmural leukocytic infiltration into the lamina propria
[0366] The therapeutic effect of SCFA2, SCFA4 and SCFA4v is tested
in the TNBS-treated animals by administering daily doses of up to 4
mg/Kg (100 .mu.g/mouse; iv), beginning at day 3 following
administration of TNBS (group III). Animals from each group are
sacrificed at day 7 or day 10. The tissues are removed, and
histological evaluation, morphometric analysis, and proliferative
and apoptotic indices are determined, as described in the examples
above.
Sequence CWU 1 SEQUENCE LISTING <160> NUMBER OF SEQ ID
NOS: 55 <210> SEQ ID NO 1 <211> LENGTH: 427 <212>
TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE:
1 tttcgtggcg agtctccctc tgagtcctcc ccagcagcgc ggccggcgcc ggctctttgg
60 gcgaaccctc cagttcctag actttgagag gcgtctctcc cccgcccgac
cgcccagatg 120 cagtttcgcc ttttctcctt tgccctcatc attctgaact
gcatggatta cagccactgc 180 caaggcaacc gatggagacg cagtaagcga
ggtgggtcct tctctgccaa agctagttat 240 gtatcaaatc ccatttgcaa
gggttgtttg tcttgttcaa aggacaatgg gtgtagccga 300 tgtcaacaga
agttgttctt cttccttcga agagaaggga tgcgccagta tggagagtgc 360
ctgcattcct gcccatccgg gtactatgga caccgagccc cagatatgaa cagatgtgca
420 agatgca 427 <210> SEQ ID NO 2 <211> LENGTH: 1356
<212> TYPE: DNA <213> ORGANISM: Homo sapiens
<220> FEATURE: <221> NAME/KEY: CDS <222>
LOCATION: (262)..(993) <400> SEQUENCE: 2 cccagcccac
gtgctaacca agcggctcgc ttcccgagcc cgggatggag caccgcgcct 60
agggaggccg cgccgcccga gacgtgcgca cggttcgtgg cggagagatg ctgatcgcgc
120 tgaactgacc ggtgcggccc gggggtgagt ggcgagtctc cctctgagtc
ctccccagca 180 gcgcggccgg cgccggctct ttgggcgaac cctccagttc
ctagactttg agaggcgtct 240 ctcccccgcc cgaccgccca g atg cag ttt cgc
ctt ttc tcc ttt gcc ctc 291 Met Gln Phe Arg Leu Phe Ser Phe Ala Leu
1 5 10 atc att ctg aac tgc atg gat tac agc cac tgc caa ggc aac cga
tgg 339 Ile Ile Leu Asn Cys Met Asp Tyr Ser His Cys Gln Gly Asn Arg
Trp 15 20 25 aga cgc agt aag cga gct agt tat gta tca aat ccc att
tgc aag ggt 387 Arg Arg Ser Lys Arg Ala Ser Tyr Val Ser Asn Pro Ile
Cys Lys Gly 30 35 40 tgt ttg tct tgt tca aag gac aat ggg tgt agc
cga tgt caa cag aag 435 Cys Leu Ser Cys Ser Lys Asp Asn Gly Cys Ser
Arg Cys Gln Gln Lys 45 50 55 ttg ttc ttc ttc ctt cga aga gaa ggg
atg cgc cag tat gga gag tgc 483 Leu Phe Phe Phe Leu Arg Arg Glu Gly
Met Arg Gln Tyr Gly Glu Cys 60 65 70 ctg cat tcc tgc cca tcc ggg
tac tat gga cac cga gcc cca gat atg 531 Leu His Ser Cys Pro Ser Gly
Tyr Tyr Gly His Arg Ala Pro Asp Met 75 80 85 90 aac aga tgt gca aga
tgc aga ata gaa aac tgt gat tct tgc ttt agc 579 Asn Arg Cys Ala Arg
Cys Arg Ile Glu Asn Cys Asp Ser Cys Phe Ser 95 100 105 aaa gac ttt
tgt acc aag tgc aaa gta ggc ttt tat ttg cat aga ggc 627 Lys Asp Phe
Cys Thr Lys Cys Lys Val Gly Phe Tyr Leu His Arg Gly 110 115 120 cgt
tgc ttt gat gaa tgt cca gat ggt ttt gca cca tta gaa gaa acc 675 Arg
Cys Phe Asp Glu Cys Pro Asp Gly Phe Ala Pro Leu Glu Glu Thr 125 130
135 atg gaa tgt gtg gaa gga tgt gaa gtt ggt cat tgg agc gaa tgg gga
723 Met Glu Cys Val Glu Gly Cys Glu Val Gly His Trp Ser Glu Trp Gly
140 145 150 act tgt agc aga aat aat cgc aca tgt gga ttt aaa tgg ggt
ctg gaa 771 Thr Cys Ser Arg Asn Asn Arg Thr Cys Gly Phe Lys Trp Gly
Leu Glu 155 160 165 170 acc aga aca cgg caa att gtt aaa aag cca gtg
aaa gac aca ata ccg 819 Thr Arg Thr Arg Gln Ile Val Lys Lys Pro Val
Lys Asp Thr Ile Pro 175 180 185 tgt cca acc att gct gaa tcc agg aga
tgc aag atg aca atg agg cat 867 Cys Pro Thr Ile Ala Glu Ser Arg Arg
Cys Lys Met Thr Met Arg His 190 195 200 tgt cca gga ggg aag aga aca
cca aag gcg aag gag aag agg aac aag 915 Cys Pro Gly Gly Lys Arg Thr
Pro Lys Ala Lys Glu Lys Arg Asn Lys 205 210 215 aaa aag aaa agg aag
ctg ata gaa agg gcc cag gag caa cac agc gtc 963 Lys Lys Lys Arg Lys
Leu Ile Glu Arg Ala Gln Glu Gln His Ser Val 220 225 230 ttc cta gct
aca gac aga gct aac caa taa aacaagagat ccggtagatt 1013 Phe Leu Ala
Thr Asp Arg Ala Asn Gln 235 240 tttaggggtt tttgtttttg caaatgtgca
caaagctact ctccactcct gcacactggg 1073 gtgcagcctt tgtgctgctc
tgcccagtat ctgttcccag taacatggtg aaaggaagca 1133 ccaccaggca
tgcccctgtg ttatttatgc tttgatttga atctggagac tgtgaaggca 1193
ggagtaagtg cacagccccg tgacttggct cagtgtgtgc tgagagaatc cgtcccccgc
1253 accatggaca tgctagaggt gtgaggctgc agaacaccgc tggaggacgg
acttgtgcct 1313 atttatgtga aagaagatgc ttggcaggca atccgcgtgt att
1356 <210> SEQ ID NO 3 <211> LENGTH: 243 <212>
TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE:
3 Met Gln Phe Arg Leu Phe Ser Phe Ala Leu Ile Ile Leu Asn Cys Met 1
5 10 15 Asp Tyr Ser His Cys Gln Gly Asn Arg Trp Arg Arg Ser Lys Arg
Ala 20 25 30 Ser Tyr Val Ser Asn Pro Ile Cys Lys Gly Cys Leu Ser
Cys Ser Lys 35 40 45 Asp Asn Gly Cys Ser Arg Cys Gln Gln Lys Leu
Phe Phe Phe Leu Arg 50 55 60 Arg Glu Gly Met Arg Gln Tyr Gly Glu
Cys Leu His Ser Cys Pro Ser 65 70 75 80 Gly Tyr Tyr Gly His Arg Ala
Pro Asp Met Asn Arg Cys Ala Arg Cys 85 90 95 Arg Ile Glu Asn Cys
Asp Ser Cys Phe Ser Lys Asp Phe Cys Thr Lys 100 105 110 Cys Lys Val
Gly Phe Tyr Leu His Arg Gly Arg Cys Phe Asp Glu Cys 115 120 125 Pro
Asp Gly Phe Ala Pro Leu Glu Glu Thr Met Glu Cys Val Glu Gly 130 135
140 Cys Glu Val Gly His Trp Ser Glu Trp Gly Thr Cys Ser Arg Asn Asn
145 150 155 160 Arg Thr Cys Gly Phe Lys Trp Gly Leu Glu Thr Arg Thr
Arg Gln Ile 165 170 175 Val Lys Lys Pro Val Lys Asp Thr Ile Pro Cys
Pro Thr Ile Ala Glu 180 185 190 Ser Arg Arg Cys Lys Met Thr Met Arg
His Cys Pro Gly Gly Lys Arg 195 200 205 Thr Pro Lys Ala Lys Glu Lys
Arg Asn Lys Lys Lys Lys Arg Lys Leu 210 215 220 Ile Glu Arg Ala Gln
Glu Gln His Ser Val Phe Leu Ala Thr Asp Arg 225 230 235 240 Ala Asn
Gln <210> SEQ ID NO 4 <211> LENGTH: 729 <212>
TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE:
4 atgcagtttc gccttttctc ctttgccctc atcattctga actgcatgga ttacagccac
60 tgccaaggca accgatggag acgcagtaag cgagctagtt atgtatcaaa
tcccatttgc 120 aagggttgtt tgtcttgttc aaaggacaat gggtgtagcc
gatgtcaaca gaagttgttc 180 ttcttccttc gaagagaagg gatgcgccag
tatggagagt gcctgcattc ctgcccatcc 240 gggtactatg gacaccgagc
cccagatatg aacagatgtg caagatgcag aatagaaaac 300 tgtgattctt
gctttagcaa agacttttgt accaagtgca aagtaggctt ttatttgcat 360
agaggccgtt gctttgatga atgtccagat ggttttgcac cattagaaga aaccatggaa
420 tgtgtggaag gatgtgaagt tggtcattgg agcgaatggg gaacttgtag
cagaaataat 480 cgcacatgtg gatttaaatg gggtctggaa accagaacac
ggcaaattgt taaaaagcca 540 gtgaaagaca caataccgtg tccaaccatt
gctgaatcca ggagatgcaa gatgacaatg 600 aggcattgtc caggagggaa
gagaacacca aaggcgaagg agaagaggaa caagaaaaag 660 aaaaggaagc
tgatagaaag ggcccaggag caacacagcg tcttcctagc tacagacaga 720
gctaaccaa 729 <210> SEQ ID NO 5 <211> LENGTH: 669
<212> TYPE: DNA <213> ORGANISM: Homo sapiens
<220> FEATURE: <221> NAME/KEY: CDS <222>
LOCATION: (1)..(669) <400> SEQUENCE: 5 caa ggc aac cga tgg
aga cgc agt aag cga gct agt tat gta tca aat 48 Gln Gly Asn Arg Trp
Arg Arg Ser Lys Arg Ala Ser Tyr Val Ser Asn 1 5 10 15 ccc att tgc
aag ggt tgt ttg tct tgt tca aag gac aat ggg tgt agc 96 Pro Ile Cys
Lys Gly Cys Leu Ser Cys Ser Lys Asp Asn Gly Cys Ser 20 25 30 cga
tgt caa cag aag ttg ttc ttc ttc ctt cga aga gaa ggg atg cgc 144 Arg
Cys Gln Gln Lys Leu Phe Phe Phe Leu Arg Arg Glu Gly Met Arg 35 40
45 cag tat gga gag tgc ctg cat tcc tgc cca tcc ggg tac tat gga cac
192 Gln Tyr Gly Glu Cys Leu His Ser Cys Pro Ser Gly Tyr Tyr Gly His
50 55 60 cga gcc cca gat atg aac aga tgt gca aga tgc aga ata gaa
aac tgt 240 Arg Ala Pro Asp Met Asn Arg Cys Ala Arg Cys Arg Ile Glu
Asn Cys 65 70 75 80 gat tct tgc ttt agc aaa gac ttt tgt acc aag tgc
aaa gta ggc ttt 288 Asp Ser Cys Phe Ser Lys Asp Phe Cys Thr Lys Cys
Lys Val Gly Phe 85 90 95 tat ttg cgt aga ggc cgt tgc ttt gat gaa
tgt cca gat ggt ttt gca 336 Tyr Leu Arg Arg Gly Arg Cys Phe Asp Glu
Cys Pro Asp Gly Phe Ala 100 105 110 cca tta gaa gaa acc atg gaa tgt
gtg gaa gga tgt gaa gtt ggt cat 384 Pro Leu Glu Glu Thr Met Glu Cys
Val Glu Gly Cys Glu Val Gly His 115 120 125 tgg agc gaa tgg gga act
tgt agc aga aat aat cgc aca tgt gga ttt 432 Trp Ser Glu Trp Gly Thr
Cys Ser Arg Asn Asn Arg Thr Cys Gly Phe 130 135 140 aaa tgg ggt ctg
gaa acc aga aca cgg caa att gtt aaa aag cca gtg 480 Lys Trp Gly Leu
Glu Thr Arg Thr Arg Gln Ile Val Lys Lys Pro Val 145 150 155 160 aaa
gac aca ata ccg tgt cca acc att gct gaa tcc agg aga tgc aag 528 Lys
Asp Thr Ile Pro Cys Pro Thr Ile Ala Glu Ser Arg Arg Cys Lys 165 170
175 atg aca atg agg cat tgt cca gga ggg aag aga aca cca aag gcg aag
576 Met Thr Met Arg His Cys Pro Gly Gly Lys Arg Thr Pro Lys Ala Lys
180 185 190 gag aag agg aac aag aaa aag aaa agg aag ctg ata gaa agg
gcc cag 624 Glu Lys Arg Asn Lys Lys Lys Lys Arg Lys Leu Ile Glu Arg
Ala Gln 195 200 205 gag caa cac agc gtc ttc cta gct aca gac aga gct
aac caa taa 669 Glu Gln His Ser Val Phe Leu Ala Thr Asp Arg Ala Asn
Gln 210 215 220 <210> SEQ ID NO 6 <211> LENGTH: 222
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 6 Gln Gly Asn Arg Trp Arg Arg Ser Lys Arg Ala
Ser Tyr Val Ser Asn 1 5 10 15 Pro Ile Cys Lys Gly Cys Leu Ser Cys
Ser Lys Asp Asn Gly Cys Ser 20 25 30 Arg Cys Gln Gln Lys Leu Phe
Phe Phe Leu Arg Arg Glu Gly Met Arg 35 40 45 Gln Tyr Gly Glu Cys
Leu His Ser Cys Pro Ser Gly Tyr Tyr Gly His 50 55 60 Arg Ala Pro
Asp Met Asn Arg Cys Ala Arg Cys Arg Ile Glu Asn Cys 65 70 75 80 Asp
Ser Cys Phe Ser Lys Asp Phe Cys Thr Lys Cys Lys Val Gly Phe 85 90
95 Tyr Leu Arg Arg Gly Arg Cys Phe Asp Glu Cys Pro Asp Gly Phe Ala
100 105 110 Pro Leu Glu Glu Thr Met Glu Cys Val Glu Gly Cys Glu Val
Gly His 115 120 125 Trp Ser Glu Trp Gly Thr Cys Ser Arg Asn Asn Arg
Thr Cys Gly Phe 130 135 140 Lys Trp Gly Leu Glu Thr Arg Thr Arg Gln
Ile Val Lys Lys Pro Val 145 150 155 160 Lys Asp Thr Ile Pro Cys Pro
Thr Ile Ala Glu Ser Arg Arg Cys Lys 165 170 175 Met Thr Met Arg His
Cys Pro Gly Gly Lys Arg Thr Pro Lys Ala Lys 180 185 190 Glu Lys Arg
Asn Lys Lys Lys Lys Arg Lys Leu Ile Glu Arg Ala Gln 195 200 205 Glu
Gln His Ser Val Phe Leu Ala Thr Asp Arg Ala Asn Gln 210 215 220
<210> SEQ ID NO 7 <211> LENGTH: 639 <212> TYPE:
DNA <213> ORGANISM: Homo sapiens <220> FEATURE:
<221> NAME/KEY: CDS <222> LOCATION: (1)..(639)
<400> SEQUENCE: 7 gct agt tat gta tca aat ccc att tgc aag ggt
tgt ttg tct tgt tca 48 Ala Ser Tyr Val Ser Asn Pro Ile Cys Lys Gly
Cys Leu Ser Cys Ser 1 5 10 15 aag gac aat ggg tgt agc cga tgt caa
cag aag ttg ttc ttc ttc ctt 96 Lys Asp Asn Gly Cys Ser Arg Cys Gln
Gln Lys Leu Phe Phe Phe Leu 20 25 30 cga aga gaa ggg atg cgc cag
tat gga gag tgc ctg cat tcc tgc cca 144 Arg Arg Glu Gly Met Arg Gln
Tyr Gly Glu Cys Leu His Ser Cys Pro 35 40 45 tcc ggg tac tat gga
cac cga gcc cca gat atg aac aga tgt gca aga 192 Ser Gly Tyr Tyr Gly
His Arg Ala Pro Asp Met Asn Arg Cys Ala Arg 50 55 60 tgc aga ata
gaa aac tgt gat tct tgc ttt agc aaa gac ttt tgt acc 240 Cys Arg Ile
Glu Asn Cys Asp Ser Cys Phe Ser Lys Asp Phe Cys Thr 65 70 75 80 aag
tgc aaa gta ggc ttt tat ttg cat aga ggc cgt tgc ttt gat gaa 288 Lys
Cys Lys Val Gly Phe Tyr Leu His Arg Gly Arg Cys Phe Asp Glu 85 90
95 tgt cca gat ggt ttt gca cca tta gaa gaa acc atg gaa tgt gtg gaa
336 Cys Pro Asp Gly Phe Ala Pro Leu Glu Glu Thr Met Glu Cys Val Glu
100 105 110 gga tgt gaa gtt ggt cat tgg agc gaa tgg gga act tgt agc
aga aat 384 Gly Cys Glu Val Gly His Trp Ser Glu Trp Gly Thr Cys Ser
Arg Asn 115 120 125 aat cgc aca tgt gga ttt aaa tgg ggt ctg gaa acc
aga aca cgg caa 432 Asn Arg Thr Cys Gly Phe Lys Trp Gly Leu Glu Thr
Arg Thr Arg Gln 130 135 140 att gtt aaa aag cca gtg aaa gac aca ata
ccg tgt cca acc att gct 480 Ile Val Lys Lys Pro Val Lys Asp Thr Ile
Pro Cys Pro Thr Ile Ala 145 150 155 160 gaa tcc agg aga tgc aag atg
aca atg agg cat tgt cca gga ggg aag 528 Glu Ser Arg Arg Cys Lys Met
Thr Met Arg His Cys Pro Gly Gly Lys 165 170 175 aga aca cca aag gcg
aag gag aag agg aac aag aaa aag aaa agg aag 576 Arg Thr Pro Lys Ala
Lys Glu Lys Arg Asn Lys Lys Lys Lys Arg Lys 180 185 190 ctg ata gaa
agg gcc cag gag caa cac agc gtc ttc cta gct aca gac 624 Leu Ile Glu
Arg Ala Gln Glu Gln His Ser Val Phe Leu Ala Thr Asp 195 200 205 aga
gct aac caa taa 639 Arg Ala Asn Gln 210 <210> SEQ ID NO 8
<211> LENGTH: 212 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 8 Ala Ser Tyr Val Ser Asn Pro
Ile Cys Lys Gly Cys Leu Ser Cys Ser 1 5 10 15 Lys Asp Asn Gly Cys
Ser Arg Cys Gln Gln Lys Leu Phe Phe Phe Leu 20 25 30 Arg Arg Glu
Gly Met Arg Gln Tyr Gly Glu Cys Leu His Ser Cys Pro 35 40 45 Ser
Gly Tyr Tyr Gly His Arg Ala Pro Asp Met Asn Arg Cys Ala Arg 50 55
60 Cys Arg Ile Glu Asn Cys Asp Ser Cys Phe Ser Lys Asp Phe Cys Thr
65 70 75 80 Lys Cys Lys Val Gly Phe Tyr Leu His Arg Gly Arg Cys Phe
Asp Glu 85 90 95 Cys Pro Asp Gly Phe Ala Pro Leu Glu Glu Thr Met
Glu Cys Val Glu 100 105 110 Gly Cys Glu Val Gly His Trp Ser Glu Trp
Gly Thr Cys Ser Arg Asn 115 120 125 Asn Arg Thr Cys Gly Phe Lys Trp
Gly Leu Glu Thr Arg Thr Arg Gln 130 135 140 Ile Val Lys Lys Pro Val
Lys Asp Thr Ile Pro Cys Pro Thr Ile Ala 145 150 155 160 Glu Ser Arg
Arg Cys Lys Met Thr Met Arg His Cys Pro Gly Gly Lys 165 170 175 Arg
Thr Pro Lys Ala Lys Glu Lys Arg Asn Lys Lys Lys Lys Arg Lys 180 185
190 Leu Ile Glu Arg Ala Gln Glu Gln His Ser Val Phe Leu Ala Thr Asp
195 200 205 Arg Ala Asn Gln 210 <210> SEQ ID NO 9 <211>
LENGTH: 282 <212> TYPE: DNA <213> ORGANISM: Homo
sapiens <220> FEATURE: <221> NAME/KEY: CDS <222>
LOCATION: (1)..(282) <400> SEQUENCE: 9 att tgc aag ggt tgt
ttg tct tgt tca aag gac aat ggg tgt agc cga 48 Ile Cys Lys Gly Cys
Leu Ser Cys Ser Lys Asp Asn Gly Cys Ser Arg 1 5 10 15 tgt caa cag
aag ttg ttc ttc ttc ctt cga aga gaa ggg atg cgc cag 96 Cys Gln Gln
Lys Leu Phe Phe Phe Leu Arg Arg Glu Gly Met Arg Gln 20 25 30 tat
gga gag tgc ctg cat tcc tgc cca tcc ggg tac tat gga cac cga 144 Tyr
Gly Glu Cys Leu His Ser Cys Pro Ser Gly Tyr Tyr Gly His Arg 35 40
45 gcc cca gat atg aac aga tgt gca aga tgc aga ata gaa aac tgt gat
192 Ala Pro Asp Met Asn Arg Cys Ala Arg Cys Arg Ile Glu Asn Cys Asp
50 55 60 tct tgc ttt agc aaa gac ttt tgt acc aag tgc aaa gta ggc
ttt tat 240 Ser Cys Phe Ser Lys Asp Phe Cys Thr Lys Cys Lys Val Gly
Phe Tyr 65 70 75 80 ttg cat aga ggc cgt tgc ttt gat gaa tgt cca gat
ggt ttt 282 Leu His Arg Gly Arg Cys Phe Asp Glu Cys Pro Asp Gly Phe
85 90 <210> SEQ ID NO 10 <211> LENGTH: 94 <212>
TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE:
10 Ile Cys Lys Gly Cys Leu Ser Cys Ser Lys Asp Asn Gly Cys Ser Arg
1 5 10 15 Cys Gln Gln Lys Leu Phe Phe Phe Leu Arg Arg Glu Gly Met
Arg Gln 20 25 30 Tyr Gly Glu Cys Leu His Ser Cys Pro Ser Gly Tyr
Tyr Gly His Arg 35 40 45 Ala Pro Asp Met Asn Arg Cys Ala Arg Cys
Arg Ile Glu Asn Cys Asp 50 55 60 Ser Cys Phe Ser Lys Asp Phe Cys
Thr Lys Cys Lys Val Gly Phe Tyr 65 70 75 80 Leu His Arg Gly Arg Cys
Phe Asp Glu Cys Pro Asp Gly Phe 85 90 <210> SEQ ID NO 11
<211> LENGTH: 177 <212> TYPE: DNA <213> ORGANISM:
Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS
<222> LOCATION: (1)..(177) <400> SEQUENCE: 11 gtt ggt
cat tgg agc gaa tgg gga act tgt agc aga aat aat cgc aca 48 Val Gly
His Trp Ser Glu Trp Gly Thr Cys Ser Arg Asn Asn Arg Thr 1 5 10 15
tgt gga ttt aaa tgg ggt ctg gaa acc aga aca cgg caa att gtt aaa 96
Cys Gly Phe Lys Trp Gly Leu Glu Thr Arg Thr Arg Gln Ile Val Lys 20
25 30 aag cca gtg aaa gac aca ata ccg tgt cca acc att gct gaa tcc
agg 144 Lys Pro Val Lys Asp Thr Ile Pro Cys Pro Thr Ile Ala Glu Ser
Arg 35 40 45 aga tgc aag atg aca atg agg cat tgt cca gga 177 Arg
Cys Lys Met Thr Met Arg His Cys Pro Gly 50 55 <210> SEQ ID NO
12 <211> LENGTH: 59 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 12 Val Gly His Trp Ser
Glu Trp Gly Thr Cys Ser Arg Asn Asn Arg Thr 1 5 10 15 Cys Gly Phe
Lys Trp Gly Leu Glu Thr Arg Thr Arg Gln Ile Val Lys 20 25 30 Lys
Pro Val Lys Asp Thr Ile Pro Cys Pro Thr Ile Ala Glu Ser Arg 35 40
45 Arg Cys Lys Met Thr Met Arg His Cys Pro Gly 50 55 <210>
SEQ ID NO 13 <211> LENGTH: 908 <212> TYPE: DNA
<213> ORGANISM: Homo sapiens <220> FEATURE: <221>
NAME/KEY: CDS <222> LOCATION: (101)..(805) <400>
SEQUENCE: 13 gcccacagca gcccccgcgc ccgccgtgcc gccgccggga cgtggggccc
ttgggccgtc 60 gggccgcctg gggagcgcca gcccggatcc ggctgcccag atg cgg
gcg cca ctc 115 Met Arg Ala Pro Leu 1 5 tgc ctg ctc ctg ctc gtc gcc
cac gcc gtg gac atg ctc gcc ctg aac 163 Cys Leu Leu Leu Leu Val Ala
His Ala Val Asp Met Leu Ala Leu Asn 10 15 20 cga agg aag aag caa
gtg ggc act ggc ctg ggg ggc aac tgc aca ggc 211 Arg Arg Lys Lys Gln
Val Gly Thr Gly Leu Gly Gly Asn Cys Thr Gly 25 30 35 tgt atc atc
tgc tca gag gag aac ggc tgt tcc acc tgc cag cag agg 259 Cys Ile Ile
Cys Ser Glu Glu Asn Gly Cys Ser Thr Cys Gln Gln Arg 40 45 50 ctc
ttc ctg ttc atc cgc cgg gaa ggc atc cgc cag tac ggc aag tgc 307 Leu
Phe Leu Phe Ile Arg Arg Glu Gly Ile Arg Gln Tyr Gly Lys Cys 55 60
65 ctg cac gac tgt ccc cct ggg tac ttc ggc atc cgc ggc cag gag gtc
355 Leu His Asp Cys Pro Pro Gly Tyr Phe Gly Ile Arg Gly Gln Glu Val
70 75 80 85 aac agg tgc aaa aaa tgt ggg gcc act tgt gag agc tgc ttc
agc cag 403 Asn Arg Cys Lys Lys Cys Gly Ala Thr Cys Glu Ser Cys Phe
Ser Gln 90 95 100 gac ttc tgc atc cgg tgc aag agg cag ttt tac ttg
tac aag ggg aag 451 Asp Phe Cys Ile Arg Cys Lys Arg Gln Phe Tyr Leu
Tyr Lys Gly Lys 105 110 115 tgt ctg ccc acc tgc ccg ccg gtc act ttg
gcc cac cag aac aca cgg 499 Cys Leu Pro Thr Cys Pro Pro Val Thr Leu
Ala His Gln Asn Thr Arg 120 125 130 gag tgc cag ggg gag tgt gaa ctg
ggt ccc tgg ggc ggc tgg agc ccc 547 Glu Cys Gln Gly Glu Cys Glu Leu
Gly Pro Trp Gly Gly Trp Ser Pro 135 140 145 tgc aca cac aat gga aag
acc tgc ggc tcg gct tgg ggc ctg gag agc 595 Cys Thr His Asn Gly Lys
Thr Cys Gly Ser Ala Trp Gly Leu Glu Ser 150 155 160 165 cgg gta cga
gag gct ggc cgg gct ggg cat gag gag gca gcc acc tgc 643 Arg Val Arg
Glu Ala Gly Arg Ala Gly His Glu Glu Ala Ala Thr Cys 170 175 180 cag
gtg ctt tct gag tca agg aaa tgt ccc atc cag agg ccc tgc cca 691 Gln
Val Leu Ser Glu Ser Arg Lys Cys Pro Ile Gln Arg Pro Cys Pro 185 190
195 gga gag agg agc ccc ggc cag aag aag ggc agg aag gac cgg cgc cca
739 Gly Glu Arg Ser Pro Gly Gln Lys Lys Gly Arg Lys Asp Arg Arg Pro
200 205 210 cgc aag gac agg aag ctg gac cgc agg ctg gac gtg agg ccg
cgc cag 787 Arg Lys Asp Arg Lys Leu Asp Arg Arg Leu Asp Val Arg Pro
Arg Gln 215 220 225 ccc ggc ctg cag ccc tga ccgccggctc tcccgactct
ctggtcctag 835 Pro Gly Leu Gln Pro 230 tcctcggccc ctgcacacct
cctcctgctc cttctcctcc tctcctctta ctctttctcc 895 tctgtcttct cca 908
<210> SEQ ID NO 14 <211> LENGTH: 234 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 14 Met
Arg Ala Pro Leu Cys Leu Leu Leu Leu Val Ala His Ala Val Asp 1 5 10
15 Met Leu Ala Leu Asn Arg Arg Lys Lys Gln Val Gly Thr Gly Leu Gly
20 25 30 Gly Asn Cys Thr Gly Cys Ile Ile Cys Ser Glu Glu Asn Gly
Cys Ser 35 40 45 Thr Cys Gln Gln Arg Leu Phe Leu Phe Ile Arg Arg
Glu Gly Ile Arg 50 55 60 Gln Tyr Gly Lys Cys Leu His Asp Cys Pro
Pro Gly Tyr Phe Gly Ile 65 70 75 80 Arg Gly Gln Glu Val Asn Arg Cys
Lys Lys Cys Gly Ala Thr Cys Glu 85 90 95 Ser Cys Phe Ser Gln Asp
Phe Cys Ile Arg Cys Lys Arg Gln Phe Tyr 100 105 110 Leu Tyr Lys Gly
Lys Cys Leu Pro Thr Cys Pro Pro Val Thr Leu Ala 115 120 125 His Gln
Asn Thr Arg Glu Cys Gln Gly Glu Cys Glu Leu Gly Pro Trp 130 135 140
Gly Gly Trp Ser Pro Cys Thr His Asn Gly Lys Thr Cys Gly Ser Ala 145
150 155 160 Trp Gly Leu Glu Ser Arg Val Arg Glu Ala Gly Arg Ala Gly
His Glu 165 170 175 Glu Ala Ala Thr Cys Gln Val Leu Ser Glu Ser Arg
Lys Cys Pro Ile 180 185 190 Gln Arg Pro Cys Pro Gly Glu Arg Ser Pro
Gly Gln Lys Lys Gly Arg 195 200 205 Lys Asp Arg Arg Pro Arg Lys Asp
Arg Lys Leu Asp Arg Arg Leu Asp 210 215 220 Val Arg Pro Arg Gln Pro
Gly Leu Gln Pro 225 230 <210> SEQ ID NO 15 <211>
LENGTH: 705 <212> TYPE: DNA <213> ORGANISM: Homo
sapiens <400> SEQUENCE: 15 atgcgggcgc cactctgcct gctcctgctc
gtcgcccacg ccgtggacat gctcgccctg 60 aaccgaagga agaagcaagt
gggcactggc ctggggggca actgcacagg ctgtatcatc 120 tgctcagagg
agaacggctg ttccacctgc cagcagaggc tcttcctgtt catccgccgg 180
gaaggcatcc gccagtacgg caagtgcctg cacgactgtc cccctgggta cttcggcatc
240 cgcggccagg aggtcaacag gtgcaaaaaa tgtggggcca cttgtgagag
ctgcttcagc 300 caggacttct gcatccggtg caagaggcag ttttacttgt
acaaggggaa gtgtctgccc 360 acctgcccgc cgggcacttt ggcccaccag
aacacacggg agtgccaggg ggagtgtgaa 420 ctgggtccct ggggcggctg
gagcccctgc acacacaatg gaaagacctg cggctcggct 480 tggggcctgg
agagccgggt acgagaggct ggccgggctg ggcatgagga ggcagccacc 540
tgccaggtgc tttctgagtc aaggaaatgt cccatccaga ggccctgccc aggagagagg
600 agccccggcc agaagaaggg caggaaggac cggcgcccac gcaaggacag
gaagctggac 660 cgcaggctgg acgtgaggcc gcgccagccc ggcctgcagc cctga
705 <210> SEQ ID NO 16 <211> LENGTH: 645 <212>
TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE:
<221> NAME/KEY: CDS <222> LOCATION: (1)..(645)
<400> SEQUENCE: 16 aac cga agg aag aag caa gtg ggc act ggc
ctg ggg ggc aac tgc aca 48 Asn Arg Arg Lys Lys Gln Val Gly Thr Gly
Leu Gly Gly Asn Cys Thr 1 5 10 15 ggc tgt atc atc tgc tca gag gag
aac ggc tgt tcc acc tgc cag cag 96 Gly Cys Ile Ile Cys Ser Glu Glu
Asn Gly Cys Ser Thr Cys Gln Gln 20 25 30 agg ctc ttc ctg ttc atc
cgc cgg gaa ggc atc cgc cag tac ggc aag 144 Arg Leu Phe Leu Phe Ile
Arg Arg Glu Gly Ile Arg Gln Tyr Gly Lys 35 40 45 tgc ctg cac gac
tgt ccc cct ggg tac ttc ggc atc cgc ggc cag gag 192 Cys Leu His Asp
Cys Pro Pro Gly Tyr Phe Gly Ile Arg Gly Gln Glu 50 55 60 gtc aac
agg tgc aaa aaa tgt ggg gcc act tgt gag agc tgc ttc agc 240 Val Asn
Arg Cys Lys Lys Cys Gly Ala Thr Cys Glu Ser Cys Phe Ser 65 70 75 80
cag gac ttc tgc atc cgg tgc aag agg cag ttt tac ttg tac aag ggg 288
Gln Asp Phe Cys Ile Arg Cys Lys Arg Gln Phe Tyr Leu Tyr Lys Gly 85
90 95 aag tgt ctg ccc acc tgc ccg ccg ggc act ttg gcc cac cag aac
aca 336 Lys Cys Leu Pro Thr Cys Pro Pro Gly Thr Leu Ala His Gln Asn
Thr 100 105 110 cgg gag tgc cag ggg gag tgt gaa ctg ggt ccc tgg ggc
ggc tgg agc 384 Arg Glu Cys Gln Gly Glu Cys Glu Leu Gly Pro Trp Gly
Gly Trp Ser 115 120 125 ccc tgc aca cac aat gga aag acc tgc ggc tcg
gct tgg ggc ctg gag 432 Pro Cys Thr His Asn Gly Lys Thr Cys Gly Ser
Ala Trp Gly Leu Glu 130 135 140 agc cgg gta cga gag gct ggc cgg gct
ggg cat gag gag gca gcc acc 480 Ser Arg Val Arg Glu Ala Gly Arg Ala
Gly His Glu Glu Ala Ala Thr 145 150 155 160 tgc cag gtg ctt tct gag
tca agg aaa tgt ccc atc cag agg ccc tgc 528 Cys Gln Val Leu Ser Glu
Ser Arg Lys Cys Pro Ile Gln Arg Pro Cys 165 170 175 cca gga gag agg
agc ccc ggc cag aag aag ggc agg aag gac cgg cgc 576 Pro Gly Glu Arg
Ser Pro Gly Gln Lys Lys Gly Arg Lys Asp Arg Arg 180 185 190 cca cgc
aag gac agg aag ctg gac cgc agg ctg gac gtg agg ccg cgc 624 Pro Arg
Lys Asp Arg Lys Leu Asp Arg Arg Leu Asp Val Arg Pro Arg 195 200 205
cag ccc ggc ctg cag ccc tga 645 Gln Pro Gly Leu Gln Pro 210
<210> SEQ ID NO 17 <211> LENGTH: 214 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 17 Asn
Arg Arg Lys Lys Gln Val Gly Thr Gly Leu Gly Gly Asn Cys Thr 1 5 10
15 Gly Cys Ile Ile Cys Ser Glu Glu Asn Gly Cys Ser Thr Cys Gln Gln
20 25 30 Arg Leu Phe Leu Phe Ile Arg Arg Glu Gly Ile Arg Gln Tyr
Gly Lys 35 40 45 Cys Leu His Asp Cys Pro Pro Gly Tyr Phe Gly Ile
Arg Gly Gln Glu 50 55 60 Val Asn Arg Cys Lys Lys Cys Gly Ala Thr
Cys Glu Ser Cys Phe Ser 65 70 75 80 Gln Asp Phe Cys Ile Arg Cys Lys
Arg Gln Phe Tyr Leu Tyr Lys Gly 85 90 95 Lys Cys Leu Pro Thr Cys
Pro Pro Gly Thr Leu Ala His Gln Asn Thr 100 105 110 Arg Glu Cys Gln
Gly Glu Cys Glu Leu Gly Pro Trp Gly Gly Trp Ser 115 120 125 Pro Cys
Thr His Asn Gly Lys Thr Cys Gly Ser Ala Trp Gly Leu Glu 130 135 140
Ser Arg Val Arg Glu Ala Gly Arg Ala Gly His Glu Glu Ala Ala Thr 145
150 155 160 Cys Gln Val Leu Ser Glu Ser Arg Lys Cys Pro Ile Gln Arg
Pro Cys 165 170 175 Pro Gly Glu Arg Ser Pro Gly Gln Lys Lys Gly Arg
Lys Asp Arg Arg 180 185 190 Pro Arg Lys Asp Arg Lys Leu Asp Arg Arg
Leu Asp Val Arg Pro Arg 195 200 205 Gln Pro Gly Leu Gln Pro 210
<210> SEQ ID NO 18 <211> LENGTH: 279 <212> TYPE:
DNA <213> ORGANISM: Homo sapiens <220> FEATURE:
<221> NAME/KEY: CDS <222> LOCATION: (1)..(279)
<400> SEQUENCE: 18 aac tgc aca ggc tgt atc atc tgc tca gag
gag aac ggc tgt tcc acc 48 Asn Cys Thr Gly Cys Ile Ile Cys Ser Glu
Glu Asn Gly Cys Ser Thr 1 5 10 15 tgc cag cag agg ctc ttc ctg ttc
atc cgc cgg gaa ggc atc cgc cag 96 Cys Gln Gln Arg Leu Phe Leu Phe
Ile Arg Arg Glu Gly Ile Arg Gln 20 25 30 tac ggc aag tgc ctg cac
gac tgt ccc cct ggg tac ttc ggc atc cgc 144 Tyr Gly Lys Cys Leu His
Asp Cys Pro Pro Gly Tyr Phe Gly Ile Arg 35 40 45 ggc cag gag gtc
aac agg tgc aaa aaa tgt ggg gcc act tgt gag agc 192 Gly Gln Glu Val
Asn Arg Cys Lys Lys Cys Gly Ala Thr Cys Glu Ser 50 55 60 tgc ttc
agc cag gac ttc tgc atc cgg tgc aag agg cag ttt tac ttg 240 Cys Phe
Ser Gln Asp Phe Cys Ile Arg Cys Lys Arg Gln Phe Tyr Leu 65 70 75 80
tac aag ggg aag tgt ctg ccc acc tgc ccg ccg ggc act 279 Tyr Lys Gly
Lys Cys Leu Pro Thr Cys Pro Pro Gly Thr 85 90 <210> SEQ ID NO
19 <211> LENGTH: 93 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 19 Asn Cys Thr Gly Cys
Ile Ile Cys Ser Glu Glu Asn Gly Cys Ser Thr 1 5 10 15 Cys Gln Gln
Arg Leu Phe Leu Phe Ile Arg Arg Glu Gly Ile Arg Gln 20 25 30 Tyr
Gly Lys Cys Leu His Asp Cys Pro Pro Gly Tyr Phe Gly Ile Arg 35 40
45 Gly Gln Glu Val Asn Arg Cys Lys Lys Cys Gly Ala Thr Cys Glu Ser
50 55 60 Cys Phe Ser Gln Asp Phe Cys Ile Arg Cys Lys Arg Gln Phe
Tyr Leu 65 70 75 80 Tyr Lys Gly Lys Cys Leu Pro Thr Cys Pro Pro Gly
Thr 85 90 <210> SEQ ID NO 20 <211> LENGTH: 171
<212> TYPE: DNA <213> ORGANISM: Homo sapiens
<220> FEATURE: <221> NAME/KEY: CDS <222>
LOCATION: (1)..(171) <400> SEQUENCE: 20 ctg ggt ccc tgg ggc
ggc tgg agc ccc tgc aca cac aat gga aag acc 48 Leu Gly Pro Trp Gly
Gly Trp Ser Pro Cys Thr His Asn Gly Lys Thr 1 5 10 15 tgc ggc tcg
gct tgg ggc ctg gag agc cgg gta cga gag gct ggc cgg 96 Cys Gly Ser
Ala Trp Gly Leu Glu Ser Arg Val Arg Glu Ala Gly Arg 20 25 30 gct
ggg cat gag gag gca gcc acc tgc cag gtg ctt tct gag tca agg 144 Ala
Gly His Glu Glu Ala Ala Thr Cys Gln Val Leu Ser Glu Ser Arg 35 40
45 aaa tgt ccc atc cag agg ccc tgc cta 171 Lys Cys Pro Ile Gln Arg
Pro Cys Leu 50 55 <210> SEQ ID NO 21 <211> LENGTH: 57
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 21 Leu Gly Pro Trp Gly Gly Trp Ser Pro Cys
Thr His Asn Gly Lys Thr 1 5 10 15 Cys Gly Ser Ala Trp Gly Leu Glu
Ser Arg Val Arg Glu Ala Gly Arg 20 25 30 Ala Gly His Glu Glu Ala
Ala Thr Cys Gln Val Leu Ser Glu Ser Arg 35 40 45 Lys Cys Pro Ile
Gln Arg Pro Cys Leu 50 55 <210> SEQ ID NO 22 <211>
LENGTH: 722 <212> TYPE: DNA <213> ORGANISM: Homo
sapiens <220> FEATURE: <221> NAME/KEY: CDS <222>
LOCATION: (101)..(619) <400> SEQUENCE: 22 gcccacagca
gcccccgcgc ccgccgtgcc gccgccggga cgtggggccc ttgggccgtc 60
gggccgcctg gggagcgcca gcccggatcc ggctgcccag atg cgg gcg cca ctc 115
Met Arg Ala Pro Leu 1 5 tgc ctg ctc ctg ctc gtc gcc cac gcc gtg gac
atg ctc gcc ctg aac 163 Cys Leu Leu Leu Leu Val Ala His Ala Val Asp
Met Leu Ala Leu Asn 10 15 20 cga agg aag aag caa gtg ggc act ggc
ctg ggg ggc aac tgc aca ggc 211 Arg Arg Lys Lys Gln Val Gly Thr Gly
Leu Gly Gly Asn Cys Thr Gly 25 30 35 tgt atc atc tgc tca gag gag
aac ggc tgt tcc acc tgc cag cag agg 259 Cys Ile Ile Cys Ser Glu Glu
Asn Gly Cys Ser Thr Cys Gln Gln Arg 40 45 50 ctc ttc ctg ttc atc
cgc cgg gaa ggc atc cgc cag tac ggc aag tgc 307 Leu Phe Leu Phe Ile
Arg Arg Glu Gly Ile Arg Gln Tyr Gly Lys Cys 55 60 65 ctg cac gac
tgt ccc cct ggg tac ttc ggc atc cgc ggc cag gag gtc 355 Leu His Asp
Cys Pro Pro Gly Tyr Phe Gly Ile Arg Gly Gln Glu Val 70 75 80 85 aac
agg tgc aaa aaa tgt ggg gcc act tgt gag agc tgc ttc agc cag 403 Asn
Arg Cys Lys Lys Cys Gly Ala Thr Cys Glu Ser Cys Phe Ser Gln 90 95
100 gac ttc tgc atc cgg tgc aag agg cag ttt tac ttg tac aag ggg aag
451 Asp Phe Cys Ile Arg Cys Lys Arg Gln Phe Tyr Leu Tyr Lys Gly Lys
105 110 115 tgt ctg ccc acc tgc ccg ccg ggc act ttg gcc cac cag aac
aca cgg 499 Cys Leu Pro Thr Cys Pro Pro Gly Thr Leu Ala His Gln Asn
Thr Arg 120 125 130 gag tgc cag gag agg agc ccc ggc cag aag aag ggc
agg aag gac cgg 547 Glu Cys Gln Glu Arg Ser Pro Gly Gln Lys Lys Gly
Arg Lys Asp Arg 135 140 145 cgc cca cgc gag gac agg aag ctg gac cgc
agg ctg gac gtg agg ccg 595 Arg Pro Arg Glu Asp Arg Lys Leu Asp Arg
Arg Leu Asp Val Arg Pro 150 155 160 165 cgc cag ccc ggc ctg cag ccc
tga ccgccggctc tcccgactct ctggtcctag 649 Arg Gln Pro Gly Leu Gln
Pro 170 tcctcggccc ctgcacacct cctcctgctc cttctcctcc tctcctctta
ctctttctcc 709 tctgtcttct cca 722 <210> SEQ ID NO 23
<211> LENGTH: 172 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 23 Met Arg Ala Pro Leu Cys Leu
Leu Leu Leu Val Ala His Ala Val Asp 1 5 10 15 Met Leu Ala Leu Asn
Arg Arg Lys Lys Gln Val Gly Thr Gly Leu Gly 20 25 30 Gly Asn Cys
Thr Gly Cys Ile Ile Cys Ser Glu Glu Asn Gly Cys Ser 35 40 45 Thr
Cys Gln Gln Arg Leu Phe Leu Phe Ile Arg Arg Glu Gly Ile Arg 50 55
60 Gln Tyr Gly Lys Cys Leu His Asp Cys Pro Pro Gly Tyr Phe Gly Ile
65 70 75 80 Arg Gly Gln Glu Val Asn Arg Cys Lys Lys Cys Gly Ala Thr
Cys Glu 85 90 95 Ser Cys Phe Ser Gln Asp Phe Cys Ile Arg Cys Lys
Arg Gln Phe Tyr 100 105 110 Leu Tyr Lys Gly Lys Cys Leu Pro Thr Cys
Pro Pro Gly Thr Leu Ala 115 120 125 His Gln Asn Thr Arg Glu Cys Gln
Glu Arg Ser Pro Gly Gln Lys Lys 130 135 140 Gly Arg Lys Asp Arg Arg
Pro Arg Glu Asp Arg Lys Leu Asp Arg Arg 145 150 155 160 Leu Asp Val
Arg Pro Arg Gln Pro Gly Leu Gln Pro 165 170 <210> SEQ ID NO
24 <211> LENGTH: 519 <212> TYPE: DNA <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 24 atgcgggcgc
cactctgcct gctcctgctc gtcgcccacg ccgtggacat gctcgccctg 60
aaccgaagga agaagcaagt gggcactggc ctggggggca actgcacagg ctgtatcatc
120 tgctcagagg agaacggctg ttccacctgc cagcagaggc tcttcctgtt
catccgccgg 180 gaaggcatcc gccagtacgg caagtgcctg cacgactgtc
cccctgggta cttcggcatc 240 cgcggccagg aggtcaacag gtgcaaaaaa
tgtggggcca cttgtgagag ctgcttcagc 300 caggacttct gcatccggtg
caagaggcag ttttacttgt acaaggggaa gtgtctgccc 360 acctgcccgc
cgggcacttt ggcccaccag aacacacggg agtgccagga gaggagcccc 420
ggccagaaga agggcaggaa ggaccggcgc ccacgcaagg acaggaagct ggaccgcagg
480 ctggacgtga ggccgcgcca gcccggcctg cagccctga 519 <210> SEQ
ID NO 25 <211> LENGTH: 459 <212> TYPE: DNA <213>
ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY:
CDS <222> LOCATION: (1)..(459) <400> SEQUENCE: 25 aac
cga agg aag aag caa gtg ggc act ggc ctg ggg ggc aac tgc aca 48 Asn
Arg Arg Lys Lys Gln Val Gly Thr Gly Leu Gly Gly Asn Cys Thr 1 5 10
15 ggc tgt atc atc tgc tca gag gag aac ggc tgt tcc acc tgc cag cag
96 Gly Cys Ile Ile Cys Ser Glu Glu Asn Gly Cys Ser Thr Cys Gln Gln
20 25 30 agg ctc ttc ctg ttc atc cgc cgg gaa ggc atc cgc cag tac
ggc aag 144 Arg Leu Phe Leu Phe Ile Arg Arg Glu Gly Ile Arg Gln Tyr
Gly Lys 35 40 45 tgc ctg cac gac tgt ccc cct ggg tac ttc ggc atc
cgc ggc cag gag 192 Cys Leu His Asp Cys Pro Pro Gly Tyr Phe Gly Ile
Arg Gly Gln Glu 50 55 60 gtc aac agg tgc aaa aaa tgt ggg gcc act
tgt gag agc tgc ttc agc 240 Val Asn Arg Cys Lys Lys Cys Gly Ala Thr
Cys Glu Ser Cys Phe Ser 65 70 75 80 cag gac ttc tgc atc cgg tgc aag
agg cag ttt tac ttg tac aag ggg 288 Gln Asp Phe Cys Ile Arg Cys Lys
Arg Gln Phe Tyr Leu Tyr Lys Gly 85 90 95 aag tgt ctg ccc acc tgc
ccg ccg ggc act ttg gcc cac cag aac aca 336 Lys Cys Leu Pro Thr Cys
Pro Pro Gly Thr Leu Ala His Gln Asn Thr 100 105 110 cgg gag tgc cag
gag agg agc ccc ggc cag aag aag ggc agg aag gac 384 Arg Glu Cys Gln
Glu Arg Ser Pro Gly Gln Lys Lys Gly Arg Lys Asp 115 120 125 cgg cgc
cca cgc aag gac agg aag ctg gac cgc agg ctg gac gtg agg 432 Arg Arg
Pro Arg Lys Asp Arg Lys Leu Asp Arg Arg Leu Asp Val Arg 130 135 140
ccg cgc cag ccc ggc ctg cag ccc tga 459 Pro Arg Gln Pro Gly Leu Gln
Pro 145 150 <210> SEQ ID NO 26 <211> LENGTH: 152
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 26 Asn Arg Arg Lys Lys Gln Val Gly Thr Gly
Leu Gly Gly Asn Cys Thr 1 5 10 15 Gly Cys Ile Ile Cys Ser Glu Glu
Asn Gly Cys Ser Thr Cys Gln Gln 20 25 30 Arg Leu Phe Leu Phe Ile
Arg Arg Glu Gly Ile Arg Gln Tyr Gly Lys 35 40 45 Cys Leu His Asp
Cys Pro Pro Gly Tyr Phe Gly Ile Arg Gly Gln Glu 50 55 60 Val Asn
Arg Cys Lys Lys Cys Gly Ala Thr Cys Glu Ser Cys Phe Ser 65 70 75 80
Gln Asp Phe Cys Ile Arg Cys Lys Arg Gln Phe Tyr Leu Tyr Lys Gly 85
90 95 Lys Cys Leu Pro Thr Cys Pro Pro Gly Thr Leu Ala His Gln Asn
Thr 100 105 110 Arg Glu Cys Gln Glu Arg Ser Pro Gly Gln Lys Lys Gly
Arg Lys Asp 115 120 125 Arg Arg Pro Arg Lys Asp Arg Lys Leu Asp Arg
Arg Leu Asp Val Arg 130 135 140 Pro Arg Gln Pro Gly Leu Gln Pro 145
150 <210> SEQ ID NO 27 <211> LENGTH: 19 <212>
TYPE: DNA <213> ORGANISM: F primer for cloning SCFA2 into
plntron/Igk 1round PCR <400> SEQUENCE: 27 ctttgggcga
accctccag 19 <210> SEQ ID NO 28 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: R primer for cloning
SCFA2 into plntron/Igk 1round PCR <400> SEQUENCE: 28
gagcagcaca aaggctgcac 20 <210> SEQ ID NO 29 <211>
LENGTH: 37 <212> TYPE: DNA <213> ORGANISM: F primer
SCFA2 cloning 2nd PCR round for cloning SCFA2 into plntron/Igk
<400> SEQUENCE: 29 ccggctagcg ctagttatgt atcaaatccc atttgca
37 <210> SEQ ID NO 30 <211> LENGTH: 36 <212>
TYPE: DNA <213> ORGANISM: R primer SCFA2 cloning 2nd PCR
round for cloning SCFA2 into plntron/Igk <400> SEQUENCE: 30
tgctctagac tttggttagc tctgtctgta gctagg 36 <210> SEQ ID NO 31
<211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM:
F primer for cloning SCFA4-4v into plntron/Igk 1round PCR
<400> SEQUENCE: 31 tggggccctt gggccgtcgg gc 22 <210>
SEQ ID NO 32 <211> LENGTH: 21 <212> TYPE: DNA
<213> ORGANISM: R primer for cloning SCFA4-4v into
plntron/Igk 1round PCR <400> SEQUENCE: 32 aaggagcagg
aggaggtgtg c 21 <210> SEQ ID NO 33 <211> LENGTH: 32
<212> TYPE: DNA <213> ORGANISM: F primer for cloning
SCFA4 and 4v into plntron/Igk 2nd round PCR <400> SEQUENCE:
33 ctgagctagc ctgaaccgaa ggaagaagca ag 32 <210> SEQ ID NO 34
<211> LENGTH: 33 <212> TYPE: DNA <213> ORGANISM:
R primer for cloning SCFA4 and 4v into plntron/Igk 2nd round PCR
<400> SEQUENCE: 34 ctgatctaga ccgggctgca ggccgggctg gcg 33
<210> SEQ ID NO 35 <211> LENGTH: 813 <212> TYPE:
DNA <213> ORGANISM: IgK-SCFA2-V5His6 <220> FEATURE:
<221> NAME/KEY: CDS <222> LOCATION: (1)..(813)
<400> SEQUENCE: 35 atg gag aca gac aca ctc ctg cta tgg gta
ctg ctg ctc tgg gtt cca 48 Met Glu Thr Asp Thr Leu Leu Leu Trp Val
Leu Leu Leu Trp Val Pro 1 5 10 15 ggt tcc act ggt gac gct agc gct
agt tat gta tca aat ccc att tgc 96 Gly Ser Thr Gly Asp Ala Ser Ala
Ser Tyr Val Ser Asn Pro Ile Cys 20 25 30 aag ggt tgt ttg tct tgt
tca aag gac aat ggg tgt agc cga tgt caa 144 Lys Gly Cys Leu Ser Cys
Ser Lys Asp Asn Gly Cys Ser Arg Cys Gln 35 40 45 cag aag ttg ttc
ttc ttc ctt cga aga gaa ggg atg cgc cag tat gga 192 Gln Lys Leu Phe
Phe Phe Leu Arg Arg Glu Gly Met Arg Gln Tyr Gly 50 55 60 gag tgc
ctg cat tcc tgc cca tcc ggg tac tat gga cac cga gcc cca 240 Glu Cys
Leu His Ser Cys Pro Ser Gly Tyr Tyr Gly His Arg Ala Pro 65 70 75 80
gat atg aac aga tgt gca aga tgc aga ata gaa aac tgt gat tct tgc 288
Asp Met Asn Arg Cys Ala Arg Cys Arg Ile Glu Asn Cys Asp Ser Cys 85
90 95 ttt agc aaa gac ttt tgt acc aag tgc aaa gta ggc ttt tat ttg
cat 336 Phe Ser Lys Asp Phe Cys Thr Lys Cys Lys Val Gly Phe Tyr Leu
His 100 105 110 aga ggc cgt tgc ttt gat gaa tgt cca gat ggt ttt gca
cca tta gaa 384 Arg Gly Arg Cys Phe Asp Glu Cys Pro Asp Gly Phe Ala
Pro Leu Glu 115 120 125 gaa acc atg gaa tgt gtg gaa gga tgt gaa gtt
ggt cat tgg agc gaa 432 Glu Thr Met Glu Cys Val Glu Gly Cys Glu Val
Gly His Trp Ser Glu 130 135 140 tgg gga act tgt agc aga aat aat cgc
aca tgt gga ttt aaa tgg ggt 480 Trp Gly Thr Cys Ser Arg Asn Asn Arg
Thr Cys Gly Phe Lys Trp Gly 145 150 155 160 ctg gaa acc aga aca cgg
caa att gtt aaa aag cca gtg aaa gac aca 528 Leu Glu Thr Arg Thr Arg
Gln Ile Val Lys Lys Pro Val Lys Asp Thr 165 170 175 ata ccg tgt cca
acc att gct gaa tcc agg aga tgc aag atg aca atg 576 Ile Pro Cys Pro
Thr Ile Ala Glu Ser Arg Arg Cys Lys Met Thr Met 180 185 190 agg cat
tgt cca gga ggg aag aga aca cca aag gcg aag gag aag agg 624 Arg His
Cys Pro Gly Gly Lys Arg Thr Pro Lys Ala Lys Glu Lys Arg 195 200 205
aac aag aaa aag aaa agg aag ctg ata gaa agg gcc cag gag caa cac 672
Asn Lys Lys Lys Lys Arg Lys Leu Ile Glu Arg Ala Gln Glu Gln His 210
215 220 agc gtc ttc cta gct aca gac aga gct aac caa ggc ggc cgc tcg
agt 720 Ser Val Phe Leu Ala Thr Asp Arg Ala Asn Gln Gly Gly Arg Ser
Ser 225 230 235 240 cta gag ggc ccg cgg ttc gaa ggt aag cct atc cct
aac cct ctc ctc 768 Leu Glu Gly Pro Arg Phe Glu Gly Lys Pro Ile Pro
Asn Pro Leu Leu 245 250 255 ggt ctc gat tct acg cgt acc ggt cat cat
cac cat cac cat tga 813 Gly Leu Asp Ser Thr Arg Thr Gly His His His
His His His 260 265 270 <210> SEQ ID NO 36 <211>
LENGTH: 270 <212> TYPE: PRT <213> ORGANISM:
IgK-SCFA2-V5His6 <400> SEQUENCE: 36 Met Glu Thr Asp Thr Leu
Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly
Asp Ala Ser Ala Ser Tyr Val Ser Asn Pro Ile Cys 20 25 30 Lys Gly
Cys Leu Ser Cys Ser Lys Asp Asn Gly Cys Ser Arg Cys Gln 35 40 45
Gln Lys Leu Phe Phe Phe Leu Arg Arg Glu Gly Met Arg Gln Tyr Gly 50
55 60 Glu Cys Leu His Ser Cys Pro Ser Gly Tyr Tyr Gly His Arg Ala
Pro 65 70 75 80 Asp Met Asn Arg Cys Ala Arg Cys Arg Ile Glu Asn Cys
Asp Ser Cys 85 90 95 Phe Ser Lys Asp Phe Cys Thr Lys Cys Lys Val
Gly Phe Tyr Leu His 100 105 110 Arg Gly Arg Cys Phe Asp Glu Cys Pro
Asp Gly Phe Ala Pro Leu Glu 115 120 125 Glu Thr Met Glu Cys Val Glu
Gly Cys Glu Val Gly His Trp Ser Glu 130 135 140 Trp Gly Thr Cys Ser
Arg Asn Asn Arg Thr Cys Gly Phe Lys Trp Gly 145 150 155 160 Leu Glu
Thr Arg Thr Arg Gln Ile Val Lys Lys Pro Val Lys Asp Thr 165 170 175
Ile Pro Cys Pro Thr Ile Ala Glu Ser Arg Arg Cys Lys Met Thr Met 180
185 190 Arg His Cys Pro Gly Gly Lys Arg Thr Pro Lys Ala Lys Glu Lys
Arg 195 200 205 Asn Lys Lys Lys Lys Arg Lys Leu Ile Glu Arg Ala Gln
Glu Gln His 210 215 220 Ser Val Phe Leu Ala Thr Asp Arg Ala Asn Gln
Gly Gly Arg Ser Ser 225 230 235 240 Leu Glu Gly Pro Arg Phe Glu Gly
Lys Pro Ile Pro Asn Pro Leu Leu 245 250 255 Gly Leu Asp Ser Thr Arg
Thr Gly His His His His His His 260 265 270 <210> SEQ ID NO
37 <211> LENGTH: 35 <212> TYPE: DNA <213>
ORGANISM: F primer for cloning out IgK-SCFA2-V5His from pIntron
into Adeno <400> SEQUENCE: 37 tgctctagac accatggaga
cagacacact cctgc 35 <210> SEQ ID NO 38 <211> LENGTH: 38
<212> TYPE: DNA <213> ORGANISM: R primer for cloning
out IgK-SCFA2-V5His from pIntron into Adeno <400> SEQUENCE:
38 ccatgcggcc gccttggtta gctctgtctg tagctagg 38 <210> SEQ ID
NO 39 <211> LENGTH: 822 <212> TYPE: DNA <213>
ORGANISM: IgK-SCFA4-V5His <220> FEATURE: <221>
NAME/KEY: CDS <222> LOCATION: (1)..(822) <400>
SEQUENCE: 39 atg gag aca gac aca ctc ctg cta tgg gta ctg ctg ctc
tgg gtt cca 48 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu
Trp Val Pro 1 5 10 15 ggt tcc act ggt gac gct agc ctg aac cga agg
aag aag caa gtg ggc 96 Gly Ser Thr Gly Asp Ala Ser Leu Asn Arg Arg
Lys Lys Gln Val Gly 20 25 30 act ggc ctg ggg ggc aac tgc aca ggc
tgt atc atc tgc tca gag gag 144 Thr Gly Leu Gly Gly Asn Cys Thr Gly
Cys Ile Ile Cys Ser Glu Glu 35 40 45 aac ggc tgt tcc acc tgc cag
cag agg ctc ttc ctg ttc atc cgc cgg 192 Asn Gly Cys Ser Thr Cys Gln
Gln Arg Leu Phe Leu Phe Ile Arg Arg 50 55 60 gaa ggc atc cgc cag
tac ggc aag tgc ctg cac gac tgt ccc cct ggg 240 Glu Gly Ile Arg Gln
Tyr Gly Lys Cys Leu His Asp Cys Pro Pro Gly 65 70 75 80 tac ttc ggc
atc cgc ggc cag gag gtc aac agg tgc aaa aaa tgt ggg 288 Tyr Phe Gly
Ile Arg Gly Gln Glu Val Asn Arg Cys Lys Lys Cys Gly 85 90 95 gcc
act tgt gag agc tgc ttc agc cag gac ttc tgc atc cgg tgc aag 336 Ala
Thr Cys Glu Ser Cys Phe Ser Gln Asp Phe Cys Ile Arg Cys Lys 100 105
110 agg cag ttt tac ttg tac aag ggg aag tgt ctg ccc acc tgc ccg ccg
384 Arg Gln Phe Tyr Leu Tyr Lys Gly Lys Cys Leu Pro Thr Cys Pro Pro
115 120 125 ggc act ttg gct cac cag aac aca cgg gag tgc cag ggg gag
tgt gaa 432 Gly Thr Leu Ala His Gln Asn Thr Arg Glu Cys Gln Gly Glu
Cys Glu 130 135 140 ctg ggt ccc tgg ggc ggc tgg agc ccc tgc aca cac
aat gga aag acc 480 Leu Gly Pro Trp Gly Gly Trp Ser Pro Cys Thr His
Asn Gly Lys Thr 145 150 155 160 tgc ggc tcg gct tgg ggc ctg gag agc
cgg gta cga gag gct ggc cgg 528 Cys Gly Ser Ala Trp Gly Leu Glu Ser
Arg Val Arg Glu Ala Gly Arg 165 170 175 gct ggg cat gag gag gca gcc
acc tgc cag gtg ctt tct gag tca agg 576 Ala Gly His Glu Glu Ala Ala
Thr Cys Gln Val Leu Ser Glu Ser Arg 180 185 190 aaa tgt ccc atc cag
agg ccc tgc cca gga gag agg agc ccc ggc cag 624 Lys Cys Pro Ile Gln
Arg Pro Cys Pro Gly Glu Arg Ser Pro Gly Gln 195 200 205 aag aag ggc
agg aag gac cgg cgc cca cgc aag gac agg aag ctg gac 672 Lys Lys Gly
Arg Lys Asp Arg Arg Pro Arg Lys Asp Arg Lys Leu Asp 210 215 220 cgc
agg ctg gac gtg agg ccg cgc cag ccc ggc ctg cag ccc ggc ggc 720 Arg
Arg Leu Asp Val Arg Pro Arg Gln Pro Gly Leu Gln Pro Gly Gly 225 230
235 240 cgc tcg agt cta gag ggc ccg cgg ttc gaa ggt aag cct atc cct
aac 768 Arg Ser Ser Leu Glu Gly Pro Arg Phe Glu Gly Lys Pro Ile Pro
Asn 245 250 255 cct ctc ctc ggt ctc gat tct acg cgt acc ggt cat cat
cac cat cac 816 Pro Leu Leu Gly Leu Asp Ser Thr Arg Thr Gly His His
His His His 260 265 270 cat tga 822 His <210> SEQ ID NO 40
<211> LENGTH: 273 <212> TYPE: PRT <213> ORGANISM:
IgK-SCFA4-V5His <400> SEQUENCE: 40 Met Glu Thr Asp Thr Leu
Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly
Asp Ala Ser Leu Asn Arg Arg Lys Lys Gln Val Gly 20 25 30 Thr Gly
Leu Gly Gly Asn Cys Thr Gly Cys Ile Ile Cys Ser Glu Glu 35 40 45
Asn Gly Cys Ser Thr Cys Gln Gln Arg Leu Phe Leu Phe Ile Arg Arg 50
55 60 Glu Gly Ile Arg Gln Tyr Gly Lys Cys Leu His Asp Cys Pro Pro
Gly 65 70 75 80 Tyr Phe Gly Ile Arg Gly Gln Glu Val Asn Arg Cys Lys
Lys Cys Gly 85 90 95 Ala Thr Cys Glu Ser Cys Phe Ser Gln Asp Phe
Cys Ile Arg Cys Lys 100 105 110 Arg Gln Phe Tyr Leu Tyr Lys Gly Lys
Cys Leu Pro Thr Cys Pro Pro 115 120 125 Gly Thr Leu Ala His Gln Asn
Thr Arg Glu Cys Gln Gly Glu Cys Glu 130 135 140 Leu Gly Pro Trp Gly
Gly Trp Ser Pro Cys Thr His Asn Gly Lys Thr 145 150 155 160 Cys Gly
Ser Ala Trp Gly Leu Glu Ser Arg Val Arg Glu Ala Gly Arg 165 170 175
Ala Gly His Glu Glu Ala Ala Thr Cys Gln Val Leu Ser Glu Ser Arg 180
185 190 Lys Cys Pro Ile Gln Arg Pro Cys Pro Gly Glu Arg Ser Pro Gly
Gln 195 200 205 Lys Lys Gly Arg Lys Asp Arg Arg Pro Arg Lys Asp Arg
Lys Leu Asp 210 215 220 Arg Arg Leu Asp Val Arg Pro Arg Gln Pro Gly
Leu Gln Pro Gly Gly 225 230 235 240 Arg Ser Ser Leu Glu Gly Pro Arg
Phe Glu Gly Lys Pro Ile Pro Asn 245 250 255 Pro Leu Leu Gly Leu Asp
Ser Thr Arg Thr Gly His His His His His 260 265 270 His <210>
SEQ ID NO 41 <211> LENGTH: 35 <212> TYPE: DNA
<213> ORGANISM: F primer for cloning out IgK-SCFA4(4v)-V5His
from pIntron into <400> SEQUENCE: 41 tgctctagac accatggaga
cagacacact cctgc 35 <210> SEQ ID NO 42 <211> LENGTH: 31
<212> TYPE: DNA <213> ORGANISM: R primer for cloning
out IgK-SCFA4(4v)-V5His from plntron into <400> SEQUENCE: 42
ccatgcggcc gccgggctgc aggccgggct g 31 <210> SEQ ID NO 43
<211> LENGTH: 636 <212> TYPE: DNA <213> ORGANISM:
IgK-SCFA4v-v5His6 <220> FEATURE: <221> NAME/KEY: CDS
<222> LOCATION: (1)..(636) <400> SEQUENCE: 43 atg gag
aca gac aca ctc ctg cta tgg gta ctg ctg ctc tgg gtt cca 48 Met Glu
Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15
ggt tcc act ggt gac gct agc ctg aac cga agg aag aag caa gtg ggc 96
Gly Ser Thr Gly Asp Ala Ser Leu Asn Arg Arg Lys Lys Gln Val Gly 20
25 30 act ggc ctg ggg ggc aac tgc aca ggc tgt atc atc tgc tca gag
gag 144 Thr Gly Leu Gly Gly Asn Cys Thr Gly Cys Ile Ile Cys Ser Glu
Glu 35 40 45 aac ggc tgt tcc acc tgc cag cag agg ctc ttc ctg ttc
atc cgc cgg 192 Asn Gly Cys Ser Thr Cys Gln Gln Arg Leu Phe Leu Phe
Ile Arg Arg 50 55 60 gaa ggc atc cgc cag tac ggc aag tgc ctg cac
gac tgt ccc cct ggg 240 Glu Gly Ile Arg Gln Tyr Gly Lys Cys Leu His
Asp Cys Pro Pro Gly 65 70 75 80 tac ttc ggc atc cgc ggc cag gag gtc
aac agg tgc aaa aaa tgt ggg 288 Tyr Phe Gly Ile Arg Gly Gln Glu Val
Asn Arg Cys Lys Lys Cys Gly 85 90 95 gcc act tgt gag agc tgc ttc
agc cag gac ttc tgc atc cgg tgc aag 336 Ala Thr Cys Glu Ser Cys Phe
Ser Gln Asp Phe Cys Ile Arg Cys Lys 100 105 110 agg cag ttt tac ttg
tac aag ggg aag tgt ctg ccc acc tgc ccg ccg 384 Arg Gln Phe Tyr Leu
Tyr Lys Gly Lys Cys Leu Pro Thr Cys Pro Pro 115 120 125 ggc act ttg
gcc cac cag aac aca cgg gag tgc cag gag agg agc ccc 432 Gly Thr Leu
Ala His Gln Asn Thr Arg Glu Cys Gln Glu Arg Ser Pro 130 135 140 ggc
cag aag aag ggc agg aag gac cgg cgc cca cgc aag gac agg aag 480 Gly
Gln Lys Lys Gly Arg Lys Asp Arg Arg Pro Arg Lys Asp Arg Lys 145 150
155 160 ctg gac cgc agg ctg gac gtg agg ccg cgc cag ccc ggc ctg cag
ccc 528 Leu Asp Arg Arg Leu Asp Val Arg Pro Arg Gln Pro Gly Leu Gln
Pro 165 170 175 ggc ggc cgc tcg agt cta gag ggc ccg cgg ttc gaa ggt
aag cct atc 576 Gly Gly Arg Ser Ser Leu Glu Gly Pro Arg Phe Glu Gly
Lys Pro Ile 180 185 190 cct aac cct ctc ctc ggt ctc gat tct acg cgt
acc ggt cat cat cac 624 Pro Asn Pro Leu Leu Gly Leu Asp Ser Thr Arg
Thr Gly His His His 195 200 205 cat cac cat tga 636 His His His 210
<210> SEQ ID NO 44 <211> LENGTH: 211 <212> TYPE:
PRT <213> ORGANISM: IgK-SCFA4v-v5His6 <400> SEQUENCE:
44 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1 5 10 15 Gly Ser Thr Gly Asp Ala Ser Leu Asn Arg Arg Lys Lys Gln
Val Gly 20 25 30 Thr Gly Leu Gly Gly Asn Cys Thr Gly Cys Ile Ile
Cys Ser Glu Glu 35 40 45 Asn Gly Cys Ser Thr Cys Gln Gln Arg Leu
Phe Leu Phe Ile Arg Arg 50 55 60 Glu Gly Ile Arg Gln Tyr Gly Lys
Cys Leu His Asp Cys Pro Pro Gly 65 70 75 80 Tyr Phe Gly Ile Arg Gly
Gln Glu Val Asn Arg Cys Lys Lys Cys Gly 85 90 95 Ala Thr Cys Glu
Ser Cys Phe Ser Gln Asp Phe Cys Ile Arg Cys Lys 100 105 110 Arg Gln
Phe Tyr Leu Tyr Lys Gly Lys Cys Leu Pro Thr Cys Pro Pro 115 120 125
Gly Thr Leu Ala His Gln Asn Thr Arg Glu Cys Gln Glu Arg Ser Pro 130
135 140 Gly Gln Lys Lys Gly Arg Lys Asp Arg Arg Pro Arg Lys Asp Arg
Lys 145 150 155 160 Leu Asp Arg Arg Leu Asp Val Arg Pro Arg Gln Pro
Gly Leu Gln Pro 165 170 175 Gly Gly Arg Ser Ser Leu Glu Gly Pro Arg
Phe Glu Gly Lys Pro Ile 180 185 190 Pro Asn Pro Leu Leu Gly Leu Asp
Ser Thr Arg Thr Gly His His His 195 200 205 His His His 210
<210> SEQ ID NO 45 <211> LENGTH: 28 <212> TYPE:
DNA <213> ORGANISM: F primer for making adenovator CMv5
Intron modification EG 6 <400> SEQUENCE: 45 cacccctagg
tcaatattgg ccattagc 28 <210> SEQ ID NO 46 <211> LENGTH:
28 <212> TYPE: DNA <213> ORGANISM: R primer for making
adenovator CMV5 Intron modification EG 6 <400> SEQUENCE: 46
cacccctagg taggcatccc cagcatgc 28 <210> SEQ ID NO 47
<211> LENGTH: 8913 <212> TYPE: DNA <213>
ORGANISM: pAdenovator-CMVIntron(Transfer vector): <400>
SEQUENCE: 47 taacatcatc aataatatac cttattttgg attgaagcca atatgataat
gagggggtgg 60 agtttgtgac gtggcgcggg gcgtgggaac ggggcgggtg
acgtagtagt gtggcggaag 120 tgtgatgttg caagtgtggc ggaacacatg
taagcgacgg atgtggcaaa agtgacgttt 180 ttggtgtgcg ccggtgtaca
caggaagtga caattttcgc gcggttttag gcggatgttg 240 tagtaaattt
gggcgtaacc gagtaagatt tggccatttt cgcgggaaaa ctgaataaga 300
ggaagtgaaa tctgaataat tttgtgttac tcatagcgcg taatactgcg atctatacat
360 tgaatcaata ttggcaatta gccatattag tcattggtta tatagcataa
atcaatattg 420 gctattggcc attgcatacg ttgtatctat atcataatat
gtacatttat attggctcat 480 gtccaatatg accgccatgt tgacattgat
tattgactag gtcaatattg gccattagcc 540 atattattca ttggttatat
agcataaatc aatattggct attggccatt gcatacgttg 600 tatctatatc
ataatatgta catttatatt ggctcatgtc caatatgacc gccatgttgg 660
cattgattat tgactagtta ttaatagtaa tcaattacgg ggtcattagt tcatagccca
720 tatatggagt tccgcgttac ataacttacg gtaaatggcc cgcctggctg
accgcccaac 780 gacccccgcc cattgacgtc aataatgacg tatgttccca
tagtaacgcc aatagggact 840 ttccattgac gtcaatgggt ggagtattta
cggtaaactg cccacttggc agtacatcaa 900 gtgtatcata tgccaagtcc
gccccctatt gacgtcaatg acggtaaatg gcccgcctgg 960 cattatgccc
agtacatgac cttacgggac tttcctactt ggcagtacat ctacgtatta 1020
gtcatcgcta ttaccatggt gatgcggttt tggcagtaca ccaatgggcg tggatagcgg
1080 tttgactcac ggggatttcc aagtctccac cccattgacg tcaatgggag
tttgttttgg 1140 caccaaaatc aacgggactt tccaaaatgt cgtaataacc
ccgccccgtt gacgcaaatg 1200 ggcggtaggc gtgtacggtg ggaggtctat
ataagcagag ctcgtttagt gaaccgtcag 1260 atcactagaa gctttattgc
ggtagtttat cacagttaaa ttgctaacgc agtcagtgct 1320 tctgacacaa
cagtctcgaa cttaagctgc agaagttggt cgtgaggcac tgggcaggta 1380
agtatcaagg ttacaagaca ggtttaagga gaccaataga aactgggctt gtcgagacag
1440 agaagactct tgcgtttctg ataggcacct attggtctta ctgacatcca
ctttgccttt 1500 ctctccacag gtgtccactc ccagttcaat tacagctctt
aaggctagag tacttaatac 1560 gactcactat aggctagcct cgagaattca
cgcgtggtac cgagctcgga tccactagtc 1620 cagtgtggtg gaattgccct
taagggcaat tctgcagata tccagcacag tggcggccgc 1680 tcgagtctag
agggcccgcg gttcgaaggt aagcctatcc ctaaccctct cctcggtctc 1740
gattctacgc gtaccggtca tcatcaccat caccattgag ttcaaacccg ctgatcagcc
1800 tcgactgtgc cttctagttg ccagccatct gttgtttgcc cctcccccgt
gccttccttg 1860 accctggaag gtgccactcc cactgtcctt tcctaataaa
atgaggaaat tgcatcgcat 1920 tgtctgagta ggtgtcattc tattctgggg
ggtggggtgg ggcaggacag caagggggag 1980 gattgggaag acaatagcag
gcatgctggg gatgcctacc tagtcactac tctgtgctat 2040 ggtgttcaat
gcttttcaag atacccggat catatgaaac ggcatgactt tttcaagagt 2100
gccatgcccg aaggttatgt acaggaaagg accatcttct tcaaagatga cggcaactac
2160 aagacacgtg ctgaagtcaa gtttgaaggt gatacccttg ttaatagaat
cgagttaaaa 2220 ggtattgact tcaaggaaga tggcaacatt ctgggacaca
aattggaata caactataac 2280 tcacacaatg tatacatcat ggcagacaaa
caaaagaatg gaatcaaagt gaacttcaag 2340 acccgccaca acattgaaga
tggaagcgtt caactagcag accattatca acaaaatact 2400 ccaattggcg
atggccctgt ccttttacca gacaaccatt acctgtccac acaatctgcc 2460
ctttcgaaag atcccaacga aaagagagac cacatggtcc ttcttgagtt tgtaacagct
2520 gctgggatta cacatggcat ggatgaactg tacaactgag gatcccccga
cctcgacctc 2580 tggctaataa aggaaattta ttttcattgc aatagtgtgt
tggaattttt tgtgtctctc 2640 actcggaagg acatatggga gggcaaatca
tttggtcgag atccctcgga gatcggatct 2700 gggcgtggtt aagggtggga
aagaatatat aaggtggggg tcttatgtag ttttgtatct 2760 gttttgcagc
agccgccgcc gccatgagca ccaactcgtt tgatggaagc attgtgagct 2820
catatttgac aacgcgcatg cccccatggg ccggggtgcg tcagaatgtg atgggctcca
2880 gcattgatgg tcgccccgtc ctgcccgcaa actctactac cttgacctac
gagaccgtgt 2940 ctggaacgcc gttggagact gcagcctccg ccgccgcttc
agccgctgca gccaccgccc 3000 gcgggattgt gactgacttt gctttcctga
gcccgcttgc aagcagtgca gcttcccgtt 3060 catccgcccg cgatgacaag
ttgacggctc ttttggcaca attggattct ttgacccggg 3120 aacttaatgt
cgtttctcag cagctgttgg atctgcgcca gcaggtttct gccctgaagg 3180
cttcctcccc tcccaatgcg gtttaaaaca taaataaaaa accagactct gtttggattt
3240 ggatcaagca agtgtcttgc tgtctttatt taggggtttt gcgcgcgcgg
taggcccggg 3300 accagcggtc tcggtcgttg agggtcctgt gtattttttc
caggacgtgg taaaggtgac 3360 tctggatgtt cagatacatg ggcataagcc
cgtctctggg gtggaggtag caccactgca 3420 gagcttcatg ctgcggggtg
gtgttgtaga tgatccagtc gtagcaggag cgctgggcgt 3480 ggtgcctaaa
aatgtctttc agtagcaagc tgattgccag gggcaggccc ttggtgtaag 3540
tgtttacaaa gcggttaagc tgggatgggt gcatacgtgg ggatatgaga tgcatcttgg
3600 actgtatttt taggttggct atgttcccag ccatatccct ccggggattc
atgttgtgca 3660 gaaccaccag cacagtgtat ccggtgcact tgggaaattt
gtcatgtagc ttagaaggaa 3720 atgcgtggaa gaacttggag acgcccttgt
gacctccaag attttccatg cattcgtcca 3780 taatgatggc aatgggccca
cgggcggcgg cctgggcgaa gatatttctg ggatcactaa 3840 cgtcatagtt
gtgttccagg atggatcgtc ataggccatt tttacaaagc gcgggcggag 3900
ggtgccagac tgcggtataa tggttccatc cggcccaggg gcgtagttac cctcacagat
3960 ttgcatttcc cacgctttga gttcagatgg ggggatcatg tctacctgcg
gggcgatgaa 4020 gaaaacggtt tccggggtag gggagatcag ctgggaagaa
agcaggttcc tgagcagctg 4080 cgacttaccg cagccggtgg gcccgtaaat
cacacctatt accgggtgca actggtagtt 4140 aagagagctg cagctgccgt
catccctgag caggggggcc acttcgttaa gcatgtccct 4200 gactcgcatg
ttttccctga ccaaatccgc cagaaggcgc tcgccgccca gcgatagcag 4260
ttcttgcaag gaagcaaagt ttttcaacgg tttgagaccg tccgccgtag gcatgctttt
4320 gagcgtttga ccaagcagtt ccaggcggtc ccacagctcg gtcacctgct
ctacggcatc 4380 tcgatccagc atatctcctc gtttcgcggg ttggggcggc
tttcgctgta cggcagtagt 4440 cggtgctcgt ccagacgggc cagggtcatg
tctttccacg ggcgcagggt cctcgtcagc 4500 gtagtctggg tcacggtgaa
ggggtgcgct ccgggctgcg cgctggccag ggtgcgcttg 4560 aggctggtcc
tgctggtgct gaagcgctgc cggtcttcgc cctgcgcgtc ggccaggtag 4620
catttgacca tggtgtcata gtccagcccc tccgcggcgt ggcccttggc gcgcagcttg
4680 cccttggagg aggcgccgca cgaggggcag tgcagacttt tgagggcgta
gagcttgggc 4740 gcgagaaata ccgattccgg ggagtaggca tccgcgccgc
aggccccgca gacggtctcg 4800 cattccacga gccaggtgag ctctggccgt
tcggggtcaa aaaccaggtt tcccccatgc 4860 tttttgatgc gtttcttacc
tctggtttcc atgagccggt gtccacgctc ggtgacgaaa 4920 aggctgtccg
tgtccccgta tacagacttg agagggagtt taaacgaatt caatagcttg 4980
ttgcatgggc ggcgatataa aatgcaaggt gctgctcaaa aaatcaggca aagcctcgcg
5040 caaaaaagaa agcacatcgt agtcatgctc atgcagataa aggcaggtaa
gctccggaac 5100 caccacagaa aaagacacca tttttctctc aaacatgtct
gcgggtttct gcataaacac 5160 aaaataaaat aacaaaaaaa catttaaaca
ttagaagcct gtcttacaac aggaaaaaca 5220 acccttataa gcataagacg
gactacggcc atgccggcgt gaccgtaaaa aaactggtca 5280 ccgtgattaa
aaagcaccac cgacagctcc tcggtcatgt ccggagtcat aatgtaagac 5340
tcggtaaaca catcaggttg attcatcggt cagtgctaaa aagcgaccga aatagcccgg
5400 gggaatacat acccgcaggc gtagagacaa cattacagcc cccataggag
gtataacaaa 5460 attaatagga gagaaaaaca cataaacacc tgaaaaaccc
tcctgcctag gcaaaatagc 5520 accctcccgc tccagaacaa catacagcgc
ttcacagcgg cagcctaaca gtcagcctta 5580 ccagtaaaaa agaaaaccta
ttaaaaaaac accactcgac acggcaccag ctcaatcagt 5640 cacagtgtaa
aaaagggcca agtgcagagc gagtatatat aggactaaaa aatgacgtaa 5700
cggttaaagt ccacaaaaaa cacccagaaa accgcacgcg aacctacgcc cagaaacgaa
5760 agccaaaaaa cccacaactt cctcaaatcg tcacttccgt tttcccacgt
tacgtaactt 5820 cccattttaa gaaaactaca attcccaaca catacaagtt
actccgccct aaaacctacg 5880 tcacccgccc cgttcccacg ccccgcgcca
cgtcacaaac tccaccccct cattatcata 5940 ttggcttcaa tccaaaataa
ggtatattat tgatgatgtt aattaacatg catggatcca 6000 tatgcggtgt
gaaataccgc acagatgcgt aaggagaaaa taccgcatca ggcgctcttc 6060
cgcttcctcg ctcactgact cgctgcgctc ggtcgttcgg ctgcggcgag cggtatcagc
6120 tcactcaaag gcggtaatac ggttatccac agaatcaggg gataacgcag
gaaagaacat 6180 gtgagcaaaa ggccagcaaa aggccaggaa ccgtaaaaag
gccgcgttgc tggcgttttt 6240 ccataggctc cgcccccctg acgagcatca
caaaaatcga cgctcaagtc agaggtggcg 6300 aaacccgaca ggactataaa
gataccaggc gtttccccct ggaagctccc tcgtgcgctc 6360 tcctgttccg
accctgccgc ttaccggata cctgtccgcc tttctccctt cgggaagcgt 6420
ggcgctttct catagctcac gctgtaggta tctcagttcg gtgtaggtcg ttcgctccaa
6480 gctgggctgt gtgcacgaac cccccgttca gcccgaccgc tgcgccttat
ccggtaacta 6540 tcgtcttgag tccaacccgg taagacacga cttatcgcca
ctggcagcag ccactggtaa 6600 caggattagc agagcgaggt atgtaggcgg
tgctacagag ttcttgaagt ggtggcctaa 6660 ctacggctac actagaagga
cagtatttgg tatctgcgct ctgctgaagc cagttacctt 6720 cggaaaaaga
gttggtagct cttgatccgg caaacaaacc accgctggta gcggtggttt 6780
ttttgtttgc aagcagcaga ttacgcgcag aaaaaaagga tctcaagaag atcctttgat
6840 cttttctacg gggtctgacg ctcagtggaa cgaaaactca cgttaaggga
ttttggtcat 6900 gagattatca aaaaggatct tcacctagat ccttttaaat
taaaaatgaa gttttaaatc 6960 aatctaaagt atatatgagt aaacttggtc
tgacagttac caatgcttaa tcagtgaggc 7020 acctatctca gcgatctgtc
tatttcgttc atccatagtt gcctgactcc ccgtcgtgta 7080 gataactacg
atacgggagg gcttaccatc tggccccagt gctgcaatga taccgcgaga 7140
cccacgctca ccggctccag atttatcagc aataaaccag ccagccggaa gggccgagcg
7200 cagaagtggt cctgcaactt tatccgcctc catccagtct attaattgtt
gccgggaagc 7260 tagagtaagt agttcgccag ttaatagttt gcgcaacgtt
gttgccattg ctgcagccat 7320 gagattatca aaaaggatct tcacctagat
ccttttcacg tagaaagcca gtccgcagaa 7380 acggtgctga ccccggatga
atgtcagcta ctgggctatc tggacaaggg aaaacgcaag 7440 cgcaaagaga
aagcaggtag cttgcagtgg gcttacatgg cgatagctag actgggcggt 7500
tttatggaca gcaagcgaac cggaattgcc agctggggcg ccctctggta aggttgggaa
7560 gccctgcaaa gtaaactgga tggctttctc gccgccaagg atctgatggc
gcaggggatc 7620 aagctctgat caagagacag gatgaggatc gtttcgcatg
attgaacaag atggattgca 7680 cgcaggttct ccggccgctt gggtggagag
gctattcggc tatgactggg cacaacagac 7740 aatcggctgc tctgatgccg
ccgtgttccg gctgtcagcg caggggcgcc cggttctttt 7800 tgtcaagacc
gacctgtccg gtgccctgaa tgaactgcaa gacgaggcag cgcggctatc 7860
gtggctggcc acgacgggcg ttccttgcgc agctgtgctc gacgttgtca ctgaagcggg
7920 aagggactgg ctgctattgg gcgaagtgcc ggggcaggat ctcctgtcat
ctcaccttgc 7980 tcctgccgag aaagtatcca tcatggctga tgcaatgcgg
cggctgcata cgcttgatcc 8040 ggctacctgc ccattcgacc accaagcgaa
acatcgcatc gagcgagcac gtactcggat 8100 ggaagccggt cttgtcgatc
aggatgatct ggacgaagag catcaggggc tcgcgccagc 8160 cgaactgttc
gccaggctca aggcgagcat gcccgacggc gaggatctcg tcgtgaccca 8220
tggcgatgcc tgcttgccga atatcatggt ggaaaatggc cgcttttctg gattcatcga
8280 ctgtggccgg ctgggtgtgg cggaccgcta tcaggacata gcgttggcta
cccgtgatat 8340 tgctgaagag cttggcggcg aatgggctga ccgcttcctc
gtgctttacg gtatcgccgc 8400 tcccgattcg cagcgcatcg ccttctatcg
ccttcttgac gagttcttct gaattttgtt 8460 aaaatttttg ttaaatcagc
tcatttttta accaataggc cgaaatcggc aacatccctt 8520 ataaatcaaa
agaatagacc gcgatagggt tgagtgttgt tccagtttgg aacaagagtc 8580
cactattaaa gaacgtggac tccaacgtca aagggcgaaa aaccgtctat cagggcgatg
8640 gcccactacg tgaaccatca cccaaatcaa gttttttgcg gtcgaggtgc
cgtaaagctc 8700 taaatcggaa ccctaaaggg agcccccgat ttagagcttg
acggggaaag ccggcgaacg 8760 tggcgagaaa ggaagggaag aaagcgaaag
gagcgggcgc tagggcgctg gcaagtgtag 8820 cggtcacgct gcgcgtaacc
accacacccg cgcgcttaat gcgccgctac agggcgcgtc 8880 cattcgccat
tcaggatcga attaattctt aat 8913 <210> SEQ ID NO 48 <211>
LENGTH: 224 <212> TYPE: PRT <213> ORGANISM: Homo
sapiens <400> SEQUENCE: 48 Met Arg Ala Pro Leu Cys Leu Leu
Leu Leu Val Ala His Ala Val Asp 1 5 10 15 Met Leu Ala Leu Asn Arg
Arg Lys Lys Gln Val Gly Thr Gly Leu Gly 20 25 30 Gly Asn Cys Thr
Gly Cys Ile Ile Cys Ser Glu Glu Asn Gly Cys Ser 35 40 45 Thr Cys
Gln Gln Arg Leu Phe Leu Phe Ile Arg Arg Glu Gly Ile Arg 50 55 60
Gln Tyr Gly Lys Cys Leu His Asp Cys Pro Pro Gly Tyr Phe Gly Ile 65
70 75 80 Arg Gly Gln Glu Val Asn Arg Cys Lys Lys Cys Gly Ala Thr
Cys Glu 85 90 95 Ser Cys Phe Ser Gln Asp Phe Cys Ile Arg Cys Lys
Arg Gln Phe Tyr 100 105 110 Leu Tyr Lys Gly Lys Cys Leu Pro Thr Cys
Pro Pro Gly Thr Leu Ala 115 120 125 His Gln Asn Thr Arg Glu Cys Gln
Gly Glu Cys Glu Leu Gly Pro Trp 130 135 140 Gly Gly Trp Ser Pro Cys
Thr His Asn Gly Lys Thr Cys Gly Ser Ala 145 150 155 160 Trp Gly Leu
Glu Ser Arg Val Arg Glu Ala Gly Arg Ala Gly His Glu 165 170 175 Glu
Ala Ala Thr Cys Gln Val Leu Ser Glu Ser Arg Lys Cys Pro Ile 180 185
190 Gln Arg Pro Cys Pro Gly Glu Arg Ser Pro Gly Gln Lys Lys Gly Arg
195 200 205 Lys Asp Arg Arg Pro Arg Lys Asp Arg Lys Leu Asp Arg Arg
Leu Asp 210 215 220 <210> SEQ ID NO 49 <211> LENGTH:
243 <212> TYPE: PRT <213> ORGANISM: Xenopus laevis
<400> SEQUENCE: 49 Met Gln Phe Gln Leu Phe Ser Phe Ala Leu
Ile Ile Leu Asn Cys Val 1 5 10 15 Asp Tyr Ser His Cys Gln Ala Ser
Arg Trp Arg Arg Ser Lys Arg Ala 20 25 30 Ser Tyr Gly Thr Asn Pro
Ile Cys Lys Gly Cys Leu Ser Cys Ser Lys 35 40 45 Asp Asn Gly Cys
Leu Arg Cys Gln Pro Lys Leu Phe Phe Phe Leu Arg 50 55 60 Arg Glu
Gly Met Arg Gln Tyr Gly Glu Cys Leu Gln Ser Cys Pro Pro 65 70 75 80
Gly Tyr Tyr Gly Val Arg Gly Pro Asp Met Asn Arg Cys Ser Arg Cys 85
90 95 Arg Ile Glu Asn Cys Asp Ser Cys Phe Ser Arg Asp Phe Cys Ile
Lys 100 105 110 Cys Lys Ser Gly Phe Tyr Ser Leu Lys Gly Gln Cys Phe
Glu Glu Cys 115 120 125 Pro Glu Gly Phe Ala Pro Leu Asp Asp Thr Met
Val Cys Val Asp Gly 130 135 140 Cys Glu Val Gly Pro Trp Ser Glu Trp
Gly Thr Cys Ser Arg Asn Asn 145 150 155 160 Arg Thr Cys Gly Phe Lys
Trp Gly Leu Glu Thr Arg Thr Arg Gln Ile 165 170 175 Val Lys Lys Pro
Ala Lys Asp Thr Ile Pro Cys Pro Thr Ile Ala Glu 180 185 190 Ser Arg
Arg Cys Lys Met Ala Ile Arg His Cys Pro Gly Gly Lys Arg 195 200 205
Thr Thr Lys Lys Lys Asp Lys Arg Asn Lys Lys Lys Lys Lys Lys Leu 210
215 220 Leu Glu Arg Ala Gln Glu Gln His Ser Val Val Leu Ala Thr Asp
Arg 225 230 235 240 Ser Ser Gln <210> SEQ ID NO 50
<211> LENGTH: 732 <212> TYPE: DNA <213> ORGANISM:
Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS
<222> LOCATION: (1)..(732) <400> SEQUENCE: 50 atg cag
ttt cgc ctt ttc tcc ttt gcc ctc atc att ctg aac tgc atg 48 Met Gln
Phe Arg Leu Phe Ser Phe Ala Leu Ile Ile Leu Asn Cys Met 1 5 10 15
gat tac agc cac tgc caa ggc aac cga tgg aga cgc agt aag cga gct 96
Asp Tyr Ser His Cys Gln Gly Asn Arg Trp Arg Arg Ser Lys Arg Ala 20
25 30 agt tat gta tca aat ccc att tgc aag ggt tgt ttg tct tgt tca
aag 144 Ser Tyr Val Ser Asn Pro Ile Cys Lys Gly Cys Leu Ser Cys Ser
Lys 35 40 45 gac aat ggg tgt agc cga tgt caa cag aag ttg ttc ttc
ttc ctt cga 192 Asp Asn Gly Cys Ser Arg Cys Gln Gln Lys Leu Phe Phe
Phe Leu Arg 50 55 60 aga gaa ggg atg cgc cag tat gga gag tgc ctg
cat tcc tgc cca tcc 240 Arg Glu Gly Met Arg Gln Tyr Gly Glu Cys Leu
His Ser Cys Pro Ser 65 70 75 80 ggg tac tat gga cac cga gcc cca gat
atg aac aga tgt gca aga tgc 288 Gly Tyr Tyr Gly His Arg Ala Pro Asp
Met Asn Arg Cys Ala Arg Cys 85 90 95 aga ata gaa aac tgt gat tct
tgc ttt agc aaa gac ttt tgt acc aag 336 Arg Ile Glu Asn Cys Asp Ser
Cys Phe Ser Lys Asp Phe Cys Thr Lys 100 105 110 tgc aaa gta ggc ttt
tat ttg cat aga ggc cgt tgc ttt gat gaa tgt 384 Cys Lys Val Gly Phe
Tyr Leu His Arg Gly Arg Cys Phe Asp Glu Cys 115 120 125 cca gat ggt
ttt gca cca tta gaa gaa acc atg gaa tgt gtg gaa gga 432 Pro Asp Gly
Phe Ala Pro Leu Glu Glu Thr Met Glu Cys Val Glu Gly 130 135 140 tgt
gaa gtt ggt cat tgg agc gaa tgg gga act tgt agc aga aat aat 480 Cys
Glu Val Gly His Trp Ser Glu Trp Gly Thr Cys Ser Arg Asn Asn 145 150
155 160 cgc aca tgt gga ttt aaa tgg ggt ctg gaa acc aga aca cgg caa
att 528 Arg Thr Cys Gly Phe Lys Trp Gly Leu Glu Thr Arg Thr Arg Gln
Ile 165 170 175 gtt aaa aag cca gtg aaa gac aca ata ccg tgt cca acc
att gct gaa 576 Val Lys Lys Pro Val Lys Asp Thr Ile Pro Cys Pro Thr
Ile Ala Glu 180 185 190 tcc agg aga tgc aag atg aca atg agg cat tgt
cca gga ggg aag aga 624 Ser Arg Arg Cys Lys Met Thr Met Arg His Cys
Pro Gly Gly Lys Arg 195 200 205 aca cca aag gcg aag gag aag agg aac
aag aaa aag aaa agg aag ctg 672 Thr Pro Lys Ala Lys Glu Lys Arg Asn
Lys Lys Lys Lys Arg Lys Leu 210 215 220 ata gaa agg gcc cag gag caa
cac agc gtc ttc cta gct aca gac aga 720 Ile Glu Arg Ala Gln Glu Gln
His Ser Val Phe Leu Ala Thr Asp Arg 225 230 235 240 gct aac caa taa
732 Ala Asn Gln <210> SEQ ID NO 51 <211> LENGTH: 243
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 51 Met Gln Phe Arg Leu Phe Ser Phe Ala Leu
Ile Ile Leu Asn Cys Met 1 5 10 15 Asp Tyr Ser His Cys Gln Gly Asn
Arg Trp Arg Arg Ser Lys Arg Ala 20 25 30 Ser Tyr Val Ser Asn Pro
Ile Cys Lys Gly Cys Leu Ser Cys Ser Lys 35 40 45 Asp Asn Gly Cys
Ser Arg Cys Gln Gln Lys Leu Phe Phe Phe Leu Arg 50 55 60 Arg Glu
Gly Met Arg Gln Tyr Gly Glu Cys Leu His Ser Cys Pro Ser 65 70 75 80
Gly Tyr Tyr Gly His Arg Ala Pro Asp Met Asn Arg Cys Ala Arg Cys 85
90 95 Arg Ile Glu Asn Cys Asp Ser Cys Phe Ser Lys Asp Phe Cys Thr
Lys 100 105 110 Cys Lys Val Gly Phe Tyr Leu His Arg Gly Arg Cys Phe
Asp Glu Cys 115 120 125 Pro Asp Gly Phe Ala Pro Leu Glu Glu Thr Met
Glu Cys Val Glu Gly 130 135 140 Cys Glu Val Gly His Trp Ser Glu Trp
Gly Thr Cys Ser Arg Asn Asn 145 150 155 160 Arg Thr Cys Gly Phe Lys
Trp Gly Leu Glu Thr Arg Thr Arg Gln Ile 165 170 175 Val Lys Lys Pro
Val Lys Asp Thr Ile Pro Cys Pro Thr Ile Ala Glu 180 185 190 Ser Arg
Arg Cys Lys Met Thr Met Arg His Cys Pro Gly Gly Lys Arg 195 200 205
Thr Pro Lys Ala Lys Glu Lys Arg Asn Lys Lys Lys Lys Arg Lys Leu 210
215 220 Ile Glu Arg Ala Gln Glu Gln His Ser Val Phe Leu Ala Thr Asp
Arg 225 230 235 240 Ala Asn Gln <210> SEQ ID NO 52
<211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Synthetic primer <400> SEQUENCE: 52 ccggctagcc
aaggcaaccg atggagacg 29 <210> SEQ ID NO 53 <211>
LENGTH: 34 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Synthetic primer <400> SEQUENCE: 53 gtagcggccg ctcaccctcc
tggacaatgc ctca 34 <210> SEQ ID NO 54 <211> LENGTH: 702
<212> TYPE: DNA <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 54 atggagacag acacactcct gctatgggta
ctgctgctct gggttccagg ttccactggt 60 gacgctagcg ctagttatgt
atcaaatccc atttgcaagg gttgtttgtc ttgttcaaag 120 gacaatgggt
gtagccgatg tcaacagaag ttgttcttct tccttcgaag agaagggatg 180
cgccagtatg gagagtgcct gcattcctgc ccatccgggt actatggaca ccgagcccca
240 gatatgaaca gatgtgcaag atgcagaata gaaaactgtg attcttgctt
tagcaaagac 300 ttttgtacca agtgcaaagt aggcttttat ttgcatagag
gccgttgctt tgatgaatgt 360 ccagatggtt ttgcaccatt agaagaaacc
atggaatgtg tggaaggatg tgaagttggt 420 cattggagcg aatggggaac
ttgtagcaga aataatcgca catgtggatt taaatggggt 480 ctggaaacca
gaacacggca aattgttaaa aagccagtga aagacacaat accgtgtcca 540
accattgctg aatccaggag atgcaagatg acaatgaggc attgtccagg agggggcggc
600 cgctcgagtc tagagggccc gcggttcgaa ggtaagccta tccctaaccc
tctcctcggt 660 ctcgattcta cgcgtaccgg tcatcatcac catcaccatt ga 702
<210> SEQ ID NO 55 <211> LENGTH: 233 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 55 Met
Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10
15 Gly Ser Thr Gly Asp Ala Ser Ala Ser Tyr Val Ser Asn Pro Ile Cys
20 25 30 Lys Gly Cys Leu Ser Cys Ser Lys Asp Asn Gly Cys Ser Arg
Cys Gln 35 40 45 Gln Lys Leu Phe Phe Phe Leu Arg Arg Glu Gly Met
Arg Gln Tyr Gly 50 55 60 Glu Cys Leu His Ser Cys Pro Ser Gly Tyr
Tyr Gly His Arg Ala Pro 65 70 75 80 Asp Met Asn Arg Cys Ala Arg Cys
Arg Ile Glu Asn Cys Asp Ser Cys 85 90 95 Phe Ser Lys Asp Phe Cys
Thr Lys Cys Lys Val Gly Phe Tyr Leu His 100 105 110 Arg Gly Arg Cys
Phe Asp Glu Cys Pro Asp Gly Phe Ala Pro Leu Glu 115 120 125 Glu Thr
Met Glu Cys Val Glu Gly Cys Glu Val Gly His Trp Ser Glu 130 135 140
Trp Gly Thr Cys Ser Arg Asn Asn Arg Thr Cys Gly Phe Lys Trp Gly 145
150 155 160 Leu Glu Thr Arg Thr Arg Gln Ile Val Lys Lys Pro Val Lys
Asp Thr 165 170 175 Ile Pro Cys Pro Thr Ile Ala Glu Ser Arg Arg Cys
Lys Met Thr Met 180 185 190 Arg His Cys Pro Gly Gly Gly Gly Arg Ser
Ser Leu Glu Gly Pro Arg 195 200 205 Phe Glu Gly Lys Pro Ile Pro Asn
Pro Leu Leu Gly Leu Asp Ser Thr 210 215 220 Arg Thr Gly His His His
His His His 225 230
1 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 55 <210>
SEQ ID NO 1 <211> LENGTH: 427 <212> TYPE: DNA
<213> ORGANISM: Homo sapiens <400> SEQUENCE: 1
tttcgtggcg agtctccctc tgagtcctcc ccagcagcgc ggccggcgcc ggctctttgg
60 gcgaaccctc cagttcctag actttgagag gcgtctctcc cccgcccgac
cgcccagatg 120 cagtttcgcc ttttctcctt tgccctcatc attctgaact
gcatggatta cagccactgc 180 caaggcaacc gatggagacg cagtaagcga
ggtgggtcct tctctgccaa agctagttat 240 gtatcaaatc ccatttgcaa
gggttgtttg tcttgttcaa aggacaatgg gtgtagccga 300 tgtcaacaga
agttgttctt cttccttcga agagaaggga tgcgccagta tggagagtgc 360
ctgcattcct gcccatccgg gtactatgga caccgagccc cagatatgaa cagatgtgca
420 agatgca 427 <210> SEQ ID NO 2 <211> LENGTH: 1356
<212> TYPE: DNA <213> ORGANISM: Homo sapiens
<220> FEATURE: <221> NAME/KEY: CDS <222>
LOCATION: (262)..(993) <400> SEQUENCE: 2 cccagcccac
gtgctaacca agcggctcgc ttcccgagcc cgggatggag caccgcgcct 60
agggaggccg cgccgcccga gacgtgcgca cggttcgtgg cggagagatg ctgatcgcgc
120 tgaactgacc ggtgcggccc gggggtgagt ggcgagtctc cctctgagtc
ctccccagca 180 gcgcggccgg cgccggctct ttgggcgaac cctccagttc
ctagactttg agaggcgtct 240 ctcccccgcc cgaccgccca g atg cag ttt cgc
ctt ttc tcc ttt gcc ctc 291 Met Gln Phe Arg Leu Phe Ser Phe Ala Leu
1 5 10 atc att ctg aac tgc atg gat tac agc cac tgc caa ggc aac cga
tgg 339 Ile Ile Leu Asn Cys Met Asp Tyr Ser His Cys Gln Gly Asn Arg
Trp 15 20 25 aga cgc agt aag cga gct agt tat gta tca aat ccc att
tgc aag ggt 387 Arg Arg Ser Lys Arg Ala Ser Tyr Val Ser Asn Pro Ile
Cys Lys Gly 30 35 40 tgt ttg tct tgt tca aag gac aat ggg tgt agc
cga tgt caa cag aag 435 Cys Leu Ser Cys Ser Lys Asp Asn Gly Cys Ser
Arg Cys Gln Gln Lys 45 50 55 ttg ttc ttc ttc ctt cga aga gaa ggg
atg cgc cag tat gga gag tgc 483 Leu Phe Phe Phe Leu Arg Arg Glu Gly
Met Arg Gln Tyr Gly Glu Cys 60 65 70 ctg cat tcc tgc cca tcc ggg
tac tat gga cac cga gcc cca gat atg 531 Leu His Ser Cys Pro Ser Gly
Tyr Tyr Gly His Arg Ala Pro Asp Met 75 80 85 90 aac aga tgt gca aga
tgc aga ata gaa aac tgt gat tct tgc ttt agc 579 Asn Arg Cys Ala Arg
Cys Arg Ile Glu Asn Cys Asp Ser Cys Phe Ser 95 100 105 aaa gac ttt
tgt acc aag tgc aaa gta ggc ttt tat ttg cat aga ggc 627 Lys Asp Phe
Cys Thr Lys Cys Lys Val Gly Phe Tyr Leu His Arg Gly 110 115 120 cgt
tgc ttt gat gaa tgt cca gat ggt ttt gca cca tta gaa gaa acc 675 Arg
Cys Phe Asp Glu Cys Pro Asp Gly Phe Ala Pro Leu Glu Glu Thr 125 130
135 atg gaa tgt gtg gaa gga tgt gaa gtt ggt cat tgg agc gaa tgg gga
723 Met Glu Cys Val Glu Gly Cys Glu Val Gly His Trp Ser Glu Trp Gly
140 145 150 act tgt agc aga aat aat cgc aca tgt gga ttt aaa tgg ggt
ctg gaa 771 Thr Cys Ser Arg Asn Asn Arg Thr Cys Gly Phe Lys Trp Gly
Leu Glu 155 160 165 170 acc aga aca cgg caa att gtt aaa aag cca gtg
aaa gac aca ata ccg 819 Thr Arg Thr Arg Gln Ile Val Lys Lys Pro Val
Lys Asp Thr Ile Pro 175 180 185 tgt cca acc att gct gaa tcc agg aga
tgc aag atg aca atg agg cat 867 Cys Pro Thr Ile Ala Glu Ser Arg Arg
Cys Lys Met Thr Met Arg His 190 195 200 tgt cca gga ggg aag aga aca
cca aag gcg aag gag aag agg aac aag 915 Cys Pro Gly Gly Lys Arg Thr
Pro Lys Ala Lys Glu Lys Arg Asn Lys 205 210 215 aaa aag aaa agg aag
ctg ata gaa agg gcc cag gag caa cac agc gtc 963 Lys Lys Lys Arg Lys
Leu Ile Glu Arg Ala Gln Glu Gln His Ser Val 220 225 230 ttc cta gct
aca gac aga gct aac caa taa aacaagagat ccggtagatt 1013 Phe Leu Ala
Thr Asp Arg Ala Asn Gln 235 240 tttaggggtt tttgtttttg caaatgtgca
caaagctact ctccactcct gcacactggg 1073 gtgcagcctt tgtgctgctc
tgcccagtat ctgttcccag taacatggtg aaaggaagca 1133 ccaccaggca
tgcccctgtg ttatttatgc tttgatttga atctggagac tgtgaaggca 1193
ggagtaagtg cacagccccg tgacttggct cagtgtgtgc tgagagaatc cgtcccccgc
1253 accatggaca tgctagaggt gtgaggctgc agaacaccgc tggaggacgg
acttgtgcct 1313 atttatgtga aagaagatgc ttggcaggca atccgcgtgt att
1356 <210> SEQ ID NO 3 <211> LENGTH: 243 <212>
TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE:
3 Met Gln Phe Arg Leu Phe Ser Phe Ala Leu Ile Ile Leu Asn Cys Met 1
5 10 15 Asp Tyr Ser His Cys Gln Gly Asn Arg Trp Arg Arg Ser Lys Arg
Ala 20 25 30 Ser Tyr Val Ser Asn Pro Ile Cys Lys Gly Cys Leu Ser
Cys Ser Lys 35 40 45 Asp Asn Gly Cys Ser Arg Cys Gln Gln Lys Leu
Phe Phe Phe Leu Arg 50 55 60 Arg Glu Gly Met Arg Gln Tyr Gly Glu
Cys Leu His Ser Cys Pro Ser 65 70 75 80 Gly Tyr Tyr Gly His Arg Ala
Pro Asp Met Asn Arg Cys Ala Arg Cys 85 90 95 Arg Ile Glu Asn Cys
Asp Ser Cys Phe Ser Lys Asp Phe Cys Thr Lys 100 105 110 Cys Lys Val
Gly Phe Tyr Leu His Arg Gly Arg Cys Phe Asp Glu Cys 115 120 125 Pro
Asp Gly Phe Ala Pro Leu Glu Glu Thr Met Glu Cys Val Glu Gly 130 135
140 Cys Glu Val Gly His Trp Ser Glu Trp Gly Thr Cys Ser Arg Asn Asn
145 150 155 160 Arg Thr Cys Gly Phe Lys Trp Gly Leu Glu Thr Arg Thr
Arg Gln Ile 165 170 175 Val Lys Lys Pro Val Lys Asp Thr Ile Pro Cys
Pro Thr Ile Ala Glu 180 185 190 Ser Arg Arg Cys Lys Met Thr Met Arg
His Cys Pro Gly Gly Lys Arg 195 200 205 Thr Pro Lys Ala Lys Glu Lys
Arg Asn Lys Lys Lys Lys Arg Lys Leu 210 215 220 Ile Glu Arg Ala Gln
Glu Gln His Ser Val Phe Leu Ala Thr Asp Arg 225 230 235 240 Ala Asn
Gln <210> SEQ ID NO 4 <211> LENGTH: 729 <212>
TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE:
4 atgcagtttc gccttttctc ctttgccctc atcattctga actgcatgga ttacagccac
60 tgccaaggca accgatggag acgcagtaag cgagctagtt atgtatcaaa
tcccatttgc 120 aagggttgtt tgtcttgttc aaaggacaat gggtgtagcc
gatgtcaaca gaagttgttc 180 ttcttccttc gaagagaagg gatgcgccag
tatggagagt gcctgcattc ctgcccatcc 240 gggtactatg gacaccgagc
cccagatatg aacagatgtg caagatgcag aatagaaaac 300 tgtgattctt
gctttagcaa agacttttgt accaagtgca aagtaggctt ttatttgcat 360
agaggccgtt gctttgatga atgtccagat ggttttgcac cattagaaga aaccatggaa
420 tgtgtggaag gatgtgaagt tggtcattgg agcgaatggg gaacttgtag
cagaaataat 480 cgcacatgtg gatttaaatg gggtctggaa accagaacac
ggcaaattgt taaaaagcca 540 gtgaaagaca caataccgtg tccaaccatt
gctgaatcca ggagatgcaa gatgacaatg 600 aggcattgtc caggagggaa
gagaacacca aaggcgaagg agaagaggaa caagaaaaag 660 aaaaggaagc
tgatagaaag ggcccaggag caacacagcg tcttcctagc tacagacaga 720
gctaaccaa 729 <210> SEQ ID NO 5 <211> LENGTH: 669
<212> TYPE: DNA <213> ORGANISM: Homo sapiens
<220> FEATURE: <221> NAME/KEY: CDS <222>
LOCATION: (1)..(669) <400> SEQUENCE: 5 caa ggc aac cga tgg
aga cgc agt aag cga gct agt tat gta tca aat 48 Gln Gly Asn Arg Trp
Arg Arg Ser Lys Arg Ala Ser Tyr Val Ser Asn 1 5 10 15 ccc att tgc
aag ggt tgt ttg tct tgt tca aag gac aat ggg tgt agc 96 Pro Ile Cys
Lys Gly Cys Leu Ser Cys Ser Lys Asp Asn Gly Cys Ser 20 25 30 cga
tgt caa cag aag ttg ttc ttc ttc ctt cga aga gaa ggg atg cgc 144 Arg
Cys Gln Gln Lys Leu Phe Phe Phe Leu Arg Arg Glu Gly Met Arg 35 40
45 cag tat gga gag tgc ctg cat tcc tgc cca tcc ggg tac tat gga cac
192 Gln Tyr Gly Glu Cys Leu His Ser Cys Pro Ser Gly Tyr Tyr Gly His
50 55 60 cga gcc cca gat atg aac aga tgt gca aga tgc aga ata gaa
aac tgt 240 Arg Ala Pro Asp Met Asn Arg Cys Ala Arg Cys Arg Ile Glu
Asn Cys 65 70 75 80 gat tct tgc ttt agc aaa gac ttt tgt acc aag tgc
aaa gta ggc ttt 288 Asp Ser Cys Phe Ser Lys Asp Phe Cys Thr Lys Cys
Lys Val Gly Phe 85 90 95 tat ttg cgt aga ggc cgt tgc ttt gat gaa
tgt cca gat ggt ttt gca 336 Tyr Leu Arg Arg Gly Arg Cys Phe Asp Glu
Cys Pro Asp Gly Phe Ala
100 105 110 cca tta gaa gaa acc atg gaa tgt gtg gaa gga tgt gaa gtt
ggt cat 384 Pro Leu Glu Glu Thr Met Glu Cys Val Glu Gly Cys Glu Val
Gly His 115 120 125 tgg agc gaa tgg gga act tgt agc aga aat aat cgc
aca tgt gga ttt 432 Trp Ser Glu Trp Gly Thr Cys Ser Arg Asn Asn Arg
Thr Cys Gly Phe 130 135 140 aaa tgg ggt ctg gaa acc aga aca cgg caa
att gtt aaa aag cca gtg 480 Lys Trp Gly Leu Glu Thr Arg Thr Arg Gln
Ile Val Lys Lys Pro Val 145 150 155 160 aaa gac aca ata ccg tgt cca
acc att gct gaa tcc agg aga tgc aag 528 Lys Asp Thr Ile Pro Cys Pro
Thr Ile Ala Glu Ser Arg Arg Cys Lys 165 170 175 atg aca atg agg cat
tgt cca gga ggg aag aga aca cca aag gcg aag 576 Met Thr Met Arg His
Cys Pro Gly Gly Lys Arg Thr Pro Lys Ala Lys 180 185 190 gag aag agg
aac aag aaa aag aaa agg aag ctg ata gaa agg gcc cag 624 Glu Lys Arg
Asn Lys Lys Lys Lys Arg Lys Leu Ile Glu Arg Ala Gln 195 200 205 gag
caa cac agc gtc ttc cta gct aca gac aga gct aac caa taa 669 Glu Gln
His Ser Val Phe Leu Ala Thr Asp Arg Ala Asn Gln 210 215 220
<210> SEQ ID NO 6 <211> LENGTH: 222 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 6 Gln
Gly Asn Arg Trp Arg Arg Ser Lys Arg Ala Ser Tyr Val Ser Asn 1 5 10
15 Pro Ile Cys Lys Gly Cys Leu Ser Cys Ser Lys Asp Asn Gly Cys Ser
20 25 30 Arg Cys Gln Gln Lys Leu Phe Phe Phe Leu Arg Arg Glu Gly
Met Arg 35 40 45 Gln Tyr Gly Glu Cys Leu His Ser Cys Pro Ser Gly
Tyr Tyr Gly His 50 55 60 Arg Ala Pro Asp Met Asn Arg Cys Ala Arg
Cys Arg Ile Glu Asn Cys 65 70 75 80 Asp Ser Cys Phe Ser Lys Asp Phe
Cys Thr Lys Cys Lys Val Gly Phe 85 90 95 Tyr Leu Arg Arg Gly Arg
Cys Phe Asp Glu Cys Pro Asp Gly Phe Ala 100 105 110 Pro Leu Glu Glu
Thr Met Glu Cys Val Glu Gly Cys Glu Val Gly His 115 120 125 Trp Ser
Glu Trp Gly Thr Cys Ser Arg Asn Asn Arg Thr Cys Gly Phe 130 135 140
Lys Trp Gly Leu Glu Thr Arg Thr Arg Gln Ile Val Lys Lys Pro Val 145
150 155 160 Lys Asp Thr Ile Pro Cys Pro Thr Ile Ala Glu Ser Arg Arg
Cys Lys 165 170 175 Met Thr Met Arg His Cys Pro Gly Gly Lys Arg Thr
Pro Lys Ala Lys 180 185 190 Glu Lys Arg Asn Lys Lys Lys Lys Arg Lys
Leu Ile Glu Arg Ala Gln 195 200 205 Glu Gln His Ser Val Phe Leu Ala
Thr Asp Arg Ala Asn Gln 210 215 220 <210> SEQ ID NO 7
<211> LENGTH: 639 <212> TYPE: DNA <213> ORGANISM:
Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS
<222> LOCATION: (1)..(639) <400> SEQUENCE: 7 gct agt
tat gta tca aat ccc att tgc aag ggt tgt ttg tct tgt tca 48 Ala Ser
Tyr Val Ser Asn Pro Ile Cys Lys Gly Cys Leu Ser Cys Ser 1 5 10 15
aag gac aat ggg tgt agc cga tgt caa cag aag ttg ttc ttc ttc ctt 96
Lys Asp Asn Gly Cys Ser Arg Cys Gln Gln Lys Leu Phe Phe Phe Leu 20
25 30 cga aga gaa ggg atg cgc cag tat gga gag tgc ctg cat tcc tgc
cca 144 Arg Arg Glu Gly Met Arg Gln Tyr Gly Glu Cys Leu His Ser Cys
Pro 35 40 45 tcc ggg tac tat gga cac cga gcc cca gat atg aac aga
tgt gca aga 192 Ser Gly Tyr Tyr Gly His Arg Ala Pro Asp Met Asn Arg
Cys Ala Arg 50 55 60 tgc aga ata gaa aac tgt gat tct tgc ttt agc
aaa gac ttt tgt acc 240 Cys Arg Ile Glu Asn Cys Asp Ser Cys Phe Ser
Lys Asp Phe Cys Thr 65 70 75 80 aag tgc aaa gta ggc ttt tat ttg cat
aga ggc cgt tgc ttt gat gaa 288 Lys Cys Lys Val Gly Phe Tyr Leu His
Arg Gly Arg Cys Phe Asp Glu 85 90 95 tgt cca gat ggt ttt gca cca
tta gaa gaa acc atg gaa tgt gtg gaa 336 Cys Pro Asp Gly Phe Ala Pro
Leu Glu Glu Thr Met Glu Cys Val Glu 100 105 110 gga tgt gaa gtt ggt
cat tgg agc gaa tgg gga act tgt agc aga aat 384 Gly Cys Glu Val Gly
His Trp Ser Glu Trp Gly Thr Cys Ser Arg Asn 115 120 125 aat cgc aca
tgt gga ttt aaa tgg ggt ctg gaa acc aga aca cgg caa 432 Asn Arg Thr
Cys Gly Phe Lys Trp Gly Leu Glu Thr Arg Thr Arg Gln 130 135 140 att
gtt aaa aag cca gtg aaa gac aca ata ccg tgt cca acc att gct 480 Ile
Val Lys Lys Pro Val Lys Asp Thr Ile Pro Cys Pro Thr Ile Ala 145 150
155 160 gaa tcc agg aga tgc aag atg aca atg agg cat tgt cca gga ggg
aag 528 Glu Ser Arg Arg Cys Lys Met Thr Met Arg His Cys Pro Gly Gly
Lys 165 170 175 aga aca cca aag gcg aag gag aag agg aac aag aaa aag
aaa agg aag 576 Arg Thr Pro Lys Ala Lys Glu Lys Arg Asn Lys Lys Lys
Lys Arg Lys 180 185 190 ctg ata gaa agg gcc cag gag caa cac agc gtc
ttc cta gct aca gac 624 Leu Ile Glu Arg Ala Gln Glu Gln His Ser Val
Phe Leu Ala Thr Asp 195 200 205 aga gct aac caa taa 639 Arg Ala Asn
Gln 210 <210> SEQ ID NO 8 <211> LENGTH: 212 <212>
TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE:
8 Ala Ser Tyr Val Ser Asn Pro Ile Cys Lys Gly Cys Leu Ser Cys Ser 1
5 10 15 Lys Asp Asn Gly Cys Ser Arg Cys Gln Gln Lys Leu Phe Phe Phe
Leu 20 25 30 Arg Arg Glu Gly Met Arg Gln Tyr Gly Glu Cys Leu His
Ser Cys Pro 35 40 45 Ser Gly Tyr Tyr Gly His Arg Ala Pro Asp Met
Asn Arg Cys Ala Arg 50 55 60 Cys Arg Ile Glu Asn Cys Asp Ser Cys
Phe Ser Lys Asp Phe Cys Thr 65 70 75 80 Lys Cys Lys Val Gly Phe Tyr
Leu His Arg Gly Arg Cys Phe Asp Glu 85 90 95 Cys Pro Asp Gly Phe
Ala Pro Leu Glu Glu Thr Met Glu Cys Val Glu 100 105 110 Gly Cys Glu
Val Gly His Trp Ser Glu Trp Gly Thr Cys Ser Arg Asn 115 120 125 Asn
Arg Thr Cys Gly Phe Lys Trp Gly Leu Glu Thr Arg Thr Arg Gln 130 135
140 Ile Val Lys Lys Pro Val Lys Asp Thr Ile Pro Cys Pro Thr Ile Ala
145 150 155 160 Glu Ser Arg Arg Cys Lys Met Thr Met Arg His Cys Pro
Gly Gly Lys 165 170 175 Arg Thr Pro Lys Ala Lys Glu Lys Arg Asn Lys
Lys Lys Lys Arg Lys 180 185 190 Leu Ile Glu Arg Ala Gln Glu Gln His
Ser Val Phe Leu Ala Thr Asp 195 200 205 Arg Ala Asn Gln 210
<210> SEQ ID NO 9 <211> LENGTH: 282 <212> TYPE:
DNA <213> ORGANISM: Homo sapiens <220> FEATURE:
<221> NAME/KEY: CDS <222> LOCATION: (1)..(282)
<400> SEQUENCE: 9 att tgc aag ggt tgt ttg tct tgt tca aag gac
aat ggg tgt agc cga 48 Ile Cys Lys Gly Cys Leu Ser Cys Ser Lys Asp
Asn Gly Cys Ser Arg 1 5 10 15 tgt caa cag aag ttg ttc ttc ttc ctt
cga aga gaa ggg atg cgc cag 96 Cys Gln Gln Lys Leu Phe Phe Phe Leu
Arg Arg Glu Gly Met Arg Gln 20 25 30 tat gga gag tgc ctg cat tcc
tgc cca tcc ggg tac tat gga cac cga 144 Tyr Gly Glu Cys Leu His Ser
Cys Pro Ser Gly Tyr Tyr Gly His Arg 35 40 45 gcc cca gat atg aac
aga tgt gca aga tgc aga ata gaa aac tgt gat 192 Ala Pro Asp Met Asn
Arg Cys Ala Arg Cys Arg Ile Glu Asn Cys Asp 50 55 60 tct tgc ttt
agc aaa gac ttt tgt acc aag tgc aaa gta ggc ttt tat 240 Ser Cys Phe
Ser Lys Asp Phe Cys Thr Lys Cys Lys Val Gly Phe Tyr 65 70 75 80 ttg
cat aga ggc cgt tgc ttt gat gaa tgt cca gat ggt ttt 282 Leu His Arg
Gly Arg Cys Phe Asp Glu Cys Pro Asp Gly Phe 85 90 <210> SEQ
ID NO 10 <211> LENGTH: 94 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 10 Ile Cys Lys Gly Cys
Leu Ser Cys Ser Lys Asp Asn Gly Cys Ser Arg 1 5 10 15 Cys Gln Gln
Lys Leu Phe Phe Phe Leu Arg Arg Glu Gly Met Arg Gln 20 25 30 Tyr
Gly Glu Cys Leu His Ser Cys Pro Ser Gly Tyr Tyr Gly His Arg 35 40
45 Ala Pro Asp Met Asn Arg Cys Ala Arg Cys Arg Ile Glu Asn Cys Asp
50 55 60
Ser Cys Phe Ser Lys Asp Phe Cys Thr Lys Cys Lys Val Gly Phe Tyr 65
70 75 80 Leu His Arg Gly Arg Cys Phe Asp Glu Cys Pro Asp Gly Phe 85
90 <210> SEQ ID NO 11 <211> LENGTH: 177 <212>
TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE:
<221> NAME/KEY: CDS <222> LOCATION: (1)..(177)
<400> SEQUENCE: 11 gtt ggt cat tgg agc gaa tgg gga act tgt
agc aga aat aat cgc aca 48 Val Gly His Trp Ser Glu Trp Gly Thr Cys
Ser Arg Asn Asn Arg Thr 1 5 10 15 tgt gga ttt aaa tgg ggt ctg gaa
acc aga aca cgg caa att gtt aaa 96 Cys Gly Phe Lys Trp Gly Leu Glu
Thr Arg Thr Arg Gln Ile Val Lys 20 25 30 aag cca gtg aaa gac aca
ata ccg tgt cca acc att gct gaa tcc agg 144 Lys Pro Val Lys Asp Thr
Ile Pro Cys Pro Thr Ile Ala Glu Ser Arg 35 40 45 aga tgc aag atg
aca atg agg cat tgt cca gga 177 Arg Cys Lys Met Thr Met Arg His Cys
Pro Gly 50 55 <210> SEQ ID NO 12 <211> LENGTH: 59
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 12 Val Gly His Trp Ser Glu Trp Gly Thr Cys
Ser Arg Asn Asn Arg Thr 1 5 10 15 Cys Gly Phe Lys Trp Gly Leu Glu
Thr Arg Thr Arg Gln Ile Val Lys 20 25 30 Lys Pro Val Lys Asp Thr
Ile Pro Cys Pro Thr Ile Ala Glu Ser Arg 35 40 45 Arg Cys Lys Met
Thr Met Arg His Cys Pro Gly 50 55 <210> SEQ ID NO 13
<211> LENGTH: 908 <212> TYPE: DNA <213> ORGANISM:
Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS
<222> LOCATION: (101)..(805) <400> SEQUENCE: 13
gcccacagca gcccccgcgc ccgccgtgcc gccgccggga cgtggggccc ttgggccgtc
60 gggccgcctg gggagcgcca gcccggatcc ggctgcccag atg cgg gcg cca ctc
115 Met Arg Ala Pro Leu 1 5 tgc ctg ctc ctg ctc gtc gcc cac gcc gtg
gac atg ctc gcc ctg aac 163 Cys Leu Leu Leu Leu Val Ala His Ala Val
Asp Met Leu Ala Leu Asn 10 15 20 cga agg aag aag caa gtg ggc act
ggc ctg ggg ggc aac tgc aca ggc 211 Arg Arg Lys Lys Gln Val Gly Thr
Gly Leu Gly Gly Asn Cys Thr Gly 25 30 35 tgt atc atc tgc tca gag
gag aac ggc tgt tcc acc tgc cag cag agg 259 Cys Ile Ile Cys Ser Glu
Glu Asn Gly Cys Ser Thr Cys Gln Gln Arg 40 45 50 ctc ttc ctg ttc
atc cgc cgg gaa ggc atc cgc cag tac ggc aag tgc 307 Leu Phe Leu Phe
Ile Arg Arg Glu Gly Ile Arg Gln Tyr Gly Lys Cys 55 60 65 ctg cac
gac tgt ccc cct ggg tac ttc ggc atc cgc ggc cag gag gtc 355 Leu His
Asp Cys Pro Pro Gly Tyr Phe Gly Ile Arg Gly Gln Glu Val 70 75 80 85
aac agg tgc aaa aaa tgt ggg gcc act tgt gag agc tgc ttc agc cag 403
Asn Arg Cys Lys Lys Cys Gly Ala Thr Cys Glu Ser Cys Phe Ser Gln 90
95 100 gac ttc tgc atc cgg tgc aag agg cag ttt tac ttg tac aag ggg
aag 451 Asp Phe Cys Ile Arg Cys Lys Arg Gln Phe Tyr Leu Tyr Lys Gly
Lys 105 110 115 tgt ctg ccc acc tgc ccg ccg gtc act ttg gcc cac cag
aac aca cgg 499 Cys Leu Pro Thr Cys Pro Pro Val Thr Leu Ala His Gln
Asn Thr Arg 120 125 130 gag tgc cag ggg gag tgt gaa ctg ggt ccc tgg
ggc ggc tgg agc ccc 547 Glu Cys Gln Gly Glu Cys Glu Leu Gly Pro Trp
Gly Gly Trp Ser Pro 135 140 145 tgc aca cac aat gga aag acc tgc ggc
tcg gct tgg ggc ctg gag agc 595 Cys Thr His Asn Gly Lys Thr Cys Gly
Ser Ala Trp Gly Leu Glu Ser 150 155 160 165 cgg gta cga gag gct ggc
cgg gct ggg cat gag gag gca gcc acc tgc 643 Arg Val Arg Glu Ala Gly
Arg Ala Gly His Glu Glu Ala Ala Thr Cys 170 175 180 cag gtg ctt tct
gag tca agg aaa tgt ccc atc cag agg ccc tgc cca 691 Gln Val Leu Ser
Glu Ser Arg Lys Cys Pro Ile Gln Arg Pro Cys Pro 185 190 195 gga gag
agg agc ccc ggc cag aag aag ggc agg aag gac cgg cgc cca 739 Gly Glu
Arg Ser Pro Gly Gln Lys Lys Gly Arg Lys Asp Arg Arg Pro 200 205 210
cgc aag gac agg aag ctg gac cgc agg ctg gac gtg agg ccg cgc cag 787
Arg Lys Asp Arg Lys Leu Asp Arg Arg Leu Asp Val Arg Pro Arg Gln 215
220 225 ccc ggc ctg cag ccc tga ccgccggctc tcccgactct ctggtcctag
835 Pro Gly Leu Gln Pro 230 tcctcggccc ctgcacacct cctcctgctc
cttctcctcc tctcctctta ctctttctcc 895 tctgtcttct cca 908 <210>
SEQ ID NO 14 <211> LENGTH: 234 <212> TYPE: PRT
<213> ORGANISM: Homo sapiens <400> SEQUENCE: 14 Met Arg
Ala Pro Leu Cys Leu Leu Leu Leu Val Ala His Ala Val Asp 1 5 10 15
Met Leu Ala Leu Asn Arg Arg Lys Lys Gln Val Gly Thr Gly Leu Gly 20
25 30 Gly Asn Cys Thr Gly Cys Ile Ile Cys Ser Glu Glu Asn Gly Cys
Ser 35 40 45 Thr Cys Gln Gln Arg Leu Phe Leu Phe Ile Arg Arg Glu
Gly Ile Arg 50 55 60 Gln Tyr Gly Lys Cys Leu His Asp Cys Pro Pro
Gly Tyr Phe Gly Ile 65 70 75 80 Arg Gly Gln Glu Val Asn Arg Cys Lys
Lys Cys Gly Ala Thr Cys Glu 85 90 95 Ser Cys Phe Ser Gln Asp Phe
Cys Ile Arg Cys Lys Arg Gln Phe Tyr 100 105 110 Leu Tyr Lys Gly Lys
Cys Leu Pro Thr Cys Pro Pro Val Thr Leu Ala 115 120 125 His Gln Asn
Thr Arg Glu Cys Gln Gly Glu Cys Glu Leu Gly Pro Trp 130 135 140 Gly
Gly Trp Ser Pro Cys Thr His Asn Gly Lys Thr Cys Gly Ser Ala 145 150
155 160 Trp Gly Leu Glu Ser Arg Val Arg Glu Ala Gly Arg Ala Gly His
Glu 165 170 175 Glu Ala Ala Thr Cys Gln Val Leu Ser Glu Ser Arg Lys
Cys Pro Ile 180 185 190 Gln Arg Pro Cys Pro Gly Glu Arg Ser Pro Gly
Gln Lys Lys Gly Arg 195 200 205 Lys Asp Arg Arg Pro Arg Lys Asp Arg
Lys Leu Asp Arg Arg Leu Asp 210 215 220 Val Arg Pro Arg Gln Pro Gly
Leu Gln Pro 225 230 <210> SEQ ID NO 15 <211> LENGTH:
705 <212> TYPE: DNA <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 15 atgcgggcgc cactctgcct gctcctgctc
gtcgcccacg ccgtggacat gctcgccctg 60 aaccgaagga agaagcaagt
gggcactggc ctggggggca actgcacagg ctgtatcatc 120 tgctcagagg
agaacggctg ttccacctgc cagcagaggc tcttcctgtt catccgccgg 180
gaaggcatcc gccagtacgg caagtgcctg cacgactgtc cccctgggta cttcggcatc
240 cgcggccagg aggtcaacag gtgcaaaaaa tgtggggcca cttgtgagag
ctgcttcagc 300 caggacttct gcatccggtg caagaggcag ttttacttgt
acaaggggaa gtgtctgccc 360 acctgcccgc cgggcacttt ggcccaccag
aacacacggg agtgccaggg ggagtgtgaa 420 ctgggtccct ggggcggctg
gagcccctgc acacacaatg gaaagacctg cggctcggct 480 tggggcctgg
agagccgggt acgagaggct ggccgggctg ggcatgagga ggcagccacc 540
tgccaggtgc tttctgagtc aaggaaatgt cccatccaga ggccctgccc aggagagagg
600 agccccggcc agaagaaggg caggaaggac cggcgcccac gcaaggacag
gaagctggac 660 cgcaggctgg acgtgaggcc gcgccagccc ggcctgcagc cctga
705 <210> SEQ ID NO 16 <211> LENGTH: 645 <212>
TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE:
<221> NAME/KEY: CDS <222> LOCATION: (1)..(645)
<400> SEQUENCE: 16 aac cga agg aag aag caa gtg ggc act ggc
ctg ggg ggc aac tgc aca 48 Asn Arg Arg Lys Lys Gln Val Gly Thr Gly
Leu Gly Gly Asn Cys Thr 1 5 10 15 ggc tgt atc atc tgc tca gag gag
aac ggc tgt tcc acc tgc cag cag 96 Gly Cys Ile Ile Cys Ser Glu Glu
Asn Gly Cys Ser Thr Cys Gln Gln 20 25 30 agg ctc ttc ctg ttc atc
cgc cgg gaa ggc atc cgc cag tac ggc aag 144 Arg Leu Phe Leu Phe Ile
Arg Arg Glu Gly Ile Arg Gln Tyr Gly Lys 35 40 45 tgc ctg cac gac
tgt ccc cct ggg tac ttc ggc atc cgc ggc cag gag 192 Cys Leu His Asp
Cys Pro Pro Gly Tyr Phe Gly Ile Arg Gly Gln Glu 50 55 60 gtc aac
agg tgc aaa aaa tgt ggg gcc act tgt gag agc tgc ttc agc 240 Val Asn
Arg Cys Lys Lys Cys Gly Ala Thr Cys Glu Ser Cys Phe Ser 65 70 75
80
cag gac ttc tgc atc cgg tgc aag agg cag ttt tac ttg tac aag ggg 288
Gln Asp Phe Cys Ile Arg Cys Lys Arg Gln Phe Tyr Leu Tyr Lys Gly 85
90 95 aag tgt ctg ccc acc tgc ccg ccg ggc act ttg gcc cac cag aac
aca 336 Lys Cys Leu Pro Thr Cys Pro Pro Gly Thr Leu Ala His Gln Asn
Thr 100 105 110 cgg gag tgc cag ggg gag tgt gaa ctg ggt ccc tgg ggc
ggc tgg agc 384 Arg Glu Cys Gln Gly Glu Cys Glu Leu Gly Pro Trp Gly
Gly Trp Ser 115 120 125 ccc tgc aca cac aat gga aag acc tgc ggc tcg
gct tgg ggc ctg gag 432 Pro Cys Thr His Asn Gly Lys Thr Cys Gly Ser
Ala Trp Gly Leu Glu 130 135 140 agc cgg gta cga gag gct ggc cgg gct
ggg cat gag gag gca gcc acc 480 Ser Arg Val Arg Glu Ala Gly Arg Ala
Gly His Glu Glu Ala Ala Thr 145 150 155 160 tgc cag gtg ctt tct gag
tca agg aaa tgt ccc atc cag agg ccc tgc 528 Cys Gln Val Leu Ser Glu
Ser Arg Lys Cys Pro Ile Gln Arg Pro Cys 165 170 175 cca gga gag agg
agc ccc ggc cag aag aag ggc agg aag gac cgg cgc 576 Pro Gly Glu Arg
Ser Pro Gly Gln Lys Lys Gly Arg Lys Asp Arg Arg 180 185 190 cca cgc
aag gac agg aag ctg gac cgc agg ctg gac gtg agg ccg cgc 624 Pro Arg
Lys Asp Arg Lys Leu Asp Arg Arg Leu Asp Val Arg Pro Arg 195 200 205
cag ccc ggc ctg cag ccc tga 645 Gln Pro Gly Leu Gln Pro 210
<210> SEQ ID NO 17 <211> LENGTH: 214 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 17 Asn
Arg Arg Lys Lys Gln Val Gly Thr Gly Leu Gly Gly Asn Cys Thr 1 5 10
15 Gly Cys Ile Ile Cys Ser Glu Glu Asn Gly Cys Ser Thr Cys Gln Gln
20 25 30 Arg Leu Phe Leu Phe Ile Arg Arg Glu Gly Ile Arg Gln Tyr
Gly Lys 35 40 45 Cys Leu His Asp Cys Pro Pro Gly Tyr Phe Gly Ile
Arg Gly Gln Glu 50 55 60 Val Asn Arg Cys Lys Lys Cys Gly Ala Thr
Cys Glu Ser Cys Phe Ser 65 70 75 80 Gln Asp Phe Cys Ile Arg Cys Lys
Arg Gln Phe Tyr Leu Tyr Lys Gly 85 90 95 Lys Cys Leu Pro Thr Cys
Pro Pro Gly Thr Leu Ala His Gln Asn Thr 100 105 110 Arg Glu Cys Gln
Gly Glu Cys Glu Leu Gly Pro Trp Gly Gly Trp Ser 115 120 125 Pro Cys
Thr His Asn Gly Lys Thr Cys Gly Ser Ala Trp Gly Leu Glu 130 135 140
Ser Arg Val Arg Glu Ala Gly Arg Ala Gly His Glu Glu Ala Ala Thr 145
150 155 160 Cys Gln Val Leu Ser Glu Ser Arg Lys Cys Pro Ile Gln Arg
Pro Cys 165 170 175 Pro Gly Glu Arg Ser Pro Gly Gln Lys Lys Gly Arg
Lys Asp Arg Arg 180 185 190 Pro Arg Lys Asp Arg Lys Leu Asp Arg Arg
Leu Asp Val Arg Pro Arg 195 200 205 Gln Pro Gly Leu Gln Pro 210
<210> SEQ ID NO 18 <211> LENGTH: 279 <212> TYPE:
DNA <213> ORGANISM: Homo sapiens <220> FEATURE:
<221> NAME/KEY: CDS <222> LOCATION: (1)..(279)
<400> SEQUENCE: 18 aac tgc aca ggc tgt atc atc tgc tca gag
gag aac ggc tgt tcc acc 48 Asn Cys Thr Gly Cys Ile Ile Cys Ser Glu
Glu Asn Gly Cys Ser Thr 1 5 10 15 tgc cag cag agg ctc ttc ctg ttc
atc cgc cgg gaa ggc atc cgc cag 96 Cys Gln Gln Arg Leu Phe Leu Phe
Ile Arg Arg Glu Gly Ile Arg Gln 20 25 30 tac ggc aag tgc ctg cac
gac tgt ccc cct ggg tac ttc ggc atc cgc 144 Tyr Gly Lys Cys Leu His
Asp Cys Pro Pro Gly Tyr Phe Gly Ile Arg 35 40 45 ggc cag gag gtc
aac agg tgc aaa aaa tgt ggg gcc act tgt gag agc 192 Gly Gln Glu Val
Asn Arg Cys Lys Lys Cys Gly Ala Thr Cys Glu Ser 50 55 60 tgc ttc
agc cag gac ttc tgc atc cgg tgc aag agg cag ttt tac ttg 240 Cys Phe
Ser Gln Asp Phe Cys Ile Arg Cys Lys Arg Gln Phe Tyr Leu 65 70 75 80
tac aag ggg aag tgt ctg ccc acc tgc ccg ccg ggc act 279 Tyr Lys Gly
Lys Cys Leu Pro Thr Cys Pro Pro Gly Thr 85 90 <210> SEQ ID NO
19 <211> LENGTH: 93 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 19 Asn Cys Thr Gly Cys
Ile Ile Cys Ser Glu Glu Asn Gly Cys Ser Thr 1 5 10 15 Cys Gln Gln
Arg Leu Phe Leu Phe Ile Arg Arg Glu Gly Ile Arg Gln 20 25 30 Tyr
Gly Lys Cys Leu His Asp Cys Pro Pro Gly Tyr Phe Gly Ile Arg 35 40
45 Gly Gln Glu Val Asn Arg Cys Lys Lys Cys Gly Ala Thr Cys Glu Ser
50 55 60 Cys Phe Ser Gln Asp Phe Cys Ile Arg Cys Lys Arg Gln Phe
Tyr Leu 65 70 75 80 Tyr Lys Gly Lys Cys Leu Pro Thr Cys Pro Pro Gly
Thr 85 90 <210> SEQ ID NO 20 <211> LENGTH: 171
<212> TYPE: DNA <213> ORGANISM: Homo sapiens
<220> FEATURE: <221> NAME/KEY: CDS <222>
LOCATION: (1)..(171) <400> SEQUENCE: 20 ctg ggt ccc tgg ggc
ggc tgg agc ccc tgc aca cac aat gga aag acc 48 Leu Gly Pro Trp Gly
Gly Trp Ser Pro Cys Thr His Asn Gly Lys Thr 1 5 10 15 tgc ggc tcg
gct tgg ggc ctg gag agc cgg gta cga gag gct ggc cgg 96 Cys Gly Ser
Ala Trp Gly Leu Glu Ser Arg Val Arg Glu Ala Gly Arg 20 25 30 gct
ggg cat gag gag gca gcc acc tgc cag gtg ctt tct gag tca agg 144 Ala
Gly His Glu Glu Ala Ala Thr Cys Gln Val Leu Ser Glu Ser Arg 35 40
45 aaa tgt ccc atc cag agg ccc tgc cta 171 Lys Cys Pro Ile Gln Arg
Pro Cys Leu 50 55 <210> SEQ ID NO 21 <211> LENGTH: 57
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 21 Leu Gly Pro Trp Gly Gly Trp Ser Pro Cys
Thr His Asn Gly Lys Thr 1 5 10 15 Cys Gly Ser Ala Trp Gly Leu Glu
Ser Arg Val Arg Glu Ala Gly Arg 20 25 30 Ala Gly His Glu Glu Ala
Ala Thr Cys Gln Val Leu Ser Glu Ser Arg 35 40 45 Lys Cys Pro Ile
Gln Arg Pro Cys Leu 50 55 <210> SEQ ID NO 22 <211>
LENGTH: 722 <212> TYPE: DNA <213> ORGANISM: Homo
sapiens <220> FEATURE: <221> NAME/KEY: CDS <222>
LOCATION: (101)..(619) <400> SEQUENCE: 22 gcccacagca
gcccccgcgc ccgccgtgcc gccgccggga cgtggggccc ttgggccgtc 60
gggccgcctg gggagcgcca gcccggatcc ggctgcccag atg cgg gcg cca ctc 115
Met Arg Ala Pro Leu 1 5 tgc ctg ctc ctg ctc gtc gcc cac gcc gtg gac
atg ctc gcc ctg aac 163 Cys Leu Leu Leu Leu Val Ala His Ala Val Asp
Met Leu Ala Leu Asn 10 15 20 cga agg aag aag caa gtg ggc act ggc
ctg ggg ggc aac tgc aca ggc 211 Arg Arg Lys Lys Gln Val Gly Thr Gly
Leu Gly Gly Asn Cys Thr Gly 25 30 35 tgt atc atc tgc tca gag gag
aac ggc tgt tcc acc tgc cag cag agg 259 Cys Ile Ile Cys Ser Glu Glu
Asn Gly Cys Ser Thr Cys Gln Gln Arg 40 45 50 ctc ttc ctg ttc atc
cgc cgg gaa ggc atc cgc cag tac ggc aag tgc 307 Leu Phe Leu Phe Ile
Arg Arg Glu Gly Ile Arg Gln Tyr Gly Lys Cys 55 60 65 ctg cac gac
tgt ccc cct ggg tac ttc ggc atc cgc ggc cag gag gtc 355 Leu His Asp
Cys Pro Pro Gly Tyr Phe Gly Ile Arg Gly Gln Glu Val 70 75 80 85 aac
agg tgc aaa aaa tgt ggg gcc act tgt gag agc tgc ttc agc cag 403 Asn
Arg Cys Lys Lys Cys Gly Ala Thr Cys Glu Ser Cys Phe Ser Gln 90 95
100 gac ttc tgc atc cgg tgc aag agg cag ttt tac ttg tac aag ggg aag
451 Asp Phe Cys Ile Arg Cys Lys Arg Gln Phe Tyr Leu Tyr Lys Gly Lys
105 110 115 tgt ctg ccc acc tgc ccg ccg ggc act ttg gcc cac cag aac
aca cgg 499 Cys Leu Pro Thr Cys Pro Pro Gly Thr Leu Ala His Gln Asn
Thr Arg 120 125 130 gag tgc cag gag agg agc ccc ggc cag aag aag ggc
agg aag gac cgg 547 Glu Cys Gln Glu Arg Ser Pro Gly Gln Lys Lys Gly
Arg Lys Asp Arg 135 140 145 cgc cca cgc gag gac agg aag ctg gac cgc
agg ctg gac gtg agg ccg 595 Arg Pro Arg Glu Asp Arg Lys Leu Asp Arg
Arg Leu Asp Val Arg Pro 150 155 160 165
cgc cag ccc ggc ctg cag ccc tga ccgccggctc tcccgactct ctggtcctag
649 Arg Gln Pro Gly Leu Gln Pro 170 tcctcggccc ctgcacacct
cctcctgctc cttctcctcc tctcctctta ctctttctcc 709 tctgtcttct cca 722
<210> SEQ ID NO 23 <211> LENGTH: 172 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 23 Met
Arg Ala Pro Leu Cys Leu Leu Leu Leu Val Ala His Ala Val Asp 1 5 10
15 Met Leu Ala Leu Asn Arg Arg Lys Lys Gln Val Gly Thr Gly Leu Gly
20 25 30 Gly Asn Cys Thr Gly Cys Ile Ile Cys Ser Glu Glu Asn Gly
Cys Ser 35 40 45 Thr Cys Gln Gln Arg Leu Phe Leu Phe Ile Arg Arg
Glu Gly Ile Arg 50 55 60 Gln Tyr Gly Lys Cys Leu His Asp Cys Pro
Pro Gly Tyr Phe Gly Ile 65 70 75 80 Arg Gly Gln Glu Val Asn Arg Cys
Lys Lys Cys Gly Ala Thr Cys Glu 85 90 95 Ser Cys Phe Ser Gln Asp
Phe Cys Ile Arg Cys Lys Arg Gln Phe Tyr 100 105 110 Leu Tyr Lys Gly
Lys Cys Leu Pro Thr Cys Pro Pro Gly Thr Leu Ala 115 120 125 His Gln
Asn Thr Arg Glu Cys Gln Glu Arg Ser Pro Gly Gln Lys Lys 130 135 140
Gly Arg Lys Asp Arg Arg Pro Arg Glu Asp Arg Lys Leu Asp Arg Arg 145
150 155 160 Leu Asp Val Arg Pro Arg Gln Pro Gly Leu Gln Pro 165 170
<210> SEQ ID NO 24 <211> LENGTH: 519 <212> TYPE:
DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 24
atgcgggcgc cactctgcct gctcctgctc gtcgcccacg ccgtggacat gctcgccctg
60 aaccgaagga agaagcaagt gggcactggc ctggggggca actgcacagg
ctgtatcatc 120 tgctcagagg agaacggctg ttccacctgc cagcagaggc
tcttcctgtt catccgccgg 180 gaaggcatcc gccagtacgg caagtgcctg
cacgactgtc cccctgggta cttcggcatc 240 cgcggccagg aggtcaacag
gtgcaaaaaa tgtggggcca cttgtgagag ctgcttcagc 300 caggacttct
gcatccggtg caagaggcag ttttacttgt acaaggggaa gtgtctgccc 360
acctgcccgc cgggcacttt ggcccaccag aacacacggg agtgccagga gaggagcccc
420 ggccagaaga agggcaggaa ggaccggcgc ccacgcaagg acaggaagct
ggaccgcagg 480 ctggacgtga ggccgcgcca gcccggcctg cagccctga 519
<210> SEQ ID NO 25 <211> LENGTH: 459 <212> TYPE:
DNA <213> ORGANISM: Homo sapiens <220> FEATURE:
<221> NAME/KEY: CDS <222> LOCATION: (1)..(459)
<400> SEQUENCE: 25 aac cga agg aag aag caa gtg ggc act ggc
ctg ggg ggc aac tgc aca 48 Asn Arg Arg Lys Lys Gln Val Gly Thr Gly
Leu Gly Gly Asn Cys Thr 1 5 10 15 ggc tgt atc atc tgc tca gag gag
aac ggc tgt tcc acc tgc cag cag 96 Gly Cys Ile Ile Cys Ser Glu Glu
Asn Gly Cys Ser Thr Cys Gln Gln 20 25 30 agg ctc ttc ctg ttc atc
cgc cgg gaa ggc atc cgc cag tac ggc aag 144 Arg Leu Phe Leu Phe Ile
Arg Arg Glu Gly Ile Arg Gln Tyr Gly Lys 35 40 45 tgc ctg cac gac
tgt ccc cct ggg tac ttc ggc atc cgc ggc cag gag 192 Cys Leu His Asp
Cys Pro Pro Gly Tyr Phe Gly Ile Arg Gly Gln Glu 50 55 60 gtc aac
agg tgc aaa aaa tgt ggg gcc act tgt gag agc tgc ttc agc 240 Val Asn
Arg Cys Lys Lys Cys Gly Ala Thr Cys Glu Ser Cys Phe Ser 65 70 75 80
cag gac ttc tgc atc cgg tgc aag agg cag ttt tac ttg tac aag ggg 288
Gln Asp Phe Cys Ile Arg Cys Lys Arg Gln Phe Tyr Leu Tyr Lys Gly 85
90 95 aag tgt ctg ccc acc tgc ccg ccg ggc act ttg gcc cac cag aac
aca 336 Lys Cys Leu Pro Thr Cys Pro Pro Gly Thr Leu Ala His Gln Asn
Thr 100 105 110 cgg gag tgc cag gag agg agc ccc ggc cag aag aag ggc
agg aag gac 384 Arg Glu Cys Gln Glu Arg Ser Pro Gly Gln Lys Lys Gly
Arg Lys Asp 115 120 125 cgg cgc cca cgc aag gac agg aag ctg gac cgc
agg ctg gac gtg agg 432 Arg Arg Pro Arg Lys Asp Arg Lys Leu Asp Arg
Arg Leu Asp Val Arg 130 135 140 ccg cgc cag ccc ggc ctg cag ccc tga
459 Pro Arg Gln Pro Gly Leu Gln Pro 145 150 <210> SEQ ID NO
26 <211> LENGTH: 152 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 26 Asn Arg Arg Lys Lys
Gln Val Gly Thr Gly Leu Gly Gly Asn Cys Thr 1 5 10 15 Gly Cys Ile
Ile Cys Ser Glu Glu Asn Gly Cys Ser Thr Cys Gln Gln 20 25 30 Arg
Leu Phe Leu Phe Ile Arg Arg Glu Gly Ile Arg Gln Tyr Gly Lys 35 40
45 Cys Leu His Asp Cys Pro Pro Gly Tyr Phe Gly Ile Arg Gly Gln Glu
50 55 60 Val Asn Arg Cys Lys Lys Cys Gly Ala Thr Cys Glu Ser Cys
Phe Ser 65 70 75 80 Gln Asp Phe Cys Ile Arg Cys Lys Arg Gln Phe Tyr
Leu Tyr Lys Gly 85 90 95 Lys Cys Leu Pro Thr Cys Pro Pro Gly Thr
Leu Ala His Gln Asn Thr 100 105 110 Arg Glu Cys Gln Glu Arg Ser Pro
Gly Gln Lys Lys Gly Arg Lys Asp 115 120 125 Arg Arg Pro Arg Lys Asp
Arg Lys Leu Asp Arg Arg Leu Asp Val Arg 130 135 140 Pro Arg Gln Pro
Gly Leu Gln Pro 145 150 <210> SEQ ID NO 27 <211>
LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: F primer for
cloning SCFA2 into plntron/Igk 1round PCR <400> SEQUENCE: 27
ctttgggcga accctccag 19 <210> SEQ ID NO 28 <211>
LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: R primer for
cloning SCFA2 into plntron/Igk 1round PCR <400> SEQUENCE: 28
gagcagcaca aaggctgcac 20 <210> SEQ ID NO 29 <211>
LENGTH: 37 <212> TYPE: DNA <213> ORGANISM: F primer
SCFA2 cloning 2nd PCR round for cloning SCFA2 into plntron/Igk
<400> SEQUENCE: 29 ccggctagcg ctagttatgt atcaaatccc atttgca
37 <210> SEQ ID NO 30 <211> LENGTH: 36 <212>
TYPE: DNA <213> ORGANISM: R primer SCFA2 cloning 2nd PCR
round for cloning SCFA2 into plntron/Igk <400> SEQUENCE: 30
tgctctagac tttggttagc tctgtctgta gctagg 36 <210> SEQ ID NO 31
<211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM:
F primer for cloning SCFA4-4v into plntron/Igk 1round PCR
<400> SEQUENCE: 31 tggggccctt gggccgtcgg gc 22 <210>
SEQ ID NO 32 <211> LENGTH: 21 <212> TYPE: DNA
<213> ORGANISM: R primer for cloning SCFA4-4v into
plntron/Igk 1round PCR <400> SEQUENCE: 32 aaggagcagg
aggaggtgtg c 21 <210> SEQ ID NO 33 <211> LENGTH: 32
<212> TYPE: DNA <213> ORGANISM: F primer for cloning
SCFA4 and 4v into plntron/Igk 2nd round PCR <400> SEQUENCE:
33 ctgagctagc ctgaaccgaa ggaagaagca ag 32 <210> SEQ ID NO 34
<211> LENGTH: 33 <212> TYPE: DNA <213> ORGANISM:
R primer for cloning SCFA4 and 4v into plntron/Igk 2nd round PCR
<400> SEQUENCE: 34
ctgatctaga ccgggctgca ggccgggctg gcg 33 <210> SEQ ID NO 35
<211> LENGTH: 813 <212> TYPE: DNA <213> ORGANISM:
IgK-SCFA2-V5His6 <220> FEATURE: <221> NAME/KEY: CDS
<222> LOCATION: (1)..(813) <400> SEQUENCE: 35 atg gag
aca gac aca ctc ctg cta tgg gta ctg ctg ctc tgg gtt cca 48 Met Glu
Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15
ggt tcc act ggt gac gct agc gct agt tat gta tca aat ccc att tgc 96
Gly Ser Thr Gly Asp Ala Ser Ala Ser Tyr Val Ser Asn Pro Ile Cys 20
25 30 aag ggt tgt ttg tct tgt tca aag gac aat ggg tgt agc cga tgt
caa 144 Lys Gly Cys Leu Ser Cys Ser Lys Asp Asn Gly Cys Ser Arg Cys
Gln 35 40 45 cag aag ttg ttc ttc ttc ctt cga aga gaa ggg atg cgc
cag tat gga 192 Gln Lys Leu Phe Phe Phe Leu Arg Arg Glu Gly Met Arg
Gln Tyr Gly 50 55 60 gag tgc ctg cat tcc tgc cca tcc ggg tac tat
gga cac cga gcc cca 240 Glu Cys Leu His Ser Cys Pro Ser Gly Tyr Tyr
Gly His Arg Ala Pro 65 70 75 80 gat atg aac aga tgt gca aga tgc aga
ata gaa aac tgt gat tct tgc 288 Asp Met Asn Arg Cys Ala Arg Cys Arg
Ile Glu Asn Cys Asp Ser Cys 85 90 95 ttt agc aaa gac ttt tgt acc
aag tgc aaa gta ggc ttt tat ttg cat 336 Phe Ser Lys Asp Phe Cys Thr
Lys Cys Lys Val Gly Phe Tyr Leu His 100 105 110 aga ggc cgt tgc ttt
gat gaa tgt cca gat ggt ttt gca cca tta gaa 384 Arg Gly Arg Cys Phe
Asp Glu Cys Pro Asp Gly Phe Ala Pro Leu Glu 115 120 125 gaa acc atg
gaa tgt gtg gaa gga tgt gaa gtt ggt cat tgg agc gaa 432 Glu Thr Met
Glu Cys Val Glu Gly Cys Glu Val Gly His Trp Ser Glu 130 135 140 tgg
gga act tgt agc aga aat aat cgc aca tgt gga ttt aaa tgg ggt 480 Trp
Gly Thr Cys Ser Arg Asn Asn Arg Thr Cys Gly Phe Lys Trp Gly 145 150
155 160 ctg gaa acc aga aca cgg caa att gtt aaa aag cca gtg aaa gac
aca 528 Leu Glu Thr Arg Thr Arg Gln Ile Val Lys Lys Pro Val Lys Asp
Thr 165 170 175 ata ccg tgt cca acc att gct gaa tcc agg aga tgc aag
atg aca atg 576 Ile Pro Cys Pro Thr Ile Ala Glu Ser Arg Arg Cys Lys
Met Thr Met 180 185 190 agg cat tgt cca gga ggg aag aga aca cca aag
gcg aag gag aag agg 624 Arg His Cys Pro Gly Gly Lys Arg Thr Pro Lys
Ala Lys Glu Lys Arg 195 200 205 aac aag aaa aag aaa agg aag ctg ata
gaa agg gcc cag gag caa cac 672 Asn Lys Lys Lys Lys Arg Lys Leu Ile
Glu Arg Ala Gln Glu Gln His 210 215 220 agc gtc ttc cta gct aca gac
aga gct aac caa ggc ggc cgc tcg agt 720 Ser Val Phe Leu Ala Thr Asp
Arg Ala Asn Gln Gly Gly Arg Ser Ser 225 230 235 240 cta gag ggc ccg
cgg ttc gaa ggt aag cct atc cct aac cct ctc ctc 768 Leu Glu Gly Pro
Arg Phe Glu Gly Lys Pro Ile Pro Asn Pro Leu Leu 245 250 255 ggt ctc
gat tct acg cgt acc ggt cat cat cac cat cac cat tga 813 Gly Leu Asp
Ser Thr Arg Thr Gly His His His His His His 260 265 270 <210>
SEQ ID NO 36 <211> LENGTH: 270 <212> TYPE: PRT
<213> ORGANISM: IgK-SCFA2-V5His6 <400> SEQUENCE: 36 Met
Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10
15 Gly Ser Thr Gly Asp Ala Ser Ala Ser Tyr Val Ser Asn Pro Ile Cys
20 25 30 Lys Gly Cys Leu Ser Cys Ser Lys Asp Asn Gly Cys Ser Arg
Cys Gln 35 40 45 Gln Lys Leu Phe Phe Phe Leu Arg Arg Glu Gly Met
Arg Gln Tyr Gly 50 55 60 Glu Cys Leu His Ser Cys Pro Ser Gly Tyr
Tyr Gly His Arg Ala Pro 65 70 75 80 Asp Met Asn Arg Cys Ala Arg Cys
Arg Ile Glu Asn Cys Asp Ser Cys 85 90 95 Phe Ser Lys Asp Phe Cys
Thr Lys Cys Lys Val Gly Phe Tyr Leu His 100 105 110 Arg Gly Arg Cys
Phe Asp Glu Cys Pro Asp Gly Phe Ala Pro Leu Glu 115 120 125 Glu Thr
Met Glu Cys Val Glu Gly Cys Glu Val Gly His Trp Ser Glu 130 135 140
Trp Gly Thr Cys Ser Arg Asn Asn Arg Thr Cys Gly Phe Lys Trp Gly 145
150 155 160 Leu Glu Thr Arg Thr Arg Gln Ile Val Lys Lys Pro Val Lys
Asp Thr 165 170 175 Ile Pro Cys Pro Thr Ile Ala Glu Ser Arg Arg Cys
Lys Met Thr Met 180 185 190 Arg His Cys Pro Gly Gly Lys Arg Thr Pro
Lys Ala Lys Glu Lys Arg 195 200 205 Asn Lys Lys Lys Lys Arg Lys Leu
Ile Glu Arg Ala Gln Glu Gln His 210 215 220 Ser Val Phe Leu Ala Thr
Asp Arg Ala Asn Gln Gly Gly Arg Ser Ser 225 230 235 240 Leu Glu Gly
Pro Arg Phe Glu Gly Lys Pro Ile Pro Asn Pro Leu Leu 245 250 255 Gly
Leu Asp Ser Thr Arg Thr Gly His His His His His His 260 265 270
<210> SEQ ID NO 37 <211> LENGTH: 35 <212> TYPE:
DNA <213> ORGANISM: F primer for cloning out IgK-SCFA2-V5His
from pIntron into Adeno <400> SEQUENCE: 37 tgctctagac
accatggaga cagacacact cctgc 35 <210> SEQ ID NO 38 <211>
LENGTH: 38 <212> TYPE: DNA <213> ORGANISM: R primer for
cloning out IgK-SCFA2-V5His from pIntron into Adeno <400>
SEQUENCE: 38 ccatgcggcc gccttggtta gctctgtctg tagctagg 38
<210> SEQ ID NO 39 <211> LENGTH: 822 <212> TYPE:
DNA <213> ORGANISM: IgK-SCFA4-V5His <220> FEATURE:
<221> NAME/KEY: CDS <222> LOCATION: (1)..(822)
<400> SEQUENCE: 39 atg gag aca gac aca ctc ctg cta tgg gta
ctg ctg ctc tgg gtt cca 48 Met Glu Thr Asp Thr Leu Leu Leu Trp Val
Leu Leu Leu Trp Val Pro 1 5 10 15 ggt tcc act ggt gac gct agc ctg
aac cga agg aag aag caa gtg ggc 96 Gly Ser Thr Gly Asp Ala Ser Leu
Asn Arg Arg Lys Lys Gln Val Gly 20 25 30 act ggc ctg ggg ggc aac
tgc aca ggc tgt atc atc tgc tca gag gag 144 Thr Gly Leu Gly Gly Asn
Cys Thr Gly Cys Ile Ile Cys Ser Glu Glu 35 40 45 aac ggc tgt tcc
acc tgc cag cag agg ctc ttc ctg ttc atc cgc cgg 192 Asn Gly Cys Ser
Thr Cys Gln Gln Arg Leu Phe Leu Phe Ile Arg Arg 50 55 60 gaa ggc
atc cgc cag tac ggc aag tgc ctg cac gac tgt ccc cct ggg 240 Glu Gly
Ile Arg Gln Tyr Gly Lys Cys Leu His Asp Cys Pro Pro Gly 65 70 75 80
tac ttc ggc atc cgc ggc cag gag gtc aac agg tgc aaa aaa tgt ggg 288
Tyr Phe Gly Ile Arg Gly Gln Glu Val Asn Arg Cys Lys Lys Cys Gly 85
90 95 gcc act tgt gag agc tgc ttc agc cag gac ttc tgc atc cgg tgc
aag 336 Ala Thr Cys Glu Ser Cys Phe Ser Gln Asp Phe Cys Ile Arg Cys
Lys 100 105 110 agg cag ttt tac ttg tac aag ggg aag tgt ctg ccc acc
tgc ccg ccg 384 Arg Gln Phe Tyr Leu Tyr Lys Gly Lys Cys Leu Pro Thr
Cys Pro Pro 115 120 125 ggc act ttg gct cac cag aac aca cgg gag tgc
cag ggg gag tgt gaa 432 Gly Thr Leu Ala His Gln Asn Thr Arg Glu Cys
Gln Gly Glu Cys Glu 130 135 140 ctg ggt ccc tgg ggc ggc tgg agc ccc
tgc aca cac aat gga aag acc 480 Leu Gly Pro Trp Gly Gly Trp Ser Pro
Cys Thr His Asn Gly Lys Thr 145 150 155 160 tgc ggc tcg gct tgg ggc
ctg gag agc cgg gta cga gag gct ggc cgg 528 Cys Gly Ser Ala Trp Gly
Leu Glu Ser Arg Val Arg Glu Ala Gly Arg 165 170 175 gct ggg cat gag
gag gca gcc acc tgc cag gtg ctt tct gag tca agg 576 Ala Gly His Glu
Glu Ala Ala Thr Cys Gln Val Leu Ser Glu Ser Arg 180 185 190 aaa tgt
ccc atc cag agg ccc tgc cca gga gag agg agc ccc ggc cag 624 Lys Cys
Pro Ile Gln Arg Pro Cys Pro Gly Glu Arg Ser Pro Gly Gln 195 200 205
aag aag ggc agg aag gac cgg cgc cca cgc aag gac agg aag ctg gac 672
Lys Lys Gly Arg Lys Asp Arg Arg Pro Arg Lys Asp Arg Lys Leu Asp 210
215 220 cgc agg ctg gac gtg agg ccg cgc cag ccc ggc ctg cag ccc ggc
ggc 720 Arg Arg Leu Asp Val Arg Pro Arg Gln Pro Gly Leu Gln Pro Gly
Gly 225 230 235 240 cgc tcg agt cta gag ggc ccg cgg ttc gaa ggt aag
cct atc cct aac 768 Arg Ser Ser Leu Glu Gly Pro Arg Phe Glu Gly Lys
Pro Ile Pro Asn 245 250 255 cct ctc ctc ggt ctc gat tct acg cgt acc
ggt cat cat cac cat cac 816 Pro Leu Leu Gly Leu Asp Ser Thr Arg Thr
Gly His His His His His 260 265 270 cat tga 822 His <210> SEQ
ID NO 40 <211> LENGTH: 273 <212> TYPE: PRT <213>
ORGANISM: IgK-SCFA4-V5His
<400> SEQUENCE: 40 Met Glu Thr Asp Thr Leu Leu Leu Trp Val
Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Ala Ser Leu
Asn Arg Arg Lys Lys Gln Val Gly 20 25 30 Thr Gly Leu Gly Gly Asn
Cys Thr Gly Cys Ile Ile Cys Ser Glu Glu 35 40 45 Asn Gly Cys Ser
Thr Cys Gln Gln Arg Leu Phe Leu Phe Ile Arg Arg 50 55 60 Glu Gly
Ile Arg Gln Tyr Gly Lys Cys Leu His Asp Cys Pro Pro Gly 65 70 75 80
Tyr Phe Gly Ile Arg Gly Gln Glu Val Asn Arg Cys Lys Lys Cys Gly 85
90 95 Ala Thr Cys Glu Ser Cys Phe Ser Gln Asp Phe Cys Ile Arg Cys
Lys 100 105 110 Arg Gln Phe Tyr Leu Tyr Lys Gly Lys Cys Leu Pro Thr
Cys Pro Pro 115 120 125 Gly Thr Leu Ala His Gln Asn Thr Arg Glu Cys
Gln Gly Glu Cys Glu 130 135 140 Leu Gly Pro Trp Gly Gly Trp Ser Pro
Cys Thr His Asn Gly Lys Thr 145 150 155 160 Cys Gly Ser Ala Trp Gly
Leu Glu Ser Arg Val Arg Glu Ala Gly Arg 165 170 175 Ala Gly His Glu
Glu Ala Ala Thr Cys Gln Val Leu Ser Glu Ser Arg 180 185 190 Lys Cys
Pro Ile Gln Arg Pro Cys Pro Gly Glu Arg Ser Pro Gly Gln 195 200 205
Lys Lys Gly Arg Lys Asp Arg Arg Pro Arg Lys Asp Arg Lys Leu Asp 210
215 220 Arg Arg Leu Asp Val Arg Pro Arg Gln Pro Gly Leu Gln Pro Gly
Gly 225 230 235 240 Arg Ser Ser Leu Glu Gly Pro Arg Phe Glu Gly Lys
Pro Ile Pro Asn 245 250 255 Pro Leu Leu Gly Leu Asp Ser Thr Arg Thr
Gly His His His His His 260 265 270 His <210> SEQ ID NO 41
<211> LENGTH: 35 <212> TYPE: DNA <213> ORGANISM:
F primer for cloning out IgK-SCFA4(4v)-V5His from pIntron into
<400> SEQUENCE: 41 tgctctagac accatggaga cagacacact cctgc 35
<210> SEQ ID NO 42 <211> LENGTH: 31 <212> TYPE:
DNA <213> ORGANISM: R primer for cloning out
IgK-SCFA4(4v)-V5His from plntron into <400> SEQUENCE: 42
ccatgcggcc gccgggctgc aggccgggct g 31 <210> SEQ ID NO 43
<211> LENGTH: 636 <212> TYPE: DNA <213> ORGANISM:
IgK-SCFA4v-v5His6 <220> FEATURE: <221> NAME/KEY: CDS
<222> LOCATION: (1)..(636) <400> SEQUENCE: 43 atg gag
aca gac aca ctc ctg cta tgg gta ctg ctg ctc tgg gtt cca 48 Met Glu
Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15
ggt tcc act ggt gac gct agc ctg aac cga agg aag aag caa gtg ggc 96
Gly Ser Thr Gly Asp Ala Ser Leu Asn Arg Arg Lys Lys Gln Val Gly 20
25 30 act ggc ctg ggg ggc aac tgc aca ggc tgt atc atc tgc tca gag
gag 144 Thr Gly Leu Gly Gly Asn Cys Thr Gly Cys Ile Ile Cys Ser Glu
Glu 35 40 45 aac ggc tgt tcc acc tgc cag cag agg ctc ttc ctg ttc
atc cgc cgg 192 Asn Gly Cys Ser Thr Cys Gln Gln Arg Leu Phe Leu Phe
Ile Arg Arg 50 55 60 gaa ggc atc cgc cag tac ggc aag tgc ctg cac
gac tgt ccc cct ggg 240 Glu Gly Ile Arg Gln Tyr Gly Lys Cys Leu His
Asp Cys Pro Pro Gly 65 70 75 80 tac ttc ggc atc cgc ggc cag gag gtc
aac agg tgc aaa aaa tgt ggg 288 Tyr Phe Gly Ile Arg Gly Gln Glu Val
Asn Arg Cys Lys Lys Cys Gly 85 90 95 gcc act tgt gag agc tgc ttc
agc cag gac ttc tgc atc cgg tgc aag 336 Ala Thr Cys Glu Ser Cys Phe
Ser Gln Asp Phe Cys Ile Arg Cys Lys 100 105 110 agg cag ttt tac ttg
tac aag ggg aag tgt ctg ccc acc tgc ccg ccg 384 Arg Gln Phe Tyr Leu
Tyr Lys Gly Lys Cys Leu Pro Thr Cys Pro Pro 115 120 125 ggc act ttg
gcc cac cag aac aca cgg gag tgc cag gag agg agc ccc 432 Gly Thr Leu
Ala His Gln Asn Thr Arg Glu Cys Gln Glu Arg Ser Pro 130 135 140 ggc
cag aag aag ggc agg aag gac cgg cgc cca cgc aag gac agg aag 480 Gly
Gln Lys Lys Gly Arg Lys Asp Arg Arg Pro Arg Lys Asp Arg Lys 145 150
155 160 ctg gac cgc agg ctg gac gtg agg ccg cgc cag ccc ggc ctg cag
ccc 528 Leu Asp Arg Arg Leu Asp Val Arg Pro Arg Gln Pro Gly Leu Gln
Pro 165 170 175 ggc ggc cgc tcg agt cta gag ggc ccg cgg ttc gaa ggt
aag cct atc 576 Gly Gly Arg Ser Ser Leu Glu Gly Pro Arg Phe Glu Gly
Lys Pro Ile 180 185 190 cct aac cct ctc ctc ggt ctc gat tct acg cgt
acc ggt cat cat cac 624 Pro Asn Pro Leu Leu Gly Leu Asp Ser Thr Arg
Thr Gly His His His 195 200 205 cat cac cat tga 636 His His His 210
<210> SEQ ID NO 44 <211> LENGTH: 211 <212> TYPE:
PRT <213> ORGANISM: IgK-SCFA4v-v5His6 <400> SEQUENCE:
44 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1 5 10 15 Gly Ser Thr Gly Asp Ala Ser Leu Asn Arg Arg Lys Lys Gln
Val Gly 20 25 30 Thr Gly Leu Gly Gly Asn Cys Thr Gly Cys Ile Ile
Cys Ser Glu Glu 35 40 45 Asn Gly Cys Ser Thr Cys Gln Gln Arg Leu
Phe Leu Phe Ile Arg Arg 50 55 60 Glu Gly Ile Arg Gln Tyr Gly Lys
Cys Leu His Asp Cys Pro Pro Gly 65 70 75 80 Tyr Phe Gly Ile Arg Gly
Gln Glu Val Asn Arg Cys Lys Lys Cys Gly 85 90 95 Ala Thr Cys Glu
Ser Cys Phe Ser Gln Asp Phe Cys Ile Arg Cys Lys 100 105 110 Arg Gln
Phe Tyr Leu Tyr Lys Gly Lys Cys Leu Pro Thr Cys Pro Pro 115 120 125
Gly Thr Leu Ala His Gln Asn Thr Arg Glu Cys Gln Glu Arg Ser Pro 130
135 140 Gly Gln Lys Lys Gly Arg Lys Asp Arg Arg Pro Arg Lys Asp Arg
Lys 145 150 155 160 Leu Asp Arg Arg Leu Asp Val Arg Pro Arg Gln Pro
Gly Leu Gln Pro 165 170 175 Gly Gly Arg Ser Ser Leu Glu Gly Pro Arg
Phe Glu Gly Lys Pro Ile 180 185 190 Pro Asn Pro Leu Leu Gly Leu Asp
Ser Thr Arg Thr Gly His His His 195 200 205 His His His 210
<210> SEQ ID NO 45 <211> LENGTH: 28 <212> TYPE:
DNA <213> ORGANISM: F primer for making adenovator CMv5
Intron modification EG 6 <400> SEQUENCE: 45 cacccctagg
tcaatattgg ccattagc 28 <210> SEQ ID NO 46 <211> LENGTH:
28 <212> TYPE: DNA <213> ORGANISM: R primer for making
adenovator CMV5 Intron modification EG 6 <400> SEQUENCE: 46
cacccctagg taggcatccc cagcatgc 28 <210> SEQ ID NO 47
<211> LENGTH: 8913 <212> TYPE: DNA <213>
ORGANISM: pAdenovator-CMVIntron(Transfer vector): <400>
SEQUENCE: 47 taacatcatc aataatatac cttattttgg attgaagcca atatgataat
gagggggtgg 60 agtttgtgac gtggcgcggg gcgtgggaac ggggcgggtg
acgtagtagt gtggcggaag 120 tgtgatgttg caagtgtggc ggaacacatg
taagcgacgg atgtggcaaa agtgacgttt 180 ttggtgtgcg ccggtgtaca
caggaagtga caattttcgc gcggttttag gcggatgttg 240 tagtaaattt
gggcgtaacc gagtaagatt tggccatttt cgcgggaaaa ctgaataaga 300
ggaagtgaaa tctgaataat tttgtgttac tcatagcgcg taatactgcg atctatacat
360 tgaatcaata ttggcaatta gccatattag tcattggtta tatagcataa
atcaatattg 420 gctattggcc attgcatacg ttgtatctat atcataatat
gtacatttat attggctcat 480 gtccaatatg accgccatgt tgacattgat
tattgactag gtcaatattg gccattagcc 540 atattattca ttggttatat
agcataaatc aatattggct attggccatt gcatacgttg 600 tatctatatc
ataatatgta catttatatt ggctcatgtc caatatgacc gccatgttgg 660
cattgattat tgactagtta ttaatagtaa tcaattacgg ggtcattagt tcatagccca
720 tatatggagt tccgcgttac ataacttacg gtaaatggcc cgcctggctg
accgcccaac 780 gacccccgcc cattgacgtc aataatgacg tatgttccca
tagtaacgcc aatagggact 840
ttccattgac gtcaatgggt ggagtattta cggtaaactg cccacttggc agtacatcaa
900 gtgtatcata tgccaagtcc gccccctatt gacgtcaatg acggtaaatg
gcccgcctgg 960 cattatgccc agtacatgac cttacgggac tttcctactt
ggcagtacat ctacgtatta 1020 gtcatcgcta ttaccatggt gatgcggttt
tggcagtaca ccaatgggcg tggatagcgg 1080 tttgactcac ggggatttcc
aagtctccac cccattgacg tcaatgggag tttgttttgg 1140 caccaaaatc
aacgggactt tccaaaatgt cgtaataacc ccgccccgtt gacgcaaatg 1200
ggcggtaggc gtgtacggtg ggaggtctat ataagcagag ctcgtttagt gaaccgtcag
1260 atcactagaa gctttattgc ggtagtttat cacagttaaa ttgctaacgc
agtcagtgct 1320 tctgacacaa cagtctcgaa cttaagctgc agaagttggt
cgtgaggcac tgggcaggta 1380 agtatcaagg ttacaagaca ggtttaagga
gaccaataga aactgggctt gtcgagacag 1440 agaagactct tgcgtttctg
ataggcacct attggtctta ctgacatcca ctttgccttt 1500 ctctccacag
gtgtccactc ccagttcaat tacagctctt aaggctagag tacttaatac 1560
gactcactat aggctagcct cgagaattca cgcgtggtac cgagctcgga tccactagtc
1620 cagtgtggtg gaattgccct taagggcaat tctgcagata tccagcacag
tggcggccgc 1680 tcgagtctag agggcccgcg gttcgaaggt aagcctatcc
ctaaccctct cctcggtctc 1740 gattctacgc gtaccggtca tcatcaccat
caccattgag ttcaaacccg ctgatcagcc 1800 tcgactgtgc cttctagttg
ccagccatct gttgtttgcc cctcccccgt gccttccttg 1860 accctggaag
gtgccactcc cactgtcctt tcctaataaa atgaggaaat tgcatcgcat 1920
tgtctgagta ggtgtcattc tattctgggg ggtggggtgg ggcaggacag caagggggag
1980 gattgggaag acaatagcag gcatgctggg gatgcctacc tagtcactac
tctgtgctat 2040 ggtgttcaat gcttttcaag atacccggat catatgaaac
ggcatgactt tttcaagagt 2100 gccatgcccg aaggttatgt acaggaaagg
accatcttct tcaaagatga cggcaactac 2160 aagacacgtg ctgaagtcaa
gtttgaaggt gatacccttg ttaatagaat cgagttaaaa 2220 ggtattgact
tcaaggaaga tggcaacatt ctgggacaca aattggaata caactataac 2280
tcacacaatg tatacatcat ggcagacaaa caaaagaatg gaatcaaagt gaacttcaag
2340 acccgccaca acattgaaga tggaagcgtt caactagcag accattatca
acaaaatact 2400 ccaattggcg atggccctgt ccttttacca gacaaccatt
acctgtccac acaatctgcc 2460 ctttcgaaag atcccaacga aaagagagac
cacatggtcc ttcttgagtt tgtaacagct 2520 gctgggatta cacatggcat
ggatgaactg tacaactgag gatcccccga cctcgacctc 2580 tggctaataa
aggaaattta ttttcattgc aatagtgtgt tggaattttt tgtgtctctc 2640
actcggaagg acatatggga gggcaaatca tttggtcgag atccctcgga gatcggatct
2700 gggcgtggtt aagggtggga aagaatatat aaggtggggg tcttatgtag
ttttgtatct 2760 gttttgcagc agccgccgcc gccatgagca ccaactcgtt
tgatggaagc attgtgagct 2820 catatttgac aacgcgcatg cccccatggg
ccggggtgcg tcagaatgtg atgggctcca 2880 gcattgatgg tcgccccgtc
ctgcccgcaa actctactac cttgacctac gagaccgtgt 2940 ctggaacgcc
gttggagact gcagcctccg ccgccgcttc agccgctgca gccaccgccc 3000
gcgggattgt gactgacttt gctttcctga gcccgcttgc aagcagtgca gcttcccgtt
3060 catccgcccg cgatgacaag ttgacggctc ttttggcaca attggattct
ttgacccggg 3120 aacttaatgt cgtttctcag cagctgttgg atctgcgcca
gcaggtttct gccctgaagg 3180 cttcctcccc tcccaatgcg gtttaaaaca
taaataaaaa accagactct gtttggattt 3240 ggatcaagca agtgtcttgc
tgtctttatt taggggtttt gcgcgcgcgg taggcccggg 3300 accagcggtc
tcggtcgttg agggtcctgt gtattttttc caggacgtgg taaaggtgac 3360
tctggatgtt cagatacatg ggcataagcc cgtctctggg gtggaggtag caccactgca
3420 gagcttcatg ctgcggggtg gtgttgtaga tgatccagtc gtagcaggag
cgctgggcgt 3480 ggtgcctaaa aatgtctttc agtagcaagc tgattgccag
gggcaggccc ttggtgtaag 3540 tgtttacaaa gcggttaagc tgggatgggt
gcatacgtgg ggatatgaga tgcatcttgg 3600 actgtatttt taggttggct
atgttcccag ccatatccct ccggggattc atgttgtgca 3660 gaaccaccag
cacagtgtat ccggtgcact tgggaaattt gtcatgtagc ttagaaggaa 3720
atgcgtggaa gaacttggag acgcccttgt gacctccaag attttccatg cattcgtcca
3780 taatgatggc aatgggccca cgggcggcgg cctgggcgaa gatatttctg
ggatcactaa 3840 cgtcatagtt gtgttccagg atggatcgtc ataggccatt
tttacaaagc gcgggcggag 3900 ggtgccagac tgcggtataa tggttccatc
cggcccaggg gcgtagttac cctcacagat 3960 ttgcatttcc cacgctttga
gttcagatgg ggggatcatg tctacctgcg gggcgatgaa 4020 gaaaacggtt
tccggggtag gggagatcag ctgggaagaa agcaggttcc tgagcagctg 4080
cgacttaccg cagccggtgg gcccgtaaat cacacctatt accgggtgca actggtagtt
4140 aagagagctg cagctgccgt catccctgag caggggggcc acttcgttaa
gcatgtccct 4200 gactcgcatg ttttccctga ccaaatccgc cagaaggcgc
tcgccgccca gcgatagcag 4260 ttcttgcaag gaagcaaagt ttttcaacgg
tttgagaccg tccgccgtag gcatgctttt 4320 gagcgtttga ccaagcagtt
ccaggcggtc ccacagctcg gtcacctgct ctacggcatc 4380 tcgatccagc
atatctcctc gtttcgcggg ttggggcggc tttcgctgta cggcagtagt 4440
cggtgctcgt ccagacgggc cagggtcatg tctttccacg ggcgcagggt cctcgtcagc
4500 gtagtctggg tcacggtgaa ggggtgcgct ccgggctgcg cgctggccag
ggtgcgcttg 4560 aggctggtcc tgctggtgct gaagcgctgc cggtcttcgc
cctgcgcgtc ggccaggtag 4620 catttgacca tggtgtcata gtccagcccc
tccgcggcgt ggcccttggc gcgcagcttg 4680 cccttggagg aggcgccgca
cgaggggcag tgcagacttt tgagggcgta gagcttgggc 4740 gcgagaaata
ccgattccgg ggagtaggca tccgcgccgc aggccccgca gacggtctcg 4800
cattccacga gccaggtgag ctctggccgt tcggggtcaa aaaccaggtt tcccccatgc
4860 tttttgatgc gtttcttacc tctggtttcc atgagccggt gtccacgctc
ggtgacgaaa 4920 aggctgtccg tgtccccgta tacagacttg agagggagtt
taaacgaatt caatagcttg 4980 ttgcatgggc ggcgatataa aatgcaaggt
gctgctcaaa aaatcaggca aagcctcgcg 5040 caaaaaagaa agcacatcgt
agtcatgctc atgcagataa aggcaggtaa gctccggaac 5100 caccacagaa
aaagacacca tttttctctc aaacatgtct gcgggtttct gcataaacac 5160
aaaataaaat aacaaaaaaa catttaaaca ttagaagcct gtcttacaac aggaaaaaca
5220 acccttataa gcataagacg gactacggcc atgccggcgt gaccgtaaaa
aaactggtca 5280 ccgtgattaa aaagcaccac cgacagctcc tcggtcatgt
ccggagtcat aatgtaagac 5340 tcggtaaaca catcaggttg attcatcggt
cagtgctaaa aagcgaccga aatagcccgg 5400 gggaatacat acccgcaggc
gtagagacaa cattacagcc cccataggag gtataacaaa 5460 attaatagga
gagaaaaaca cataaacacc tgaaaaaccc tcctgcctag gcaaaatagc 5520
accctcccgc tccagaacaa catacagcgc ttcacagcgg cagcctaaca gtcagcctta
5580 ccagtaaaaa agaaaaccta ttaaaaaaac accactcgac acggcaccag
ctcaatcagt 5640 cacagtgtaa aaaagggcca agtgcagagc gagtatatat
aggactaaaa aatgacgtaa 5700 cggttaaagt ccacaaaaaa cacccagaaa
accgcacgcg aacctacgcc cagaaacgaa 5760 agccaaaaaa cccacaactt
cctcaaatcg tcacttccgt tttcccacgt tacgtaactt 5820 cccattttaa
gaaaactaca attcccaaca catacaagtt actccgccct aaaacctacg 5880
tcacccgccc cgttcccacg ccccgcgcca cgtcacaaac tccaccccct cattatcata
5940 ttggcttcaa tccaaaataa ggtatattat tgatgatgtt aattaacatg
catggatcca 6000 tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa
taccgcatca ggcgctcttc 6060 cgcttcctcg ctcactgact cgctgcgctc
ggtcgttcgg ctgcggcgag cggtatcagc 6120 tcactcaaag gcggtaatac
ggttatccac agaatcaggg gataacgcag gaaagaacat 6180 gtgagcaaaa
ggccagcaaa aggccaggaa ccgtaaaaag gccgcgttgc tggcgttttt 6240
ccataggctc cgcccccctg acgagcatca caaaaatcga cgctcaagtc agaggtggcg
6300 aaacccgaca ggactataaa gataccaggc gtttccccct ggaagctccc
tcgtgcgctc 6360 tcctgttccg accctgccgc ttaccggata cctgtccgcc
tttctccctt cgggaagcgt 6420 ggcgctttct catagctcac gctgtaggta
tctcagttcg gtgtaggtcg ttcgctccaa 6480 gctgggctgt gtgcacgaac
cccccgttca gcccgaccgc tgcgccttat ccggtaacta 6540 tcgtcttgag
tccaacccgg taagacacga cttatcgcca ctggcagcag ccactggtaa 6600
caggattagc agagcgaggt atgtaggcgg tgctacagag ttcttgaagt ggtggcctaa
6660 ctacggctac actagaagga cagtatttgg tatctgcgct ctgctgaagc
cagttacctt 6720 cggaaaaaga gttggtagct cttgatccgg caaacaaacc
accgctggta gcggtggttt 6780 ttttgtttgc aagcagcaga ttacgcgcag
aaaaaaagga tctcaagaag atcctttgat 6840 cttttctacg gggtctgacg
ctcagtggaa cgaaaactca cgttaaggga ttttggtcat 6900 gagattatca
aaaaggatct tcacctagat ccttttaaat taaaaatgaa gttttaaatc 6960
aatctaaagt atatatgagt aaacttggtc tgacagttac caatgcttaa tcagtgaggc
7020 acctatctca gcgatctgtc tatttcgttc atccatagtt gcctgactcc
ccgtcgtgta 7080 gataactacg atacgggagg gcttaccatc tggccccagt
gctgcaatga taccgcgaga 7140 cccacgctca ccggctccag atttatcagc
aataaaccag ccagccggaa gggccgagcg 7200 cagaagtggt cctgcaactt
tatccgcctc catccagtct attaattgtt gccgggaagc 7260 tagagtaagt
agttcgccag ttaatagttt gcgcaacgtt gttgccattg ctgcagccat 7320
gagattatca aaaaggatct tcacctagat ccttttcacg tagaaagcca gtccgcagaa
7380 acggtgctga ccccggatga atgtcagcta ctgggctatc tggacaaggg
aaaacgcaag 7440 cgcaaagaga aagcaggtag cttgcagtgg gcttacatgg
cgatagctag actgggcggt 7500 tttatggaca gcaagcgaac cggaattgcc
agctggggcg ccctctggta aggttgggaa 7560 gccctgcaaa gtaaactgga
tggctttctc gccgccaagg atctgatggc gcaggggatc 7620 aagctctgat
caagagacag gatgaggatc gtttcgcatg attgaacaag atggattgca 7680
cgcaggttct ccggccgctt gggtggagag gctattcggc tatgactggg cacaacagac
7740 aatcggctgc tctgatgccg ccgtgttccg gctgtcagcg caggggcgcc
cggttctttt 7800 tgtcaagacc gacctgtccg gtgccctgaa tgaactgcaa
gacgaggcag cgcggctatc 7860 gtggctggcc acgacgggcg ttccttgcgc
agctgtgctc gacgttgtca ctgaagcggg 7920 aagggactgg ctgctattgg
gcgaagtgcc ggggcaggat ctcctgtcat ctcaccttgc 7980 tcctgccgag
aaagtatcca tcatggctga tgcaatgcgg cggctgcata cgcttgatcc 8040
ggctacctgc ccattcgacc accaagcgaa acatcgcatc gagcgagcac gtactcggat
8100 ggaagccggt cttgtcgatc aggatgatct ggacgaagag catcaggggc
tcgcgccagc 8160 cgaactgttc gccaggctca aggcgagcat gcccgacggc
gaggatctcg tcgtgaccca 8220 tggcgatgcc tgcttgccga atatcatggt
ggaaaatggc cgcttttctg gattcatcga 8280 ctgtggccgg ctgggtgtgg
cggaccgcta tcaggacata gcgttggcta cccgtgatat 8340
tgctgaagag cttggcggcg aatgggctga ccgcttcctc gtgctttacg gtatcgccgc
8400 tcccgattcg cagcgcatcg ccttctatcg ccttcttgac gagttcttct
gaattttgtt 8460 aaaatttttg ttaaatcagc tcatttttta accaataggc
cgaaatcggc aacatccctt 8520 ataaatcaaa agaatagacc gcgatagggt
tgagtgttgt tccagtttgg aacaagagtc 8580 cactattaaa gaacgtggac
tccaacgtca aagggcgaaa aaccgtctat cagggcgatg 8640 gcccactacg
tgaaccatca cccaaatcaa gttttttgcg gtcgaggtgc cgtaaagctc 8700
taaatcggaa ccctaaaggg agcccccgat ttagagcttg acggggaaag ccggcgaacg
8760 tggcgagaaa ggaagggaag aaagcgaaag gagcgggcgc tagggcgctg
gcaagtgtag 8820 cggtcacgct gcgcgtaacc accacacccg cgcgcttaat
gcgccgctac agggcgcgtc 8880 cattcgccat tcaggatcga attaattctt aat
8913 <210> SEQ ID NO 48 <211> LENGTH: 224 <212>
TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE:
48 Met Arg Ala Pro Leu Cys Leu Leu Leu Leu Val Ala His Ala Val Asp
1 5 10 15 Met Leu Ala Leu Asn Arg Arg Lys Lys Gln Val Gly Thr Gly
Leu Gly 20 25 30 Gly Asn Cys Thr Gly Cys Ile Ile Cys Ser Glu Glu
Asn Gly Cys Ser 35 40 45 Thr Cys Gln Gln Arg Leu Phe Leu Phe Ile
Arg Arg Glu Gly Ile Arg 50 55 60 Gln Tyr Gly Lys Cys Leu His Asp
Cys Pro Pro Gly Tyr Phe Gly Ile 65 70 75 80 Arg Gly Gln Glu Val Asn
Arg Cys Lys Lys Cys Gly Ala Thr Cys Glu 85 90 95 Ser Cys Phe Ser
Gln Asp Phe Cys Ile Arg Cys Lys Arg Gln Phe Tyr 100 105 110 Leu Tyr
Lys Gly Lys Cys Leu Pro Thr Cys Pro Pro Gly Thr Leu Ala 115 120 125
His Gln Asn Thr Arg Glu Cys Gln Gly Glu Cys Glu Leu Gly Pro Trp 130
135 140 Gly Gly Trp Ser Pro Cys Thr His Asn Gly Lys Thr Cys Gly Ser
Ala 145 150 155 160 Trp Gly Leu Glu Ser Arg Val Arg Glu Ala Gly Arg
Ala Gly His Glu 165 170 175 Glu Ala Ala Thr Cys Gln Val Leu Ser Glu
Ser Arg Lys Cys Pro Ile 180 185 190 Gln Arg Pro Cys Pro Gly Glu Arg
Ser Pro Gly Gln Lys Lys Gly Arg 195 200 205 Lys Asp Arg Arg Pro Arg
Lys Asp Arg Lys Leu Asp Arg Arg Leu Asp 210 215 220 <210> SEQ
ID NO 49 <211> LENGTH: 243 <212> TYPE: PRT <213>
ORGANISM: Xenopus laevis <400> SEQUENCE: 49 Met Gln Phe Gln
Leu Phe Ser Phe Ala Leu Ile Ile Leu Asn Cys Val 1 5 10 15 Asp Tyr
Ser His Cys Gln Ala Ser Arg Trp Arg Arg Ser Lys Arg Ala 20 25 30
Ser Tyr Gly Thr Asn Pro Ile Cys Lys Gly Cys Leu Ser Cys Ser Lys 35
40 45 Asp Asn Gly Cys Leu Arg Cys Gln Pro Lys Leu Phe Phe Phe Leu
Arg 50 55 60 Arg Glu Gly Met Arg Gln Tyr Gly Glu Cys Leu Gln Ser
Cys Pro Pro 65 70 75 80 Gly Tyr Tyr Gly Val Arg Gly Pro Asp Met Asn
Arg Cys Ser Arg Cys 85 90 95 Arg Ile Glu Asn Cys Asp Ser Cys Phe
Ser Arg Asp Phe Cys Ile Lys 100 105 110 Cys Lys Ser Gly Phe Tyr Ser
Leu Lys Gly Gln Cys Phe Glu Glu Cys 115 120 125 Pro Glu Gly Phe Ala
Pro Leu Asp Asp Thr Met Val Cys Val Asp Gly 130 135 140 Cys Glu Val
Gly Pro Trp Ser Glu Trp Gly Thr Cys Ser Arg Asn Asn 145 150 155 160
Arg Thr Cys Gly Phe Lys Trp Gly Leu Glu Thr Arg Thr Arg Gln Ile 165
170 175 Val Lys Lys Pro Ala Lys Asp Thr Ile Pro Cys Pro Thr Ile Ala
Glu 180 185 190 Ser Arg Arg Cys Lys Met Ala Ile Arg His Cys Pro Gly
Gly Lys Arg 195 200 205 Thr Thr Lys Lys Lys Asp Lys Arg Asn Lys Lys
Lys Lys Lys Lys Leu 210 215 220 Leu Glu Arg Ala Gln Glu Gln His Ser
Val Val Leu Ala Thr Asp Arg 225 230 235 240 Ser Ser Gln <210>
SEQ ID NO 50 <211> LENGTH: 732 <212> TYPE: DNA
<213> ORGANISM: Homo sapiens <220> FEATURE: <221>
NAME/KEY: CDS <222> LOCATION: (1)..(732) <400>
SEQUENCE: 50 atg cag ttt cgc ctt ttc tcc ttt gcc ctc atc att ctg
aac tgc atg 48 Met Gln Phe Arg Leu Phe Ser Phe Ala Leu Ile Ile Leu
Asn Cys Met 1 5 10 15 gat tac agc cac tgc caa ggc aac cga tgg aga
cgc agt aag cga gct 96 Asp Tyr Ser His Cys Gln Gly Asn Arg Trp Arg
Arg Ser Lys Arg Ala 20 25 30 agt tat gta tca aat ccc att tgc aag
ggt tgt ttg tct tgt tca aag 144 Ser Tyr Val Ser Asn Pro Ile Cys Lys
Gly Cys Leu Ser Cys Ser Lys 35 40 45 gac aat ggg tgt agc cga tgt
caa cag aag ttg ttc ttc ttc ctt cga 192 Asp Asn Gly Cys Ser Arg Cys
Gln Gln Lys Leu Phe Phe Phe Leu Arg 50 55 60 aga gaa ggg atg cgc
cag tat gga gag tgc ctg cat tcc tgc cca tcc 240 Arg Glu Gly Met Arg
Gln Tyr Gly Glu Cys Leu His Ser Cys Pro Ser 65 70 75 80 ggg tac tat
gga cac cga gcc cca gat atg aac aga tgt gca aga tgc 288 Gly Tyr Tyr
Gly His Arg Ala Pro Asp Met Asn Arg Cys Ala Arg Cys 85 90 95 aga
ata gaa aac tgt gat tct tgc ttt agc aaa gac ttt tgt acc aag 336 Arg
Ile Glu Asn Cys Asp Ser Cys Phe Ser Lys Asp Phe Cys Thr Lys 100 105
110 tgc aaa gta ggc ttt tat ttg cat aga ggc cgt tgc ttt gat gaa tgt
384 Cys Lys Val Gly Phe Tyr Leu His Arg Gly Arg Cys Phe Asp Glu Cys
115 120 125 cca gat ggt ttt gca cca tta gaa gaa acc atg gaa tgt gtg
gaa gga 432 Pro Asp Gly Phe Ala Pro Leu Glu Glu Thr Met Glu Cys Val
Glu Gly 130 135 140 tgt gaa gtt ggt cat tgg agc gaa tgg gga act tgt
agc aga aat aat 480 Cys Glu Val Gly His Trp Ser Glu Trp Gly Thr Cys
Ser Arg Asn Asn 145 150 155 160 cgc aca tgt gga ttt aaa tgg ggt ctg
gaa acc aga aca cgg caa att 528 Arg Thr Cys Gly Phe Lys Trp Gly Leu
Glu Thr Arg Thr Arg Gln Ile 165 170 175 gtt aaa aag cca gtg aaa gac
aca ata ccg tgt cca acc att gct gaa 576 Val Lys Lys Pro Val Lys Asp
Thr Ile Pro Cys Pro Thr Ile Ala Glu 180 185 190 tcc agg aga tgc aag
atg aca atg agg cat tgt cca gga ggg aag aga 624 Ser Arg Arg Cys Lys
Met Thr Met Arg His Cys Pro Gly Gly Lys Arg 195 200 205 aca cca aag
gcg aag gag aag agg aac aag aaa aag aaa agg aag ctg 672 Thr Pro Lys
Ala Lys Glu Lys Arg Asn Lys Lys Lys Lys Arg Lys Leu 210 215 220 ata
gaa agg gcc cag gag caa cac agc gtc ttc cta gct aca gac aga 720 Ile
Glu Arg Ala Gln Glu Gln His Ser Val Phe Leu Ala Thr Asp Arg 225 230
235 240 gct aac caa taa 732 Ala Asn Gln <210> SEQ ID NO 51
<211> LENGTH: 243 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 51 Met Gln Phe Arg Leu Phe Ser
Phe Ala Leu Ile Ile Leu Asn Cys Met 1 5 10 15 Asp Tyr Ser His Cys
Gln Gly Asn Arg Trp Arg Arg Ser Lys Arg Ala 20 25 30 Ser Tyr Val
Ser Asn Pro Ile Cys Lys Gly Cys Leu Ser Cys Ser Lys 35 40 45 Asp
Asn Gly Cys Ser Arg Cys Gln Gln Lys Leu Phe Phe Phe Leu Arg 50 55
60 Arg Glu Gly Met Arg Gln Tyr Gly Glu Cys Leu His Ser Cys Pro Ser
65 70 75 80 Gly Tyr Tyr Gly His Arg Ala Pro Asp Met Asn Arg Cys Ala
Arg Cys 85 90 95 Arg Ile Glu Asn Cys Asp Ser Cys Phe Ser Lys Asp
Phe Cys Thr Lys 100 105 110 Cys Lys Val Gly Phe Tyr Leu His Arg Gly
Arg Cys Phe Asp Glu Cys 115 120 125 Pro Asp Gly Phe Ala Pro Leu Glu
Glu Thr Met Glu Cys Val Glu Gly 130 135 140 Cys Glu Val Gly His Trp
Ser Glu Trp Gly Thr Cys Ser Arg Asn Asn 145 150 155 160 Arg Thr Cys
Gly Phe Lys Trp Gly Leu Glu Thr Arg Thr Arg Gln Ile 165 170 175 Val
Lys Lys Pro Val Lys Asp Thr Ile Pro Cys Pro Thr Ile Ala Glu 180 185
190 Ser Arg Arg Cys Lys Met Thr Met Arg His Cys Pro Gly Gly Lys Arg
195 200 205 Thr Pro Lys Ala Lys Glu Lys Arg Asn Lys Lys Lys Lys Arg
Lys Leu 210 215 220 Ile Glu Arg Ala Gln Glu Gln His Ser Val Phe Leu
Ala Thr Asp Arg 225 230 235 240
Ala Asn Gln <210> SEQ ID NO 52 <211> LENGTH: 29
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Synthetic
primer <400> SEQUENCE: 52 ccggctagcc aaggcaaccg atggagacg 29
<210> SEQ ID NO 53 <211> LENGTH: 34 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Synthetic primer <400>
SEQUENCE: 53 gtagcggccg ctcaccctcc tggacaatgc ctca 34 <210>
SEQ ID NO 54 <211> LENGTH: 702 <212> TYPE: DNA
<213> ORGANISM: Homo sapiens <400> SEQUENCE: 54
atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt
60 gacgctagcg ctagttatgt atcaaatccc atttgcaagg gttgtttgtc
ttgttcaaag 120 gacaatgggt gtagccgatg tcaacagaag ttgttcttct
tccttcgaag agaagggatg 180 cgccagtatg gagagtgcct gcattcctgc
ccatccgggt actatggaca ccgagcccca 240 gatatgaaca gatgtgcaag
atgcagaata gaaaactgtg attcttgctt tagcaaagac 300 ttttgtacca
agtgcaaagt aggcttttat ttgcatagag gccgttgctt tgatgaatgt 360
ccagatggtt ttgcaccatt agaagaaacc atggaatgtg tggaaggatg tgaagttggt
420 cattggagcg aatggggaac ttgtagcaga aataatcgca catgtggatt
taaatggggt 480 ctggaaacca gaacacggca aattgttaaa aagccagtga
aagacacaat accgtgtcca 540 accattgctg aatccaggag atgcaagatg
acaatgaggc attgtccagg agggggcggc 600 cgctcgagtc tagagggccc
gcggttcgaa ggtaagccta tccctaaccc tctcctcggt 660 ctcgattcta
cgcgtaccgg tcatcatcac catcaccatt ga 702 <210> SEQ ID NO 55
<211> LENGTH: 233 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 55 Met Glu Thr Asp Thr Leu Leu
Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp
Ala Ser Ala Ser Tyr Val Ser Asn Pro Ile Cys 20 25 30 Lys Gly Cys
Leu Ser Cys Ser Lys Asp Asn Gly Cys Ser Arg Cys Gln 35 40 45 Gln
Lys Leu Phe Phe Phe Leu Arg Arg Glu Gly Met Arg Gln Tyr Gly 50 55
60 Glu Cys Leu His Ser Cys Pro Ser Gly Tyr Tyr Gly His Arg Ala Pro
65 70 75 80 Asp Met Asn Arg Cys Ala Arg Cys Arg Ile Glu Asn Cys Asp
Ser Cys 85 90 95 Phe Ser Lys Asp Phe Cys Thr Lys Cys Lys Val Gly
Phe Tyr Leu His 100 105 110 Arg Gly Arg Cys Phe Asp Glu Cys Pro Asp
Gly Phe Ala Pro Leu Glu 115 120 125 Glu Thr Met Glu Cys Val Glu Gly
Cys Glu Val Gly His Trp Ser Glu 130 135 140 Trp Gly Thr Cys Ser Arg
Asn Asn Arg Thr Cys Gly Phe Lys Trp Gly 145 150 155 160 Leu Glu Thr
Arg Thr Arg Gln Ile Val Lys Lys Pro Val Lys Asp Thr 165 170 175 Ile
Pro Cys Pro Thr Ile Ala Glu Ser Arg Arg Cys Lys Met Thr Met 180 185
190 Arg His Cys Pro Gly Gly Gly Gly Arg Ser Ser Leu Glu Gly Pro Arg
195 200 205 Phe Glu Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp
Ser Thr 210 215 220 Arg Thr Gly His His His His His His 225 230
* * * * *